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ABSTRACT 
Heart failure is a common condition which carries a high mortality and morbidity. Despite 
improved medical therapy the outcomes for heart failure with a reduced ejection fraction 
remain poor. Cardiac resynchronisation therapy has revolutioned the treatment of patients 
with heart failure with a reduced ejection fraction and dyssynchrony, refactory to medical 
therapy, improving morbidity and mortality. Unfortunately a significant minority fail to 
respond to this expensive therapy, which is challenging for both the patient and society.  
 
Over the last 15 years research has focused on attempting to predict non-response. 
Evidence suggests wider QRS duration and bundle branch morphology on the resting 
electrocardiograph are the most important predictors of response and outcome following 
implantation of a cardiac resynchronisation device. However, the non-response rate 
remains unchanged despite extensive research. 
 
Molecular systems have been shown to alter with the development and progression of 
heart failure. Many of these systems are now utilised in the diagnosis and prognostication of 
heart failure. Cardiac resynctonisation therapy device implantation has been shown to alter 
these dysregulated molecular systems. Specific circulating biomarkers reflect these 
respective systems. Cardiac extracellular matrix is a dynamic support structure that has 
altered turnover in heart failure and is affected when cardiac resynchonisation devices are 
implantted. Micro ribonucleic acids have been observed recently to be important in 
molecular systems regulation and dysregulation has been observed in heart failure. 
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Futhermore altered expression following cardiac resynchronisation therapy device 
implantation has been reported. The evidence suggests circulating biomarkers for these 
systems have the potential to predict response. Our prospective study examined specific 
biomarkers that the literature suggests has the potential to predict response, but the 
evidence is currently inconclusive. Moreover we utilised other important patient variables 
known to be predictors from the wider literature and our own retrospective cohort analysis 
of response to test alongside specific circulating biomarkers. We offer an informed pilot 
study to test important circulating biomarkers for their clinical ultility to predict heart failure 
patient’s ability to respond to cardiac resynchronisation therapy.  
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Chapter One 
 
INTRODUCTION AND BACKGROUND 
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1.1 HEART FAILURE  
Chronic Heart Failure (CHF) is a common condition defined as an abnormality in cardiac 
structure and function that leads to the inability of the heart to deliver adequate levels of 
oxygen to match metabolic demand of the tissues.2 Patients suffer from a plethora of 
symptoms including breathlessness, ankle oedema and fatigue.2 Heart Failure (HF) affects 
800,000 people in the UK alone.2-4 The estimated lifetime risk of developing HF in the 
general population is approximately 1 in 5 for a person aged 40 years.5 Adjusting for age, 
the incidence of HF has remained stable over the last 20 years, but the prevalence continue 
to increase.5 One of the largest drivers on the increasing burden of HF in the developed 
world is ischaemic heart disease (IHD).6  HF is associated with a high mortality with an 
estimated 30-40% mortality rate within the first year of diagnosis.7 However, there is an 
improving trend in mortality demonstrated by the six month survival rate decreasing  from 
26% in 1995 to 14% in 2005.8 The HF burden has implications for national health systems as 
it accounts for 5% of all acute medical and geriatric hospital admissions and is the 
commonest hospital admission cause in the over 65 year old population. It is estimated that 
hospital admissions due to HF will rise by 50% over the next 25 years.4,9 The burden has 
eased slightly with an age–adjusted hospitalisation rate having decreased by 1–1.5% per 
annum since 1992/1993.10 The improvements in mortality and hospitalisation is due to 
more effective treatments,2,11-14 however the burden of the aging population and improved 
survival from HF means it remains a significant problem.   
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1.1.1 Reduced Ejection Fraction Heart Failure and Cardiac Dyssynchrony 
Many patients with HF with reduced ejection fractions (HFrEF) develop dyssynchronous 
contraction of the heart due to damage of the underlying conduction tissue leading to 
inefficient cardiac contraction that leads to symptoms. Cardiac dyssynchrony is a complex 
and multifactorial process which impacts function.15 Prolongation of the atrioventricular 
interval, can encroach on the starting of systole and filling within early diastole.15 Ventricular 
contraction being delayed, the left ventricle (LV) diastolic pressures will exceed the left atrial 
pressure during passive filling, leading to the development of functional mitral regurgitation 
(MR).15 The impact of reducing ventricular pre-load, leads to a reduction in LV contractility, 
by the Starling mechanism.15 Moreover, the occurrence of intra- and inter-ventricular 
conduction delays leads to asynchronous contraction on the regional wall segments 
(ventricular/mechanical dyssynchrony), which leads to reduced stroke volume, LV ejection 
fraction (LVEF) and systolic blood pressure.15 Ventricular dyssynchrony leads to 
incoordination of papillary wall contraction and further contributes to the development and 
progression of functional mitral regurgitation.15 The development and progression of this 
process leads to or contributes to LV adverse remodelling.15 
 
1.2 CARDIAC RESYNCHRONISATION THERAPY 
Cardiac Resynchronisation Therapy (CRT) or ‘biventricular pacing’ involves implanting pacing 
leads into the heart to pace the left and right heart. The pacemaker leads are implanted via 
the transvenous route into the right ventricle (RV) and a branch of the coronary sinus 
(venous drainage of heart) to pace the LV , to resynchronise ventricular contraction. A lead 
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is implanted into the right atrium (RA) to achieve atrioventricular synchrony, this lead is not 
necessarily implanted in patients where pacing is not possible (e.g. Chronic Atrial 
Fibrillation). Figure 1.1 demonstrates implantation of the CRT pacing leads. CRT can 
‘resynchronise’ cardiac contraction through restorations of inter- and intra- ventricular and 
atrioventricular dyssynchrony.15 Resynchronisation induces reverse LV remodelling by 
improving LVEF, contractility and LV filling time.15  
 
Figure 1.1 Cardiac Resynchronisation Therapy. Figure taken from Hare J et al.NEJM, 200216 
 
1.2.1 The Cost of CRT  
CRT implantation is a costly intervention with a large up-front cost of an estimated £3,411 
for a CRT Pacemaker (CRT-p) and £12,293 for a CRT Defibrillator (CRT-d).17 Additionally there 
are ongoing costs of monitoring and replacement of pulse generators of CRTs.18 The up-
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front cost is larger than for many other medical devices.18 Randomised Control Trials (RCT) 
have been used to model the quality adjusted life year (QALY) costs of a CRT. It is widely 
accepted that this falls below $50,000 per QALY which is the accepted cost of an 
intervention in the USA, and equates to approximately £39,000.18 Efforts have focused on 
minimising this cost, by better identifying the CHF population who will benefit, streamlining 
implantation and distance monitoring to reduce patient visits to hospital 18. However, the 
burden of cost to the healthcare system will continue to rise with the growing population of 
CHF patients who might benefit from CRT. 
 
1.2.2 The Evidence for CRT 
Over the last 25 years CRT has become one of the most effective treatments for CHF and is 
applicable to an estimated 25-30% of CHF patients.19 In 1994 Cazeau et al,20 demonstrated a 
four lead pacemaker in a 54 year old advancing HF patient improved New York Heart 
Association (NYHA) symptoms classification.  Since then multiple RCTS have demonstrated 
the benefit of CRT for HFrEF patients with mechanical Dyssynchrony; reduced mortality and 
hospitalisation,21-23 alongside improved quality of life (QoL),23-27 symptoms,21,28,29 functional 
performance28,30 and LV volumes.25,29,31  Table 1.1 summarises the main RCTs demonstrating 
the benefit of CRT on HFrEF patients.   
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Table 1.1 Randomised control trials evaluating CRT in sinus rhythm (Adapted15). 
 
Trial (ref) Pts Study Design Inclusion Outcome Main Findings 
MUSTIC-SR 
2001 21 
58 
Single-blinded, 
crossover, 
randomised - 
CRT-p vs. OMT, 
6months 
NYHA III, 
LVEF<35%, 
QRS 
>150msec 
1o: 6MWD 
2o: NYHA, QoL, peak 
VO2, LV volumes, 
hospitalisations, 
mortality 
CRT-p ↑6MWD, 
↓NYHA, ↑QoL, ↑peak 
VO2 & reduced LV 
volumes, MR, 
hospitalisations 
MIRACLE 2002 
28 
453 
Double-blinded, 
randomised CRT 
vs. OMT, 6 
months 
NYHA III-IV, 
LVEF<35%, 
QRS 
>130msec 
1o: NYHA, 6MWD, QoL 
2o: Peak VO2, LVEDD, 
LVEF, MR, Clinical 
Composite response 
CRT-p improved 
6MWD, NYHA, QoL, 
LVEF & reduced LVEDD,  
MR 
MIRACLE-ICD 
2003 30 
369 
Double-blinded, 
randomised 
CRT-d vs. ICD, 6 
months 
NYHA III-IV, 
LVEF<35%, 
QRS 
>130msec 
1o: NYHA, 6MWD, QoL 
2o: Peak VO2, LVEDD, 
LVEF, MR, Clinical 
Composite response 
CRT-d improved NYHA, 
QoL, peak VO2 
CONTAK-CD 
2003 25 
490 
Double-blinded, 
randomised 
CRT-d vs. ICD, 6 
months 
NYHA II-IV, 
LVEF<35%, 
QRS 
>120msec 
1o: Clinical Composite 
2o: NYHA, 6MWD, QoL, 
peak VO2, LV volume, 
LVEF 
CRT-d improved peak 
VO2, 6MWD & reduced 
LVEF 
MIRACLE-ICD 
II 2004 29 
186 
Double-blinded, 
randomised 
CRT-d vs. ICD, 6 
months 
NYHA II, 
LVEF<35%, 
QRS 
>130msec 
1o: Peak VO2 
2o: VE/VCO2, NYHA, QoL, 
6MWD, LVEF, 
LV Volumes, 
Clinical Composite 
CRT-d improved NYHA, 
VE/VCO2, LVEF & 
reduced LV volumes 
COMPANION 
2004 22 
1520 
Double-blinded, 
randomised - 
OMT vs. CRT-d 
/or CRT-p , 15 
months 
NYHA III-IV, 
LVEF<35%, 
QRS 
>120msec 
1o: All-cause mortality or 
hospitalisations 
2o: All-cause mortality, 
cardiac mortality 
CRT-d & CRT-p reduced 
all-cause mortality & 
hospitalisation 
CARE-HF 
2005 23 
813 
Double-blinded 
randomised - 
OMT vs. CRT-p 
29.4 months 
NYHA III-IV, 
LVEF<35%, 
QRS 
>120msec 
1o: All-cause mortality or 
hospitalisations 
2o:All-cause mortality, 
NYHA, QoL 
CRT-p reduced all-cause 
mortality, 
hospitalisations & 
improved NYHA, QoL 
REVERSE 
2008 31 
610 
Double-blinded, 
randomised - 
CRT-ON vs. CRT-
OFF, 12 months 
NYHA I-II, 
LVEF<40%, 
QRS 
>120msec 
1o: % worsened HF 
clinical composite 
2o: LVESVi, HF 
hospitalisations, All-
cause mortality 
CRT-p/CRT-d did not 
change the primary 
endpoint, reduced 
LVESVi, HF 
hospitalisations 
MADIT-CRT 
2009 27 
1820 
Single-blinded, 
randomised - 
CRT-d vs. ICD, 
12 months 
NYHA I-II, 
LVEF<30%, 
QRS 
>130msec 
1o: All-cause mortality or 
HF hospitalisations 
2o: All-cause mortality, 
LVESV 
CRT-d reduced the 
primary endpoint & 
LVESV, CRT-d did not 
reduce All-cause 
mortality 
RAFT 
2010 26 
1798 
Double-blinded, 
randomised - 
CRT-d vs. ICD, 
40 months 
NYHA II-III, 
LVEF<30%, 
QRS 
>120msec 
1o: All-cause mortality or 
HF hospitalisations 
2o: All-cause mortality & 
CV death 
CRT-d reduced primary 
endpoint CRT-d (NYHA 
III) reduced All-cause 
mortality 
6MWD = Six Minute Walk Distance, CARE-HF = Cardiac Resynchronization Heart Failure, CONTAK-CD = CONTAK-
Cardiac Defibrillator, COMPANION = Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure, 
MADIT-CRT = Multicenter Automatic  Defibrillator Implantation Trial with Cardiac Resynchronization Therapy, 
MIRACLE = Multicentre InSync Randomized Clinical Evaluation, MIRACLE-ICD= Multicentre InSync ImplanTable 
Cardioverter Defibrillator trial, MUSTIC =Multisite Stimulation in Cardiomyopathies, RAFT=Resynchronization-
Defibrillation for Ambulatory Heart Failure, 1o = Primary Outcome, 2o= Secondary Outcome 
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The RCTs for CRT represent benefit from CRT for patients with significantly reduced LVEF 
(<35%), symptoms despite optimal medical therapy and a prolonged QRS duration 
(>120msec) on resting electrocardiogram in sinus rhythm (Table 1.1). The detailed analysis 
of all the RCTs, related systematic review, sub-group analyses and the observational studies 
refines the groups of HFrEF patients that derive the most benefit and influence response to 
CRT. This evidence is the basis of the international CRT implantation guidelines and the 
weighting given to the evidence. 
 
1.2.3 Left Ventricular Ejection Fraction and CRT 
Studies have only examined patients with severe LV systolic dysfunction (LVEF <30-40%), 
with the specific exception for patients who have a bradycardia pacing indication and 
whether a CRT should be implanted over an simple RV pacing only device. Consistent trends 
suggest that sustained RV pacing induces deterioration in LV systolic function, therefore 
anticipating the deterioration with a CRT might prevent this.15,32-34 The biventricular versus 
right ventricular pacing in patients with AV block (BLOCK HF) trial32 was the largest (n=691) 
RCT examining RV pacing versus CRT on composite outcomes (all-cause mortality, HF 
hospitalisation ↓<15% LV end systolic volume indexed to body surface area (m2)(LVESVi)) 
for patients with LVEF <50% (mean = 40%) with atrioventricular node block. BLOCK-HF 
demonstrated following a 37 month observation period that patients undergoing a CRT 
implantation had a 26% greater reduction in outcome occurrence, although it should be 
noted some of the echocardiogram data was missing, so censoring of these patients 
occurred, excluding end-points from this study.32 The evidence demonstrated that in 
patients with moderate /severe LV systolic dysfunction and a pacing indication a CRT could 
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be implanted in stead of a pacemaker when weighed against the small risks of the 
procedure. 32  Comparisons between RV pacing and CRT implantation for preserved systolic 
function demonstrated no statistical difference.35,36  
 
1.2.4 New York Heart Association Symptom Classification and CRT 
The strength of evidence around CRT implantation for all NYHA symptom classification is 
highly variable. The trials tended to recruit a higher proportion of NYHA II/III patients 
dependent on the specific inclusion criteria (Table 1.1). In the mild / no symptom trials 
(NYHA I-II) with severe LV systolic dysfunction (LVEF<30-40%), QRS duration >120-130msec 
improvement in cardiovascular outcomes and reverse LV remodelling was 
demonstrated.27,29,31 NYHA I patients represented a small proportion (<20%) of the 
participants in all trials and showed a trend towards a benefit to improving cardiovascular 
outcomes.27,29,31 Moreover, NYHA IV patients were under represented in the RCTs, 
representing between 7% and 15%.15 The evidence for specific outcomes for NYHA IV 
patients with LV systolic dysfunction (LVEF<30-40%) and QRS duration >120-130msec is 
limited. One retrospective cohort study observed that 5 years survival was 40.4% following 
CRT, however this was based upon only 5 patients (n=723).37  
 
1.2.5 QRS Duration and CRT 
QRS duration is the most powerful predictor of benefit and response when a patient has a 
CRT implanted. Sub-group analyses of the MADIT-CRT27,38 REVERSE31 and RAFT26 RCTs 
consistently demonstrate that patients with the greatest reduction in cardiovascular 
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outcomes are those with a QRS duration >150msec. These trials represent patients in NYHA 
class I-III and LVEF<30-40%. Cleland et al39 performed a large meta-analysis of individual 
patients (n=3782) from 5 Medtronic Ltd (Minneapolis, USA) sponsored RCTs (MIRACLE,28 
MIRACLE-ICD,30 CARE-HF,23 REVERSE31  and RAFT26) comparing either CRT with OMT23,28,31 or 
CRT-d with implantable cardiac defibrillators (ICD).26 Pre-defined variables were examined 
for their ability to predict CRT cardiovascular outcomes (composite all-cause mortality/HF 
admissions or all-cause mortality alone).39  For uniformity of the review, patients with atrial 
fibrillation (AF) and NYHA I symptoms had individual records removed from the analysis as 
they were only present in a small proportion of patients within one RCT cohort. Cleland et 
al39  accounted for the influence of having an actual CRT implanted and treated it as a fixed 
affect variable in the prediction models. Increasing QRS duration was shown to be beneficial 
for patients undergoing CRT and predicted a reduction in cardiovascular outcomes.39 Figure 
1.2 shows the hazard ratio (HR) and 95% confidence interval (CI) for CRT vs. control for the 
composite of all-cause mortality or HF hospitalisation plotted against QRS duration. Cleland 
et al39 demonstrate a greater magnitude of benefit from incremental increases in QRS 
duration following CRT implantation improving outcomes. The definitive benefit was 
observed at >140msec (CI lines cross the HR 1.0).39 The benefit reached a plateau beyond 
180msec for composite outcome alone.39 Interestingly left bundle branch block (LBBB) 
morphology was associated with broader QRS durations, generating the question of 
whether the observed predictive power of QRS duration was due to this cofounding factor. 
Cleland et al39 demonstrated non-LBBB had an increased trend towards higher mortality, 
however when QRS duration was removed from the multivariable prediction model, little 
difference was noted between LBBB and non-LBBB in terms of impact on mortality. 39 The 
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Cleland et al39 meta-analysis is powerful due to the access to individual participant records 
across 5 RCTs. Other reviews quoted in this body of work are aggregate reviews and do not 
account for individual study confounders. However, only Medtronic Ltd sponsored RCTs 
were included, which the authors do acknowledge as a major limitation.  
 
Figure 1.2 Relationship of CRT on all-cause mortality or HF hospitalisation and QRS 
duration. Models demonstrating Hazard Ratio’s and 95% confidence interval for CRT vs. 
controls (OMT/ICD/Back up pacing) against the QRS duration. (Adapted39)  
 
There is definitive evidence demonstrating that patients with a QRS duration 120-129msec 
do not benefit from CRT implantation. In 2007, the ‘CRT IN Patients with Heart Failure and 
Narrow QRS’ (RethinQ) trial40 recruited patients (n=172) with standard implantation criteria 
with QRS complexes <130msec and cardiac dyssynchrony, randomising participants to 
therapy CRT-ON or CRT-OFF (after implantation). Over six months, the CRT-ON group 
demonstrated an improvement in peak O2 consumption (peak VO2) (p=0.02), however in a 
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pre-defined subgroup analysis those with a QRS<120msec demonstrated no difference 
(p=0.45).40 The RethinQ40 RCT observation period was too short to be able to examine the 
impact of biventricular pacing on a narrow QRS upon morbidity and mortality. More 
recently, ‘the Cardiac Resynchronization Therapy in Heart Failure with a Narrow QRS’ 
Complex (Echo-CRT) trial41 enrolled patients (n=855) across 115 centres who met standard 
implantation criteria and had a QRS complex <130msec with evidence of cardiac 
dyssynchrony. Following CRT implantation they were randomised to either  CRT-ON or CRT-
OFF to examine impact on all-cause mortality and HF hospitalisation (treated as a composite 
outcome). The Echo-CRT41 RCT was stopped early on ‘the basis of futility with a potential for 
harm’. The trial demonstrated CRT-ON had a higher rate of  composite primary end-points 
occurring compared to CRT-OFF group (28.7% vs. 25.2%), which was not statistically 
significant (p=0.15).41 However, when all-cause mortality was examined on its own CRT-ON, 
had a statistically higher occurrence than CRT-OFF (11.1% vs. 6.4%, p=0.02).41 The definitive 
benefit of CRT is in those with a widened QRS, despite the presence of mechanical cardiac 
dyssynchrony.  
 
1.2.6 QRS Morphology and CRT 
QRS morphology has been demonstrated to be important in determining response to CRT 
implantation. Subsequent sub-group analyses of the MADIT-CRT42, RAFT26 and REVERSE43 
trials all identified complete LBBB demonstrated a better outcome on the composite of all-
cause mortality and hospitalisation compared with right bundle branch block (RBBB) and 
non-specific intraventricular conduction delay (NIVCD). In 2012 Sipahi et al44 performed a 
large meta-analysis (n=5,356) examining CRT RCTs that reported clinical outcomes (all-cause 
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mortality/HF hospitalisations) corresponding with Bundle Branch Block (BBB) morphology. 
COMPANION22, CARE-HF23, MADIT-CRT42 and RAFT26 were the only trials that met the 
eligibility criteria.44 Sipahi et al44 demonstrated a highly significant reduction in the 
composite outcome for patients undergoing CRT implantation with complete LBBB (Risk 
Ratio (RR) 0.64, CI (95%) 0.52-0.77, p<0.0001). Within the included RCTs of the meta-
analysis, patients with LBBB tended to have wider QRS’s, which may have confound the 
results.44  
 
Cunnington et al45 in a meta-analysis of six landmark CRT RCTs22,23,26-28,31 analysed 6914 
participants and compared those with and without LBBB (Non-LBBB was a classification for 
QRS morphology in four included trials22,26,27,31 and RBBB was used in the other two RCTs 
23,28). The two trials which classified non-LBBB as RBBB were not involved in the sensitivity 
analysis.45 NIVCD was accounted for, in the definition of BBB in four trials.23,26,27,31 The 
review summarises that the six trials represented participants with NYHA I-IV, LVEF<30-40% 
and QRS>120msec.45  Table 1.1 summarises the characteristics of all the included studies. 
Cunnington et al45 demonstrated no benefit from CRT for patients with non-LBBB QRS 
morphology for a pooled outcome of all-cause mortality and HF hospitalisation (HR 1.09, CI 
(95%) 0.85 – 1.39). It should be noted that Cunnington et al45 only studied cardiovascular 
end-points and did not examine symptom, functional or echocardiographic outcomes. It is 
also acknowledged that NYHA classes I and IV are underrepresented in the RCTs and the 
observations are driven by those with class II and III symptoms.  The MADIT-CRT trial27 
enrolled 536 non-LBBB participants with NYHA I-II. This RCT demonstrated no clinical benefit 
from CRT  for non-LBBB patients and actually showed it increased the risk of mortality (HR 
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1.57, CI (95%) 1.03-2.39).46 A meta-analysis by Sipahi et al44  also demonstrated there was 
no benefit to implanting CRTs in patients with non-LBBB. The challenge remains how to 
treat those with non-LBBB with a widen QRS, which remains an active indication for 
implanting a CRT.15,17,47 Cleland et al39 in a large meta-analysis observed that non-LBBB did 
not predict cardiovascular outcomes when QRS duration was removed from the analysis. 
Different BBB patterns have been demonstrated on recent electrocardiographic activation 
mapping studies to have heterogeneous patterns and should be considered as different 
entities,24,48 whereas QRS durations can be considered on a continuous spectrum with 
incremental benefit the wider the duration when a CRT is implanted.39 Currently QRS 
duration represents the most powerful predictor and BBB morphology should be considered 
separately with LBBB being more favourable for a successful outcome.  
 
1.2.7 Atrial Fibrillation and CRT 
AF commonly co-exists in patients with HF and its presence can reduce the success of CRT.49  
Understanding the true influence of AF on the success of CRT is difficult as patients with AF 
tend to be older, have more co-morbidities and are more unwell. Comparison between 
sinus rhythm and AF is influenced by these confounding factors, which often infer worse 
prognosis.15 AF is underrepresented in CRT RCTs and reliance is needed upon meta-analyses. 
It has been observed that AF patients receiving CRT have a similar improvement in LVEF 
compared with those in sinus rhythm, but have worse symptom and functional response.49 
In a large (n=7495) meta-analysis of 33 observational studies, Wilton et al 49 compared those 
with AF (22.5%) to sinus rhythm receiving CRT and observed a significantly higher all-cause 
mortality and non-responder rate in the AF group.  Evidence on the precise 
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recommendations for CRT in patients with AF remains weak and is based on limited 
evidence and expert opinion.  However, implantation is favoured if >99% biventricular 
pacing percentage can be achieved.15 
   
1.2.8 Cardiac Dyssynchrony and CRT  
One of the recent significant changes to the international guidelines was the removal for the 
need to demonstrate cardiac dyssynchrony on echocardiography if the patient’s QRS 
duration is 120-149msec on resting ECG.  The CARE-HF trial23 eligibility criteria required 
patients with a QRS duration of 120-149 msec to have cardiac dyssynchrony demonstrated 
on echocardiography. Cardiac dyssynchrony was defined as achieving two of three criteria: 
aortic pre-ejection delay >140msec,  interventricular mechanical delay (IVMD) of 40msec, or 
delayed activation of the posterolateral LV wall. The IVMD was calculated as the time 
difference between the onset of forward flow in the Aortic pre-ejection time (APET) and 
Pulmonary pre-ejection time (PPET) outflow tracts (IVMD = APET – PPET).23 A sub-group 
analysis of CARE-HF demonstrated those patients with an IVMD >49.2msec implanted with a 
CRT had a reduced composite outcome (all-cause mortality or hospitalisation for a major 
cardiovascular event) (HR 0.50, CI (95%) 0.36-0.70).23 A pre-defined sub-study50 of CARE-
HF23 observed that patients with IVMD (>49.2msec) benefitted more from CRT from a 
greater reduction in the composite outcome (HR 0.99, 95% CI 0.98–1.00). The 
demonstration of the benefit of CRT on patients who demonstrated cardiac dyssynchrony 
(as per CARE-HF) formed a part of the implantation guidelines.51  
Cardiac dyssynchrony as an indicator of CRT success was seen sceptically, as the data was 
based upon a sub-group analysis of CARE-HF.23 These suspicions were validated by the 
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results of the prospective, multicentre Predictors of Response to Cardiac Resynchronization 
Therapy (PROSPECT) study.52 PROSPECT recruited 426 participants who successfully had 
CRTs implanted across 53 international centres with standard CRT implantation indications 
to measure the ability of 12 pre-defined echocardiographic measures of cardiac 
dyssynchrony (including IVMD) abilities to predict response, alongside their validity and 
reliability as measurments.52 Two definitions of response were utilised at six months follow-
up; a clinical (HF clinical composite score) and echocardiographic (>↓15% LVESV).52 The 12 
predefined cardiac dyssynchrony measures demonstrated wide variability in their ability to 
predict clinical and echocardiographic response. For echocardiographic response prediction, 
the sensitivity ranged from 9% to 77% and specificity from 31% to 93%.52 None of the 
cardiac dyssynchrony variables achieved an area under the receiver operating curve (ROC) 
for either response definition <0.62; representing a poor ability to discriminate response.52 
PROSPECT also identified a high variability between operators to accurately reproduce 
cardiac dyssynchrony measurements.52  Notably only 286 participants had paired baseline 
and six month follow-up echocardiogram completed successfully, due to a combination of 
poor quality images, presence of AF and mortality events.52 The results of PROSEPCT 
demonstrated weak predictive power and high inter-operator variability of cardiac 
dyssynchrony echocardiographic markers when used in multiple centres.52 Currently other 
echocardiographic measurements of cardiac dyssynchrony continue to be researched, 
echocardiographic strain analysis offers some future potential,53-55 however for now the 
best discriminator is QRS duration on resting ECGs and this is now used in the current 
guidelines.15,17,47  
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1.2.9 Cardiac Resynchronisation Therapy Implantation Criteria 
The current evidence has been significantly modified over the last 15 years of implantation 
as more evidence has been produced. The previous section demonstrated the evolution and 
refinement of the current evidence, which reflects the current International guidelines 
(European Society of Cardiology (ESC)15 and American Heart Association(AHA)47). These 
guidelines have recently changed to reflect more recent evidence including now implanting 
patients with AF and bradycardia pacemaker indications.15,47,56,57 In June 2014, in the UK, 
NICE revised guidance on CRT implantation that reflect the updated international 
guidelines.17 Current indications are for CHF (LVEF <35%) with NYHA II/III/IV symptoms on 
optimal medical therapy (Angiotensin Converting Enzyme, Beta-Blocker +/- 
Mineralocorticoid Antagonist) with a QRS duration on resting ECG with either:  120-149msec 
with LBBB or >150msec duration. Patients in atrial fibrillation who can be rate controlled 
(medication or AV node ablation) and fulfil the CRT criteria should be considered for a CRT.47 
Patients (LVEF <35%) who are anticipated to require ventricular pacing >40% of the time 
should be considered for CRT.47 Table 1.2 summarises the NICE 2014 CRT implantation 
guidelines. 
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Table 1.2 NICE 2014 (TA314) Indications for Implantable Cardiac Defibrillator and CRT in 
Patients with LVEF<35%. (Adapted17) 
  NYHA Class 
QRS Interval I II III IV 
<120 msec 
ICD if there is a high risk                                                      
of sudden cardiac death 
ICD and CRT not
clinically indicated 
120-149msec without 
LBBB ICD ICD ICD CRT-p 
120-149msec with LBBB ICD CRT-d CRT-p or CRT-d CRT-P 
>150msec CRT-d CRT-d CRT-p or CRT-d CRT-P 
 
The ESC introduced new recommendations for CRT implantation in August 2016 at their 
annual conference.58 Referring to the issues raised by the strength of evidence about 
implanting CRT into patients with a low QRS 120-130msec raised by Cleland et al39 and the 
ECHO-CRT41 RCT the new guidelines recommend CRT should only now be implanted with a 
QRS>130msec. The NICE 201417 guidelines (Table 1.2) remain applicable currently, however 
this is likely to change in the near future.58 
 
1.2.10 UK Cardiac Resynchronisation Therapy Implantation 
Over the last decade several hundred thousand CRTs have been implanted worldwide.19 In 
2013 the UK was the fourth highest total CRT implanter in Western Europe.59 Figure 1.3 
demonstrates the increasing CRT implantation year-on-year in the UK, over the last 10 
years. Scotland’s national implantation figures are not presented as there was an 
incomplete dataset provided to the national audit of cardiac rhythm management.59 These 
figures represent a broadening of the international/national implantation guidelines as the 
evidence has become more extensive and refined. Figure 1.3 compares the changes in the 
national and international implantation criteria with UK procedure rates. The increasing 
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implantation rates also represent increasing number of secondary care centres in the UK to 
implanting CRTs.51 
Figure 1.3 United Kingdom total CRT implant rates 2003-2014 compared with release in 
national and international implantation criteria.The 2013/2014 years are combined as the 
data collection changed to reflect a March to March data collection period. (Adapted59) 
 
1.3 CRT NON-RESPONSE 
Despite two decades of refined RCTs and detailed observational trials examining those 
patients that benefit from CRT, there remains an unchanging minority of 20-40% of HFrEF 
patients that meet criteria for CRT placement but fail to respond.22,23,26,27,60 QRS duration 
and morphology have consistently been demonstrated to be the strongest predictors of 
cardiovascular outcomes, as summarised in the earlier discussions.39 Cleland et al39 
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demonstrated the incremental strength of increasing QRS above 140msec to predict 
improved outcomes (figure 1.2). QRS morphology does not demonstrate such clear strength 
to predict response,39 though it is clear the non-LBBB morphology favours poorer 
response.45 Questions still remain around the benefit of CRT in patients with QRS durations 
120-140msec and the additional benefit LBBB morphology offers.45 Calls have recently been 
made  for an RCT of patients with CRT already in-situ to have their devices de-activated for a 
period of observation who have a narrow QRS and/or non-LBBB to examine for any 
benefits.61,62 Moreover the apparent influence of BBB morphology on QRS duration 
>150msec remains unclear.  
 
Beyond QRS durations and BBB morphology, many other predictors of response to CRT have 
been identified. Sub-studies of the large CRT RCTs have identified multiple variables that 
improve morbidity and mortality. In a sub-study of the MADIT-CRT trial,27 Hsu et al38 
performed a best-subset regression on patients whom had paired echocardiograms at 12 
months and had been assigned to have a CRT-d (n=752) to examine for predictors of 
echocardiogram super-responders (top quartile of LVEF change). Six predictors were 
identified as being associated with LVEF super-response; female gender (Odds Ratio (OR) 
1.96, p=0.001), no prior myocardial infarction (MI) (OR 1.80; p<0.01), QRS duration 
>150msec (OR 1.79, p<0.01), LBBB (OR 2.05, p<0.01), body mass index (BMI) <30 kg/m2 (OR 
1.51, p=0.035), and smaller baseline left atrial volume index (OR 1.47, p=0.001).38 The 
impact of the CRT was not accounted for in this analysis by Hsu et al,38  further this was a 
sub-study analysis and to be included there had to be paired echocardiograms 
demonstrating a selection bias towards participants that had survived to that time.  
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Cleland et al39 examined multiple predefined potential predictor variables (age, gender, 
NYHA class, HF aetiology, QRS morphology, QRS duration, LVEF, and systolic blood pressure) 
and only QRS duration demonstrated the ability to predict CRT outcomes. Cleland et al62,63 
consistently make the argument that much of the evidence for predictors is based upon sub-
group analyses. Moreover, in these subset studies and meta-analyses based on the CRT 
RCTs the impact of the device is not accounted for and confounds the results observed.62,63  
Many observational studies have been performed in the intervening two decades to 
examine the potential of different variables to predict CRT response/outcome. These 
observational studies tend to be of limited value, often being under-powered, have flaws in 
their study methodology, not accounting for CRT implantation and using a variety of 
different response/outcome definitions.63 Their value shadows that of the often quoted CRT 
RCT sub-studies and more importantly meta-analyses. However, observational studies tend 
to emphasise the value of response in terms of patient centred criteria (symptoms, function 
and quality-of-life) compared to the majority of CRT trials with their composite 
cardiovascular outcomes (Table 1.1). There are also well conducted observational studies 
that often generate new lines of hypothesis and investigation; therefore they still have value 
in the investigation of non-response. Table 1.3 summarises important observational studies 
examining clinical predictors.   
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Table 1.3 Summary of observational studies examining pre-implant ‘predictors’ of CRT response 
Trial (ref) Patients Study Design Inclusion Response Criteria Main Findings 
Diaz-Infante 
et al  
2005 64 
143 
Prospective Observational 
Study; Multicentre (Spain); 
All successful CRT implants; 
6 months 
NYHA II-IV, 
LVEF <45%, QRS 
>130msec 
Clinical: ↑>10% 6MWD 
& Survived & No Heart 
Transplant 
Predictor Non-Response:  
Ischaemic Aetiology,  LVEDD (>75mm) 
& severity of MR 
Shanks et al 
2011 65 
581 
Observational study ; 
Single centre (Holland); 6 
months 
Not clear which  
NYHA, 
LVEF<35%, 
QRS>120msec 
Clinical & 
Echocardiographic: 
↓NYHA >1  & survival & 
no heart transplantation  
↑>15% LVESV 
Predict Non-Response:  
Ischaemic Aetiology, Shorter 6MWD 
at baseline, less baseline cardiac 
dyssynchrony & LV lead position 
Lin et al 2014 
66 
193 
Retrospective 
Observational Study 
(China); Single centre; All 
consecutive CRTs; 12 
months 
NYHA II-IV, 
LVEF<35%, 
QRS>120msec 
Echocardiographic: 
↑>5%LVEF & survived & 
being free from HF 
hospitalisation 
Predicts Non-response: non-LBBB & 
non-optimal LV lead position 
Rinkuniene 
et al  
2014 67 
82 
Retrospective 
Observational Study; Single 
centre (Lithuania);  12 
months 
NYHA III-IV, 
LVEF<35%, 
QRS>120msec, 
LBBB 
Clinical:↓>1 NYHA & 
↑>15% 6MWD 
Echocardiographic: 
↑>15% LVESV 
Predicts Response:   
Non-Ischaemic Aetiology (Clinical) & 
LVEDD (<75mm) (Echo) 
Sassone  
et al  
2015 68 
243 
Retrospective 
Observational Study; All 
consecutive CRTs; Majority 
CRT-d; Single centre (Italy);  
6 months; LBBB in 
predictor analysis  
NYHA II-IV, 
LVEF<35%, 
QRS>120msec 
Echocardiographic: 
↑>15% LVESV  
Clinical Composite: HF 
hospitalisation, mortality 
& first sustained VT  
Predict Non-Response:  
Ischaemic Aetiology & 
 QRS duration (>178msec)  
Clinical Composite:   
non-LBBB ↑ rate events 
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Diaz-Infante et al64 offered a large multicentre prospective observational study, which was 
not powered. There were 197 patients who originally met the eligibility criteria, however 54 
(27.4%) were excluded (6-minute walk test (6MWT) not performed, CRT unsuccessful etc).64 
Interpretation of the results must be performed in the context that this study started 
recruiting in 2001 and with all the advances in technology and skills since then, this will have 
affected the results.64 Critically the variables being tested in the prediction model were not 
pre-defined. In terms of observation study, this is a strong one given its prospective and 
multicentre design, but suffers from selection bias.  
 
Shanks et al65 undertook a large observational study, with short follow-up. From the report 
itself, it is unclear if this is prospective or retrospective in design with a small number of 
NYHA IV patients.65 The variables being tested in the predictor model were not pre-
specified; moreover multiple statistical testing was not corrected for.65  The results support 
others observed in other studies, including the MADIT-CRT substudy.38  
 
Lin et al66 performed a non-powered observational study. The predictors that were tested 
were listed in the methods. LV geometric measures including LVEF were used as predictors 
of response; a difference between response and non-response was identified, this however 
was to expected given the ‘response’ definition echocardiographic variables (table 1.3)66 LV 
lead position was observed to be a predictor of non-response, however there is no 
discussion about selection of LV lead position selection and pacing programing involved. 
Interestingly pre-implant QRS duration is a strong univariate predictor of response (OR 1.02, 
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CI (95%) 1.01-1.04), p=0.001), however in multivariable analysis the association is lost (OR 
1.00, CI (95%)  0.98-1.03,  p=0.81).66 Lin et al66 observed responders had significantly larger 
QRS durations and more LBBB than non-responders.66 Non-LBBB morphology was found to 
be a significant predictor of non-response. In the literature QRS duration is a more powerful 
predictor than bundle branch morphology, however in this study confounding effect of both 
variables is not adequately dealt with to determine the true effect.  
 
Rinkuniene et al67 was a single centre study observational study with small participant 
numbers and was not powered, therefore the observations made are questionnable. 
Furthermore there were a couple of other flaws with the study; it is somewhat surprising 
that all procedures were successful and variables examined as predictors were not 
predefined.67 These factors suggest a flawed observation study that likely suffers from 
selection and reporter bias.  
 
Sassone et al68 present a large retrospective, single centre cohort study, which was not 
powered. They utilised two different outcome measures.68 The focus of the study was on 
LBBB (59.7%) vs non-LBBB (n=74).68 No pattern was noted with non-LBBB, however a ‘U’ 
shaped distribution was noted with LBBB with clusters on echocardiographic non-response 
clustered at <130msec and >180msec.68 Despite this observation, BBB status was not tested 
as a predictor, but presumed to be.68 The regression modelling was only performed on 
participants with defined LBBB. QRS durations >178msec was defined as being the best cut 
off to define echocardiographic non-response in patients with a CRT and LBBB. Sassone et 
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al68 implies BBB is the greatest predictor, without testing it and goes on to look at additional 
factors like QRS durations.68 Conversely, higher level evidence has demonstrated similar 
observations with the plateau effect of benefit to patients with a QRS >180msec, but this 
was separate to BBB morphology (figure 1.2).39 Sassone et al68 identified findings that had 
already been demonstrated by Cleland et al39. 
 
The observational studies discussed and summarised (Table 1.3) are not exhaustive, but 
reflect the most important published in conjunction with the sub-group studies of the CRT 
RCTs and the meta-analyses to investigate pre-implant factors that might predict response. 
The observational studies have several flaws that limit their value in drawing conclusions 
which can be implemented clinically.  These observational studies do however offer insights 
into specific patient population’s, reflect real world cohorts, and test response criterion 
beyond absolute endpoints. A criticism of the major CRT RCTs and meta-analyses is that 
they deal with response in terms of absolute outcomes and don’t necessarily reflect those 
factors important to patients; e.g symptoms, exercise tolerance and QoL. Many of these 
observational studies do reproduce findings of other analyses. However, these findings are 
not reliably reproduced between different studies, resulting in a variety of variables being 
identified as potential predictos.  QRS duration and BBB morphology are the most important 
and consistently reported factors that predict response/outcomes.39 Additional factors like 
aetiology appear to be important as well in predicting response. Yet in spite of extensive 
investigation non-response has remained entrenched throughout the last two decades at 
20-40%.63 
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1.4 DEFINING CRT RESPONSE 
The consistent issue across all research examining CRT response is the variety of different 
definitions applied in the literature. This makes comparing and pooling data for comparison 
difficult due to the heterogeneity of the criterion used for response.1,19 Fonwalt et al1 
performed a seminal systematic review of the 26 most cited papers on predicting CRT 
response and extrapolated 17 different criterion (Table 1.4). Fifteen criteria were all applied 
to the PROSPECT trial cohort (2 criteria could not be calculated).1,52 The application of the 
different definitions demonstrated response varied between 32% and 91%.1,52 All 15 criteria 
were compared to each other to measure the amount of agreement between definitions 
(105 combinations).1 Overall 79 (75.2%) pairs of definitions had ‘poor agreement’.1 
Moreover, a strong association of agreement was only observed in 4 (3.8%) pairs of 
definitions. All echocardiographic and clinical definition combinations had a poor 
association.1 Bleeker et al69observed 76% agreement when applying a clinical (↓≥1 NYHA 
classification) and (↓>15% LVESV) to 144 consecutive patients undergoing CRT.69 These 
results suggested a better clinical and echocardiography definition agreement than Fornwalt 
et al1 had identified. Agreement was not tested in this analysis and the Bleeker et al69 study 
was included in the Fornwalt et al1 systematic review.  
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Agreement between the definitions is poor, even between similar categories of criteria.1 A 
definition for response is still required to define success of CRT implantation. The problem 
Table 1.4 Different CRT response definitions identified by Fornwalt et al  (Adapted1) 
 
Echocardiographic  Response criteria 
     1. ↑≥5% LVEF (absolute)70,71  
     2. ↑≥15% LVEF72,73 
     3. ↓ ≥10% LVESV and survived progressive HF by 6 months74,75 
     4. ↓>15% LVESV52,71,76-80 
     5. LVESV <115% of baseline81 
     6. ↓>15% LVESVI82  
     7. ↓>15% LVEDV71  
     8. ↑≥15% Stroke volume73,83,84  
Clinical Response Criteria 
     9. ↓≥1NYHA85-87  
    10. ↓≥1 NYHA & survived progressive CHF by 6 months88 
    11. ↓≥1 NYHA & ↑≥25% 6MWD89  
    12. ↓≥1 NYHA & ↑6MWD ≥25% &  survived  progressive HF by 6 months69,90 
    13. ↑>10% 6MWT & no heart transplant & survived by 6 months 64 
14. (↓≥1 NYHA or ↑>10%  peak V̇O2max or ↑>10% 6MWD)  & survived & no HF        
hospitalisation91 
    15. 2 out of 3:76 
        ↓≥1 NYHA  
        ↑≥50metres 6MWT  
        ↓≥15QOL  
    16. Clinical composite score improved52 
Combined Response Criteria 
    17. (↑≥5% LVEF [absolute] or ↑≥30 m 6MWT) &(↓≥1 NYHA or ↓≥10 QOL)92 
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continues to persist in current practice. Table 1.3 demonstrates this inconsistency in 
response definition application in observational studies over the last three years.66-68  
However, the combination of echocardiographic and clinical criterion to form a composite 
definition seem to have abated given the poor agreement between them.1,66-68 In defining a 
response criteria, as Fornwalt et al1 comments HF should be considered as a ‘debilitating 
life-threatening disease’ where an effective treatment must improve ‘symptoms, quality and 
duration of life’. An effective definition should reflect these elements. Packer et al93 in the 
seminal paper on HF composite scores, identified the pitfalls of using one individual metric 
to measure response, composite scores can minimise this problem. No universal response 
definition has yet to be agreed upon, however the consensus is a composite criterion is 
required. 93  
 
1.5 BIOMARKERS AND CARDIAC RESYNCHRONISATION THERAPY 
CHF is a heterogeneous condition, which develops as a result of cardiac injury from a variety 
of potential mechanisms. The development and progression of HFrEF leads to profound 
changes at the macroscopic and molecular level in the body. Adverse cardiac remodelling 
leads to neurohormonal activation, pro-inflammatory changes, extracellular matrix 
remodelling, myocardial stress leading to apoptosis and cardiac fibrosis.94 Unabated these 
processes contribute to the progression of adverse cardiac remodelling and poor outcomes 
from CHF. The identification of the alteration and progression of these processes has been 
observed through measuring related circulating biomarkers. Kimmenade94 summaries many 
biomarkers related to these processes that are associated with HF development, prognosis 
and outcomes. CRT is applicable to 25-30% of patients with CHF and ever more 
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implantations are occurring both globally and within the UK. Yet non-response remains an 
unchanging and expensive problem for patients and the National Health Service.15,18,59 Over 
the last 15 years circulating biomarkers have been studied to see if they may be potential 
predictors of CRT response. Figure 1.4 demonstrates the increasing studies in the literature 
looking as CRT and biomarkers.  
 
Figure 1.4 Number of publications on ‘CRT and biomarkers’ over 14 years. Search results 
from PubMed for ‘Biomarker AND Cardiac Resynchronization Therapy’  
 
1.5.1 Brain natriuretic Peptide 
Brain Natriuretic Peptide (BNP) and its derivative (NT-pro-BNP) are released from cardiac 
myocytes in response to myocardial stress in relation to volume and pressure overload.95 
BNP was the first target to study as a potential circulating biomarker given its role in HF 
diagnosis and prognostication.2 BNP has been demonstrated to alter following CRT. When 
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BNP levels decline it has been shown to be associated with reverse cardiac remodelling and 
improved outcomes.96-99 BNP decline has been considered to be a superior response 
definition that others previously used.100 Hoogslag et al100 observed that change in BNP was 
a reasonable definition of response and compared to other definitions used.   
 
The ability of baseline BNP to predict response has also been studied. Lellouche et al101 
performed a retrospective study on patients undergoing CRT and determined that a higher 
BNP at baseline was the strongest independent predictor of response. They determined that 
a BNP value >447 pg/ml demonstrated a sensitivity of 62% and specificity of 79% in 
identifying CRT response.101 However, Berger et al102 in a subgroup study of the CARE-HF 
trial identified that a lower median BNP at baseline was a predictor of better cardiovascular 
outcomes (sudden death and death from HF).102  
 
Natriuretic peptides have been shown to be highly related to the clinical outcome and CRT 
response.103 The challenge with the use of BNP and NT-pro-BNP is the high variability 
demonstrated in healthy patients and those with CHF.103 In healthy people, the sequential 
change in BNP and NT-pro-BNP has been observed to up to 92% and 168% respectively.104 
This observation was also seen in stable CHF patients with a week to week intra-individual 
coefficient up to 35%.105 This inherent individual variability is a challenge to BNP being a 
useful circulating biomarker of response.103  
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1.5.2 Growth Differentiation Factor-15  
Growth Differentiation Factor-15 (GDF-15) is a member of the growth factor-ß cytokine 
superfamily and is implicated in the regulation of cell survival, proliferation and 
differentiation.106 GDF-15 is also implicated in protection from ischaemia/ reperfusion 
injury.107,108 In acute coronary syndrome patients GDF-15 demonstrated an ability to predict 
future risk of developing HF.109 In the Valsartan Heart Failure (Val-HeFT)  Trial110 a raised 
GDF-15 was shown to be an independent predictor of poor HF outcomes, moreover it added  
prognostic value to other variables; NYHA, LVEF and NT-pro-BNP levels. The intra-individual 
variability of GDF-15 was been shown to be better than BNP/NT-pro-BNP.111  
 
Foley et al112 demonstrated in a single centre, prospective observation study, that GDF-15 is 
an independent predictor of mortality and morbidity in CHF patients (LVEF<35%) 
undergoing CRT.112 When added to NT-pro-BNP the predictive value was additive.112 
However Foley et al112 demonstrated that GDF-15 did not predict CRT response (survival & 
no HF hospitalisations; ↓>1 NYHA class or ↑>25% 6MWD at 1 year). GDF-15 was only 
powered to predict cardiovascular outcomes and not response.112  Furthermore Foley et 
al112 accounts for this result because of ‘very high biological variability of these analytes’. 
GDF-15 is reported to be better than BNP at predicting response, however questions still 
remain over its predictive valve. No more recent studies or trials have yet been performed 
on GDF-15 and should be considered in studies in the future. 
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1.6 EXTRACELLULAR CARDIAC MATRIX  
The cardiac extracellular matrix (ECM) is a dynamic support structure that remodels 
following cardiac injury.94,113 Progressive ECM remodelling is closely linked to the 
development of cardiac fibrosis.113 The cardiac ECM remodelling is closely associated with 
the development, severity and progression of HF.113 Biomarkers that highlight remodelling 
have been associated with HF outcomes.94,113   
 
1.6.1 Cardiac Extracellular Matrix Structure  
The heart consists of 30% myocardial cells and 70% non-myocardial support cells.114 These 
support cells include; endothelial cells, fibroblasts, vascular smooth muscle cells and 
macrophages. The most common non-myocardial cells are fibroblasts’, contributing 67% of 
the total. 114 These cells are critical to myocardial homeostasis. 114 Fibroblasts primary 
function is to maintain ECM homeostasis, including releasing signalling molecules, cytokines 
and growth factors.114,115 Fibroblasts are responsible for production of the collagens.116 
Diverse cell types adhere to the ECM including fibroblasts, myocytes and endothelial 
cells.114,115 The main structural protein is type I collagen but also includes type III, IV, V, VI, 
glycoproteins and proteoglycans.115 Type I has high tensile strength and type III provides 
greater distensibility.116 Figure 1.5 demonstrates the cardiac ECM in the myocyte bundle 
and the interaction with the cardiomyocyte cell membrane. 
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Figure 1.5 The Cardiac Extracellular Matrix. Cardiomyocytes arrange in a ‘myocyte bundle’ 
and the presence of the non-myocardial support cells and extracellular matrix (A) and a 
zoomed image of the cell membrane and the structures of the Cardiac ECM (B). 
 
1.6.2 Extracellular Cardiac Matrix Function 
The cardiac ECM facilitates enough force transduction to performed the mechanical work  of 
the myocardium, alongside facilitation of intracellular communication and metabolism.117 
Structurally myocyte bundles and collagen fibres are uniquely distributed in the 
myocardium (Figure 1.5).117 Myocyte bundles are grouped into sheets. The orientation of 
the myocyte bundles differs within the myocardium. The collagen fibres connect to 
individual myocytes and adjacent sheets.117 Figure 1.6 demonstrated the structural 
relationship of myocytes and collagen fibres in the LV.117 
 
A B
A 
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Figure 1.6 Normal 3-dimensional representation of cardiac microstructure. A 
representative transmural block taken from the ventricular wall (A) shows myofiber 
orientation which varies transmurally. Myocyte bundles are organized in sheets (B). Fibrillar 
collagens are seen interconnecting individual myocytes as well as adjacent sheets. Adapted 
from Ai-Hsien Li et al. Circ Res. 2014117   
 
1.6.3 Cardiac Extracellular Matrix and Heart Failure 
The cardiac ECM is a dynamic support structure that remodels following cardiac injury and 
HF.94,113  ECM holds core roles in force transmission and alignment of myocardial fascicles 
(Figure 1.6) and provides substrate for the adhesion of myocytes.113 Alteration in cardiac 
ECM turnover can impact cardiac structure and function directly. Loss of ECM can impact 
000transduction of contractile force and change intracellular signalling of myocytes, which 
will change ventricular systolic function.113 Accumulation of ECM can affect the myocardial 
passive stiffness properties, which will directly impact diastolic ventricular function.113 In 
many pathophysiological situations following cardiac injury significant heterogeneity in ECM 
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remodelling can occur, where loss of ECM can also be accompanied by excessive 
accumulation leading to both ventricular systolic and diastolic impairment.113 Cardiac ECM 
remodelling is closely related to adverse cardiac remodelling that occurs in HFrEF.94,113 
Progression remodelling is linked with severity and prognosis of HF.94,113 Myocardial 
hypertrophy and overloaded hearts demonstrate alterations in collagen synthesis and 
degradation, which is linked to cardiac fibrosis and myocardial stiffness.118-120 Development 
of cardiac fibrosis following ECM remodelling is linked to poor outcomes in HF.121,122  
 
1.6.4 Collagen Turnover Biomarkers 
Cardiac collagen turnover alterations are central to the development and progression of 
cardiac fibrosis and HF.113 Collagenous cardiac ECM had been demonstrated to have a 
particular high turnover rate and this has been linked to diastolic stiffness.115 Collagen 
turnover has the potential to generate biomarkers’ of the pathophysiological ECM 
remodelling processes. Specific biomarkers of type I and type III collagen synthesis (N-
terminal propeptides of type I and III procollagens (PINP and PIIINP)),123,124 (carboxy-
terminal propeptide of procollagen type I (PICP))125,126 and degradation (carboxy-terminal 
telopeptide of type I collagen (ICTP or CITP))119,126 products are associated with poor 
outcomes in HF. PINP and PICP markers have a stoichiometric 1:1 relationship upon 
deposition of type I collagen.127 These markers offer the opportunity to examine cardiac 
ECM collagenous turnover in cardiac remodelling. Collagen turnover turnover biomarkers 
pose interesting predictors for CRT response. Chapter 4 explores the current evidence 
through a systematic review to examine collagen biomarkers ability to predict CRT response 
in CHF. 
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There is a high amount of pre-analytical variation in collagen turnover biomarkers within 
and between subjects that should be accounted for and controlled where possible.128,129 
Collagen is an extracellular matrix protein found in all body tissues. Factors that particularly 
influence variability are age, gender, menopause, medication (e.g. anti-epileptics, 
bisphosphonates, steroids), fractures, bone pathology (osteoporosis), circadian rhythm, 
fasting and exercise.128,129 The menopause has a large change on bone matrix turnover to 
the point that a different reference range is used for these patients.128 Important 
controllable factors for collagen turnover biomarker variation are identified as the circadian 
rhythm, fasting and exercise. These factors should be accounted for study designs.128,129 The 
other unmodifiable factors cannot be changed or planned around at a patient level and 
should be accounted for in the research design. 
 
1.6.5 Matrix Metalloprotineases 
The proteolytic enzyme system matrix metalloproteinases (MMPs) and their regulators 
tissue inhibitors of MMPs (TIMPs) are the main process by which collagen degradation is 
controlled. In normal physiological conditions, there is a balance between MMPs that 
degrade cardiac ECM components and TIMPs.115 These proteases when an imbalance 
develops are linked to fibrotic diseases, cancer and cardiovascular disease115,122,130,131. In the 
heart the collagenase MMP-1 degrades structural collagens and gelatinases (MMP-2 and -9) 
degrade basement-membrane components and gelatins.116 MMPs are secreted by a variety 
of cardiac cell types, including myocytes in an inactive form. Activation occurs by cleavage of 
the propeptide sequence, this can happen through several endogenous pathways including 
the urokinase/plasminogen cascade.116 MMPs are also regulated at the transcriptional level, 
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by cytokines and growth factors. Neurohormonal systems have also been implicated as 
activators.116 TIMPs are the counterbalance to this, the proteolytic enzyme system.116 MMP 
activity (as opposed to expression level) has been linked to a large spectre of cardiovascular 
disease including atherosclerosis, aneurysms, myocarditis, hypertension and HF.113,115,132,133 
MMPs and TIMPs have been implicated in HF development and progression.94,113 
Specifically, MMP-1,134 MMP-2135 and MMP-9136 and TIMP-1134 are associated with HF 
outcomes. Alteration in MMP expression has been observed in small observational studies 
to reduce expression following CRT implantation in the short term.132,137 MMPs and TIMPs 
pose interesting targets as biomarkers for CRT response predictors. Chapter 2 explores the 
current evidence for MMPs and TIMPs ability to predict CRT response on CHF. Caution in 
interpretation must be demonstrated though at there are variations between the levels of 
expression between the literature113,132,134 and other conditions can affect vascular MMP 
expression.130 
 
1.6.6 Galnectin-3 
Galectin-3 (Gal-3) is a beta-galactoside-binding lectin released by activated cardiac 
macrophages, which are up-regulated in HF, causing increased fibroblast proliferation, 
collagen deposition and ventricular dysfunction.138 Gal-3’ is strongly associated with 
inflammation and fibrosis with raised levels strongly predict poor HF outcomes.138  
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3.1 MiRNA 
Micro Ribonucleic Acids (MiRNA) are short endogenous non-coding ribonucleic acids which 
are typically 20-22 nucleotides in length and there are in excess of 2000 in humans.139,140 
MiRNA were discovered in 1993 and found in humans at the turn of the century.139 Figure 
1.7 schematically describes the transcription of miRNA from the genome into mature miRNA 
that regulate protein expression at the post transcriptional level.139 Mature miRNA at the 
end of the transcription process enter RNA-induced silencing complexes (RISC) by 
associating with Argonaute proteins.139,141 MiRNA inhibit protein translation and/or 
promote messenger ribonucleic acids (mRNA) degradation by specific targeting of the RISC 
to mRNA(s) (Figure 1.8).142 Importantly, miRNA are now being recognised as key regulators 
of complex biological systems.139 Fundamentally this is due to a single miRNA having the 
ability to regulate the expression of several genes.139 This characteristic is dependent on the 
specificity of the target sequence.139 Conversely, individual genes can be regulated by 
multiple miRNAs.139  
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Figure 1.7 Biogenesis of miRNA. The miRNA genes are transcribed by RNA polymerase II 
(RNA-Pol-II) into molecules called primary miRNAs (pri-miRNAs). Inside the nucleus, these 
are cleaved into precursor miRNAs (pre-miRNAs) by an RNase III enzyme (Drosha), in 
conjunction with RNA-binding protein (DGCR8). Pre-miRNAs have a hairpin structure and 
are approximately 60–100 nucleotides in length. An alternative processing pathway of 
miRNAs exists, which bypasses the Drosha step and involves direct splicing of introns to 
create pre-miRNAs (represented by the dashed arrow), these are known as mirtrons. Both 
pre-miRNAs and mirtrons are actively transported to the cytoplasm by the Ran-GTP 
dependent transporter (Exportin 5). Once in the cytoplasm, pre-miRNAs are cleaved by 
RNase III (Dicer) generating a miRNA duplex (20-22 nucleotides) consisting of a functional 
(guide) and passenger. Dicer initiates formation of the RISC, involving the unwinding of the 
miRNA duplex and shedding of the passenger strand which is degraded. The RISC contains 
the mature miRNA, which can target mRNA. Depending on the extent of complementarity, 
the mRNA either gets degraded, or its translation is repressed. Taken from Romaine S et al. 
Heart 2015139 
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Figure 1.8 MiRNA Mechanisms of Action . Synthesis of a specific protein starts with mRNA 
being transcribed from DNA (transcription). When no miRNA is present, the mRNA 
transcripts are converted into protein (translation) (A). When miRNA with partial or near-
perfect complementarity to the mRNA binds to the 30 untranslated region (UTR) it 
represses translation, which inhibits protein synthesis (B). When miRNA with perfect 
complementarity to the mRNA binds to the 30 UTR, it inhibits protein synthesis by inducing 
of mRNA degradation (C). In humans, perfect complementarity is rare, with varying degrees 
of partial complementarity the predominant situation. Taken from Romaine S et al. Heart 
2015139 
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1.8 CIRCULATING MiRNA  
Mitchell et al,143 in their seminal paper, observed endogenous miRNA were present in 
human plasma and remarkably stable in the circulation. Stability was demonstrated by 
Mitchell et al143 at room temperature and repeated freeze-thaw cycles. Resistance of 
circulating endogenous miRNA to RNAase activity was demonstrated, compared to 
exogenous synthetic miRNA that were degraded rapidly.144 Circulating ‘naked’ miRNA are 
susceptible to rapid degradation, however miRNA residing in microvesicles (exosomes, 
microparticles and apoptotic bodies) remain protected.141,144 A non-vesicle source of 
circulating miRNA is suggested following their detection after microvesicles isolation and 
subsequent high-speed centrifugation of plasma.141,145,146  MiRNAs are also highly expressed 
in platelets.147  
 
Circulating miRNA’s represent exciting potential biomarkers for disease, given the 
limitations of other circulating biomarkers, especially the intra and inter individual 
variability. MiRNA are ideal biomarkers as they are easily accessible, relatively stable and in 
many instances tissue specific.141 Circulating miRNA offer new potential biomarkers that 
may increase diagnostic yield, strengthen current risk stratification and deepen 
understanding of current biological/pathological processes.  
 
1.9 MiRNA AND CARDIOVASCULAR DISEASE 
MiRNA have emerged as having important mechanisms in human diseases including 
cardiovascular disease, diabetes and cancer.142 Circulating miRNA have been observed to 
have altered expression in many different cardiovascular conditions compared to healthy 
patients.148-151 Van Rooij et al152 was the first to observe differentially expressed miRNA in 
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cardiac hypertrophy and HF in mouse models. Van Rooij et al152 amongst the altered 
expression identified miR-195 was shown to promote cardiomyocyte hypertrophy and lead 
to HF.  
 
Atherosclerosis is a multifaceted and complex pathology that is associated with multiple 
miRNAs altering expression.139 Specific miRNAs have been shown to be associated with this 
process; miR-126-5p is associated with endothelial cell dysfunction due to reduced 
proliferation reserve promoting plaque formation,153 and miR-143/145 complex is key 
regulator of vascular smooth muscle differentiation and is implicated in plaque formation.154  
 
MiRNA differential expression has been observed in patients undergoing acute coronary 
syndrome events. MiR-1,155,156 miR-208, 157 miR-133a155 and miR-499158 have been shown to 
be elevated in patients with acute MIs. Devaux et al159 in a large (n=1,155) multicentre 
prospective observational study of unselected acute chest pain patients attending hospital 
identified significantly higher expression of miR-208b, miR-499 and miR-320a in those 
having acute MIs.159 However, no miRNA demonstrated diagnostic superiority over cardiac 
troponin or high sensitivity troponin (hs-TnT).  Zampetaki et al160 identified in a large 
prospective observational study (n=826) that differential co-expression of endothelium-
enriched miR-126 was associated with long-term risk of MIs.  
 
1.10 MiRNA AND CARDIAC REMODELLING 
Cardiac remodelling allows the heart to adapt to adverse stresses and injury. These adaption 
mechanisms allow remodelling to occur, which preserves cardiac output. These mechaisms 
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include but are not limited to; neurohormonal activation, pro-inflammatory changes, ECM 
turnover alteration and angiogenesis.139,161 Chronic activation of these molecular 
mechanisms can become maladaptation and contribute to the development and 
progression of adverse cardiac remodelling.161,162 MiRNAs hold a critical role in 
cardiovascular complex regulatory systems. Many different miRNAs are involved in 
regulatory roles of different molecular processes of cardiac homeostasis. Dysregulation of 
specific miRNAs have being observed in several cardiovascular conditions (as previously 
discussed). These processes when chronically activated aide the development and 
progression of HF.139 Specific miRNAs dysregulation has been implicated in the alteration of 
these molecular mechanisms and contribute to the pathological development of HF.161  
 
1.10.1 MiR-1 
MiR-1 was the first miRNA discovered in a mouse heart.163 It accounts for approximately 
40% of all miRNA transcripts in the mouse cell.163,164  MiR-1 has been demonstrated to be 
predominantly expressed by cardiomyocytes.165 Sayed et al166 was the first to identify a role 
for miR-1 in cardiac hypertrophy, observing in a mouse transverse aortic constriction model 
that it was down-regulated. Several targets have been shown to be down-regulated by miR-
1; MEF2a, calmoudulin, GATA4, insulin-like growth factor and twinfillin, which causes 
cardiac hypertrophy.164,167-169 Recently it has been demonstrated that adenoviral delivery of 
miR-1 to mice with transverse aortic constriction actually reversed hypertrophy, improved 
fractional shortening, reversed LV dilation and decreased fibrosis.164,170  Mechanistically 
lower miR-1 expression has been observed to be associated with the development of 
cardiac hypertrophy. 
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1.10.2 MiR-21 
Several miRNAs have been implicated in the regulation and development of fibrosis 161 MiR-
21 is highly expressed in cardiac fibroblasts compared to other cardiac specific cells in the 
failing heart of both humans and mice. 161,171 Roy et al172 first observed the miR-21 was 
upregulated in murine hearts in the infarct zone following ischaemia-reperfusion models. 
MiR-21 regulates fibrobast proliferation and survival.161 MiR-21 levels decrease apoptosis 
through inhibiting sprouty homolog-1 (SPRY1), which subsequently activates the ECM  
signal-related kinase mitogen-activated protein kinase (ERK-MAPK) enhancing the survival of 
cardiac fibroblasts.171 This mechanism contributes to the induction of cardiac hypertrophy. 
These reports are supported by observations in a study where cholesterol-conjugated 
inhibitor of miR-21 (antagomiR-21) was administered in-vivo to mice models of cardiac 
hypertrophy (transverse aortic constriction or administration of isoproterenol) and found it 
limited the fibrotic response and improved overall cardiac function.  
 
Recently in humans, the relevance of miR-21 was demonstrated in aortic stenosis patients 
undergoing surgical correction showing that levels were raised before but not after surgery 
and levels correlated with myocardial collagen.173 However, the exact action of miR-21 
remains unclear with opposing observations for the role and function of miR-21 being 
reported.174 MiR-21 expression has been observed to decrease following an MI and over 
expression can reduce the size of the infarct.175 MiR-21 is one of the most cardiac abundant 
miRNAs and demonstrates dysregulation in association with the development and 
progression of cardiac fibrosis. However, the exact behaviour remains unclear and there is 
limited information available on its clinical utility.  
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1.10.3 MiR-29 
The miR-29 family are secreted selectively by cardiac fibroblasts and target mRNAs involved 
in extracellular matrix deposition.161 In a mouse model of an induced MI, down-regulation of 
miR-29 was observed within the border zone, compared to the non-infarcted areas in the 
same heart.176 MiR-29 has been demonstrated to target genes of proteins involved in 
remodelling and fibrosis including elastin, fibrillin-1, collagens type I and III.176 Down-
regulation of miR29 is observed to induce the fibrosis processes.176 Introduction of anti-miRs 
in vitro and in vivo induces the expression of collagens, whereas over-expression of miR-29 
in fibroblasts reduces collagen expression.176  MiR-29 has also been implicated in myoblast 
transdifferation into myofibroblasts, matching its role to tissue fibrosis.177 The evidence 
suggests that miR-29 has a central role in the regulation of cardiac fibrosis and 
downregulation can exhibit deleterious effects.176 
 
1.10.4 MiR-122 
MiR-122 is thought to be liver specific and has been shown to be involved in glucose and 
lipid metabolism.178 Moreover, miR-122 has previously been demonstrated to be less 
abundant in the myocardium than the liver.179 The role of miR-122 in the myocardium has 
been shown recently to have a potentially important role in cardiac fibrosis regulation. 
Beaumont et al180 demonstrated miR-122 is down-regulated in myocardial biopsies from 
patients (n=28) with severe aortic stenosis. Futhermore, Beaumont et al180 demonstrated 
that miR-122 down-regulation is associated with over-expression of transforming growth 
factor-ß1 (TGF-ß1), which leads to extracellular synthesis and deposition of type I collagen 
(producing PINP and PICP). TGF-ß1 is considered as the cardiac fibrosis master switch and 
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had been observed to be regulated directly by miR-133 and -590.180 MiR-122 may have an 
important role in cardiac fibrosis and cardiac remodelling. The association seen in aortic 
stenosis has not been observed in other cardiovascular conditions. Moreover caution with 
interpretation of miR-122 should be taken as it is specific to the liver.  
 
1.10.5 MiR-133  
MiR-133 is one the most abundant circulating miRNAs in the human myocardium 161,164 
There are 3 related miRNA; miR-133a-1,-133a-2,-133b. Mechanistically miR-133 may 
supress connective tissue growth factor, which is an important protein in the development 
of fibrosis.181 The critical role of miR-133 in the development of cardiac fibrosis was 
demonstrated by the deletion of miR-133a-1 and -133a-2 in knockout mice leading to severe 
fibrosis.182 Further mechanistic studies have also demonstrated that higher expression of 
miR-133 is cardioprotective against the development and progression of fibrosis.161 Lower 
expression of miR-133 appears to have a role in the development of cardiac fibrosis.  
 
MiR-133 has also been described as being associated in the development of cardiac 
hypertrophy. 183 Down regulation of miR-133 has been observed in cardiac hypertrophy 
murine models (transverse aortic constriction).183 The down regulation of miR-133 was 
observed to correlate with increased LV wall stress.183  MiR-133 has also be shown to target 
central regulators of cardiac hypertrophy (NFATc-4 and calcineurin)184 and prohypertrophic 
mitogen-activated protein kinase pathways.175These results suggest that downregulation of 
miR-133 may be harmful and overexpression may offer cardioprotection.164 The relationship 
of expression of miR-133 is far more complicated and tends to be related to the exact 
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context of the dysregulation to the exact phenotypic implications. In murine models it often 
depends on the exact cardiac hypertrophy induction method utilised.164  
 
1.10.6 MiR-210 
MiR-210 is known to have a pro-angiogenic function on cardiomycytes, stimulating the 
release of leptin, interleukin-1-a and tumour necrosis factor alpha.161,185 Mechanistically 
miR-210 was observed when over-expressed in a mouse model (induced MI) to increase 
capillary formation, decrease apoptosis and minimise the size of the infarct.161 MiR-210 is 
also known to be induced in hypoxic conditions, specifically by hypoxia-inducible factor 1ɑ  
and cause angiogenesis.186 Interestingly, on this basis, miR-210 has been theorised as a 
biomarker for HF. A recent observation was made that supported this hypothesis and that 
there was a negative correlation between high BNP levels and lower expression of miR-
210.149 
 
1.11 MiRNA AND HEART FAILURE    
Differential expression of miRNAs has been repeatedly demonstrated in HF.139 Figure 1.9 
summaries the circulating miRNAs that have been found to be differentially expressed in HF, 
the double border boxes demonstrated miRNAs that have had replicated in separate 
studies. Many of the studies have been performed on smaller cohorts and with varying 
quantification techniques.139  
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Figure 1.9 Circulating miRNA associated with Heart Failure. Taken from Romaine S et al. 
Heart 2015139 
 
HF was initially explored as part of wider miRNA cardiovascular studies. Corsten et al158 
performed a small parallel case-control cross-sectional observation studies for four 
cardiovascular disease conditions (acute MI, viral myocarditis, diastolic dysfunction, acute 
HF) and examined a panel of miRNA tailored to each specific condition, using real time 
polymerase chain reaction (PCR). In the acute HF study 33 patients were compared to 34 
healthy controls (not-matched) and had expression measured for six candidate circulating 
miRNAs (miR-1, -122, -133a, -208b, -223, and -499).158 In the acute HF patients, miR-122 
(p<0.05) and miR-499 (p<0.05) were found to have significant up-regulation compared to 
healthy controls.158 MiR-122 is liver-specific and correlates with hepatic damage,187 with the 
up-regulation likely being related to venous congestion.158  This was a small explorative 
study, which was hypothesis generating only. The study undertakes several analyses in an 
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unmatched study design. Moreover the acute HF definition was based upon NT-pro-BNP 
level only, no account of cardiac structure or function was undertaken.158 This study has 
limited value beyond hypothesis generation. 
 
Studies recently have started to focus exclusively on HF cohorts to analyse different 
circulating miRNA expression patterns and whether they may have clinical value. In one of 
the earliest HF and miRNA studies Tijsen et al188 performed a small discovery and  validation 
study. The discovery phase analysed miRNA expression between 12 healthy controls and 12 
patients admitted to hospital with acute HF. A microarray quantification approach was 
utilised and they identified 108 differentially expressed miRNAs.188 Sixteen miRNA with the 
largest fold-change were selected to be tested in the validation phase, in three distinct 
patient groups (30 HF, 20 breathless without HF and 39 healthy controls) using real time 
PCR.188 Seven miRNAs (miR-18b*,-129–5p,-423-5p,-622,-675,-1254 and HS_202.1) were 
observed to be significantly up-regulated in the HF group compared to the healthy controls, 
however only miR-18b* and miR-423-5p had significant up-regulation when compared to 
the non-HF dyspnoea group.188 Only miR-423-5p was found to be a significant predictor in a 
multivariable logistic regression model of acute HF.188 Mir-423-5p also strongly correlated 
with NT-pro-BNP and LVEF.164,188 Although a potentially useful observation, the study has 
limited clinical value. First the study should only be considered exploratory given its size (HF 
n=42).188 Secondly the HF characteristics make generalising these results difficult, the HF 
group included reduced and preserved ejection fraction patients, but only those with non-
ischaemic aetiology. Thirdly a high proportion of the HF group study group were 
undertreated with OMT.188  
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Fan et al189  recently undertook a small cross-sectional study of 45 dilated cardiomyopathy 
patients and 39 sex-matched controls to examine the differential expression of five 
candidate miRNAs (miR-126,-146a,-155,-361-5p and-423-5p). MiR-423-5p was 
demonstrated to have higher expression in dilated cardiomyopathy patients (p=0.003) and a 
positive correlation with NT-pro-BNP (r=0.430, p=0.003).189 Furthermore miR-423-5p 
demonstrated a moderate ability to discriminate between dilated cardiomyopathy patients 
and healthy controls (area under the curve (AUC) ROC 0.67).189 The results from Fan et al189 
support the initial findings from Tijsen et al,188 however this was only a small exploratory 
study. Bauters et al190 in a larger prospective observational study (n=246) of patients with 
anterior MIs. Candidate miRNAs (miR-133a and -423-5p) were compared to recorded 
echocardiography and NT-pro-BNP over 12 months.190 It was observed miR-133a and miR-
423-5p were significantly raised following an anterior MI over the next year but these 
findings of Bauters et al190 did not correlate with LV geometric features or NT-pro-BNP.190 
Bauters et al190 conducted a larger clinical study, which allows more weight to be put upon 
its findings, however the results cannot be compared to Tijsen et al188and Fan et al189  due 
to the different aetiologies of HF involved.  
 
More recently Vogel et al191 undertook a case-control study with a discovery (microarray) 
and a subsequent validation experiment (real time PCR) examining miRNA differential 
expression in non-ischaemic HFrEF patients compared to healthy controls. MiR-200b, miR-
622, and miR-1228 demonstrated significant up-regulation in HFrEF patients in both 
experiments. 191 Interestingly Vogel et al191 demonstrated miR423-5p was up-regulated but 
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did not reach statistical significance, contradicting Tijsen et al.188 Vogel et al191 also 
demonstrated alteration in expression of circulating miRNA within serum and different cell 
types. This article goes some way to overcoming the limitations of Tijsen et al.188 focusing on 
a specific group of HF patients, minimising heterogeneity in the study cohort.191 The study 
however should still be considered as explorative as the cohort is small (HF n=53).191 
 
Circulating miR-210 is known to be induced by hypoxia and theoretically was queried to be 
biomarkers for HF. Endo et al149 observed in an animal model that Dahl rats with HF had up-
regulation of miR-210 in mononuclear cells and skeletal muscle. MiR-210 was examined in 
two small human cohorts with HF (classified by NYHA only); one cohort had mononuclear 
cell derived miR-210 expression compared between 13 HF and 6 healthy controls, which 
showed significant up-regulation in NYHA III/IV patients compared to controls/NYHA II. The 
second cohort involved 39 HF patients having plasma samples taken and 24 of these 
patients having repeat samples taken at least 3 months after and this observation showing 
there was no correlation with BNP, but those patients that improved (lowering BNP) had 
lower initial miR-210.149 The study is a translational study that highlights miR-210 as a 
potential biomarker for HF, however very limited clinical information can be provided by 
this study.  
 
Recently, Goren et al192 in a case-control cross sectional study analysed 186 circulating 
miRNAs in 30 HFrEF (LVEF<40% without coronary disease) against 30 age-sex matched 
controls. Goren et al192 demonstrated miR-423-5p, miR-320a, miR-22, and miR-92b had 
significant up-regulation compared to controls and a combination score of these 4 miRNAs 
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could discriminant non-ischaemia HF cases. However, this is the first and only time this 
score has been applied to a very small cohort, it requires validation. Furthermore the 
majority of the HF cohort were on OMT and 53% had a complex cardiac device. 192 None of 
the controls had a complex cardiac device or were on OMT.192 Up-regulation could be 
related to these confounding treatment.192 These results should are exploratory and 
therefore of limited clinical value. However the miR-423-5p observation replicates the Tijsen 
et al188and Fan et al189 findings.   
 
MiRNAs have also recently been examined as to whether specific miRNA expression 
signatures can differentiate HFrEF from HF with preserved ejection fraction (HFpEF). Two 
studies in 2015 examined this question and provided contrasting answers. Watson et al193 
undertook a discovery and validation study on three groups of patients (90 HFrEF, 90 HFpEF, 
90 controls). The discovery phase quantified 745 miRNAs with a microarray in 15 pooled 
plasma samples from each cohort.193 Five miRNA (miR-30c, −146a, −221, −328, and −375) 
demonstrated differential expression between both  HF vs controls and HFrEF vs HFpEF.193 
The validation phase specifically quantified those five miRNAs with PCR in the remaining 
participants from each group.193  These five circulating miRNAs showed no greater 
discriminatory power than BNP for HF or non-HF.193 MiR-375 showed  the greatest ability to 
differentiate HFrEF vs HFpEF.193 A prediction model including BNP, miR-30c, miR-221, miR-
328, and miR-375, produced the greatest ability to differentiate HFrEF vs HFpEF (AUC 
0.854).193 In contrast Wong et al194 identified different miRNAs expression patterns between 
HF vs non-HF and HFrEF vs HFpEF. Wong et al194 studied three small groups (69 HFrEF,49 
HFpEF and 58 non-HF) in a cross sectional discovery and validation study to examine for 
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differences in miRNA expression profiles.194 A microarray was used to screen miRNAs in the 
discovery phase and then specific miRNAs were validated with quantitative PCR.194 Wong et 
al194screened 806 miRNAs in the discovery phase, of which 90 had statistical significant 
different expression to meet criteria to be tested in the validation phase.194 Twelve miRNAs 
(miR-125a-5p, -183-3p, -190a, -193b-3p, -193-5p, -211-5p, -494, -545–5p,-550a-5p, -638, -
671–5p and -1233) were found to have significant differential expression between HF vs 
non-HF controls and/or HFREF vs HFPEF in both blood and plasma.194 MiR-125a-5p, -190a, -
550a-5p and -638 were significantly different between HFrEF vs HFpEF.194 Moreover miR-
183-3p, -190a, -193b-3p, -193b-5p,-211-5p, -494, -671-5p, and -1233 were found to 
differentiate between HF vs non-HF.194 MiRNA panels for HF and HFrEF were identified as 
having discrimination power greater than NT-pro-BNP.194 Interestingly Wong et al194 did not 
observe any difference in expression for miR-423-5p between HF vs non-HF. A criticism of 
Watson et al193 in the literature was that only one reading was taken from pooled samples 
in each cohort on the microarray, likely leading to some miRNA not being detected and 
outliers of others affecting the recorded expression.195 This may partly account for the 
complete contrast in miRNA observed to be predictors in the two studies.193,194 
 
Heart Failure and HFrEF in particular has had a variety of differential miRNA signatures 
demonstrated to healthy patients. In many studies these miRNA either individually or as 
part of a panel have demonstrated the ability to diagnose or prognosticate. The challenge 
remains that these are often small discovery and validation studies that cannot be applied 
clinically. They often demonstrate heterogeneity between cohorts or mRNA analytical 
techniques. MiRNA biomarkers are often not replicated consistently. MiRNA has an 
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important role in the development of adverse cardiac remodelling in HF, but a specific 
biomarker has not yet been validated. 
 
1.12 MiRNA AND CARDIAC RESYNCHRONISATION THERAPY 
Multiple miRNAs have been observed to be dysregulated and implicated in the development 
and progression of HF. The evidence remains limited due to the principle research being 
basic science and small cross section cohort studies. Based upon observations, the 
hypothesis was generated that miRNAs might be able to predict CRT response and 
outcomes. 
 
Recently Ning et al196 performed the first study examining miRNA and CRT. Ning et al196 
undertook an animal study comparing four groups of rabbits (10 in each group) and induced 
HF in three groups (by ascending aorta cerclage constriction). Two groups were paced with 
biventricular or LV alone; the third group had a sham procedure.196 Twelve weeks after the 
procedure had been performed pacing was performed for six hours a day for seven days. 
Following this period of pacing LVIDD decreased and LVEF increased significantly.196 Plasma 
was taken to measure circulating miR-133 and was found to have significantly lower 
expression in the HF sham group compared to the control. Both pacing groups had 
significantly higher expression than HF sham group. The biventricular pacing group had the 
greatest rise in expression (p<0.05). These findings support the observations miR-133 is 
cardioprotective in HF.161,181,182 Ning et al196 performed an animal study and therefore it can 
only be hypothesis generating; miR-133 up-regulation is increased with biventricular 
pacing.196  
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Simultaneously Marfella et al197 published their prospective observational, non-randomised, 
self-control study on miRNA expression in HFrEF patients before and after CRT 
implantations. All consecutive patients (NYHA III/IV, sinus rhythm QRS>120msec, OMT>6 
months and LVEF<35%) scheduled for CRT (153 patients) between January 2009 and August 
2011 were screened and 81 subjects (HF cohort) were recruited in three Italian centres.197 A 
test (15 healthy volunteers) and validation (60 controls - age, sex and co-morbidity 
matched) cohorts were recruited to compared HF miRNA expression too.197 The use of a 
healthy control cohort is an interesting one as they are not matched in any way to the HF 
group. The HF cohort underwent functional (6MWT) and transthoracic echocardiography 
assessment at baseline and 12 months follow-up.197 The 6MWT performed was not 
performed in the standardised fashion as per the American Thoracic Society guidance.102 
CRT response status was defined by degree of LV reverse remodelling (↓>10% LVESVi and 
↑>10% LVEF and no heart transplant).197 There were 55 (67.9%) responders and 26 (32.1%) 
non-responders. 197 There were four mortalities in the observation period that were 
excluded following CRT implantation, inferring a bias towards selecting healthier HF patients 
and not accounting for those that had died. 197  
 
A microarray was utilised to screen 84 miRNA pre-selected for their reported association 
with structural heart disease.197 Marfella et al197 observed the HF group had 49 down-
regulated miRNAs compared to healthy controls and 24 miRNAs compared to the validation 
cohort (all p<0.05).197 Baseline expression of five circulating miRNA’s (miR-26b-5p,-29a-3p,-
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30e-5p,-92a-3p and -145-5p) in HF patients directly and indirectly correlated with LVEF and 
NT-pro-BNP.197 Furthermore these 5 miRNAs demonstrated a high AUC (>0.83) in 
differentiating HF cases from non-HF.197 Baseline expression of all circulating miRNA showed 
no statistically significant difference between RvsNR.197  Following one year, responders had 
19 miRNAs significantly (p<0.01) up-regulated (15 miRNA had >5-fold-change increase) and 
non-responders had 6 miRNAs significantly up-regulated from baseline (from the 24 
identified from comparison with the validation cohort).197 Figure 1.10 shows that five 
miRNAs all showed up-regulation regardless of response status, however it was significantly 
higher (p<0.001) for responders.197 All these five miRNA have known mechanistic roles in 
maladaptive molecular processes; hypertrophy (miR-26b-5p and -30e-5p), fibrosis (miR-29a-
3p and miR-92a) and apoptosis (miR-145).197 Interestingly miR-885-5p was observed to be 
up-regulated in non-responders, but no change in responders.197 The changes in expression 
over 1 year for these five miRNA correlate with LVEF and NT-pro-BNP.197  
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Figure 1.10 MiRNA Expression Profiles for Responders vs. Non-Responders after one year 
of CRT. MiRNA listed are those that demonstrated a significant difference between RvsNR in 
fold change over one year observation. Panel A gives miRNA expression (arbitrary units=AU) 
after one year of CRT. Panel B provides a Table describing the degree of miRNA fold 
regulation from baseline to one year following CRT and its specific significance. *p<0.01 
responders vs non-responders. Taken from Marfella et al. EHJ. 2013197. 
 
Marfella et al197 examined several miRNAs involved in regulated maladaptive molecular 
processes implicated in adverse cardiac remodelling in HFrEF. Marfella et al197 
demonstrated altered expression of important miRNAs known to be implicated in several 
maladaptive processes in HF and furthermore demonstrated an association with LV 
echocardiographic and neurohormonal variables that are known to improve following CRT 
implantation. Moreover, variation is seen between responders and non-responders at 
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follow-up identifying alteration in the molecular processes. However, no difference between 
these miRNAs were demonstrated between responders and non-responders baseline (pre-
implant) levels, offering no predictive value for any of these biomarkers.  
 
There are several limitations of Marfella et al197 that need to be considered. Firstly this was 
a small cohort study that lacked power to support their observations. Secondly, the miRNA 
quantification method should be acknowledged as not being the gold standard. Thirdly, the 
healthy control comparison cohort was not age-sex matched, therefore the high number of 
miRNAs expression demonstrated is understandable and accountable by potentially 
multiple physiological processes.198 These limitations do challenge the use of this paper in 
the wider literature to miRNAs as predictors of CRT response. 
 
More recently Melman et al199 moved the debate on about altered miRNA expression 
profiles in HFrEF patients undergoing CRT implantation with the publication of their 
translational study. Melman et al199 performed an exploratory discovery and validation 
prospective cohort study on differential miRNA expression in 52 HFrEF patients referred for 
CRT implantation (NYHA II-IV, LVEF<35%, QRS>120msec and LBBB/RV paced) between 
responders and non-responders. Response was defined as an increase LVEF >10% at six 
months on transthoracic echocardiography for the validation phase.199 A major limitation of 
the methodology is concerned with the performance of the transthoracic echocardiography; 
only a single plane was used to calculate LVEF, this does not meet the internationally 
accepted national standard200 The standard is to perform Simpson’s biplane assessment for 
Dr Christopher J. McAloon 
 
91 
 
 
LV ejection fraction (Chapter 5.5).201  Aside from not meeting the national echocardiography 
standard it makes comparisons between different studies that measure LV geometry 
unreliable.  
 
The discovery phase was performed on 12 select patients; 6 responders with the greatest 
LVEF increase and 6 non-responders with no change/decline.199 All the participants in the 
discovery phase were men with non-ischaemic cardiomyopathy and LBBB to increase the 
sensitivity of the screening.199  A microarray was used to screen 766 human circulating 
miRNA in plasma, which identified four miRNAs (miR-30d,-99b,-409-3p and -766) had 
significantly differential expression between responders and non-responders (all p<0.05).199  
The validation study was performed in the remaining 40 participants with no significant 
characteristic differences between RvsNR.199 Surprisingly only 58% of the total validation 
cohort were on Angiotensin Converting Enzyme Inhibitors (ACEi); most HF studies have 
HFrEF patients have on higher amounts of OMT. Furthermore, the validations cohort 
included 33% AF patients and 20% ischaemic cardiomyopathy, which made the Melman et 
al199 validation cohort more heterogeneous than in the Marfella et al197 HF cohort. 
However, it does question the selection of the four miRNAs they took forward into a 
validation cohort with different baseline characteristics. 199 The was a high proportion of the 
cohort on anti-platelets (83% Aspirin, 23% Clopidogrel) and anticoagulants (45% Coumadin), 
which are known to affect miRNA expression, especially platelet derived.147,199  There were 
21 (52.5%) responders and 19 (47.5%) non-responders.199 Ten candidate miRNAs were 
quantified in the validation cohort with qPCR; 5 miRNAs were already identified and five 
miRNA (miR-18b,-29c,-129-5p,-423-5p and -622) not identified in the discovery phase. Four 
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miRNAs (miR-29c,-30d,-142-5p and -766) were significantly overexpressed in responders  
(all p<0.05).199 Multivariable logistic regression (accounting for co-variates) identified higher 
circulating miR-30d (OR=2.52, CI (95%) 1.07-5.94) and miR-142-5p (OR=2.47, CI (95%) 1.26-
4.85) predicted a better CRT response.199 A multivariable linear regression model, for degree 
of change in LVEF over six months, identified only miR-30d as being significantly associated 
(p=0.02) with change in LVEF at six months.199 Figure 3.5 demonstrates baseline miR-30d 
significantly correlated with change in LVEF over six months (Þ=0.39, p=0.01). However the 
strength of correlation is driven by the two highest changes in miRNA expression which are 
treated as outliers, when these points are removed the significance of the correlation is 
reduced (Þ=0.31, p=0.058), a point Dorn202 summaries in the sister editorial.  
 
A separate 21 HFrEF participants formed a test cohort who had undergone a CRT 
implantation and had six months samples.199 The test group was used to compare to the 
results of the validation cohort. The additional 21 baseline samples demonstrated the 
strength of miR-30d to predict CRT, supporting the validation cohort findings. The six month 
follow-up samples identified that miR-30d expression had decreased after six months 
following CRT implantation significantly in responders (p=0.05), but not in non-
responders.199 
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Figure 1.11 Relationship between circulating plasma miR-30d levels and change in LVEF six 
months after CRT. Correlation with all data points was significant (Þ=0.39, p=0.01), however 
when outliers removed correlation less significant (Þ=0.31, p=0.058). Red highlighting 
indicates miR-30d outliers, green are responders, blue are non-responders. Taken from 
Dorn EW. Circulation 2015.202  
 
Biologically Melman et al199 demonstrated that miR-30d was expressed in higher 
concentrations in the CS, synthesised and released from cardiomyocytes in extracellular 
vesicles.199 Spatial heterogeneity in the LV of miR-30d was demonstrated in a canine 
dyssynchronous HF model, with the lateral wall showing higher expression.199 Furthermore 
Melman et al199 demonstrated that miR-30d expression and release from cardiomyocytes is 
associated with increased mechanical stress, mediating cardiac hypertrophy. MiR-30d was 
observed to protect against tumour necrosis factor-α (medicates apoptosis), inferring a 
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cardioprotective role.199 Increased expression of miR30-d seems to represent a favourable 
adaptive process which may predict CRT response.  
 
Interestingly following the publication of Melman et al’s199miR-30d and CRT  translation 
study199 the authors of the first CRT and miRNA cohort expression paper197 wrote a 
published response contrasting how miRNA expression profile was measured and the 
common themes emerging regarding the miR-30 family. Sardu et al203 highlighted the 
differential miRNA expression pattern seen and that miR-30e were observed to be up-
regulated at one year follow-up.  They commented this might have potential anti-apoptosis 
effects. Structurally the miR-30 family is very similar and the biological function of members 
of the group is thought to be similar.203 Melman et al203 responded to these comments 
supporting the observation that other extracellular miRNA were likely to be implicated in 
the reverse LV remodelling. They also pointed out the differences in miRNA expression 
observed was likely to be due to small cohorts, differences in patient characteristics and the 
accepted variation in methodologies on quantifying miRNA expression. Importantly both 
authors agree on the importance of the miR-30 family in the process of reverse LV 
remodelling induction by CRT and the modification of the maladaptive molecular processes 
of apoptosis this regulates. Moreover the potential value in detecting response status and 
other extracellular miRNA are likely to be important in this regulation process.203,204 Melman 
et al199 has particularly demonstrated a striking difference between response status and the 
molecular mechanism it is involved in regulating. However the pattern of miR-30d was 
shown to contrast that reported by Marfella et al197 as it showed it was not overly expressed 
at baseline and no changes occurred in responders, unlike Melman et al.199 The translational 
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pilot offers a very robust assessment of the biological mechanism of the likely reason miR-
30d is a potential biomarker of CRT response, further validation is required.  
 
1.13 MiRNA DISCUSSION 
The research in miRNA and cardiovascular disease has sunstantially increased over the last 
decade with the identification of their stability in the circulation.143 There are patient 
specific issues that affect miRNA expression that need to be accounted for when assessing 
their potential as biomarkers. Moreover the methods available for quantification are varied 
and non-comparable  amongst the literature where different methodologies are 
avaliable.198 Heart Failure has identified that multiple miRNA are differentially expressed 
and may have the potential to diagnose and prognosticate the condition. However these 
studies are commonly small cohort studies, hence the variability in the results reported in 
the literature, resulting in most published articles being hypothesis generating only and 
lacking power to have any significant implications for patients. MiR-423-5p is an example of 
this hypothesis generation in the literature as a potential diagnostic biomarker188 but the 
results are not consistently replicated.191 MiRNA dysregulated in HF often reflects the 
development of maladaptive molecular processes that are known to be associated and 
important in the development of adverse cardiac remodelling. Cardiac devices are known to 
reverse remodel and modification of the differential expression patterns have been 
identified.205 CRT recently has shown different miRNA expression patterns following 
implantation and variation dependent on the degree of reverse LV remodelling.197 More 
recently a candidate miR-30d has been shown to alter in responders and be associated with 
a predictive response, due to over expression being demonstrated to be anti-apoptotic.199 
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Further exploration of dysregulated miRNA associated with maladaptive strategies would be 
potentially beneficial for identifying biomarkers of CRT response.  
 
1.14 HEART FAILURE METABOLISM 
Under normal physiological circumstances there is a balance between anabolic and 
catabolic metabolism and its regulation. The development and progression of HF is 
associated with neurohormonal systems activation, the development of a pro-inflammatory 
state and endothelial dysfunction.2,206,207 The imbalance in metabolism that favours a pro-
catabolic state is associated with progression of HF and alters skeletal and adipose tissue 
metabolism.206 
 
Natriuretic peptides (e.g. BNP and NT-pro-BNP) are released in response to the 
haemodynamic changes in HF and convey diagnostic and prognostic value.2 An inverse 
relationship is well established between natriuretic peptides and BMI.208 Christensen et al208 
in a small cross-sectional study observed high NT-pro-BNP were associated with low total fat 
mass (ß=-0.3, p<0.05).  
 
Adipocytes are sensitive to natriuretic peptides, activating lipolysis and enhancing the 
expression of brown adipocyte genes; increasing energy utilisation and thermogenesis.206  
Natriuretic peptides stimulate the release of adipokines, specifically adiponectin and leptin, 
which increase energy utilisation and weight reduction.206  Adipokines are involved in 
whole-body energy metabolism, and adiponectin is particularly involved in the regulation of 
skeletal muscle metabolism and weight loss in HF.209 Loncar et al209 in a cross-sectional 
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study of elderly males with stable HF and no cardiac cachexia (CC) observed adiponectin was 
independently associated with muscle mass and strength. In a pivotal prospective 
observational study of RV dysfunction and CC (n=408), Melenovsky et al207 identified 
adiponectin levels were significantly raised in participants with RV dysfunction and who 
were cachectic. Furthermore, adiponectin was one of the few variables (alongside NT-pro-
BNP, RV dysfunction and of neurohormonal antagonist therapy) to independently predict 
CC.207  Serum adiponectin is associated with severity of HF and adverse outcomes.209 
Paradoxically, adiponectin have been observed to have beneficial effects on lipid and 
glucose metabolism, alongside myocardial inflammation, hypertrophy and fibrosis.210 It has 
been identified as a well-placed potential biomarker for the cross-talk in HF metabolism.210   
 
Pro-inflammatory signals from cytokines and interlukin-6 (IL-6) are increased in HF.206 
Proteolysis in muscle occurs predominantly via the ubiquitin–proteasome system, which has 
increased activation HF due to stimulation from these increased pro-inflammatory 
signals.211 The ubiquitin–proteasome system degrades proteins, the rate of which increases 
in HF.211 Christensen et al206 described a trend towards an association between high IL6 and 
Lean mass. Adiponectin and leptin have receptors in skeletal muscle that have acute and 
chronic effects on local metabolism.209  
 
1.14.1. Adiposity and Heart Failure 
Obesity defined as a raised BMI >30.0kg/m2, is recognised as a risk factor for HF. There is a 
5% and 7% increased risk of developing HF for every one unit rise in BMI, independent of 
important co-variables, for men and women respectively.212 A graded increase in risk of 
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developing HF is recognised for increasing BMI in both males and females in different 
population groups.212 Furthermore, Clark et al212 describes the increased risk of HF from 
other raised adiposity surrogate metrics, for examples waist circumference and waist hip-
ratio.  
 
Counterintuitively, those with a raised BMI and established HF have been observed to have 
improved outcomes.212-215 Oreopoulos et al213 in a large meta-analysis of 28,209 HF patients 
who were obese or overweight (25.0-29.9 kg/m2) showed a reduction in all-cause mortality 
(-19.0% and -40.0%) and cardiovascular mortlaity (-16.0% and -33.0%) respectively 
compared to those without a raised BMI (<24.9 kg/m2) at >2years follow-up. The 
relationship between BMI and mortality has been demonstrated to have a U shaped curve 
with the lowest rates being associated with those overweight and obese and the higher 
rates being associated with leanness and severe obesity (>35.0 kg/m2),214 though not all 
datasets have replicated this finding.215 The inverse relationship of NT-pro-BNP and 
adiponectin with BMI and total percentage body fat is suggestive that a higher fat content 
protects against the pro-catabolic activity of these neurohormonal signalling pathways.208,209 
Cai et al216 demonstrated in a retrospective cohort study of Chinese patients with severe left 
ventricular systolic dysfunction (ejection fraction <35%) patients (n=219) that were 
overweight (24.0-28.0 kg/m2) and obese (>28.0 kg/m2) predicted Cardiac Resynchronisation 
Therapy response and improved survival at six months. Notably, within this study, the 
defined BMI ranges were lower than other studies due to the Chinese population having a 
lower average BMI than western populations.216 Furthermore, this study demonstrated that 
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the obese population better tolerated optimal medical therapy, an observation noted in 
other studies.207,216 
 
The significance of these paradoxical observations of the impact of adiposity are highly 
debated, does it represent a significant impact on metabolism in HF or is it a spurious 
observation from predominantly cross-sectional research articles? Several explanations and 
hypothesis have been offered to explain this phenomenon. Firstly lower natriuretic peptides 
are observed in obese patients and as a result symptoms may occur later. Secondly, the 
downgraded natriuretic peptide system is associated with adiposity and therefore offers a 
‘protective’ role.212 However the opposing antagonistic endogenous circulating renin-
angiotensin-aldosterone system (RAAS) is dysregulated in patients with adiposity due to the 
development of a local RAAS system in visceral adipocytes and angiotensin acting as a 
growth factor for adipocytes.217 The impact of the dysregulation of both systems with 
adiposity is not entirely clear.  Thirdly, BMI is a crude metric of body composition, not 
accounting for proportions of each component, but is often used in studies.212 Finally, 
obesity is a heterogeneous condition with various fat mass distributions, including; visceral 
fat deposits or subcutaneous/gluteofemoral obesity. Each have differing metabolic 
profiles.212 The presence of established adiposity is observed to slow the progression of 
metabolism to a pro-catabolic state in HF, but the true impact is not clear yet218   
 
1.14.2. Body Composition and Heart Failure 
Muscle wastage is a common occurrence in HF.211 Sarcopenia is defined as reduced muscle 
mass and limited mobility, occurs naturally with aging at of a rate of 1-2% per annum over 
Dr Christopher J. McAloon 
 
100 
 
 
50 years of age.211 Fülster et al211 recruited 200 HF patients at a single centre  and observed 
19.5% of the cohort had sarcopenia, a higher proportion than expected through natural 
aging. Significantly both reduced (68.8%) and preserved (31.2%) ejection fraction HF 
patients were recruited to this study.211  HF patients with sarcopenia had higher incidence of 
reduced left ventricular ejection fractions, reduced muscle strength, worse functional 
capacity and significantly higher IL-6 levels.211 Elevated pro-inflammatory signals in HF, 
including cytokines and interlukin-6 stimulate catabolic pathways; for example the 
ubiquitin-protease pathway and cause sarcopenia.211 Neurohormonal signalling cross-talk 
has been shown to be associated with muscle wasting.209 
 
CC is defined as the unintentional non-oedematous >5% weight loss over >6 months, though 
higher weight loss levels have been set in the literature.208,214 The imbalance of metabolic 
systems progressing towards a catabolic state in HF results in CC. One of the strongest and 
most reproducible poor prognostic signs in HF is development of CC.207,212-214 Pocock et al214 
in a sub-study of the ‘Weight loss and mortality risk in patients with chronic HF in the 
candesartan in HF: assessment of reduction in mortality and morbidity (CHARM) 
programme12 (n=6933), demonstrated that together leanness (<22.5 kg/m2) and CC 
(unintentional >5% weight loss at >6 months) increased mortality rate by 150% at 37.7 
months. Melenovsky et al207 observed CC with RV dysfunction (vs non-CC with a normal RV) 
was apredictor of adverse events in HF patients (HR 6.7, CI (95%) 4.1-10.9, p<0.0001).   
 
The prevalence of CC has improved with the introduction of new treatments and now is 
estimated to be 10.5% in the stable HF patients.208 CC represents wasting across all body 
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tissues though sarcopenia was initially described as being the critical trigger,208 though more 
recently fat mass loss has been associated with CC.207 Neurohormonal and inflammatory 
signals have also been shown to be elevated in CC and have their own prognostic value in 
HF.206-208,212 CC represents the critical step in the pro-catabolic transition of the body’s 
metabolism in advancing HF, though the cross-talk of signalling demonstrates a 
heterogeneous picture of triggers and regulation. Further understanding is required. 
 
1.14.3. Conclusion 
There is clear interplay in HF development and progression on metabolism and body 
composition. The literature in this field is limited to small cohort or cross sectional studies.  
The complexity of the interplay is clear and full understanding of development, regulation, 
progression and ultimately clinical value has yet to be achieved. The prognostic value of 
certain biomarkers is critical in predicting adverse outcomes. CRT implantation offers a good 
in-vivo model to see the impact of reverse cardiac remodelling on body composition and the 
potential clearer understanding of the interplay.  
 
1.15 PUBLICATIONS 
Section 1.2 was published as a review article entitled ‘Cardiac Resynchronisation Therapy 
and its role in Heart Failure Management: Beyond the Medication’ in the British Journal of 
Hospital Medicine 2017. (Apendix S) Section 1.15 was published as a review article entitled 
‘The interplay between heart failure, metabolism and body composition’218 in the British 
Journal of Hospital Medicine 2016.(Appendix S)  
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Chapter Two 
 
GENERAL THESIS HYPOTHESIS  
AND RESEARCH OBJECTIVES   
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2.1 GENERAL HYPOTHESIS 
CRT has been effectively demonstrated to improve cardiovascular outcomes for the majority 
of HFrEF patients. Biventricular pacing has been shown to modify complex molecular 
pathways that are associated with adverse cardiac remodelling seen in HFrEF, including the 
ECM and specific regulating miRNAs. A large problem for individual patients and healthcare 
providers is that CRT is a costly treatment and despite meeting the evidence based implant 
criteria a significant minority of patients do not respond. Many factors have been examined 
to see what best predicts of response for CRT. Unfortunately non-response rates remain 
unchanged and other variables remain inconsistently reported in the literature.  
 
Circulating biomarkers of these complex molecular pathways can be dysregulated in HFrEF 
and can prognosticate for outcomes. We hypothesise specific biomarkers have the ability to 
predict patients’ potential to respond to biventricular pacing. Cardiac ECM have dynamic 
properties and turnover alters HFrEF and circulating biomarkers of this system has been 
shown to prognosticate. Furthermore CRT has been shown to alter ECM turnover. Our 
hypothesis is that measuring individual or a combination of circulating ECM biomarkers 
before CRT implantation may predict a patient’s functional respond.  
 
Several miRNAs are involved in the regulation of complex cardiac molecular systems and are 
known to be dysregulated in HFrEF. We also hypothesise specific miRNAs expression may 
predict a patient’s ability to respond to CRT. Together these circulating biomarkers may 
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have the strength to predict wehther a patient may respond to a CRT device before 
implantation.  
 
CRT implantation in HFrEF patients offers a unique in-vivo model to examine maladapted 
complex cardiac molecular systems response to biventricular pacing and reverse cardiac 
remodelling. Limited information is available for ECM turnover and it is contradictory. 
MiRNA behaviour following CRT implantation is poorly understood and limited information 
is available. We hypothesise that CRT will alter ECM and miRNA biomarker profiles following 
implantation and the degree of alteration will depend on the patient’s response status.  
 
We also hypothesise that body composition is an important variable on predicting the 
response and outcome following CRT implantation. Determining the impact of CRT 
implantation on body composition is potentially important from a clinical perspective...  
 
Finally, we hypothesise a prediction model will need to be individually tailored to the 
specific patient population. Specific clinical variables maybe more important than others in a 
HFrEF populations. 
 
2.2 AIM 
The aim of this research work is to undertake a proof-of-concept pilot project where 
traditional clinical variables are combined with novel circulating biomarkers to attempt to 
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predict HFrEF patients who are more likely to respond to CRT. The selection of ECM 
biomarkers and miRNAs is based upon the previous literature, including systematic review 
(chapter 4). These circulating biomarkers were tested in parallel to ellicit their value 
independently and as part of a wider prediction model. This study is similar to many others 
on CRT studies, which are based at a single centre and is hypothesis generating as the 
numbers of participants is low.  
 
The design of the research focused in two areas to aid in building a real-world prediction 
model utilising relevant clinical variables and novel circulating biomarkers. The work was 
undertaken at the University Hospital Coventry and Warwickshire (UHCW) NHS Trust. The 
intricacies of the local HF population are discussed in Chapter 3.2. Firstly a retrospective 
study of all CRT implants was planned and undertaken as discussed in Chapter 6.4. The aims 
are summarised as follows and detailed in Chapter 5.2: 
1. To examine pre-determined clinical predictors of CRT response, informed by the 
literature as to potential predictors within our local HFrEF population.  
2. To inform clinical variable selection for inclusion in the prediction model alongside 
novel circulating biomarkers. 
 
A prospective observational study was designed to test a prediction model using clinical 
variables and novel circulating biomarkers for CRT response. The principle CRT response 
definition is a functional one based on a combination definition, which is detailed in Chapter 
3. The selection of novel circulating biomarkers to be tested for ECM is informed by the 
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systematic review detailed in Chapter 4 and for miRNAs Chapter 1. The selected novel 
circulating biomarkers are outlined in detail in Chapter 3. The prospective observational 
study has been designed as a proof-of-concept pilot study to test the initial prediction 
model and offer an opportunity for refinement. Body composition was studied as a sub-
study of the prospective observational study to understand the changes that occur following 
CRT implantation, which is discussed in detail in chapter 7. The aims of the prospective 
observational study are summarised below and discussed in chapter 6 and 7: 
1. To characterise novel circulating biomarker expression in reduced ejection heart 
failure (with dyssynchrony) in cardiac specific and peripheral (systemic) baseline 
samples. 
2. To characterise miRNA expression [cardiac specific and systemic] in reduced ejection 
fraction heart failure patients (with dyssynchrony) before CRT implantation and 
during follow-up  
3. To characterise the ECM biomarker expression in reduced ejection fraction heart 
failure [with Dyssynchrony] before CRT implantation and during follow-up 
4. To determine the impact of CRT implantation on body composition in patients with 
reduced ejection fraction heart failure (with dyssynchrony)  
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Chapter Three 
 
GENERAL MATERIALS AND METHODOLOGY 
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3.1 INTRODUCTION 
This chapter introduces and details all methodologies and materials utilised during this 
research project. Both main studies (retrospective and prospective) are discussed. A 
complete account of all protocols and techniques used are described in detail in this 
chapter. Specific methodologies and material used in each study are discussed with in the 
relevant section of this chapter and their results Chapters 4, 5 and 6 respectively.  
 
3.2 UHCW NHS TRUST CARDIAC RESYNCHRONISATION THERAPY IMPLANTATIONS 
3.2.1 Local Service and Patients 
This research has been conducted within the Arden Cardiac Network (Figure 3.1) with 
UHCW NHS Trust as the principle tertiary centre for CRT implantations in the network. 
UHCW directly serves more than half a million patients.219 It also serves as the tertiary 
referral centre for George Elliot Hospital NHS Trust (Nuneaton) and expert centre for South 
Warwick Hospital NHS Trust, Worcestershire Acute Hospitals NHS Trust and County Hospital 
Hereford NHS Trust ,representing an estimated population of 1.6 million.220  In recent years 
many centres have developed their own services.  
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Figure 3.1 Arden Cardiac Network 2016. Taken from National Audit of Cardiac Rhythm 
Management Devices 2012 Report.220 
The CHF population varies within the Arden geographical region, which is important in 
considering who the cohort in study II represents. The North Warwickshire region (including 
Coventry) has a 0.8% CHF prevalence, compared to 0.7% in England within 2014/15.221 
There are specific factors which differentiate the Coventry population with the rest of the 
Cardiac Network and nation. Firstly 25.9% of the Coventry population is Black, Asian or 
another minority group, which is higher than the regional and national proportion, which 
are 16.8% and 16.3% respectively.221 The South East Asian population is known to have a 
higher proportion of cardiovascular disease in the UK.222,223 The South Asian population 
accounts for 3.94% of the UK population, however it is 15.1% in Coventry and 
Warwickshire219 Outside Coventry, the remaining Arden area has an older population, who 
proportionally meet requirements for CRT implantations, reflecting the need for higher 
implantation rates.220 The dynamics of this single centres population needed to be 
accounted for in the prospective study design.  
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3.2.2 UHCW CRT Implant Service  
CRT implantation rates at UHCW and within the wider Arden Cardiac Network have 
historically been lower than the national average (Figure 3.2), but have been increasing 
annually.220 The increasing implantation rate in the network and nationally reflect the 
broadening of the national criteria, 17,47,56 increasing number of centres, improvement in 
technology and upskilling of more operators. Implantations of complex cardiac devices 
including CRTs started at UHCW in late 2008.224 UHCW year-on-year has demonstrated in an 
increase in implants in the most recent National Audit of Cardiac Rhythm of Management 
2013-14.59 Our own data shows UHCW implanted 82 CRTs in 2010 and 86 in 2012,224 a 
pattern which is reflected at the national level (Figure 5.2).  
 
Figure 3.2 CRT implantation Rates in Arden Cardiac Network compared to National Rate 
2010-2012. (Adapted220) 
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The UHCW CRT service has evolved since 2008, with more elective implantations taking 
place. These elective implantations used to require planned overnight stays, but are now 
routinely performed as day-case procedures. We performed an analysis of our overall 
elective admission procedures complication and mortality rate (30 days and 1 year).224 Table 
3.1 demonstrates our complication and mortality rates overall and by elective admission 
strategy. No significant difference between mortality and complication rates were identified 
between the different strategies.224 Our analysis of elective complications demonstrated 
rates lower than the national average.224,225 Complications however, would need to be 
accounted for in the prospective cohort study design as they would be likely to influence the 
results. 
 
Elective patients from Coventry and Warwickshire are referred directly to the arrhythmia 
clinic for consideration for a CRT device. Emergent patients are assessed as inpatients for 
CRT. Often urgent patients can be discharged and have their procedures performed as an 
urgent outpatient. All patients require cardiac imaging, resting 12-lead ECG and clinical 
assessment for an implant decision to be made. Cardiac imaging is required to assess and 
quantify LVEF and LV dimensions; this was frequently achieved on transthoracic 
echocardiography. Patients were were assessed in the context of the the NICE guidance that 
was in place at the time  (200751, 2010226 or 201417). Table 1.2 demonstrates the current 
NICE 2014 guidelines.17 The guidelines did not replace clinical decision making. Complicated 
cases were often discussed in the arrhythmia multi-disciplinary team meeting prior to an 
implantation decision being made.   
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Table 3.1 Elective Complex Cardiac Devices Complications (January 09– April 2013)224 
Outcomes 
Total Cohort 
(n=267) 
Same-day 
(n = 213) 
Overnight 
(n=54) 
P Value 
 
Failed Procedure 7 (2.6%) 7 (3.3%) 0 0.4 
Unplanned overnight stay  9 (4.3%)   
Total Complications 26 (9.7%) 20 (9.4%) 6 (11.1%) 0.8 
Immediate (≤24 hours) 9 (3.4%) 7 (3.3%) 2 (3.7%) 1.0 
RV Lead Displacement (n) 2 1 1  
Diaphragmatic Stimulation (n) 2 2 0  
Pneumothorax (n) 1 1 0  
Haematoma (n) 3 2 1  
Wound bleeding (n) 1 1 0  
Short term (>24hrs-6 weeks) 6 (2.2%) 4 (1.9%) 2 (3.7%) 0.4 
LV Lead displacement (n) 2 1 1  
RA Lead displacement (n) 1 0 1  
LV Lead not capturing (n) 1 1 0  
Wound infection (n) 1 1 0  
Pre-erosion (n) 1 1 0  
Medium term (6 wks-4 months) 4 (1.5%) 4 (1.9%) 0 (0.0%) 0.6 
LV Lead Displacement (n) 2 2 0  
RV Lead Displacement (n) 1 1 0  
Device Infection (n) 1 1 0  
Long term (>4 months) 7 (2.6%) 5 (2.3%) 2 (3.7%) 0.6 
LV Lead Displacement (n) 6 5 1  
LV Lead Not Capturing (n) 1 0 1  
Mortality:     
Mortality < 30 days  3 (1.1%) 2 (0.9%) 1 (1.9%) 1.0 
Mortality <1 years 24 (9.0%) 17 (8.0%) 7 (13.0%) 0.5 
 
3.2.3 Implantation Procedure 
All CRT implants were performed according to our centres standard operating procedure. 
The precise model of pulse generator and lead types implanted were determined by normal 
working practice and neither study affected their selection. Each procedure was performed 
or supervised directly by a Consultant Cardiologist with a specialist interest in Cardiac 
Devices. Most implants were left sided. The pulse generator was placed into a subcutaneous 
pre-pectoral pocket. CRT pacing/defibrillator leads were placed by an endocardial approach; 
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this was mostly via the cephalic or axillary veins. The subclavian vein was used if other 
routes proved unsuccessful. The RV pacing lead was placed at the RV apex (RVA) in the 
majority of patients and infrequently at the RV septum. The RA lead was implanted mostly 
at the RA appendage (RAA) and when this was not possible at the RA free wall. Patients in 
permanent AF did not have an atrial lead implanted unless an external cardioversion was 
planned in due course. The LV lead placement was via the CS. To identify the preferred 
deployment site the CS was cannulated and angiography performed to demonstrate the 
cardiac venous anatomy. The preferred LV lead deployment was the most lateral 
circumferential position and basal/mid-cavity axial position possible. Many patients with 
ischaemic cardiomyopathy have scar as a result of infarction. The scar can be identified by 
cardiac magnetic resonance imaging, LV lead placement is then avoided at this site as it can 
reduce the success of the procedure.227 Figure 3.3 demonstrates the preferred endocardial 
(RA and RV) and epicardial deployment and sites for a CRT device. Defibrillation safety 
margin testing was not performed on those having a defibrillator. 
 
All were given pre and post-procedure intravenous antibiotics: Flucloxacillin 1g IV and 
Gentamicin 1.5mg/kg IV (max dose 100mg) followed by Flucloxacillin 500mg QDS orally for  
3-days. If allergic to penicillin’s, Teicoplanin 600mg IV pre-procedure and Doxycycline 200mg 
OD for 3 days. All implants had post implant chest x-ray and device check prior to discharge. 
The CRT implant protocol altered in 2010 for elective implants to day-case procedures being 
(admitted via the Day-Case Unit) and observed for 3-4 hours post procedure before being 
discharged, if all checks were satisfactory.224 
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Figure 3.3 Cross Sectional View of Heart and Endocardial CRT Lead Placement. (Adapted16)   
 
3.2.4 Routine Aftercare 
All CRT implant patients return for a standard six week clinical and device review. Patients 
are clinically assessed by the arrhythmia nurse team. Nurse led clinics are supervised by 
Consultant Cardiologists. The CRT device checks are conducted by cardiac physiologists for 
battery life, cardiac arrhythmias, lead impedance and thresholds. CRT-d devices are checked 
for any anti-tachycardia pacing and / or shock delivery. Patients referred from other centres 
were repatriated after the six week check. Long-term CRT devices are checked as a standard 
every 6 months.  
 
LV Pacing Lead in 
CS 
RA Pacing lead 
place at RAA 
RV Pacing Lead 
at the RVA 
LV 
Aorta 
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3.3 APPLIED DEFINITIONS 
3.3.1 Outline 
Several definitions are applied throughout this project and are given in the section below for 
bundle branch block morphology and NYHA symptoms classification. Applied clinical 
definitions for ischaemic aetiology, cardiomyopathy, diabetes mellitus and chronic kidney 
disease are outline in detail in Appendix C.   
 
3.3.2 Electrocardiogram and QRS duration 
Resting 12-lead ECGs are performed routinely prior to assessment for CRT implantation. 
Prolonged/Broad was defined as a QRS duration >120msec (>3 small squares on ECG). 
Specific QRS duration was calculated on digital ECG’s by measuring from the start of the Q 
wave and to the end of the S wave.228  Manual digital measurements of QRS duration is now 
the gold standard technique to measure QRS duration.228  
 
3.3.3 Bundle Branch Block  
A broad QRS complex on a resting 12-lead ECG must meet specific morphological criteria to 
be defined as a complete LBBB or RBBB. Table 3.2 describes the AHA/ACCF/HRS 2009 
criteria for defining complete LBBB and RBBB.229 
 
3.3.3.1 Nonspecific or Unspecified Intraventricular Conduction Disturbance229 
NIVCD is defined as a QRS duration >110 msec without the criteria for LBBB or RBBB (Table 
3.2) being fulfilled.229 The definition can be applied to a pattern with RBBB criteria in the 
precordial leads and LBBB criteria in the limb leads, and vice versa.229 
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Table 3.2 Criteria for Complete LBBB and RBBB.(Adapted229) 
Complete LBBB Complete RBBB 
1 QRS duration >120 msec  1 QRS duration >120 msec  
2 Broad notched or slurred R wave in leads 
I, aVL, V5, and V6 and an occasional RS 
pattern in V5 and V6 
2 
rsr′, rsR′, or rSR′ in leads V1 or V2. The R′ or 
r′ deflection is usually wider than the 
initial R wave. In a minority of patients, a 
wide and often notched R wave pattern 
may be seen in lead V1 and/or V2 
3 
Absent q waves in leads I, V5, and V6, but 
in the lead aVL, a narrow q wave may be 
present  
3 S wave > R wave OR > 40 msec in leads I 
and V6  
4 
R wave peak time >60 msec in leads V5 
and V6 but normal in leads V1, V2, and V3, 
when small initial r waves can be 
discerned in the above leads 
4 
Normal R peak time in leads V5 and V6 but 
> 50 msec in lead V1 
5 
ST and T waves usually opposite in 
direction to QRS 
Of the above criteria, the first 3 should be 
present to make the diagnosis. When a pure 
dominant R wave with or without a notch is 
present in V1, criterion 4 should be satisfied. 
6 
Positive T wave in leads with upright QRS 
may be normal (positive concordance) 
 
3.3.4 Clinical Assessment  
3.3.4.1 New York Heart Association Symptom Classification 
The NHYA symptom classification is an ordinal scale used by clinicians to grade a patients HF 
symptoms. NYHA classification is consistently used in all CHF observational and randomised 
control trials to clinically assess symptom severity.2 Furthermore, it is used consistently in all 
the CRT randomised control trials.22,23 Table 3.3 shows the NYHA symptom classification 
scores. 
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Table 3.3 NYHA Symptom Classification. Taken from McMurray JJ et al; Eur J Heart Fail 2012.2  
Class I 
No limitation of physical activity. Ordinary physical activity does not cause undue 
breathlessness, fatigue, or palpitations. 
Class II 
Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in undue breathlessness, fatigue, or palpitations. 
Class III 
Marked limitation of physical activity. Comfortable at rest, but less than ordinary 
physical activity results in undue breathlessness, fatigue, or palpitations. 
Class IV 
Unable to carry on any physical activity without discomfort. Symptoms at rest can 
be present. If any physical activity is undertaken, discomfort is increased. 
 
The NYHA classification is often used as a metric of severity of illness and assessing response 
to treatments for CHF.2 There is a well described relationship between severity of symptoms 
and survival, however even patients with mild symptoms still have a high absolute 
hospitalisation and mortality rate.230,231 NYHA classification is known to poorly correlate 
with ventricular function.2 Application is often inconsistent; Raphael et al232, performed an 
inter-observer variability study and reported a 54% concordance for two Cardiologists in 
grading 50 patients. Progression through the ordinal NYHA scale varies on whether acute or 
chronic illness is present at the time; acute illness often demonstrated a repaid decline and 
with treatment, a rapid improvement.2  
 
Throughout this study NYHA symptom classification is an important metric for assessing and 
grading symptoms at a particular time-point. It forms an important outcome variable in both 
the cohort studies.  
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3.4 STUDY I: RETROSPECTIVE COHORT STUDY 
5.4.1 Title 
Evaluation of Potential Pre-Implant Predictors of Clinical Response and Cardiovascular 
Outcome for Cardiac Resynchronisation Therapy 
 
3.4.2 Indication for Study  
An examination of the historic implantation procedure at UHCW was important for 
informing decisions about analysis of the prospective study design and analysis within the 
context of the study population. Examining the local population and more importantly the 
previous CRT implantations informed the prospective study ahead of recruitment of the 
typical patients that had CRTs implanted at our study centre. Studying the previous implants 
also informed the study feasibility.  
 
3.4.3 Rationale for the Retrospective Study 
UHCW was the site for the prospective study (Study II) and it offered particular population 
characteristics that had to be accounted for within the subsequent study analysis. 
Performing a study on the historical implants offered an opportunity to understand the 
specific CRT implant population within Coventry, Warwickshire and the wider Arden Cardiac 
Network. The differences in the general population are important in order to consider how 
they might influence determination of CRT response and cardiovascular outcomes.  The 
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earlier analysis determines that the population is characteristically different to the regional 
and national population due to multiple factors. Moreover our own procedural analysis 
determines that our experience in terms of outcomes from our procedures is not only 
comparable at a national level but is evolving as new evidence and guidelines become more 
apparent and techniques improve. Studying previous CRT implantation patients at UHCW 
informed the prospective study as it is the closest analysis that reflects the cohort samples 
that will be achieved for the prospective cohort. Specifically pre-implant predictors we 
might want to factor into our prospective study prediction models were determined. 
Moreover, the stability in outcomes for CRT implantations, demonstrates the stability of 
implants at UHCW and the potential number of patients that might be expected to drop out 
due to procedure failure or an early complication.  
 
3.4.4 Study Governance 
An application was made to the Trust’s Research, Development and Innovation department 
for ethical review under section 2.3 of the harmonised UK-wide edition of the Governance 
Arrangements for Research Ethics Committees233 for permission to conduct and perform our 
proposed retrospective study. Permission was granted to review patient records and 
analyse anonymous patient data. Approval was provided by our local research, development 
and innovation department. The study applied the principles of the declaration of Helsinki. 
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3.4.5 Study Overview  
3.4.5.1 Design 
This is a single-centre, unselected retrospective cohort study of all consecutive CRT implants 
at UHCW performed over five years (January 2009 to December 2013). Patients were 
observed until 31st December 2014. Figure 3.4 summarises the study schema.   
 
3.4.5.2 Patient Screening 
All CRT implantations were screened. Patients had to meet the national and international 
implantation guidelines active at time of the procedure to be included in this anonymous 
retrospective cohort study.17,47,226,234  All CRT-p and CRT-d implants both de novo and 
upgrade implants were included. Figure35.4 outlines the screening and specific exclusion 
criteria. Immediate complications were excluded as the patient was required to have 
instanous biventricular pacing achieved as not to bias assessment of response.  
 
3.4.5.3 Patient Selection 
Electronic / paper case records for Cardiology / Heart Failure consultations had to be 
available and contain the information to conclude a NYHA classification for that patient at 
that contact time. Figure 5.4 summarises the process of patient selection. 
 
3.4.5.4 Patient Consent 
For the retrospective study under Governance Arrangements for Research Ethics 
Committees233 patient consent was not required, as only anonymous data is recorded.  
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Figure 3.4 Patient Screening, Selection and Study Process 
 
3.4.5.5 Investigations 
For the retrospective study no patient investigations were possible and all information was 
be obtained from sources that have already recorded information. 
 
3.4.6 Clinical Data Acquisition 
3.4.6.1 Data Sources 
Electronic (Clinical Results Reporting Systems., University Hospital Coventry and 
Warwickshire, Coventry, UK)/Paper case note records and hospital coding data were utilised 
to search for demographic, medical background, ECG, transthoracic echocardiogram 
reports, procedure information and outcomes. Referrals from external centres in the Arden 
Cardiac Network (Figure 3.1) were included in the analysis and information in referral letters 
Panel Assess NYHA Status 
Baseline & Latest Follow-up  
Consensus on NYHA classification required 
Outcome Assessment 
Response Status Determinable 
Assessed for MACE 
Retrospective Data Collection 
Exclusions: 
Failed Procedure 
Immediate Complications 
ICD Implants 
Pulse Generator Change Only 
Exclusions: 
Response Status Undeterminable 
Panel consensus could not be 
achieved 
Screening all CRT Implants 
Jan 2009 – Dec 2013 
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were utilised to complete data collection for those patients. Procedure reporting systems 
(Carddas, GE Healthcare, Horten, Norway) were also searched for information. 
Echocardiogram digital storage software (EchoPac, GE Healthcare, Horten, Norway)) was 
searched for echocardiogram reports and available images.  
 
3.4.6.2 NYHA Pre-Procedure and Follow-up classification 
Availability of NYHA symptom classification score (Table 3.3) pre-procedure and the latest 
review by a cardiologist/heart failure team member was reviewed initially as part of the 
screening and selection process. The ‘latest’ consultation was defined as that closest to the 
final observation date (31st December 2014). Patients with clearly labelled NYHA symptom 
class at both time-points were included and had available data recorded. Those with a 
description of symptoms, but no clear NYHA classification were taken to the ‘NYHA 
Consensus Panel’ (discussed later in this section). 
 
3.4.6.3 Data Collected 
The defined data collection period was from the date of the CRT implantation procedure 
until the 31st December 2014 or until mortality or a loss to follow-up. Two investigators 
separately reviewed all records for each patient included in the study. Specific data  
variables collected are outlined in Appendix D. 
 
3.4.6.4 Electrocardiograms  
All CRT implantations patient underwent a resting 12-lead ECG to determine rhythm, QRS 
duration and BBB morphology to see if the criteria for implantation had been met. 17,51,226 
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All digital / paper ECG’s available were sought for those patients in the study. The ECG had 
to be performed before the implant. ECGs were reassessed for QRS duration228 and BBB 
morphology.229 QRS duration was performed on the digital records where available. These 
measurements were performed by the lead investigator. This process was designed to 
minimise the variability in measurements. 
 
3.4.6.5 Transthoracic Echocardiogram 
All transthoracic echocardiogram images for patients included in the study if available were 
recovered from the digital archive. The original reports were not reviewed. Measurements 
were performed on post processing software (EchoPac, GE Healthcare, Horten, Norway). 
Specific measurement of LV end systolic and end diastolic volumes (LVESV and LVEDV) were 
performed in the apical four and two-chamber views. These measurements were used to 
calculate the LVEF via the modified Simpson’s Biplane method. Standard methods201 were 
used to perform all the required measurements. Recorded images had to be good enough 
quality to perform these measurements to be used. The lead investigator performed all of 
the measurements. If any new findings were identified on evaluation the lead author would 
inform the clinical consultant for the patient and allow them to directly action if needed.  
 
3.4.7 Potential Pre-implant Predictors Model 
Potential clinical predictors were considered prior to data collection and pre-selected based 
on previous reports (Chapter 1.3). Predictors identified were age and gender,38 device type 
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(CRTp/CRTd) and upgrade status,235 clinical aetiology,38,65,68 CKD,236-238 diabetes mellitus,236 
BBB morphology,38,66,68 QRS duration,38,39,68 and LV ejection fraction on 
echocardiography.38,67  
 
CKD status at implant was defined as an eGFR (estimated glomerular filtration rate)  
<60ml/min/1.73m2 using the modification of diet in renal disease equation.237,239,240 Baseline 
renal function was recorded, but was considered to have potentially high levels of missing 
variables, hence hospital coding data was utilised to define CKD status. Time from implant 
to determination of response was considered likely to be wide, therefore, time between 
implant and assessment was included as a confounding variable in the clinical predictor 
model.  
 
Pre-procedure NYHA symptom classification status was not included as a predictor due to 
the direct association with clinical response. Implantation factors were not included as they 
were not determinable prior to implant and would have no value in predicting response pre-
implant. 
 
3.4.8 Outcomes 
3.4.8.1 Overall Clinical Response  
The primary outcome was the overall clinical response assessed at the latest cardiology/HF 
consultation. The difference in NYHA symptom classification score between pre-procedure 
and at the latest consultation were used to determine clinical response. The criterion for 
clinical response was a decrease in NYHA classification >1 symptoms from baseline. 
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Determination of NYHA symptom classification was performed by reviewing all recorded 
consultations. A secondary analysis examined clinical response status determined acutely 
(<12weeks) and long-term (>12weeks) based upon the latest cardiology/HF team review in 
the defined time periods. Overall clinical response was used as the primary outcome and 
utilised the latest cardiology/HF review for the patients in the observation period, with 
information available to define NYHA symptom classification score. 
 
3.4.8.2 Clinical Response Assessment Panel  
Separate reviews of all electronic/paper case notes was performed by three clinicians 
(based at UHCW) experienced in assessing CHF patients. The reviewers were blinded to 
other reviewers. A consensus was required for each patient based upon reported evidence 
at baseline referral for CRT implantation and latest follow-up within the observation period. 
Only correspondence or documentation from a Cardiologist or HF team member was used 
as evidence of assessment. Outpatient clinics were the preferred clinical engagement to 
assess. Often clinicians recorded a specific NYHA symptom classification at the time of the 
assessment, in these cases this numeric value was used. When a specific case was not 
classified, the reported symptoms were studied. Independent clinical assessment of 
evidence was performed to judge an NYHA classification score. A description of symptoms 
and exercise tolerance was required to be documented to reach a judgement. A high 
evidence threshold was used to minimise the bias of this process. The consensus was also 
required between the reviewers given the recognised high variability in opinion in assessing 
NYHA classification.232  
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3.4.8.3 Major Adverse Cardiovascular Events   
MACE was a secondary outcome for this project. MACE is a clinical composite of all-cause 
mortality and/or first HF hospitalisation.39 This definition is applicable for both aspects of 
this project. HF hospital admissions were defined as a hospital admission requiring 
intravenous diuretics. All-cause mortality rates were generated from hospital coding data 
and electronic patient records.  
 
3.5 STUDY II: EXPLORATIVE PROSPECTIVE STUDY  
2.5.1 Title 
The Characterisation of Circulating biomarkers before and after Cardiac Resynchronisation 
Therapy in patients with Chronic Heart Failure and their Role in Predicting Response (The 
COVERT-HF Study) 
3.5.2 Research Governance 
3.5.2.1 Research Study Ethical Approval 
The application to the West Midlands REC was submitted using the online Integrated 
Research Application Service portal (IRAS application number: 135985). The South 
Birmingham REC meeting was attended by Dr Faizel Osman and I on the 30th September 
2013 where the proposed study was discussed. The REC consisted of a multi-disciplinary 
panel of clinicians, academics, healthcare professionals, statisticians and lay members. 
Following minor amendments to the protocol, permission was granted to perform the study 
on the 30th October 2013 (Appendix E). Subsequent permission was granted from the 
UHCW Research, Development & Innovation department to conduct the study. (REC 
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Number: 13/WM/0355). Subsequent amendments to the ethical approval are discussed in 
detail in Appendix E. 
 
3.5.2.2 Clinical Trial Registration 
The COVERT-HF prospective study was registered on the publically accessible Clinical Trials 
(www.clinicaltrials.gov) database (Registration Number: NCT02541773). Appendix F shows 
the uploaded Clinical Trials database information.  
 
3.5.2.3 Patient and Public Involvement 
Patients have been actively involved and were essential to the conduct of the research 
project. During the planning of the study and application to the South Birmingham Research 
Ethics Commission, patient involvement has been central. Five patients, who were listed for 
CRT implantation, were questioned to determine their opinion about the study. An 
assessment of how the study design reflected their health beliefs and whether uptake rate 
would be influenced by the study design was evaluated during these interviews.  
A subsequent consultation took place with the local comprehensive research network 
patient group in March 2014 to discuss the study and its methodology. This built on the 
initial patient involvement and comments were passed on the study design and the material 
being used, to recruit and collect data.  
The importance of reporting these findings to the specific participants and to HF patients is 
important. We have sent a summary document of the research findings to each surviving 
Dr Christopher J. McAloon 
 
128 
 
 
research study participant and have presented them at the Rugby Cardiac Rehabilitation 
group [www.rugbytakeheart.org.uk].   
 
3.5.3 Study Participants 
3.5.3.1 Participant Screening 
All patients undergoing CRT implantation at UHCW were screened against the eligibility 
criteria (section below). If the criteria were met the patients were approached to participate 
ahead of implantation. The COVERT-HF study did not alter or affect the decision to offer a 
CRT or the type of device. Screening occurred once the clinical decision had been made. 
Evaluation of the previous implants at UHCW suggested that recruiting 50 patients in two 
years was both feasible and achievable for this Proof-of-concept study.  
 
3.5.4 Study Outcomes 
The criteria for CRT functional and echocardiographic response will be applied short-term 
[six week review] and long-term (six months). Determining participant functional and 
echocardiographic status only occurred following the final follow-up study visit for the 
entire cohort and data-lock after database quality check .  
 
3.5.4.1 Response Definition 
Table 3.4 demonstrates the functional and echocardiographic response criteria’s that were 
utilised in the prospective observational study. The functional response criteria formed the 
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primary outcome. An echocardiographic definition was used as a secondary definition. The 
definition used for response did not combine functional and echocardiographic criteria’s as 
it is well established these variables poorly correlate.1 composite definition is required for a 
small obersational cohort study.  
 
The functional response definition used a composite definition. The functional response 
definition reflected symptoms, function and QoL.1 Three specifc criteria formed the 
combination definition. At least two of three parameters had to be present to determine a 
functional response. Symptoms were assessed using the NYHA classification, which is the 
commonest measure in the literature.1,23,29,76,85,86 QoL was measured using the validated 
tool; the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to detect significant 
changes. Function was assessed using the change in 6MWT.distance.241 LV remodelling has 
been defined by a echocardiographic variety of LV geometric and function measurments.1 
The most widely used echocardiographic measure of response is a ≥15% reduction in 
LVESV.52,71,242-244 This specific measure has been used to define echocardiographic response. 
 
All definitions are based upon the difference between baseline and 6 months follow-up 
(follow-up measurement - Baseline measurement). Both clinical and echocardiographic 
criteria had HF end-points (mortality or heart transplant) built in to define non-response, so 
those participants were not lost to follow-up. Including absolute end-points in definitions is 
common in more recent observational studies1,65,66,68 and minimises missing data.245  
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Table 3.4 Prospective Clinical and Echocardiographic Response Criteria 
 
 
 
 
 
3.5.4.2 Major Adverse Cardiovascular Event 
The same MACE definition has been applied throughout the entire project. A definition of 
MACE is given earlier in this chapter. In COVERT-HF participants were observed for MACE for 
12 months. Participants at each follow-up study visit (Figure 5.5) were asked about MACE. 
Approaching twelve months electronic/paper case notes alongside hospital coding data was 
reviewed. Participants were also contacted to ask about MACE.  
 
3.5.5 Eligibility Criteria 
Participants must have clinical investigations to allow assessment under the clinical criteria 
of the NICE guidance for CRT implantation.17 LVEF can be originally evaluated by 
echocardiography, cardiac magnetic resonance imaging or nuclear myocardial perfusion 
scanning (this does not replace baseline echocardiographic evaluation). 
 
 
Clinical Response at 6 months 
Two out of Three: 
↓> 1 NYHA 
↓MLHFQ score > 5 
↑> 10% 6MWT distance 
Echocardiographic Response at 6 months 
↓> 15% LVESV 
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3.5.5.1 Inclusion Criteria 
1. Age > 18 years  
2. LVEF ≤35% on echocardiography 
3. NYHA Class III/IV symptoms or milder symptoms with: 
a) NYHA I (LVEF <35% and QRS>150msec on resting electrocardiogram) 
b) NYHA II (LVEF <35% with either QRS>150msec or QRS 120-149msec with 
LBBB on resting electrocardiogram) 
4. Optimal medical therapy for heart failure that the patient tolerates (ACEi, Beta-
Blocker, Mineralocorticoid) for > 3 months 
5. QRS duration ≥120-149msec with LBBB on resting ECG or QRS duration >150msec on 
resting ECG 
6. Patient consent to participation in the study 
3.5.5.2 Exclusion Criteria 
1. Acute heart failure decompensation < 6/52 before implant  
2. Significant cognitive impairment 
3. Acute coronary syndrome < 6/52 before implant  
4. Chronic kidney disease stage V (requiring dialysis) 
5. Terminal illness with likely survival < 1 year after implant  
 
3.5.5.3 Procedure and Post Procedure Study Exclusions 
1. Failure of procedure (e.g. CS anatomy) 
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2. Complication resulting in poor/ none biventricular pacing (e.g. phrenic nerve 
stimulation, lead displacement/ damage) 
 
3.5.5.4 Informed Consent  
Patients were approached once decisions had been made regarding CRT implantation had 
been made. Patients were always approached in person by the investigator with ample time 
before the prospective implantation being performed. A patient information leaflet 
(Appendix G) was provided at this discussion, which outlined the study. Each patient was 
given adequate time to consider participation in the study and ask any questions they might 
have. Only once a patient was completely satisfied, was the patient asked to complete a 
research study consent form (Appendix H). Copies were provided for the participant, 
medical notes, General Practitioner and research notes. Enrolment in the study started in 
November 2013. 
 
3.5.6 Study Design 
3.5.6.1 Overview 
COVERT-HF was an unselected, prospective cohort study of CHF patients referred for CRT 
placement at UHCW. The COVERT-HF study as outlined in the previous study was a proof-of 
concept study examining the potential predictive strength of specific ECM and miRNA 
biomarkers for CRT response. The research protocol is provided in Appendix I. All patients 
undergoing CRT implantation were screened, as previously outlined. The study was 
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performed over 32-months between November 2013 and June 2016. Recruitment occurred 
over the first 20 months with the final 12 months used to complete follow-up assessments 
and observe for MACE outcomes. A target to recruit 50 patients was set on the basis of the 
UHCW implantation rate (82 CRT implanted 2012). 
 
Figure 3.5 outlines the COVERT-HF study schedule. Following recruitment to the study 
participants underwent three assessments at different time points (pre-procedure, 6 weeks  
and 6 months post-procedure). The pre-procedure assessment could be performed up to 
seven days before the procedure, but was planned to be done on the day of implant. The 
follow-up assessments were scheduled to take place simultaneously with routine CRT device 
reviews. Flexibility around the time of follow-up was allowed to be pragmatic and ensure 
participant retention. The specific ECM and miRNA biomarkers being investigated are stated 
in Figure 3.5. The evidence for their selection is outlined in Chapter 1 and 4 respectively.  
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Figure 3.5 Study Scheme for COVERT-HF. *=performed on the second half of cohort  
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3.5.7 Assessments  
Specific assessments were performed as per the study schedule (Figure 5.5). Clinical care for 
CHF and CRT continued with no changes to usual care. 
 
3.5.7.1. Clinical Assessment  
Appendix J outlines the specific clinical data collected at each study visit outlined in Figure 
3.5. There was slight variation in data collected between the baseline and follow-up visits. 
Specific procedure details were also collected. All the data capture forms for baseline and 
follow-up study visits are shown in Appendix K.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
3.5.7.2 CRT Device Interrogation 
Routinely at 6 weeks and 6 months following the procedure, the implanted CRT was 
interrogated to ensure the device optimisation and to identify any complications. The 
interrogation of the implanted CRT is non-invasive using a programmer for the specific pulse 
generator in-situ (2090, Medtronic, Minneapolis, Minnesota, USA or Merlin 3650, St Jude, St 
Paul, Minnesota, USA or Zoom Latitude, Boston Scientific Natick, Massachusetts, USA). The 
interrogation of the device was performed by an accredited cardiac physiologist as part of 
the patient’s routine care.  
 
The biventricular pacing percentage and battery longevity was recorded. Any 
reprogramming that was performed was documented. Device complications that were 
identified were noted. Those patient with a CRT-d implanted also had defibrillator 
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functioning documented, specifically any anti-tachycardia pacing and/or shocks that had 
been delivered. This information alongside the clinical observations allowed the post-
procedure exclusion criteria (Section 5.2) to be examined and applied if necessary.   
 
3.5.7.3 Cardiovascular Observations 
During each clinical assessment, a pulse rate was taken manually by palpating the radial 
pulse for one minute. A blood pressure reading was taken after 10 minutes of resting in a 
chair, obtaining a reading using a validated oscillometric sphygmomanometer (V100, 
Dinamap technology ®, GE Healthcare, Milwaukee, Wisconsin, USA). The same technique 
was performed for assessing blood pressure before and after the performance of the 
6MWT. 
 
3.5.7.4 Body Composition 
Every participant underwent height and total body weight measurement using a standard 
combined height/weight scale (SECA, model 701/7021094, Germany). These measurements 
allowed calculation of BMI (weight (kg) / height(cm2)). These measurements are in addition 
to the Air-displacement plethysmography measurements performed.   
 
3.5.7.5 Electrocardiogram 
All participants had a resting 12-lead ECG recorded using an electrocardiograph (MAC* 5500 
HD Resting ECG System, GE Healthcare, Horten, Norway) as per the study schedule (Figure 
5.5). Lead placement was according to standard practice and performed with all subjects in 
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the supine position by an experienced cardiac technician. Digital storage of the ECGs was 
performed for all traces. Interpretation of the ECG was by the lead investigator. Data was 
recorded (Appendix K) on rate, rhythm, pacemaker presence, PR interval, cardiac axis 
(normal/abnormal) and QRS duration/morphology on the clinical data capture form for both 
baseline and follow-up study visits. Interpretation of QRS duration and morphology applied 
previously described definitions in the literature.228,229  
 
3.5.7.6 Six Minute Walk Test  
The 6MWT is a simple and robust functional exercise capacity assessment that is easily 
performed, well tolerated by patients with cardiovascular and respiratory health problems, 
and reflects the patient’s activities better than other walk tests.241,246  It measures the 
functional exercise capacity globally and the involvement of multiple body systems, 
including the cardiac, pulmonary, circulation, blood transport and neuromuscular systems. 
In contrast to more complex functional exercise capacity testing (ie Cardiopulmonary 
exercise testing) specific measurements of these body systems cannot be performed.241 
Despite these obvious limitations, the 6MWT distance does correlate with peak oxygen 
uptake (r=0.73) in end-stage lung disease.247 Walk tests reflect self-limiting sub-maximal 
exercise testing and reflect a patient’s activity of daily living.247 The 6MWT has specifically 
been shown to be a robust sub-maximal functional exercise test in patients with 
cardiovascular and respiratory impairment.241,246,248,249 The 6MWT is well established for 
functional exercise capacity assessment in CHF248 and has been used in the majority of 
randomised control trials examining CRT intervention.23 In CHF patients undergoing CRT, the 
6MWT has been demonstrated to be safe. 22,28,250 The 6MWT is a robust test in examining 
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changes in functional exercise capacity following an intervention.241 Validity of the 6MWT 
has been shown to be high with short-term distance replication being excellent when 
circumstances are the same, including the investigator performing all the tests.241,251 
All 6MWT were performed in concordance with the American Thoracic Society 2002 
guidelines.241 Appendix L provides a summary of the specific protocol undertaken 
performing the 6MWT and the information collected for the COVERT-HF study. 6MWT were 
performed at all patient assessments (figure 3.5). Two investigators undertook each 6MWT 
assessment with each patient, one of who was always a physician with an Advanced Life 
Support qualification. Figure 3.6 demonstrates an example of a 6MWT being performed. The 
investigators were trained to perform the test by technicians who were experienced. The 
same investigator led the 6MWT for every test that was performed during the COVERT-HF 
study. Practice tests were not performed due the limitation of patient time on baseline 
assessment and the limited improvement in technique and 6MWT distance recorded on 
previous studies.241,252 
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Figure 3.6 A Replicated Example of a 6MWT. 
 
The American Thoracic Society 2002 guideline241 lists absolute contraindications to 6MWT as 
unstable angina or MI during the previous month. Acute heart failure hospitalisations in the 
last month were also treated as absolute contraindications. Relative contraindications are 
listed as resting heart rate of more than 120bpm, a systolic blood pressure of more than 180 
mmHg, and a diastolic blood pressure of more than 100 mmHg. The physician supervising 
the test or the participant had the power to decide not perform or to stop the 6MWT. 
 
3.5.7.7 Transthoracic Echocardiogram 
A full transthoracic echocardiogram (Vivid 7, GE Healthcare, Horten, Norway) was 
performed at each study visit by a British Society of Echocardiography accredited 
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sonographer meeting the national standard.253 All echocardiograms were performed in the 
Department of Cardiac Investigation at UHCW on the same machine by the same operator. 
Two dimensional echocardiography, myocardial tissue Doppler velocities and Doppler blood 
flow measurements were performed on each participant (Figure 3.7). Immediate review of 
all images was performed by the operator to ensure no significant clinical findings needed to 
be actioned. All measurements were analysed offline (EchoPac, GE Healthcare, Horten, 
Norway) by an unblinded investigator following a significant period of time after the scan 
(>1month). To partially mitigate for this reporting bias an inter-rater study was undertaken. 
 
Figure 3.7 A Transthoracic Echocardiogram on a Participant. Participant consent obtained 
for use of image in research and publications. 
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A full set of measurements were performed in each study. Emphasis was placed upon 
obtaining two dimensional LV systolic and diastolic volumes in the four and two-chamber 
views using the biplane method of discs (modified Simpson’s method).253 The biplane 
method of discs is used to calculate the respective volume through the summation of a 
stack of elliptical discs that are produced when tracing the endocardial border during 
measurement analysis.253 Figure 3.8 demonstrates the images required to be taken to 
perform LVEF calculation using modified Simpson’s method. LVEF was calculated using the 
biplane LV volumes253 (LVEF = (LVEDV-LVESV)/LVEDV). Single plane measurements pose 
particular limitations when utilising this method to calculate the LV volumes when regional 
wall motion abnormalities are present.253  The significance of LV dimensions and functional 
measurements is shown in appendix M.   
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Figure 3.8. Two Dimensional Biplane Method for LV Measurement. Apical four- and apical 
two-chamber  measuring LVEDV and LVESV respectively. Measurements biplane method of 
discs (modified Simpson’s rule), and allow calculation of LVEF. (Adapted253) 
 
Diastolic function was assessed utilising two-dimensional measures, colour flow Doppler’s 
and pulse and continuous wave Doppler Left atrial volume was calculated from the apical 
four chamber view.254 Mitral value inflow measurements were performed in the apical four-
chamber views and placing pulse wave Doppler at the coaptation point. During diastolic 
LVEDV LVESV 
Apical  
4-chamber 
Apical  
2-chamber 
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filling of the LV, peak passive filling I and peak active filling (A) were measured and allowed 
the calculation of the E/A ratio. LV compliance was measured by Tissue Doppler imaging of 
the mitral annulus. 254 Pulse wave Doppler sampling is placed at or within 1cm of the lateral 
and septal annular sites during Tissue Doppler Imaging in the apical four-chamber view.254 
The peak passive filling velocity (e’) and peak active filling velocity (a’) were recorded. An 
average of the e’ and a’ were taken from the lateral and septal to calculate the averages.254 
The ratio of early transmitral flow velocity to the mean annular mitral tissue velocity (E/e’) 
was calculated and represented an estimate of the LV end diastolic pressure.254 Participants 
in AF at the time of the scan had an average for all measurements over 3-5 cardiac cycles. 
Measurements were not taken on an ectopic of the following heartbeat.  
 
3.5.7.7.1 Inter-Rater Echocardiogram Variability Study   
Echocardiography performance and reporting were conducted by an unblinded investigator. 
Despite the temporal dissociation for reporting scans built into the study design, there was a 
reporting bias present. Blinding for performance and reporting of echocardiograms was not 
feasible within the pragmatic limitations of the study designs. An inter-rater variability study 
was undertaken examine for the degree of homogeneity between two observers.  
 
Twenty percent of echocardiograms were randomly selected to have LV volumetric (Biplane 
LVESV and LVEDV) and LVEF measurements repeated by a second independent and 
accredited sonographer (Mrs Kamerjit Rai). Block randomisation of every sequential five 
participants in order of recruitment was performed to select one to be included in the inter-
observer study. All the echocardiograms that participants had performed were included in 
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the study. Methods used to assess inter-observer variation have previously been described 
in detail.255,256   
 
3.5.7.8 Questionnaire 
Participants were asked to complete the study questionnaire at all three study visits (Figure 
3.5). Each questionnaire asked about participants symptoms and exercise tolerance. The 
baseline visit questionnaire additionally inquired about demographics gender, age and 
ethnicity. The two follow-up study visit questionnaires both enquired about any 
hospitalisations and device complications. Specific details of either of these events were 
explored. Appendix N demonstrates the symptoms questionnaire. 
 
The MLHFQ was performed at all defined three study visits to assess participants QoL. The 
MLHFQ is a validated and reliable QoL questionnaire in HF research studies. The self-
completion MLHFQ was administered to the participant as described in the literature.257-259 
Appendix O summaries how the questionnaire works and is scored. Appendix P shows the 
MLHFQ used in the study.  
 
The MLHFQ was administered at the start of the research visit. An explanation given to the 
participant explaining how to answer the questions and that all questions must be 
completed was given at each research visit. When questions were not applicable it was 
advised to give a score of 0 as per the guidance.258,259 The investigator left the room while 
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the MLHFQ was completed, but was available for clarification if needed. It was made clear 
to the participant that no aid in answering questions could be provided. A visual inspection 
was made of the score sheet upon completion to ensure no answers had been missed. 
Scoring was performed following completion of the research visit. Appendix O summarises 
the different domains and how the MLHFQ is scored.   
 
3.5.7.9 Air-displacement plethysmography (Sub-Study)  
Initially during the design of the COVERT-HF, body composition assessment was going to be 
assessed at each study visit (Figure 3.5) using the bioelectrical impedance analysis (BIA) 
method. BIA was considered due to availability to an Inner Scan®V, (Model BC-601, Tanita 
Corporation, Tokyo, Japan). CRT manufacturers St. Jude Medical (St.Paul, Minnesota, USA), 
Medtronic (Minneapolis, Minnesota, USA), Boston Scientific (Natick, Massachusetts, USA) 
advise that use of BIA is not recommended due to concerns over the possibility of 
oversensing, inappropriate shocks, inhibition of pacing, or  device malfunction.260 However, 
there is no evidence of interference from BIA devices on ICD function including telemetry 
disruption or lead oversensing.260 Despite this evidence the manufacturer recommendation 
meant we were unable to perform body composition assessment with BIA. 
 
COVERT-HF recruitment had begun when the decision to not perform BIA was taken. Whole 
body air-displacement plethysmography (BOD POD®) was considered to be a practical 
alternative to the more traditional techniques of measuring body composition and it would 
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be safe to perform for patients with CRTs in situ. The Human Metabolic Research Unit 
(HMRU) is a unique research facility designed to study human metabolism at our institution. 
Body Composition assessment is one of the facilities in the HMRU. The BOD POD® (Life 
Measurement Inc, Concord, California, USA) within the HMRU was used to perform the 
body composition assessment. Figure 3.9 shows the Bod Pod in the HRMU at UHCW. 
Appendix Q summarises why the BOD-POD® is considered to be a very reliable and 
reproducible measurement of body composition. 
.  
Figure 3.9 The BOD POD® in the HRMU at UHCW 
 
The investigator was trained to perform BOD POD® assessments independently. The first 10 
Bod Pod assessments for COVERT-HF were supervised by a trained technician. The BOD 
POD® is validated and calibrated on a weekly basis by the HMRU technician to ensure 
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measurement accuracy. The particular room the BOD POD® is contained within is designed 
to minimise measurement noise and pressure disturbances. 
 Participants were asked not to eat/drink/exercise for at least two hours prior to the test. 
The 6MWT was always performed after this. The same investigator performed all the BOD 
POD® assessments within the Sub-Study. Participants were asked to take off their clothes 
down to their underwear. All participants wore lycra swim caps to flatten their hair down. 
These steps in optimisation minimise the participants surface area, allowing for a more 
accurate estimate of body composition. A calibration of the BOD POD® is run prior to every 
test using a 50 litre cylinder. Participant details (height, gender, age) were entered into the 
BOD POD® to contribute to the calculation of the body composition. The total weight was 
measured on the attached calibrated scales. A predicted lung volume was used in the 
COVERT-HF BOD POD® procedure, due to the required participant time to learn the precise 
breathing technique.  
 
The participant then stepped into the chamber and the door was closed. Participants were 
asked to sit still and take regular breaths. A short sequence ensues where body surface area 
is measured. The sequence is repeated at least once and an average of the measurement is 
taken. When both measurements demonstrated either a >0.2% or >150ml difference, a 
third measurement was required.261 Following the test the participant’s waist circumference 
was measured, 2cm above the iliac crest line. 
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3.5.7.10 Blood Sampling 
Participants were asked to starve for two hours and rest for one hour before blood 
sampling. They were asked to refrain from smoking and drinking caffeine on the morning of 
the procedure. Anti-platelet medication is expected to be taken by a significant proportion 
of the cohort and may affect the expression platelet specific miRNA.147 No heparin is used 
during CRT implantation eliminating a recognised confounder for microRNA expression.262  
 
3.5.7.10.1 Peripheral Venous Sampling  
Peripheral blood was taken from a large peripheral vein, ideally the anterior cubital fossa 
vein in the right arm. A reasonable alternative was considered if this vein was not accessible. 
Whole blood was directly aliquoted into citrate and EDTA tubes. A total of 30ml whole blood 
was taken in total. Preparation and storage of samples is outlined below. Samples were 
taken for local laboratory analysis alongside biomarker testing. 
 
3.5.7.10.2 Coronary Sinus (Sub-Study) 
The CS is directly accessed during the CRT implantation for placement of the LV placing lead. 
Access is obtained with a catheter allowing blood samples to be directly taken from the 
venous drainage of the heart. Previous studies of ECM biomarkers has shown the potential 
value of directly sampled the CS both in physiological understanding, but also clinic value.263 
Chapter 4 specifically discusses the evidence of sampling biomarkers from the CS and the 
information this has provided. Sampling the CS was considered to be practical and safe 
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(already being performed) and would add value to the understanding of ECM and miRNA 
behaviour  
 
Additional permission was gained from a substantial amendment to sample CS blood during 
the CRT procedure, to examine variation in biomarker level in the heart and peripherally. 
Over half the cohort were eligible to take part in this sub-study (n=26). The CS was directly 
cannulated during implantation of the LV pacing lead. Following direct cannulation of the CS 
30ml of blood was sampled with the first 10ml being immediately discarded. The remaining 
20ml of whole blood was distributed appropriately to blood tubes as outlined in the above 
section. Blood was centrifuged and stored by the methods outlined below.  
 
3.5.7.10.3 Laboratory Parameter Measurements 
One citrate and EDTA blood vial from peripheral sampling was sent immediately to the 
UHCW local laboratory for measurements of Haemoglobin, renal function, NT-pro-BNP and 
in established diabetics HbA1C. 
 
3.5.7.10.4 High Sensitivity Troponin-T  
Following completion of the participant recruitment, discussions regarding ECM and miR 
biomarker analysis concluded that hs-TnT assessment would be important in novel 
biomarker analysis. Electrochemiluminescence Immunoassay (ECLIA) analysis was 
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performed at UHCW using the cobas e 602 module of the cobas ®8000 modular analyser 
series (Roche Diagnostics, Basel, Switzerland). The HS-TnT immune assay (cobas®, Roche 
Diagnostics) utilised the sandwich electrochemiluminescence (ECL) principle, which is 
discussed in later in this chapter. Hs-TnT was performed on frozen serum samples (-80oC). 
The literature and the manufacturers determine the immunoassay is stable and reliable for 
frozen samples with little variation in results.264   
 
3.5.7.10.5 Blood Preparation and Storage 
Whole blood is transferred to citrate and EDTA blood tubes immediately after being taken. 
Blood vials selected for biomarker analysis stood at room temperature for a minimum of 30 
minutes and undergo centrifugation within maximum of an hour. Centrifugation was at 
3500 rpm for 10 minutes at room temperature. Both serum and plasma was produced in 
separation phases. The top phase was taken from both plasma and serum and pipetted into 
5x1.2ml aliquots. Samples were then stored immediately at -80oC.  
 
3.6 LABORATORY METHODOLOGY 
Material Transfer Agreements were arranged between UHCW and all recipient centres 
(outlined below) before sample transfer. All participant samples analysed were anonymised 
prior to analysis. Dr Chris McAloon performed the enzyme linked immunosorbent( ELISA) 
analysis and the miRNA profiling. A blinded technician/research fellow trained and assisted 
with both analyses. Dr Jimiao Hu assisted with the assay (ELISA) assessment and Dr Temo 
Bawari guided the miRNA profiling. Batch analysis was performed for the total COVERT-HF 
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cohort (174 samples). All individual participant samples were analysed after final follow-up 
within the same batch. 
 
ELISA quantification was employed for quantification of specific ECM biomarkers (PIIINP, 
MMP-2, and -9) and GDF-15 within the Clinical Science Research Laboratory led by Professor 
Harpal Randeva, Warwick Medical School. Electrochemiluminescence immunoassay (ECL) 
for ECM biomarkers (PINP and collagen I C-terminal telopeptides (CTx)) was performed by 
the Department of Biochemistry, Royal Liverpool and Broadgreen University Hospital NHS 
Trust. MiRNA profiling (miR-21,-30d,-122,-133a,-210,-486) was performed in collaboration 
with the Cardiovascular Proteomics group, under supervision of Professor Manuel Mayr, at 
the British Heart Foundation Centre, King’s College London.  
 
3.6.1 Enzyme Linked Immunosorbent Assay  
ELISA quantification was performed on specific ECM biomarkers (PIIINP, MMP-2 and -9) and 
GDF-15. The general ELISA methods employed by our group have been previously described 
in the literature.265,266 GDF-15, MMP-2 and -9 utilised the DuoSet ® ELISA assays (R&D 
Systems Inc, Minneapolis, Minnesota, USA) and PIIINP utilised Cusabio (Wuhan, Hubei, 
China). The GDF-15 assay protocol had previously been used in a published cohort study.112  
All samples analysed were prepared plasma as previously outlined. The samples were all 
analysed on the first freeze-thaw cycle. All analyses were performed in duplicate. Analyses 
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were performed for all four assays on 96-well plates with a 6- or 7-point standard curve on 
each plate.  
 
The process and principles of quantitative sandwich ELISA are outlined in Figure 3.10 Assay-
specific protocols were followed for each analysis. For the R&D protocols capture antibodies 
were diluted to working concentrations in Phosphate-Buffered Saline (PBS). All 96 wells of 
the microplate were coated overnight with 100μl of capture antibody. Following incubation 
three automated wash cycles were performed by the Thermo Scientific Wellwash 4 Mk 2 
microplate washer (Thermo Electrical Corporation, West Chester, Pennsylvannia, USA).  
Each well was then blocked with 300μl of Blocking Buffer (1% Bovine Serum Albumin (BSA) 
in PBS) and then incubated at room temperature for one hour. A further three automated 
wash cycles were then performed. The PIIINP Cuasbio assay provided a pre-coated and 
blocked microplate as part of the kit provided by the manufacturer.   
 
Recombinant protein in known concentrations were used for each assay to prepare a six or 
seven point (dependent on protocol) standard curve, using a two-fold serial dilution. A blank 
dilution buffer sample was used for background correction. Serial dilutions were performed 
using several participants’ plasma samples to identify the optimum dilution for MMP-2 and 
PIIINP assays. For the MMP-9 and GDF-15 assays, dilutions were based upon previous 
reported studies. Based on these experiments, the following dilutions were used for the 
whole cohort: MMP-2 1:50, MMP-9 1:100 and GDF-15 1:10. PIIINP had no dilution 
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performed. Sample analysis was repeated if the results fell outside the serial dilution curve 
in duplicate.  
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(1) Capture antibody is bound to the 96-well microplate 
(2) Sample is added, and the corresponding antigen binds 
to the capture antibody 
(3) Detecting antibody is added, and binds a different 
epitope on the antigen 
(4) Enzyme-linked secondary antibody is added, and binds 
to the detecting antibody 
(5) Substrate is added, and is converted to a detectable 
signal by the enzyme 
Figure 3.10 The Process of a Sandwich ELISA, Microplates are coated with a specific 
antibody or protein (1) to bind the corresponding protein present in the samples (2). 
Unbound substances are washed away, and a monoclonal antibody specific to the protein 
being measured is added to the plate (3). A second wash removes unbound antibody and 
an enzyme linked antibody specific for the primary antibody is added (4), followed by an 
amplifier solution which develops colour in proportion to the amount of measured 
substance present (5). The reaction is stopped by addition of a stop solution (usually an 
acid); plates are then read using a microplate reader. 
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Following blocking and subsequent washing, 100μl of sample or standard were pipetted to 
each respective well and incubated at room temperature for 2 hours (PIIINP microplates 
incubated at 37oC). A further three automated wash cycles was then performed (liquid 
removed but wash was not performed for PIIINP analysis protocol). Detection antibody 
(biotinylated) was diluted in reagent diluent according to manufacturer’s instructions 
(MMP-9 analysis diluent included Normal Goat Serum) and then had 100μl added to each 
well. Incubation was for two hours at room temperature for all assays except for PIIINP 
which was for an hour at 37oC. A working dilution of Streptavidin conjugated to horseradish 
peroxidase (HRP) was prepared and 100μl was pipetted into each respective well after three 
automated washes. Incubation was then performed for 20 minutes at room temperature 
(PIIINP for one hour at 37oC) in the dark. A further three automated wash cycles were then 
performed. 100μl of substrate solution (1:1 mixture H2O2 and tetramethylbenzidine) were 
added to each well and incubated for 20 minutes at room temperature in the dark. The 
PIIINP assay protocol requires the addition of 90μl of tetramethylbenzidine substrate to 
each well and incubated for 30 minutes at 37oC, in the dark. Finally 50μl of stop solution (2N 
H2SO4) were added to each well, ensuring thorough mixing. Time between adding substrate 
and stop solution was dependent on observed intensity of the substrate colour. Microplate 
reading was performed by PHERAstar FS (BMG Labtech, Ortenberg, Germany). The microplate 
reader wavelength was set to 450nm. Background noise unrelated to the assay (such as 
optical imperfections in the plate) was corrected for by subtracting a reference 
measurement that was obtained at 570nm. 
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Quantification of the assay target concentration was calculated by plotting obtained optical 
density values to a standard curve. This standard curve was generated with the serially 
diluted assay standard following subtraction of the background noise from each well. 
Optical density values (see an example in Table 3.5) were fitted using a four-parametric 
logistic regression (4PL) curve-fit.267  
Table 3.5 Serial Dilutions Optical Densities for GDF-15 Microplate 2 
. 
 
 
 
 
 
 
The 4PL model is the most suitable for fitting a standard curve for many complex biological 
systems and is the gold standard in ELISA analysis.267  The 4PL model is summarised by the 
following equation, where four parameters are calculated to fit a curve to a set of 
standards:  
 
The known standard concentrations are logarithmically converted to produce a semi-
logarithmic scale for fitting the 4PL model. The best-fit is calculated based upon the optical 
Standard Curve GDF-15 (Microplate 2) 
Serial Dilution (pg/ml) Optical Densities 
500 1.976 1.936 
250 1.188 1.174 
125 0.585 0.459 
62.5 0.216 0.196 
31.3 0.086 0.075 
15.6 0.041 0.043 
7.81 0.023 0.026 
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densities of the set of standards (for example in Table 3.5) producing an S-shaped curve. In 
the equation y represents the response value (i.e. optical density of the standard) and the x 
represents the dose value (i.e. the known concentration of the standard), whilst a and d 
represent the maximum and minimum asymptotes (horizontals) of the curve respectively 
(and they can be interchanged). The a and d values are the same units as the y value. The c 
parameter represents the point of inflection (the midway point between a and d). The b 
parameter is the hill’s slope of the curve (relates to steepness of curve at point c).  
 
GraphPad ® PRISM 2007 version 6.0 (San Diego, California, USA) was used to calculate a 4PL 
curve to fit the set of standards and replicated on an online ELISA analysis tool 
(www.elisaanalysis.com).268-270 A 4PL curve fit was calculated for each individual microplate. 
The strength of each fit was tested with the strength of the correlation and was accepted if 
above a coefficient of >0.97. Figure 3.11 demonstrates an example of best-fit for GDF-15 
microplate 2 from the COVERT-HF study (using the values generated in Table 3.5). Samples 
of unknown concentrations are expressed relative to the calculated standard curve. The 4 
parameters calculated for this particular example is demonstrated. Reversing the 4PL curve 
when all 4 parameters and optical density is known allows interpolation of the unknown 
target concentrations. This was performed within Microsoft Excel 2010 following the 4PL 
calculations in GrapPad PRISM. Measured mean concentrations of duplicates underwent 
multiplication by the respective dilution factor (see above). 
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Figure 3.11 The 4PL Best-Fit Standard Curve for GDF-15 Plate 2. Values a,b,c and d are 
calculated for the plotting of the known set of standard concentration and best fitting a 4PL 
standard curve to the values. The standard curve allowed concentrations in samples to be 
calculated. 
 
The precision and reliability of the ELISA assay was estimated by calculating the inter- and 
intra-assay coefficient of variability (CV). The inter-assay CV is an important measure of 
plate-to-plate consistency. This is particularly important in large cohort studies like COVERT-
HF as five microplates were required to assess one biomarker assay in all samples. The 
highest and lowest duplicate values are utilised to calculate high and low microplate means. 
These high and low microplate means were combined to calculate an average mean and 
standard deviation of the means, which in turn allowed for the calculation of the percentage 
CV of means for highest and lowest values. An average of these measures allowed 
a=2.796 b=1.687 c=304.9 d=0.02211 
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calculation of the inter-assay CV. The intra-assay CV assesses the individual variation 
between duplicates upon each microplate. The results are presented as a mean of all 
individual intra-assay CV’s on one microplate. The mean concentration and the standard 
deviation of the duplicates were calculated. Subsequently the standard deviation was 
divided by the duplicate mean and the individual intra-assay CV percentage was calculated 
and the average for the plate calculated. 
 
3.6.2. Electrochemiluminescence Immunoassay  
The Royal Liverpool and Broadgreen University Hospital NHS Trust have extensive 
experience of performing this specific immunoassay (PINP and CTx) on large quantities of 
samples commercially and for research purposes. The samples were processed and analysed 
on the Cobas e 602 module of the Cobas®8000 modular analyser series (Roche Diagnostics, 
Basel, Switzerland). Immunoassays for PINP (total P1NP) and CTx (ß-CrossLaps/serum) were 
produced by Cobas® specifically for this analyser. The immunoassays inter and intra assay of 
precision for P1NP was <3.0%, and for CTx was <2.5%. The assays manufacturer calculated 
measures and were locally validated according to international Clinical and Laboratory 
Standards Institute EP05-A3 protocol.271 
 
ECL is a highly sensitive process where reactive molecules are generated from stable 
precursors at the surface of an electrode.272,273 The highly reactive species interact to 
produce light.273,274 ECL is based around two electrochemically active substances, the 
ruthenium complex and tripropylamine (TPA). Both substances remain stable until a voltage 
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is applied. Figure 3.12 outlines the ECL reaction that occurs between ruthenium and TPA 
when voltage is applied in the reaction field at the electrode.  
Three test principles underpin ECLIA; competitive, sandwich and bridging principle. Both the 
PINP and CTx immunoassays utilise the sandwich ECLIA methodology. Figure 3.13 outlines 
the process of sandwich ECLIA. Measurement of the specific antigen/analyte quantity is 
based upon the amount of ECL light emission compared to the established standard 
calibration curve. In the ECL reaction ruthenium is constantly regenerated through the 
reaction, leading to multiple photons release for every one immune complex present. The 
amplification process makes the process particularly sensitive for quantification purposes. 
TPA is depleted rapidly through the process and must be present is excess and depletes 
following peak light emission.  
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Figure3.12 The ECL Reaction occurs on the platinum electrode when voltage applied creates an 
electrical field and all materials presen react. TPA is oxidised at the electrode releasing an 
electron (e-) and forming a intermediate TPA radical cation (TPA^
+
), which further reacts by 
releasing a proton (H+) to form a TPA radical (TPA^). Simultaneously the ruthenium complex  
releases an electron at the surface of the electrode to form the Ru[bpy]
3
3+ 
cation. This cation 
reacts with the TPA radical, reducing Ru[bpy]
3
3+  
to Ru[bpy]
3
2+ 
 which forms an excited state due 
to energy transfer. This excited state is unstable and decays with the emission of a photon 
(620nm) its stable state. The reaction continues while TPA is abundant.  
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(1) Incubation of antigen, biotinylated monoclonal antibody and ruthenium complex 
labelled monoclonal antibody; antibodies capture the specific antigen during the 
incubation period 
Antigen 
Rhuthenium 
Labelled   
 Monoclonal  
Antibody 
Biotinylated  
 Monoclonal  
Antibody 
Immune Complex 
Streptavidin- coated 
Paramagnetic Microbead 
(2) Addition of strepavidin-coated paramagnetic microbeads; during incubation biotinylated 
antibody attaches to strepavidin 
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TPA 
TPA 
Photomultiplier 
LIGHT 
ECL 
Reaction 
(4) Electrochemiluminescence reaction (ECL) of  ruthenium complex  (ruthenium-tri[bipyridyl)
2+ 
 
and TPA when voltage applied at the working electrode producing light; amount of light 
proportional to the amount of the specific antigen 
Figure 3.13 The Process of sandwich ECLIA.  
Working Electrode 
 
Magnet 
TPA 
TPA TPA 
(3) Reaction mixture transported into measuring cell; immune complexes are magnetically 
entrapped on the working electrode; unbound reagent and sample are washed away with 
ProCell;TPA is simultaneously added during wash.  
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3.6.3 MiRNA Profiling 
MiRNA profiling was performed collaboratively in the British Heart Foundation Centre, 
King’s College London (Prof Manual Mayr). Six circulating miRNA specifically associated with 
cardiac adverse remodelling and ECM alteration in heart failure, alongside changes in 
expression with CRT implantation were selected to be measured in the COVERT-HF cohort. 
The specific miRNA were -21, -29b, -122, 133a, -210, and -486. Chapter 1 specifically 
discusses the literature which informed these selection decisions. Profiling miRNA was 
performed on 174 plasma samples for the entire COVERT-HF cohort at the same time. The 
plasma samples are defined as Platelet-Poor Plasma (PPP). 
 
3.6.3.1 RNA Extraction 
Total ribonucleic acid was isolated from PPP samples using the miRNeasy Mini kit (Qiagen, 
Hilden, Germany), using phenol- and chloroform-based extraction. This previously reported 
RNA extraction method is discussed in detail in this section.  
 
The 174 samples were extracted sequentially in batches of 24. Following defrosting, 500µl 
of PPP were transferred to 1.5  ml Eppendorf tubes and centrifuged at 4,000rpm at 4oC for 
10 minutes. To minimise RNA degradation, samples were kept on ice throughout. 
 
An exogenous miRNA (spike-in) was added at the start of the extraction process to allow for 
normalisation of the RNA isolation. This Spike-in is a synthetic miRNA based on the 
sequence of cel-miR-39-3p in the C. Elegans nematode. This miRNA does not occur in 
mammals, allowing for its use as an exogenous control. Following reconstitution in RNase-
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free H2O at a concentration of 10 µM, cel-miR-39-3p was further diluted to 2.5 nM with 
RNAse-free H20 in two steps, being vortexed at each stage. A mixture was prepared to be 
added to the sample, combining 4 µl of diluted cel-miR-39-3p, 194.75 µl of QIAzol lysis 
buffer, and 1.25 µl of bacteriophage-based carrier RNA (MS2). This mixture was prepared at 
the start of each sample batch, allowing for a sufficient amount for that batch. 
 
QIAzol lysis reagent is a monophasic solution of phenol and guanidine thiocyanate, designed 
to denature protein complexes and RNases, alongside removing most of the residual DNA 
and protein from the lysate by organic extraction. Under a laminar flow fume hood, 500µl 
QIAzol reagent was placed in each Eppendorf tube and subsequently 100µl of each samples 
was added, which was then vortexed, 30x inverted and incubated at room temperature for 
5 minutes. Subsequently 200µl Spike/QIAzol/MS2 mixture was added to each tube, followed 
by being immediately vortexed, 30x inverted and incubated at room temperature for 5 
minutes.  
 
Next 140µl chloroform was added to each Eppendorf tube, followed by being vortexed, 
shaken for 30 seconds and incubated at room temperate for 5 minutes. The Phenol to 
Chloroform ratio 5:1 is established with these additions, which is the optimal condition for 
producing conformational changes to proteins and lipids. Chloroform addition to phenol is 
more efficient at denaturing proteins than either reagent is individually. Furthermore, the 
addition of chloroform forces a sharper separation of the organic and aqueous phase during 
subsequent centrifugation as it is miscible with phenol and has a higher density than phenol 
(1.47g/cm3 vs 1.07g/cm3), which assists the removal of the aqueous phase with minimal 
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impact on the organic phase. Consequently, phenol on its own would retain 10-15% of the 
aqueous phase and result in a lower yield of RNA. 
 
The pH of phenol determines the separation of RNA and DNA between the two phases. 
When the pH is neutral or minimally alkaline (pH7-8), the phosphate diesters in the nucleic 
acid are negatively charged, which results in retention of RNA and DNA in the aqueous 
phase. DNA is removed from the aqueous phase as the pH lowers, to a maximum effect at a 
pH 4.8. During transfer of DNA to the aqueous phase it dissolves, due to the negative charge 
in their phosphate groups being neutralised in acid by protonation. RNA despite being 
negatively charged remains in the aqueous phase, due to being single stranded and having 
exposed nitrogen bases, which allows it to form covalent bonds with hydrogen in H2O. 
Altogether, acidic phenol causes retention of RNA in the aqueous phase and DNA in the 
organic phase; thus separating DNA from RNA. Moreover, during the centrifugation process 
and the subsequent separation, proteins contained within the samples separate out if they 
have charged domains or hydrophobic regions. These hydrophobic cores interact with the 
phenol causing precipitation at the interface between the two phases. The lipids in the 
sample dissolve in the lower organic phase.  
 
Following incubation, the tubes containing sample, Spike/MS2 mixture, QIAzol and 
chloroform were centrifuged at 12,000rpm at 4oC for 15 minutes to cause phase separation.  
Following centrifugation, 280µl of upper phase were transferred to new Eppendorf tubes 
containing 480µl 100% ethanol, mixing together with a pipette. This step allows for RNA 
recovery by precipitating and separating it from contaminants, alongside providing 
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appropriate binding conditions for all RNA molecules from 18 nucelotide and above. After 
mixing thoroughly, the sample/ethanol mixture were added to the miRNeasy Mini spin 
column, which is then centrifuged at 13,000rpm for 1 minute at room temperature. Total 
RNA binds to the silica-membrane, a process enhanced by guanidinium. The flow-through 
was discarded. The next step involved washing out the phenol and remaining additional 
contaminants, which was performed by adding 700µl RWT buffer (buffer contents are 
considered proprietary information by the company and are therefore not disclosed) to the 
column. The columns were then centrifuged at 13,000 rpm for 1 minute at room 
temperature, with the flow-through being discarded.  After this 500µl RPE buffer was 
pipetted into the column, and was centrifuged at 13,000 rpm for 1 minute at room 
temperature, with the follow-through being discarded. This step was repeated and followed 
by centrifugation for 2 minutes instead. The column was then placed in a clean collection 
tube and centrifuged at 15,000rpm for 1 minute at room temperature to facilitate further 
drying of the membrane.  
 
The column was subsequently placed in a new Eppendorf tube and 35µl RNase-free H20 was 
pipetted onto the membrane and centrifuged at 9,500 rpm for 1 minute at room 
temperature. This process elutes the RNA into the H20. The tube containing the RNA were 
then stored at -80 oC until further use. 
 
3.6.3.2 Reverse Transcription 
Quantification of total RNA first requires its conversion into a cDNA template by a reverse 
transcriptase. This enzyme naturally occurs in retroviruses, where viral genome replication 
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requires conversion of RNA into DNA inside the host cell. The methodology for reverse 
transcription in extracted RNA is previously described in the literature.147 A calibrator pool 
of RNA was created from 34 samples (9 patients) for normalisation of relative quantification 
of specific miRNA. 
 
The MegaplexTM RT Primers used in this reaction are in two predefined pools (Human Pools 
A v2.1 and B v2.0, Applied Biosystems®, Darmstadt, Germany), each pool used in separate 
reverse transcription reactions. Each pool consists of up to 380 stem-looped reverse 
transcription primers, that allows simultaneous synthesis of cDNA for mature miRNAs. The 
stem-loop primers design overcomes the problem of the short length of the mature miRNA, 
which does not allow the use of conventional linear primers for PCR. Figure 3.14 
demonstrates a stem-loop RT primer and its role in the reverse transcription reaction. There 
are further advantages associated with stem-loop primers. Firstly the annealing of a short 
RT priming sequence to the 3’miRNA provides a better specificity for discriminating similar 
miRNAs in the reverse transcription reaction. Secondly the stem-loop RT primer prevents 
hybridisation of its primer to miRNA precursors, other long RNAs and genomic DNA. Thirdly 
the base stacking of the stem enhances the thermal stability of the miRNA-DNA 
heteroduplex, further improving the reverse transcription efficiency for short primers.  
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Figure 3.14 MiRNA Detection and Quantification. (A) A stem-loop RT primer includes a 3’ 
overhang sequence, a stem and a loop. The 3’ overhang is a short sequence ranging from 5 
to 8 nucleotides that is specific to the 3’ end of the mature miRNA and when it binds 
increases the mature miRNA molecule size and adds a universal 3’ priming site for 
subsequent qPCR.(B) Reverse Transcriptase used the stem-loop primers to produce DNA, 
complementary to the mature miRNA single strand (cDNA). Pre-amplification (not 
represented on this schematic) is then performed, resulting in increased quantity of the 
targeted cDNA prior to qPCR. (C) In addition to forward and reverse primers, Taqman ® 
qPCR assays include a probe that has high affinity for the individual target, has a fluorescent 
reporter (F) and quencher (Q) attached to the probe. The quencher inhibits the omission of 
fluorescence from the reporter. A forward and reverse primer allows DNA polymerase to 
produce a complementary DNA strand from the target cDNA template. In the presence of 
DNA polymerase the TaqMan probe is hydrolysed, releasing the quencher and allowing the 
emission of fluorescence. As more PCR product accumulates exponentially with repeated 
qPCR cycles, the fluorescence emission increases, allowing for optical detection. (Adapted 
275) 
 
  
Dr Christopher J. McAloon 
 
171 
 
 
An RT MasterMix was prepared for each RT reaction; 1μl 10x RT Buffer, 0.3μl 100 mM 
deoxynucleoside triphosphates (dNTPs) with deoxythymidine triphosphates (dTTPs) 
(required for DNA synthesis), 1.2μl 25 mM MgCl2, 0.2 μl RNase Inhibitor, 1μl 10x Megaplex 
RT Primers (Pool A or B), 1.3µl 5x Cel-miR-39-3p Primer (which is not included in the 
Megaplex pools) and 2μl Multiscribe Reverse Transcriptase enzyme. The Applied 
Biosystems® MultiscribeTM is a recombinant reverse transcriptase from the Moloney murine 
leukaemia virus. Enough RT MasterMix was prepared for two 96-well plates. Using an 
Automated Liquid Handling Platform (Agilent, California, USA), 7µl of RT MasterMix was 
added to each well, then 3µl of each RNA sample was added to each corresponding well by 
hand, and mixed thoroughly. A calibrator sample (consisting of a pool of 34 samples) was 
loaded to designated wells on both 96-well plates. The RT-PCR reaction was performed in a 
Veriti Thermal Cycler (Applied Biosystems®) with settings as follows: forty cycles of 16°C for 
2 min, 42°C for 1 min and 50°C for 1 sec, followed by incubation at 85°C for 5 min to 
terminate the reaction. 
 
3.6.3.3 Pre-Amplification 
Pre-amplification is performed immediately after RT to increase the quantity of miRNA 
cDNA analysis before real-time quantitative PCR. The methods utilised for pre-amplification 
have been previously described and validated.276,277 The RT reaction products were further 
amplified using the MegaplexTM PreAmp Primers (Primers A v2.1 and B v2.0, Life 
Technologies, Massachusetts, USA). The MegaplexTM PreAmp Primers pools are miRNA-
specific forward and reverse primers that correspond to the composition of the Megaplex 
RT pools, which allow unbiased pre-amplification.  
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A pre-amplification Mastermix was prepared for each reaction; 3µl Nuclease-free H2O, 5µl 
2x TaqMan® (Applied Biosystems®) PreAmp MasterMix and 1µl 10x MegaplexTM PreAmp 
Primers.  Enough Pre-amplification MasterMix was prepared for two 96-well plates. The 
Automated Liquid Handling Platform added 9µl of pre-amplification MasterMix to each well, 
then 1µl RT product sample was manually added to corresponding wells, and mixed 
thoroughly. Calibrator RNA was loaded to the designated wells on both 96-well plates 
(Figure 6.1). The pre-amplification reaction was performed in a Veriti Thermal Cycler with 
the settings;  95°C for 10 min, followed by 12 cycles of 95°C for 15 sec and 60°C for 4 min. 
Finally, samples were heated at 95°C for 10 min to ensure enzyme inactivation. Pre-
amplification reaction products were diluted with nuclease-free H2O to a final volume of 
40µl and stored at -80°C. Prior to freezing the calibrator samples were aspirated from their 
respective wells, pooled together, mixed, and added back to the respective wells. 
 
3.6.3.4 Real Time Quantitative PCR 
The polymerase chain reaction amplifies a segment of DNA or cDNA between regions of a 
known nucleotide sequence. Two oligonucleotides are used as primers (forward and reverse 
primers), which are different in sequence and complementary to the sequence on the 
opposite sides of the DNA template flanking the segment of interest. This allows 
amplification of the area of interest which lies between the primers. Figure 3.15 
schematically highlights the stages of a qPCR reaction. TaqMan ® miRNA assay (Applied 
Biosystems) was used to determine the specific expression of miR-21,-30d,-122,-133a,-210,-
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486 and cel-miR-39-3p. TaqMan ® miRNA assays are highly sensitive and have a high affinity, 
due to the size of miRNA.  
 
Figure 3.15 The Polymerase Chain Reaction Stages. Initially cDNA template is denatured by 
heating. The reaction is then cooled to allow for annealing of the two oligonucleotide 
primers to its complementary sequence on the targeted cDNA. A polymerase then extends 
downstream from the targeted template sequence. The cycle is repeated 20-40 times 
through successive steps of denaturation, annealing and extension. Eventually, the 
concentration of accumulating products becomes high enough that double strand product 
formation is favoured over primer annealing, and the reaction plateaus. (Adapted278).  
 
A Mastermix for TaqMan® qPCR was prepared for each reaction, consisting of 2.5 μl 
TaqMan® PCR MasterMix and 0.25 μl TaqMan Assay. Separate Master mixes were prepared 
for each TaqMan® assay. Six MicroAmp Optical 384-well reaction plates (Applied 
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Biosystems) were mapped for every sample/assay to be performed for each specific miRNA 
target. Pre-amplified cDNA samples was further diluted by combining 5 µl of template with 
85 µl of nuclease-free H2O. There was 2.75μl MasterMix and 2.25μl diluted pre-amplification 
product added to each well by the Bravo Automated Liquid Handling Platform (Agilent). 
Calibrator sample/assay were mounted on each 384-well plate. The qPCR reaction was 
performed on a Viia 7 Real-Time PCR System (Applied Biosystems), set to run as follows: 
incubation at 95°C for 10 min for polymerase activation, followed by forty cycles of 95°C for 
15 sec and 60°C for 1 min.  
 
Data was analysed using ViiA 7 Software (Applied Biosystems). Relative amounts of the 
targets were calculated using the 2-ΔΔCT method.276,277 Cel-miR-39-3p and the calibrator 
sample were utilised for normalisation.  If the qPCR software reported undetermined values 
for individual replicates, a cycle threshold (Ct) value of 40 was assumed. 
 
3.7 DATA MANAGEMENT 
3.7.1 Study I 
A procedures list of all CRT implantations between January 2009 and December 2013 was 
generated formed the basis of the anonymous data collection. The list was generated from 
the procedure database (Carddas, GE Healthcare, Horten, Norway). Once CRT procedures 
were excluded (Figure 5.4) an anonymous database was created. A Microsoft Excel 2010 
(Version 14.0) database was designed to capture patient and procedure information. 
Specific columns had validated data entries, with pre-set options available to enter into a 
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particular cell. This occurred for binary and dichotomous variables. Where continuous data 
was collected this was limited to numeric data options.  
 
The database was password protected. Data collection adhered to the principles of the Data 
Protection Act 1998 and satisfied the local Caldecott Guardians. Personal information was 
anonymised upon collection. Patient information and anonymised data were stored on a 
secure Hospital hard-drive. An encrypted USB memory stick was used to store anonymised 
data. 
 
Data collection was undertaken by reviewing electronic and paper case notes. Two 
independent data reviews were performed to ensure high quality data. Hospital coding data 
on medical background and outcomes were sought. Ejection fraction and QRS duration were 
measured on all available pre-procedure echocardiograms and resting 12-lead ECGs to 
independently standardise measurements and minimise missing data.  All information 
available was collected for each anonymised patient research record.  
 
3.7.2 Study II 
Each participant was given a unique study number to cross reference the data collected with 
investigations performed, alongside biological samples stored. The original database 
contained patient identifiable information for research study activities including scheduling 
visits and tracking outcome measures  
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Prospective data collection forms (Appendix K) alongside the echocardiogram reports were 
utilised as source documentation for inputting of the data into the database. The database 
contains all the variables recorded in the COVERT-HF study design (Appendix J). The 
database was designed to have validated entries for binary or dichotomous variables only, 
preventing alternative data being inputted. The database was divided into multiple 
worksheets (i.e. clinical assessment and medications) to allow ease of navigation and 
analysis. Cardiovascular outcome (MACE) was confirmed with the source data, it was 
entered in the COVERT-HF database.  
 
Transthoracic echocardiograms reports and images were saved in the storage and analysis 
system (EchoPac, GE Healthcare, Horten, Norway). Reports were generated for each 
participant research visit and linked to the their clinical record.  
 
3.7.2.1 Study II Data Quality Check 
Prior to database lock and subsequent statistical analysis all source and electronic data was 
internally audited by a clinical trials officer to ensure accurate data entry. Where 
discrepancies were found errors were corrected if the mistake was obvious. When data 
errors were unclear, a verification conversation with the investigator was undertaken to 
ensure data integrity data.   
 
3.8 STATISTICAL ANALYSIS 
This section discusses the general approaches to handling the datasets and performance of 
statistical tests. Two specific datasets are presented in this thesis and specific statistical 
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methodological approaches for each dataset and analysis are discussed in the respective 
chapters. Clinical data was inputted into a purpose built Microsoft Excel Version 10 
database, which was discussed in chapter 2. The statistical analysis was planned and verified 
by Dr Thomas Hamborg (Division of Health Sciences Statistics and Epidemiology, Warwick 
Medical School, University of Warwick). Towards the end of the PhD Prof Alan Nevile 
(University of Wolverhampton) kindly provided statitcical support, specifically for the 
prospective study. All statistical analyses were performed using Statistical Package for Social 
Sciences [SPSS], version 22.0 (IBM, Chicago, Illinois, USA). All figures and graphs were 
produced using one or in combination of GraphPad® PRISM 2007 version 6.0 (San Diego, 
California, USA) or SPSS. Statistically significant results for both datasets is if the p-value 
<0.05.  
 
3.8.1 Database 
Databases following completion of initial data entry underwent a quality check process 
(chapter 5, section 5.6) to ensure a complete data cleaning process. After the quality check 
the datasets underwent datalock. Following data inputting quality checking the data for 
both respective datasets are transferred to the respective SPSS databases prior to 
performance of any analysis. Each participant is given a unique study number for the 
statistical database that provides complete anonymity. Continuous (scale) data was 
transferred unadjusted. Categorical (nominal and ordinal) was consistently numerically 
coded to allow accurate data handling with SPSS. For example for a recorded co-morbidity 
variable like previous myocardial, binary data is recorded (Yes or No). For allocation to the 
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statistical database in SPSS a specific coding system is employed; No=0 and Yes=1. 
Consistent coding was applied to both databases.  
 
3.8.2 Missing Data 
Missing data is common in clinical research, especially in time sensitive, resource-intensive 
or longitudinal observational data collection methods.245 Wood et al,279 in 2001 showed 
88.7% (63/71) trials reported partly missing data of which 17.8% had over 20% missing 
outcome data.279 Missing data itself and how it is handled can create biased results, 
decrease study power or lead to underestimates of uncertainty, all of which can reduce the 
chances of drawing valid conclusions.245 The causes of missing data (called ‘censoring’) can 
in itself be informative, when its absence may indicate something about the variable. For 
example a patient not attending follow-up due to travelling may be an indication of 
deterioration of health. The first step required to assess missing data is to establish a 
pattern of ‘missingness’ of which three patterns have been described; missing completely at 
random (MCAR), missing at random (MAR) and missing not at random (MNAR).245 MCAR 
means the probability of data being missing is completely unrelated to all observed and 
unobserved characteristics. MAR does not assume patients data with missing values are 
related to those with complete date, rather it assumes that observed values can help 
explain which are missing and can help predict what they might be.245 MAR is assumed to be 
a more likely mechanism of missingness than MCAR.245 Most studies plan their techniques 
for data handling on this basis.245 MNAR is the most problematic missing data pattern and is 
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dependent on unobserved or unknown factors. This mechanism is almost impossible to 
correct for.245  
 
Techniques are available within statistical software (including SPSS) to assess the pattern of 
missing data. The assessment of missing data allows the possible pattern of missingness to 
be established. Often this is assumed to be an MAR pattern, as MACR is often implausible 
and MNAR would mean nothing can specifically be done. Assessing the pattern of missing 
data within the datasets allowed the handling techniques to be implemented prior to 
analysis. 
 
Missing data handling strategies then need to be decided and implemented, the options 
include; complete case, last observation carried forward (LOCF), worst case imputation and 
multiple imputation.245,279 Complete case analysis is performed only on those subject with 
complete data (that is being tested), this method is only valid under MCAR.279 LOCF imputes 
missing values with the individual’s last observation, this is rarely realistic and often 
conservative.279 Worst case imputation fills all missing values with the worst case value, 
which leads to extreme results and is often biased. Multiple (or regression) imputation 
predicts the missing values from the observed individuals data.279 This mechanism assumes 
observed individual data can explain the missing data and is valid for MAR mechanism of 
missing data.279 Single imputation under-estimates the standard error, but is corrected by 
multiple imputations.279 Missing data handling strategy for each study within this thesis was 
implemented following review of the censored values. The analysis of the CRT registry 
concluded there was a combination of MAR and MCAR. The data handling approach first 
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adopted a complete case analysis. The degree of missing data was anticipated and 
recognised. A multiple imputation regression method was utilised to handle the missing 
data and was compared with the complete case analysis approach (Chapter 8). The COVERT-
HF study had less missing data observed due to the prospective study design and 
mechanisms to prevent it. MCAR of patterns of censoring were present, due in one case to 
post-procedural exclusions as failure of their CRT devices were due to complications not the 
individual not responding. A complete case analysis was undertaken as the assessment 
strategy. 
  
3.8.3 Descriptive and Inferential Data Analysis  
Understanding what the data collected represents is critical to the analysis. Data was 
identified as continuous (scale) or categorical (nominal or ordinal). Continuous data requires 
assessment of distribution for decisions on its handling for statistical testing. Outcome and 
potential predictor data variables were handled in an identical manner during the initial 
analysis. This next section described those initial steps in the analysis of both datasets 
before performing the more comprehensive statistical testing.   
 
3.8.3.1 Descriptive Statistics  
Categorical variables were reported as frequency and percentages. Continuous data prior to 
presentation underwent assessment of distribution (described in the next section). Normally 
distributed data were reported as mean ± standard deviation (SD).  Non-normally 
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distributed data were reported as median (range). Specific consideration to the handling of 
NYHA symptom classification was given.  NYHA symptom classification is an ordinal scale 
and was presented as a categorical variable and comparative assessment performed.  
 
3.8.3.2 Distribution of Continuous Data 
The first step in assessment of the continuous variables in both datasets was the 
distribution. This was a critical step to know how to present the data, which variables 
require transformation (discussed later in this section) on and knowing comparative or 
correlation statistical tests to perform. Initial graphical assessment of variable data 
distribution is performed using a histogram. For a normal (Gaussian) distribution, a 
histogram will demonstrate a bell shaped curve.  Figure 3.16 demonstrates examples from 
the COVERT-HF study of normal and non-normal distributed variables. An additional 
graphical assessment that was performed when histograms were challenging to interpret 
were normal probability plots or Quantile-Quantile (Q-Q) plots. For a Q-Q plot, an expected 
normal distribution is plotted against the actual distribution. When the observed datapoints 
fall on the straight line, good adherence to the expected data is demonstrated. Figure 3.17 
demonstrated examples of Q-Q plots for normal and non-normally distributed data for the 
same variables demonstrated in Figure 3.16 histograms. Following graphical plotting the 
tests of normality were undertaken on the continuous variable. Specifically the Kolmogorov-
Smirnov test was performed, which assesses the normality of the distribution of scores. 
Approximate normality is assumed if a non-significant p-value is returned.280 Assigning data 
distribution conclusion is based on statistical and graphical assessment.  
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Figure 3.16 Examples of Histograms. Illustrations both taken from the COVERT-HF dataset. 
(A) Shows normal distribution of the variable ‘Age at Implant’ which is demonstrated by the 
bell shaped curve. (B) Shows non-normal distribution of the variable ‘HS-TnT’ at six weeks 
follow-up, which is demonstrated by a positive skew.   
 
 
 
 
 
Figure 3.17 Examples of Quantile-Quantile Plots. Illustrations both taken from the COVERT-
HF dataset. The same variables are used as in Figure 7.1, for means of comparison (A) Shows 
normal distribution of the variable ‘Age at Implant’ which observed variables falling 
approximately on a straight line. (B) Shows non-distribution of the variable ‘HS-TnT’ at six 
weeks follow-up, where observed data points do not fit well with the expected data line.  
 
A B 
B A 
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3.8.3.3 Outlier Variables 
Outlier values were assessed for within each cohort as many statistical processes are 
sensitive to their presence. The potential influence of outlier variables was potentially 
problematic within the COVERT-HF cohort due to the size of the study. Extreme outliers 
were suggested on histograms (Figure 7.1) where extreme values were found in the tails on 
their own. Subsequently Boxplots were created to examine the distribution of data and 
examine outlier values. Each distribution in a Boxplot is represented by a box and whiskers. 
The length of the box is the inter-quartile range and contains fifty percent of the data. The 
whiskers contain the lowest and highest values. Boxplot extreme outlier values are present 
if they are >1.5x the box lengths from the edge of the box.280 Outlier variables are 
represented as individual data-points. Figure 3.18 demonstrates the actual Boxplot 
distribution for NT-pro-BNP at baseline as an example, which has two extreme outlier 
results.  
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Figure 3.18 A Boxplot of Baseline NT-pro-BNP (pmol/L). Illustration of a variable with 
outliers from the COVERT-HF dataset. The three outlier variable were labelled individually 
with extreme values being asterixed. 
 
3.8.3.4 Data Cleaning 
Evaluation of outlier results is undertaken to examine for the reason for the value. If an 
error is identified then the value was removed or altered. During the data quality process 
the first aspect of the data cleaning was performed, removing erroneous variables etc. 
When no error was apparent evaluation was performed as to the explanation for the value 
and whether it needed to be removed. For example NT-pro-BNP baseline levels identified 
two extreme values and these were not due to errors (Figure 7.3). These values were 
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correct and clinically expected for both participants, furthermore follow-up levels were 
similar. In this instance the values reflect the patient and remained in the dataset.  
 
3.8.3.5 Transformation 
The distribution of continuous data was assessed for normality. Non-normally distributed 
continuous data cannot be assessed using parametric statistical tests. Transformation were 
performed to normalise non-normally distributed continuous data variables, to allow 
analysis with a parametric statistical test as part of the logistic regression model in the 
COVERT-HF study. Logarithmic conversion was considered for ECM biomarkers, NT-pro-BNP, 
GDF-15 and hs-TnT expression data if their distribution was non-normal and demonstrated a 
positive skew pattern. Figure 3.16 (B) demonstrates an example of a positive skew 
distribution. Transformation was attempted on non-normally biomarker expression data to 
allow easier comparison with the miRNA relative quantification data in the statistical 
models. Performing logarithmic conversion can sometimes convert non-normally distributed 
data to a normal distribution, which allows analysis via parametric methods to be 
undertaken. Transformed data was examined for their normality of distribution. Where 
transformation meant the continuous variable was now normally distributed was that 
transformed variable used in the logistic regression prediction model.  
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3.8.3.6 Comparisons between Groups  
Grouping of the COVERT-HF cohort was performed for outcome measures. The principle 
grouping of the cohort was performed on the basis of functional response status (primary 
outcome). Further grouping was performed for echocardiographic response and MACE 
status. Moreover changes in variables were considered across all three research visits and 
by the functional response grouping.  
 
Comparison between groups for categorical data was performed using the Chi-Squared test 
for independence. When the minimum expected cell frequency was not achieved the 
Fisher’s Exact test was performed as the best alternative. Normally distributed continuous 
data used the independent t-test for unpaired cohort comparisons. The non-parametric 
equivalent test used for unpaired comparisons of non-normally distributed variables was 
the Mann-Whitney U test. Paired comparison occurred for variables that were measured in 
the same partipant at the same time, for example within the COVERT-HF study; peripheral 
vs CS baseline biomarker expression. A paired t-test or Wilcoxon Signed Rank Test was used 
for normally and non-normally distributed data respectively.  
 
Assessment of repeated measures (>2) was required within the analysis of the COVERT-HF 
study for continuous data variables that were measured at all participant study visits. One 
way repeated measures analysis of variance (ANOVA) was performed on normally 
distributed data. For non-normally distributed variables Friedman’s Test was utilised.  
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3.8.3.7 Correlation Analysis 
Relationships between two continuous variables are explored using a bivariate correlation 
analysis. The correlation analysis conducted assesses the strength and direction of the linear 
association between two continuous variables.281 Initial evaluation of the association was 
with a simple scatterplot, which provided an eyeball assessment of the association. Several 
correlation estimators are available dependent on the variables distribution.280 Two 
important measures that have been used for the COVERT-HF dataset are Pearson 
correlation (parametric) and Spearman Rank Order correlation (non-parametric). Both 
analyses provide a correlation coefficient (r), which is a calculated ratio of covariance 
between the two variables.280,281 The correlation coefficients (r) can only take on values 
between -1 and +1 to describe the linear relation between the two variables. A value of +1 
described a perfect positive linear relationship, whereas -1 demonstrates a perfect negative 
linear relationship.280,281 Categorisation of the strength of the relationship is estimated to 
be; small (r=0.10 – 0.29), medium (r=0.30 – 0.49) and large (r=0.50 – 1.0).280 Figure 3.19 
shows scatterplot with a line of best-fit and a calculated correlation coefficient (Pearson’s), 
which demonstrated a strong negative linear relationship for the COVERT-HF dataset.  
 
Correlation analysis was performed on the COVERT-HF dataset to explore relationship 
between two variables. Associations between continuous functional, echocardiographic, 
biomarkers and body composition variables at baseline and following differences following 
CRT implantation were explored. Strengths and direction of linear associations were 
reported.  
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4.5 STATISTICAL MODELLING  
 
3.8.4 Mixed Between-Within Subjects ANOVA 
The analysis of variance can be approached with a between-subject design comparing >2 
different groups) and a with in or repeated measures design (one group exposed to >2 
conditions).280 In certain situations these approaches are required to be combined when 
there are two independent variables (between-subject and within-subject) present that will 
affect the dependent variable. In the COVERT-HF study the variation in biomarkers 
expression, echocardiographic LV geometry and functional parameters (dependent variable) 
through the observation (within-subject factor) period was required to understand the 
impact of CRT following its implantation. Moreover, understanding the pattern of variation 
between responders and non-responders (between-subject factor) over the time of the 
observation period (within-subject variable) is important. A mixed between-within subjects 
ANOVA allows both independent variables (between-subject and within subject) impact on 
Figure 3.19 Scatterplot of change in LVESVi and fat mass over 6 Weeks. Illustrated from 
the COVERT-HF study 
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the dependent variable to be analysed. The first step during this analysis was to test for 
homogeneity of variances (sphericity) for each combination of the two independent 
variables. The sphericity (measures variation) of the differences between all groups of the 
independent variables should be equal.  The interaction effect was the next aspect of the 
analysis performed, which tests the impact of each independent variable on each other. 
Assuming no significant interaction the main effects were then interpreted for the with-in 
subject and between-subject variables statistical differences. The effect size was estimated 
by the Partial Eta Squared Value.280 
 
3.8.5 Logistic Regression 
Binary logistic regression was performed in  both datasets to test the pre-selected potential 
predictors (independent variables) ability to predict CRT response (binary categorical 
outcome variable). Logistic regression requires the dependent outcome variable to be 
categorical. There are several logistic regression techniques available dependent on the 
number of outcome groups. The predictors can be continuous or categorical or a mixture of 
both. The logistic regression calculated an odds ratio for a particular independent variable 
estimating its ability to predict the outcome.  
 
Univariate logistic regression analysis was performed initially to examine the relationship 
between the potential predictor and the outcome. The relationship demonstrated on 
univariate analysis may not reflect the effect of the potential predictor as an explanatory 
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variable on the outcome. It may reflect the effect of another confounder variable. A 
potential predictor variable was entered into the multivariate logistic regression model 
when the p-value on univariate analysis was <0.15. A high p-value threshold was set to allow 
inclusion of all variables that might show an effect in the multivariate analysis which might 
be excluded with a lower threshold due to the size of the cohort (to retain potentially 
important variables).282 Multivariate modelling utilises multiple potential-predictor variables 
to explain the variation in the outcome variable.  The model aims to identify the strongest 
combination of predictor variable which predict the particular outcome. The final model is 
established when all the predictor variables remaining in the model have a p<0.05. Once this 
is achieved a multiple variable equation is created that allows calculation for the odds of 
predicting the outcome probability if all the identified strong predictors are present. 
Forward selection and backward elimination techniques were performed for multivariate 
binary logistic regression to test the strength and reproducibility of the predictors.  A chi-
square statistic of the Hosmer-Lemeshow tests compared the observed frequencies with 
those anticipated in a linear model. A non-significant result was suggestive that the model 
was well attuned.  
 
3.8.6 Survival Analysis 
3.8.6.1 Life Tables and Kaplan Meier Survival Curves 
Survival analysis is broadly categorised as a set of methods used to analyse the time 
required for an event of interest to occur. An event is whatever the study design has 
designated an end-point (e.g. MACE) which is normally a terminal event. The time-to-event 
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is the critical variable that is recorded and observed. Survival analysis techniques account 
for the events or uncensored observations.283 Importantly survival analysis also accounts for 
those observations where events do not occur in the study period or a participant leaves the 
study early for an unrelated reason (called censoring).283 Censoring is unrelated to the 
unobserved times to the event. Survival analysis unlike linear regression for instance can 
account for those participants with censored observations.283  The life tables and Kaplan-
Meier curves are simple statistical procedures that account for censoring in comparison of 
groups.283   
 
The life table’s method involves the total study observation period being dividied into fixed 
intervals of time. Figure 3.20 demonstrates a simplistic life table as part of a survival analysis 
performed as part of the CRT registry analysis. The number of patients at risk of 
cardiovascular outcome (e.g. MACE) occurring was listed at the start of the study and then 
listed at each subsequent time interval until the end of the study. For the CRT registry study 
that was in 20 month intervals. Both groups (e.g. aetiology) were compared against each 
other at all intervals. Cumulative survival was calculated for each subsequent interval. The 
endpoint or event must be defined prior to the analysis, in figure 7.5 the event is MACE.  
 
The Kaplan-Meier survival curve method estimates and graphs survival probability as a 
function of time. The curves demonstrate the stepwise changes in cumulative survival 
(figure 7.5).  To test the overall differences in the estimated survival curves for two (or 
more) groups the non-parametric log-rank test can be performed.  Importantly the log-rank 
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test cannot discriminate or explore the influence of multiple independent variables 
(potential predictors) simultaneously.283 Crucially the Kaplan-Meier analysis accounts for 
whole curve and not isolated datapoints.283 To study the impact of multiple independent 
variables on the time-to-event outcome, the Cox proportional regression model was 
employed. 
 
In the CRT registry the survival analysis employed life-tables and Kaplan-Meier curves to 
estimate survival (time-to-event) for the potential binary predictors (independent 
predictors) for cardiovascular outcomes. These non-parametric techniques offered the most 
robust techniques of estimating survival rates given the potential burden of censoring (for 
example the loss to follow-up of those patients returning to local secondary care services 
and the variation in observation period for each participant). The log-rank test was used to 
examine univariate difference between two groups but would not account for other 
confounders, therefore a Cox proportional hazards regression was performed.  
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Figure 3.20 Kaplan-Meier survival curves for the CRT retrospective registry (n=300) from 
MACE for HF aetiology. Life tables are given in the table at the bottom of the survival curve 
indicating the number of patients surviving in each group at 20-month intervals. The dashed 
lines on the two curves represent censored observations. The survival analysis 
demonstrated in this figure is taken from the CRT registry and MACE outcomes grouped by 
HF aetiology is the comparison being made. IHD = Ischaemic Heart Disease.  
 
3.8.6.2 Cox Proportional Hazard Regression 
Cox proportional hazards regression is an important model for the analysis of survival data 
of multiple variables simultaneously. This regression model is semiparametric, making fewer 
Log-rank p=0.11 
Non-IHD 
IHD 
80 
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assumptions than parametric but more than non-parametric models. Most importantly it 
makes assumption about the shape of the baseline hazard function, unlike other parametric 
regression models.284 A non-linear relationship is assumed between the hazard function and 
the predictors in the model. The proportional hazards model assumes the ratio is 
approximately constant over time where the predictor variables remain constant in the 
same period. This assumption is called the proportional hazards assumption.284 This allows 
calculation of the hazard ratio, which represents the potential the event will occur, per unit 
time. The variables are entered into the model in a stepwise fashion similar to that 
described in the logistic regression section. The strongest predictive model is built for the 
pre-selected potential predictors for cardiovascular outcomes.  
 
3.8.7 Inter-Rater Variability Echocardiography Study 
An inter-rater variability study was performed to assess the degree of homogeneity 
between the two observers. Prof Alan Nevill (University of Wolverhampton) provided 
support in designing the inter-rater statistical methods and analysis.  
 
To assess inter-rater variability between available comparative LV volume measurements 
several statistical analyses were performed. Firstly inter-observer correlation was 
performed with persons or spearman ranks correlation analysis and a correlation coefficient 
(r) calculated as discussed earlier in this chapter. Correlation analysis only allows the 
strength of a linear association to be assessed and does not account for agreement between 
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observers.281  Inter-rater variability of LV volumetric measurements between observers was 
assessed using the concordance correlation coefficient.285 Paired measurement assessment 
was undertaken with paired T-tests. Inter-observer agreement was assessed with a Bland-
Altman plot.281,286 The Bland-Altman plot quantifies agreement between two quantitative 
variables by building limits of agreement.281,286 These limitations are calculated by using the 
mean and standard deviations of the differences between the two measurements. A scatter 
graph is plotted to assess the assumptions of normality of the differences.281,286  The 
difference between the variables is plotted against the mean difference.281,286  The Bland-
Altman plot does not set limits of accepted agreement, more it documents the bias and 
states the limits of agreement.281,286  Statistics specifically used to assess inter-observer 
variation in transthoracic echocardiography have previously been described in detail.255,256 
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Chapter Four 
 
CARDIAC EXTRACELLULAR MATRIX AND 
CARDIAC RESYNCHRONISATION THERAPY: A 
SYSTEMATIC REVIEW   
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4.1 INTRODUCTION 
Cardiac ECM biomarkers present a potential target to identify a credible predictor of CRT 
response. Adverse LV remodelling underpins HFrEF development, progression and severity. 
Cardiac ECM remodelling underpins the development and progression in adverse LV 
remodelling. Turnover of ECM alters in HF and with reverse cardiac remodelling following 
CRT implantation, this may offer potential biomarkers for CRT response prediction.137 A 
systematic review was undertaken to examine the current evidence on the value of ECM 
biomarkers in predicting CRT response. 
 
4.2 METHODOLOGY 
Our systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis [PRISMA] guidelines.287 It was prospectively 
registered with PROSPERO (CRD42016025864), an international registry of systematic 
reviews. A protocol was designed and implemented prospectively in-line with PRISMA-P 
2015288 (Appendix A).  
 
4.2.1 Eligibility Criteria  
Strict eligibility criteria were applied to minimise heterogeneity of included articles. 
Observational studies (prospective or retrospective) and RCTs (including sub-studies) were 
included; basic science and review articles were excluded. Included study population’s 
represented HF patients meeting international CRT implant guidelines.47 Studies had to be 
conducted on adults (age >18years). Articles were included if they examined an ECM 
biomarker previously reported to predict HF outcomes, summarised in Table 4.1.94 Baseline 
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ECM biomarkers, measured when patients were clinically stable prior to implantation, had 
to be compared to a pre-defined CRT ‘response’ criteria to evaluate their predictive value. 
CS sampling and long-term trends in peripheral ECM biomarker behaviour were analysed if 
present.  
 
Table 4.1 Extracellular Cardiac Matrix Candidate Biomarkers in Heart Failure (Adapted94) 
Extracellular Cardiac Matrix Remodelling Biomarkers Specific Biomarkers 
Matrix Metalloproteases MMP-1, MMP-2, MMP-9 
Tissue Inhibitors of Metalloproeinase-1  TIMP-1 
Collagen Propeptides PINP, PICP, PIIINP 
Collagen Telopeptides CITP or ICTP 
Myostatin   
Syndecan-4   
Galectin-3    
 
A variety of clinical, functional or echocardiographic criteria and  cardiovascular outcomes 
have been used to define CRT response in studies,1 which often correlate poorly. All 
response criteria were included in the review. Cardiovascular outcomes could form part of a 
response definition or be presented separately, their absence was not an exclusion 
criterion.  
 
4.2.2 Database Search Strategies 
Detailed searches were conducted on PubMed, Ovid SP MEDLINE, Cochrane Library 
(CENTRAL) and TRIP in February 2016 by one author and reviewed by another 
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independently. The search strategy used specific terms (cardiac resynchronization 
therapy/cardiac pacing/extracellular matrix) in combination, within titles/ abstracts or 
Medical Subject Headings. Specific circulating biomarkers (‘TIMP’ ‘MMP’ ‘collagen’ 
‘Myostatin’ ‘Syndecan-4’ and ‘Galectin-3’) were included in the search. Appendix B shows 
the complete PubMed search. A grey literature search involved searching the international 
Clinical Trials database (www.clinicaltrials.gov) and international cardiology conferences 
(European Society of Cardiology, American Heart Association, American College of 
Cardiology) indexes for ongoing, abstracts and unpublished work. All included articles had 
their references searched for relevant publications. A date limitation of the last 15 years 
(31/12/1999 – 31/12/2015) was applied. No language restrictions were applied.   
 
Title and abstract reviews were performed independently,  consensus on eligibility criteria 
was required to be taken forward to full paper review; any conflicts were decided by an 
independent reviewer. Duplications of articles or cohort use were identified and only the 
most relevant (decided by consensus) taken forward. The Critical Appraisal Skills Programme 
checklist (dependent on study design) was applied to full paper review to guide evaluation 
of article quality.289 Consensus had to be reached on full paper reviews before being 
selected for inclusion; where consensus was not reached a third reviewer made the final 
decision. Contact was attempted with all included article authors and any others at full 
paper review that were indicated. 
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4.2.3 Data Extraction and Management  
Full texts of included articles were obtained. Pilot data extraction was performed on two 
randomly selected articles and reviewed for robustness. A standardised data extraction 
form was created to collect data on each study’s design (eligibility criteria, methodology, 
assessment period), patient population (numbers, age, gender, aetiology, ECG, LV geometry, 
QoL, NYHA, functional assessment), circulating biomarker/predictor (specific ECM surrogate 
biomarkers, units, conditions of sampling, laboratory assessment, statistical prediction 
model) and outcome (response definition and cardiovascular outcomes). Data extraction 
was performed by two independent reviewers, a third independent reviewer resolved any 
disagreement.  
 
4.2.4 Risk of Bias Assessment 
Risk of bias for each study was assessed by two independent qualified reviewers utilising 
either the Risk of Bias Assessment Tool for Nonrandomised Studies or the Cochrane 
Collaboration ‘Risk of Bias’ assessment tool.290,291 Both have established criteria to examine 
selection bias, exposure measurement, blinding and completeness of outcome data.290,291  
 
4.2.5 Data Synthesis and Analysis 
A descriptive synthesis was performed to summarise findings of all selected articles. A meta-
analysis of included study data for each specific ECM biomarker was not achievable due to 
wide heterogeneity in study designs and different response definitions. Evaluation of study 
designs, defined outcomes and cohort characteristics were performed. The same 
biomarkers compared in different included articles were compared. Continuous variables 
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were summarised using the same units for each variable in the original text. Data was 
presented as mean ± standard deviation (SD), unless specified otherwise.  
 
4.3 RESULTS 
Figure 2.1 shows the screening and selection of published articles. Six articles met the 
inclusion criteria. Two abstracts,292,293 and one clinical trial entry (www.clinicaltrials.gov)  
[NCT15019908] were taken to full review (for potential inclusion). Related articles and 
information were sought, including contacting authors (all 3 kindly responded). None yet 
had articles published and additional information provided led to exclusion from review (no 
baseline biomarkers taken292 or the study design did not test biomarkers as predictors293).  
 
4.3.1 Study Design 
Five prospective cohort studies and 1 RCT sub-study11  were included. Table 4.2 summaries 
the different study designs and CRT response outcome definitions used. Studies selected 
were published between 2008 and 2014. Risk of bias was assessed in each study using the 
appropriate quality check tool (Table 4.3a and 4.3b). The lowest risk of bias was in the single 
RCT sub-study.11 The prospective cohort studies varied minimally in their bias assessment 
and none were excluded. 
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Figure 4.1 Screening and selection of articles for systematic review (Adapted287) ≠ Author 
contacted, poster presentation sent and no baseline ECM biomarker sample taken169292* 
Clinical trial [NCT15019908] author contacted and manuscript in preparation 
 
Garcia-Bolao et al126 stated 61 participants were consented; during the observation period 
there were 4 mortalities (3 cardiac/1 non-cardiac) and 1 functional assessment not 
performed at follow-up (6-minute walk test not completed due to stroke). The cohort was 
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59 but no explicit statement about the two exclusions made. Lopez-Andres et al11 published 
a sub-study in 2012 of the CARE-HF1 RCT which itself was published in 2005, interpretation 
of results is within this context. All studies included NYHA III-IV patients (mostly NYHA III). 
Two studies recruited NYHA II patients294,295 with one also requiring a bradycardia pacing 
indication.294 All studies included QRS duration>120msec, except Garcia-Bolao et al,126 who 
had a QRS>130msec. In the CARE-HF trial those with a QRS duration 120-149msec needed 
cardiac dyssynchrony on echocardiography.23,125 All transvenous LV leads were implanted 
preferably to the most lateral position possible. Dong et al,244 performed only de-novo CRT-
defibrillator (CRT-d) implants. Three studies119,244,294 commented on RV lead placement with 
two244 explicitly aiming for the RV apex. In CARE-HF (and sub-study) all had CRT-pacemaker 
(CRT-p) devices only.23,11 CRT response definitions varied between included studies. Broadly, 
response definitions used were classified as 3 clinical and 3 echocardiographic. Reported 
response rates varied between 48.9% and 71.8% (table 4.2).  
 
  
Table 4.2 Summary of included articles study designs and response definitions 
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Study ID Design 
Participants 
Recruited 
HF/CRT 
Participants Inclusion Criteria 
Observation 
Period Assessment’s 
ECM 
Biomarkers 
CRT Responder 
Definition 
Response 
Rate  
Dong 
2011244 
 
 
Prospective 
observational 
 
 
65 (20 
healthy 
controls) 
 
45 
 
 
 
LVEF<35%, NYHA III-IV, 
QRS >120msec, SR & 
OMT 
 
6 months 
 
 
 
Baseline / 3 
months / 6 
months: NYHA, 
6MWT, TTE, Blood 
samples 
PIIINP 
 
 
 
↓>15% LVESVi & 
Survived at 6 months 
 
 
22(48.9%) 
Tolosana 
2010294 
 
 
 
Prospective 
observational 
 
 
 
55 (13 
excluded 
after 
recruitment) 
 
42 
 
 
 
 
LVEF<35%, NYHA III-IV, 
QRS >120msec & OMT 
or cardiac pacing 
indication (LVEF <35%) 
12 months 
 
 
 
 
Baseline / 6 
months / 12 
months: NYHA, 
QoL (MLHFQ), 
6MWT, TTE, ECG, 
Blood samples 
MMP-2 
TIMP-1 
 
 
 
↑> 10% 6MWT or if test 
not performed ↑> 1 
NYHA & Survived/No 
heart transplant at 12 
months 
25(59.6%) 
Truong 
2014295 
 
Prospective 
observational 
 
73 
 
 
73 
 
 
LVEF <35%, NYHA II-IV, 
QRS>120msec, OMT, 
HF decompensation 
<12 months 
24 months    
(IQR 20.4-
24.0) 
 
Baseline: NYHA, 
ECG, TTE              1 
month / 3 months 
6 months Clinical 
FU 
Gal-3 
 
 
 
Improvement HF clinical 
composite score93 at 6 
months 
 
40(54.7%) 
Umar 
2008119 
 
 
Prospective 
observational 
 
64 
 
 
 
64 
 
 
 
LVEF <35%, NYHA III-
IV, QRS >120msec 
 
 
6 months 
 
 
 
Baseline / 6 
months: NYHA, 
TTE; QoL (MLHFQ), 
6MWT, Blood 
samples 
PINP 
PIIINP 
ICTP 
proMMP-1 
TIMP-1 
↓>10% LVESV at 6 
months 
 
 
46(71.8%) 
Garcia-
Bolao 
2008126 
 
Prospective 
observational 
 
 
61 
 
 
 
59 
 
 
 
LVEF<35%, NYHA III-IV, 
LBBB, QRS>130msec, 
OMT 
 
12 months 
 
 
Baseline / 12 
months: NYHA, 
QoL (MLHFQ), 
6MWT, TTE, ECG, 
Blood samples 
PICP 
CITP 
MMP-1 
MMP-2 
MMP-9 
TIMP-1 
↑>10% 6MWT & 
Survival from cardiac 
mortality at 12 months 
 
35(59.3%) 
 
Lopez-
Andres 
2012125 
 
 
Sub-Study 
Randomised 
Control Trial: 
CARE-HF 
 
260  (CARE-
HF Cohort 
available) 
 
132 (CRT-P 
only) 
 
 
LVEF <35%, NYHA III-
IV, QRS >150msec or 
120-149msec with 
echocardiographic 
dyssynchrony, OMT 
 
Sub-study: 18 
months               
CARE-HF: 29.4 
months 
(range, 18.0-
44.7) 
Sub-study - 
Baseline / 3 
months / 18 
months: TTE,  
Blood samples 
 
PINP 
PIIINP 
ICTP 
MMP-1 
Gal-3 
 
Survival  & LVEF more 
than 35%  at 18 months 
 
 
 
CRTp(n=108):        
72 (66.6%)                                                  
OMT(n=117): 
103(88.0%)  
p=0.0001 
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Table 4.3 Risk of Bias Tables 
Table 4.3a Risk of Bias Assessment Tool for Nonrandomised Studied (Adapted291) 
Study 
Selection of 
Participants  
Confounding 
Variables  
Measurement 
of Exposure  
Blinding of 
Outcome 
Incomplete 
outcome data 
Selective 
Reporting 
Dong 2011244 Low Low Low Low High High 
Tolsana 2010294 Low Low Low Low Low High 
Truong 2014295 High Low Low Low Unclear High 
Umar 2008119 Low Low Low High High High 
Garcia-Bolao 
2008126 Low Low Low High High High 
 
Table 4.3b Cochrane Collaboration ‘Risk of Bias’ assessment tool (Adapted290)  
Study 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Personnel 
Blinding of 
outcome 
Incomplete 
outcome data 
Selective 
reporting 
Other threats 
of validity 
Lopez-Andres 
2012125 Low Low High Low Low Unclear Low 
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4.3.2 Baseline Characteristics  
A total of 415 patients were included in the systematic review. Table 4.4 summarises the 
baseline characteristics of each included article. The five prospective observational studies 
had mean age of 67±10 years119,126,244,294,295 (Lopez-Andres et al125 excluded as presented as 
median and interquartile range [IQR]). Pooled here were 315 (75.9%) males in included 
studies, ranging between 67.8%126 and 83.6%295. There was a large variation in frequency of 
CRT-d /CRT-p implants in each study with two not providing this data.119,295 One study 
included a high proportion of device upgrades;295 the CARE-HF trial excluded upgrades,23,125 
the remaining four studies did not state upgrades status.119,126,244,294 AF was included in 
three prospective observational studies;126,294,295 one did not report on AF or related 
publications.119 120 Precise QRS duration was not stated in two studies.244,294 Reporting of LV 
volumetric data varied between included studies. Three reported unadjusted LV end-systolic 
volume (LVESV) and LV end diastolic volume (LVEDV) data which were similar to each other 
(table 4.4).119,294,295 Dong et al 244 presented LVESV and LVEDV volume indexed figures only. 
Garcia-Bolao et al126 provided LVEF only. LVEF was compared between the five prospective 
cohorts and showed similar mean LVEF between 25–27%.119,126,244,294,295  
 
4.3.3 Responder vs Non-Responders  
Response status (Responders vs. Non-responders [RvsNR]) was presented in four of the 
included studies.119,126,244,294 Truong et al295 did not provide characteristics of those defined 
by response. Lopez-Andres et al125 outlined characteristics by allocation to CRT-p vs. Optimal 
Medical Therapy (OMT), however not by response. There were some baseline characteristic 
differences between the four studies for RvsNR;119,126,244,294 Dong et al244 demonstrated 
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differences between RvsNR for LBBB status (15 [68.3%] vs 9 [39.1%], p=0.05) and ischaemic 
aetiology (9 [40.9%] vs 17 [73.9%], p=0.03). Tolosana et al,294 reported lower creatinine 
levels in RvsNR (1.25±0.3mg/dl vs 1.76±0.8mg/dl, p=0.01). Umar et al,119 reported 
responders were older and had longer QRS duration than non-responders (age: 66±10yrs vs 
60±11yrs, p=0.03; mean±standard error QRS: 165±3msec vs. 135±8msec, p=0.001). Notably 
Hessel et al, published a study using the same cohort as Umar et al, and reported no 
difference in QRS duration for RvsNR [165±2msec vs. 153±3msec, p=NS], suggesting one of 
these studies has recorded it incorrectly.119,120 
 
4.3.4 Extracellular Matrix Biomarkers in the Heart Analysis 
A total of 9 individual ECM biomarkers were examined across all the included studies. Table 
4.5 outlines the ECM assessments and the specific laboratory techniques employed within 
the six included studies. Several biomarkers across studies utilise different blood products or 
laboratory techniques for their analysis. PIIINP utilises radioimmunoassay for all assessing 
studies.119,125,244 MMP-2 and TIMP-1 utilise ELISA from different companies.119,294  
 
4.3.4.1 Extracellular Matrix Biomarkers 
All ECM biomarker baseline concentrations and magnitude of association (if tested) are 
summarised in Table 4.6. CS expression and trends for each ECM biomarker expression 
following CRT are discussed below. Lopez-Andres et al125 did not provide baseline 
concentrations by response status, but comparison was made with the control group. Umar 
et al119 showed baseline results for expression of ECM biomarkers studied. However, for 
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PIIINP non-responders no baseline concentration was reported in the article, however no 
statistical significance is reported RvsNR.119  
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Table 4.4 Baseline Characteristics of included articles in Systematic Review 
  
Study  ID 
Age 
(years) 
Male 
Gender 
CRT-D 
Device 
Upgrade 
Ischaemic 
Aetiology 
Atrial 
Fibrillation 
Medication LBBB 
QRS 
(msec) 
NYHA 
6MWT 
(M) 
LV 
Dong 
2011244 
68±9 
 
 
37 
(82.2%) 
 
45 
(100%) 
 
Not 
Reported 
 
26(57.8%) 
 
 
Chronic AF 
excluded 
 
ACEi/ARB  27(60.0%)                                           
BB 41(91.1%) 
23 
(53.3%) 
 
>120 
 
 
3.03±0.33 
 
 
351±186 
 
 
LVESVi 77±26ml/m2                 
LVEF 26±5% 
 
Tolosana 
2010294 
66±8 
 
 
35 
(83.3%) 
 
25 
(59.5%) 
 
Not 
Reported 
 
19(45.2%) 
 
 
8(19%) 
 
 
ACEi/ARB 33(78.5%)                                                      
BB 27(64.3%)                                                   
MRA 20(47.6%) 
Not 
Reported
 
>120
 
>III=33(78.5%)OR 
II = 9 (21.4%) → 
Pacing indication 
232±126 
 
 
LVESV 162±63ml                                                  
LVEDV 212±66ml                                                     
LVEF 27±7% 
 
Truong 
2014
295
 
68±12 
 
 
61 
(83.6%) 
 
Yes 
 
 
41(56.2%) 
 
 
39(53.4%) 
 
 
34(46.5%) 
 
 
ACEI/ARB 57(78.1%)                                                                          
BB 64(87.7%)                                                                       
MRA 16(21.9%) 
39 
(53.4%)
 
168±27
 
2.9±0.4 
 
Not done 
 
 
LVESV 163±60ml                                                
LVEDV 226±73ml                                              
LVEF 27±7% 
Umar 
2008119 
64±11 
 
 
52 
(81%) 
 
Yes 
 
 
Not 
Reported 
 
45(70.3%) 
 
 
Not 
Reported 
 
Not Reported 
 
 
Not 
Reported 
 
162±24 
 
 
3.1±0.2 
 
 
330±114 
 
 
LVESV 172±69ml                                                                     
LVEDV 229±78ml                                                                      
LVEF 25±8% 
Garcia-
Bolao 
2008126 
69±4 
 
 
40 
(67.8%) 
 
33 
(55.9%) 
 
Not 
Reported 
 
30(50.8%) 
 
 
11 (18.6%) 
 
 
ACEI/ARB 
59(100%)                                                                        
BB 34(57.6%)                                                                       
MRA 21(35.6%) 
51 
(86.4%) 
 
158±35 
 
 
3.1±0.6 
 
 
327±112 
 
 
LVEF 25±5% 
 
 
Lopez-
Andres 
2012125* 
 
66       
(59-71) 
 
 
90 
(68%) 
 
 
0(0%) 
 
 
 
Excluded in 
CARE-HF 
 
53(40.2%) 
 
 
 
AF excluded 
 
 
ACEi/ARB 131(99.2%)                                                                       
BB  88(66.7%)                                                                                      
MRA 73(55.3%) 
 
Not
Reported 
 
 
160
(152-
180) 
 
3.0±0.2 
 
 
 
Not done 
 
 
 
(n= 115)                                                     
LVESV 206ml (174-
272)                                                           
LVEDV 274ml (233–
355)                                                                                  
LVEF 25% (21-29) 
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Table 2.5 Extracellular cardiac matrix biomarker analysis summary  
Study ID 
ECM 
Biomarkers 
Other Biomarkers 
Blood 
Material 
Extracted 
Storag
e (oC) 
ECM Biomarker                        
Laboratory Analysis 
Laboratory 
Analysis 
Blinding 
CS Sampling 
Post-Implant 
Sampling 
Dong 
2011244 
PIIINP 
NT-pro-BNP 
Nerve Growth 
Factor, 
Norepinephrine 
Plasma -80 
PIIINP: Radioimmunoassay 
 
Not Reported 
 
Yes 
 
Yes 
 
Tolosana 
2010294 
MMP-2, 
TIMP-1  
Serum & 
Plasma 
-80 
 
MMP-2: Sandwich ELISA (Serum)     
TIMP-1: Sandwich ELISA (Plasma) 
Not Reported 
 
Yes 
 
No 
 
Truong 
2014295 
Gal-3 NT-pro-BNP 
Plasma 
 
-80 
 
Gal-3: ELISA                                            
sST2: ELISA 
Yes -blinded 
source and 
type of sample 
Yes 
 
No 
 
Umar 
2008119 
PINP                  
PIIINP                       
ICTP                               
proMMP-1                                 
TIMP-1 
NT-pro-BNP 
Serum & 
Plasma 
 
 
-80 
 
 
 
PINP: Radioimmunoassay (Serum)                                                                      
PIIINP: Radioimmunoassay (Serum) 
ICTP: ELISA (Serum)                                                                         
ProMMP1:ELISA (Serum)                                                                   
TIMP-1: ELISA (Plasma) 
Not Reported 
 
 
 
No 
 
 
 
Yes 
 
 
 
Garcia-
Bolao 
2008126 
PICP                                         
CITP                                                      
MMP-1                                                            
MMP-2                                                     
MMP-9                                                                       
TIMP-1 
Serum 
 
 
 
-40 
 
 
 
PICP: ELISA                                                                                                
CITP: Radioimmunoassay                                                
MMP-1: ELISA                                                                                         
MMP-2: sandwich ELISA                                                        
MMP-9: sandwich ELISA                                                                  
TIMP-1: ELISA 
Not Reported No 
 
 
Yes 
 
 
 
Lopez-
Andres 
2012125 
 
PINP                                                           
PIIINP                                                                        
ICTP                                                               
MMP-1                                                                                                  
Gal-3 
NT-pro-BNP Serum 
 
 
-80 
 
 
 
PINP: Radioimmunoassay                                                                    
PIIINP: Radioimmunoassay                                                               
ICTP: Radioimmunoassay                                                           
MMP-1:Radioimmunoassay                                                                   
Gal-3: Radioimmunoassay 
Yes, central 
laboratory 
 
 
No 
 
 
 
Yes 
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ECM Study ID Baseline Model Predicting Response 
PINP 
 
Umar 
2008119~ 
TC: 35.4±5.0ug/l, R: 32.9±2.2ug/l                                                                                                                                    
NR: 41.9±4.3ug/l, p=0.04 
Multiple Logistic   
Regression $ 
Univariate: OR 0.99, CI(95%) 0.93–1.00, p=0.05                                               
Multivariable: OR 0.96, CI(95%) 0.93-0.99, p=0.03 
 
Lopez-
Andres 
2012125* 
CRT-p: 33.0ug/l(24.6–49.4)                                                                                      
OMT: 33.1ug/l (23.0–49.3)                                       
p=NS 
Multiple Logistic  
Regression Π 
No association with response 
PICP 
 
Garcia-
Bolao 
2008126 
TC: 74.3±29.9ug/l, R:85.6±29.4ug/l                                                                                                                                              
NR: 57.8±22.2ug/L, p=<0.001 
ROC: PICP:CITP 
AUC  0.71 CI (95%) 0.57–0.85 Cut-off 14.4 CI (95%) 
9.8–17.7 Sensitivity 63% (51–80) Specificity 70% (50–
85) OR 2.07 CI (95%) 0.98–4.39 
PIIINP 
 
Dong 
2011244≠ 
TC: 0.88±0.21ug/l, R: 0.80±0.20ug/l                                                                                                                                                                              
NR: 0.96±0.19ug/l, p=0.03 
Multiple Logistic
Regression $ 
Univariate: OR 0.77, CI(95%) 0.62-0.97, p=0.03
Multivariable: OR 0.20, CI(95%) 0.03-1.17, p=0.07 
 
Umar 
2008119~ 
R: 4.59±0.24ug/L                                                                                                                      
NR: < responders, p=NS 
Multiple Logistic
Regression $ 
Univariate: OR 1.23, CI(95%) 0.86–1.76, p=0.23                                                
Multivariable: OR 1.35, CI(95%) 0.94-1.93, p=0.1 
 
Lopez-
Andres 
2012125* 
CRT-p: 4.6ug/L (3.8–6.8)                                                                                    
OMT: 4.7ug/l (3.8–6.5), p=NS 
Multiple Logistic
Regression Π 
No association with response 
ICTP 
 
Umar 
2008
119
~ 
TC: 3.1±0.8ug/l, R: 3.5±0.6ug/l                                                                                                                                                       
NR: 2.1±0.4ug/L, p=ns 
Multiple Logistic
Regression $ 
Univariate: OR 1.24, CI(95%) 0.93–1.66, p=0.13                                                                
Multivariable: No association with response 
 
Lopez-
Andres 
2012125* 
CRT-p: 4.1ug/l (2.6–6.0)                                                                                                      
OMT: 3.4ug/l (2.7–5.0), p=NS 
Multiple Logistic  
Regression Π 
No association with response 
CITP 
 
 
Garcia-
Bolao 
2008126 
TC: 5.1±2.5ug/l, R: 4.90±2.5ug/l                                                                                                                                   
NR: 5.3±2.5ug/l, p=0.51 
ROC: PICP:CITP 
AUC  0.71 CI (95%) 0.57–0.85 Cut-off value 14.4 (CI 
95% 9.8–17.7) Sensitivity 63% (51–80) Specificity 70% 
(50–85) OR 2.07  CI (95%) 0.98–4.39) 
Pro-
MMP-1 
 
Umar 
2008
119
~ 
TC: 7.7±0.8ug/l, R: 7.6±0.7ug/l                                                                                                                                  
NR:  8.0±1.1ug/L, p=0.71 
Multiple Logistic
Regression $ 
Univariate: OR 0.97, CI(95%) 0.87–1.09, p=0.71                                                                     
Multivariable: No association demonstrated 
MMP-1 
 
Garcia-
Bolao 
2008126 
TC: 8.9±11.4ug/l                                                                                                           
R: 7.3±10.5ug/l                                                                                                                                   
NR: 11.3±12.5ug/l, p= 0.17 
ROC 
Not performed as no difference                                                                
Baseline MMP-1:TIMP-1 Ratio: 0.005±0.001                                                                                                               
R: 0.004±0.0007 vs NR: 0.0063±0.0008, p=0.297 
 
Lopez-
Andres 
2012125* 
CRT-p: 2.7 ug/l (2.1–3.5)                                                                                                    
OMT: 2.7ug/l (2.0–3.9), p=NS 
Multiple Logistic
Regression Π 
Univariate ≤3ug/l: OR 2.42, CI(95%) 1.23–4.76 
p=0.011, Multivariable  ≤3ug/l: OR 3.04  CI(95%) 1.37–
6.71, p<0.01 
MMP-2 
 
Tolosana 
2010294 
TC:295±70ug/l, R:258±56ug/l                                                            
NR:325±116ug/l, p=0.02 
Cox Regression 
Model $ 
Univariate: difference already noted (p=0.02)                                                                                                                                      
Multivariable: No association demonstrated 
 
Garcia-
Bolao 
2008126 
TC: 1434±401.5ug/l                                                                                                           
R: 1393.8±374.5ug/l                                                                                                                                  
NR: 1496.6±438.9ug/l, p=0.36 
ROC Not performed as no difference demonstrated 
MMP-9 
 
Garcia-
Bolao 
2008126 
TC: 44.7±23.2ug/l, R: 41.1±22.8ug/l                                                                                                                                  
NR: 49.9±23.3ug/l, p=0.17 
ROC Not performed as no difference demonstrated 
TIMP-1 
 
Tolosana 
2010294 
TC:242±61ug/l, R:216±50ug/l                                                                                                                                                      
NR:277±59ug/l, p=0.001 
Cox Regression $;
ROC 
Multivariate: OR 0.97, CI(95%) 0.96–0.99, p=0.005                                                                              
ROC: ≥248 ug/l, Sensitivity 71%, Specificity 72%, 
OR 6.8  CI (95%) 1.5–31) 
 
Umar 
2008119~ 
TC: 120.3±8.2ug/l, R: 124±5.2ug/l                                                                                                                                  
NR: 111±7.1ug/l, p=0.16 
Multiple Logistic
Regression $ 
Univariate: OR 1.01, CI(95%) 0.99-1.03, p=0.16                                                              
Multivariable: No association demonstrated 
 
Garcia-
Bolao 
2008126 
TC: 488.9±249.5ug/l                                                                                                           
R: 437.5±136.5ug/l                                                                                                                                  
NR: 563.8±345.7ug/l, p=0.135 
ROC
Not performed as no difference                                                                
Baseline MMP-1:TIMP-1: TC: 0.005±0.001                                                                                                                 
R: 0.004±0.0007 vs NR: 0.0063±0.0008, p=0.297 
Gal-3 
 
Truong 
2014295* 
TC: 18.1ug/l (14.0-23.0)                                                                                                                                  
Positive result >25.9ug/l 
2x2 Table;
McNemar test 
Peripheral: Sensitivity 15% (5–32), Specificity 80%   
(64-91), PPV: 38% (14–68), NPV: 53% (40–66) 
 
Lopez-
2012125* 
CRTp: 25.7ug/l(20.6-31.4)                                                                                                   
OMT: 25.1ug/l(19.6–30.9, p=NS 
Multiple Logistic
Regression π 
No association with response 
NPV=Negative predictive value, NR=Non-responder, NS=Not significant, PPV=Positive predictive value, R=Responder, 
ROC=Receiver operator curve, TC=Total cohort, ≠biomarker mean±SD given in logarithmic format, ~ mean±SE margin, * 
median (IQR) given, data represented as CRT-p & OMT groups, Π=Statistical model predicts ‘non-response’, $=Statistical 
model predicts ‘response’ 
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2.3.4.2. PINP/PICP  
PINP and PICP share a 1:1 stoichiometric relationship with the collagen molecule, therefore, 
they were considered together. Umar et al119 reported similar total cohort means values to 
Lopez-Andres et al125 median values (the skew of this data is unknown). Umar et al119 
observed higher PINP baseline level predicted poor response. Garcia-Balao et al126 reported 
the opposite for PICP. Lopez-Andres et al,125 observed no significant association of baseline 
PINP with CRT response or other outcomes. Variation in pattern of reported levels between 
the 3 studies were likely due to differences in response definitions and baseline 
characteristics. Garcia-Balao et al126 utilised a clinical definition of response, whereas the 
other two studies used echocardiographic criteria.119,125 All studies varied in duration of 
follow-up. Umar et al119 had a higher proportion of men with ischaemic aetiology than the 
other studies. Lopez-Andres et al,125 excluded AF, whereas within the Garcia-Balao et al126 
cohort it was present in 18.6% of participants. Garcia-Balao et al126 tested the predictive 
value of type I collagen turnover with the PICP:CITP ratio with a ratio >14.4 predicting 
response.  
 
Variation was reported in type I collagen synthesis following CRT. Lopez-Andres et al,125 
observed no difference in PINP levels between CRT-p and OMT in the short and long-term; 
there was no analysis of RvsNR.125 Umar et al,119 observed responders had increased PINP 
levels at six months compared to baseline (32.9±2.2 ug/l vs 46.7±4.0 ug/L, p=0.001) with no 
differences in non-responders.119 In contrast, Garcia-Balao et al,126 demonstrated from 
baseline to one year follow-up PICP levels decreased in responders (85.6+29.4ug/l vs 
Dr Christopher J. McAloon 
 
213 
 
71.5+24.1ug/l, p< 0.001) and increased in non-responders (56.6±21.7ug/l vs  88.7+43.5ug/l 
p< 0.001). 
 
2.3.4.3. PIIINP  
Variation was reported in trends of PIIINP levels at baseline. Dong et al,244 reported 
logarithmic figures making absolute figure comparison challenging. Geometric means could 
be calculated, but given the small numbers of participants this was likely to underestimate 
the true mean.244 Higher PIIINP levels in HF vs healthy controls (0.88±0.21ug/l vs 
0.71±0.14ug/l, p=0.01) were observed.244  Responders had significantly lower PIIINP baseline 
levels than non-responders (p=0.03).244 Umar et al119 demonstrated no difference in 
baseline levels between RvsNR.  Lopez-Andres et al125 reported similar baseline levels 
between CRT-p vs OMT, but did observe PIIINP (>4.7ug/l) in univariate analysis predicted 
cardiovascular outcomes (death or HF hospitalisation at 18 months) (OR 1.80, 95% CI 1.06–
3.06, p=0.03).125  
 
CS and peripheral arterial expression of PIIINP was similar prior to CRT, in a sub-set of the 
Dong et al244 cohort (n=36/45). There was no difference in PIIINP expression for the entire 
cohort comparing baseline with follow-up (0.88±0.21ug/l vs 0.87±0.20ug/l p=0.22); no 
results were provided for RvsNR.244 Lopez-Andres et al,125 observed no difference between 
CRT-p and OMT groups from baseline to short and long-term follow-up. In contrast, Umar et 
al,119 observed responders had increased PIIINP expression between baseline and six 
months (4.59±0.24ug/l vs 5.13±0.36 ug/l, p<0.05) but no difference in non-responders.  
4.3.4.4 ICTP or CITP  
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Both ICTP and CITP were used to represent carboxyl-terminal peptides of type I collagen in 3 
included studies. Umar et al,13 and Garcia-Balao et al,12 demonstrated similar baseline 
means for ICTP/CITP for the entire cohort. Neither was identified as independent predictors 
of CRT response.119,126 Garcia-Bolao et al,126 identified that PICP:CITP ratio strongly predicted 
response but was driven by PICP. Lopez-Andres et al,125 observed similar expression 
between CRT-p and OMT groups and showed no predictive value. Lopez-Andres et al125 
observed that ICTP behaviour following CRT-p implant demonstrated no significant change 
at short and long-term follow-up. Umar et al119 supported this observation as no significant 
changes were observed at six months. However, Garcia-Bolao et al,126 observed that there 
was a trend towards lower CITP levels at one year follow-up for responders (4.9±2.5ug/l vs 
2.6±2.7ug/l, p=0.122) but no change in non-responders. 
  
4.3.4.5 MMP-1, MMP-2, MMP-9  
There were variations in reported baseline concentrations for MMP-1. The mean for MMP-1 
in Garcia-Bolao et al,126 was higher than median observed in CRT-p and OMT groups in 
Lopez-Andres et al,125 though the data skew is unknown. Garcia-Bolao et al,126 examined the 
predictive value of MMP-1:TIMP-1 given their intrinsic regulatory role in collagen 
turnover,113 but showed no statistical significance. Lopez-Andres et al,125 observed with a 
baseline MMP-1 <3ug/l an adjusted 3-fold increased risk of CRT non-response and an 
increased risk of death or NT-pro-BNP >1000ng/l (OR 2.23, 95% CI 1.00–5.00, p=0.051/0.073 
adjusted with/without renal function).125 A precursor to MMP-1 called pro-
matrixmetalloproteinase-1 (pro-MMP-1) was studied by Umar et al.119 They observed no 
difference in baseline pro-MMP-1 expression between RvsNR.119  
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Two studies reported cohort means for MMP-2 baseline concentration with large 
differences (Table 4.6). Responders had lower MMP-2 baseline concentrations in both 
studies. Tolosana et al,294 reported a significant difference between RvsNR (p=0.02), 
whereas Garcia-Bolao et al,126 demonstrated no difference. The differences are not fully 
explained by study design, response definition or cohort characteristics as they showed 
similarities (Tables 4.2 and 4.4). Variation in levels may be due to Tolosana et al,294 using 
plasma and Garcia-Bolao et al,126 using serum in their sandwich ELISA’s (Table 4.5). MMP-9 
was reported by Garcia-Bolao et al126, who observed a trend towards lower baseline MMP-9 
concentration for responders. Baseline MMP-9 did not predict CRT response.126  
 
Lopez-Andres et al,125 observed no change in concentration of MMP-1 from baseline to 
short and long term follow-up for both CRT-p and OMT groups. Garcia-Bolao et al,126 
observed MMP-1 levels increased significantly for responders at 1year follow-up (7.33±10.5 
ug/l vs 10.68±10.5ug/l, p= 0.032) compared to no significant difference in non-responders 
(p=0.47). A precursor to MMP-1 called pro-matrixmetalloproteinase-1 (pro-MMP-1) was 
studied by Umar et al,119  and found not to change significantly from baseline to follow-up at 
six months.119  
 
Garcia-Bolao et al126 observed MMP-2 expression did not alter at one year follow-up for 
both responders and non-responders.126 Tolosana et al294 observed MMP-2 had lower 
expression in CS than peripheral samples for responders (239±78ug/l vs 258±56ug/l) and 
non-responders (312±70ug/l vs 325±116ug/l), however this was not statistically compared. 
The mean of baseline MMP-2 expression for both participants who reverse LV remodelled 
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(↓>10% LVESV at 12 months) and those that did not demonstrated no significant difference 
in CS  (230±55ug/l vs 307±100ug/l, p=0.08) or peripherally (267±63ug/l vs 299± 100, 
p=0.32).294 CS MMP-2 did not predict CRT response.294 During their one year follow-up, 
Garcia-Bolao et al126 observed MMP-9 levels increased significantly (41.1±22.8ug/l vs 
50.9±25.2ug/l, p=0.032) yet non-responders showed no change at a year (50.7±23.3 vs 
50.9±21.2, p=1.0).126 
 
4.3.4.6 TIMP-1  
Tolosana et al294 observed responders had significantly lower concentrations at baseline of 
TIMP-1 than non-responders. Neither Umar et al119 nor Garcia-Bolao et al126 observed a 
significant difference in baseline TIMP-1 concentration between RvsNR. Higher peripheral 
TIMP-1 was identified as an independent predictor of non-response by Tolosana et al294 in 
multivariable analysis; a concentration of  >248ug/l had a 71% sensitivity and 72% specificity 
for predicting non-response. However, Umar et al119 did not identify TIMP-1 as a predictor. 
Garcia-Bolao et al126 tested TIMP-1 in the MMP-1:TIMP-1 ratio and did not identify TIMP-1 
as a significant predictor of RvsNR.  
 
Tolosana et al294 was the only study to examine CS vs peripheral concentrations of TIMP-1 
with both correlating strongly (r2=0.54). Baseline CS expression was lower than peripheral in 
responders (205±51ug/l vs 216±50ug/l) and non-responders (260±60ug/l vs 277±59ug/l), 
though this was not statistically tested.294 CS expression of TIMP-1 was lower in RvsNR 
(p=0.003).294 Tolosana et al294 compared TIMP-1 baseline concentrations between those 
that did and did not  LV reverse remodel and found significantly lower expression in the CS 
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(192±47ug/l vs 258±55 ug/l, p=0.001) and peripherally (208±46ug/l vs 267±60ug/l, p= 
0.001). CS and peripheral expression was significantly higher in those 6 patients who had 
cardiovascular mortality during the observation period.294 The trend in TIMP-1 
concentration was noted to decrease at one year in responders (437.5±136.5ug/l vs 
365.2+138.5 ug/l, p=0.002) by Garcia-Balao et al,126 with no statistically significant decrease 
in non-responders (457.3+247.5 ug/l vs 344.8+110.7 ug/l p=0.084). The MMP-1:TIMP-1 ratio 
decreased from baseline to one year follow-up for responders (0.004±0.0007 vs 
0.0066±0.001, p=0.007) with no change for non-responders.126 In contrast, Umar et al119 
observed no change in concentration of TIMP-1 for CRT response at six months for RvsNR.  
 
4.3.4.7 Galnectin-3  
Lopez-Andres et al125 reported higher baseline levels of Gal-3 than Truong et al,295 due to 
different response definitions and variation in cohort characteristics. Lopez et al125 used an 
echocardiographic definition at 18 months and Truong et al,295 utilised HF clinical composite 
score at 6 months. Truong et al,295 has higher ischaemic aetiology (53.4% vs. 40.2%) and 
included AF patients. Neither study reported baseline concentrations for RvsNR.125,295 
Truong et al295 observed that peripheral baseline Gal-3 above a pre-set concentration 
(>25.9ug/l) had low sensitivity and high specificity for predicting CRT response.  
 
CS expression of Gal-3 at baseline was 10% lower than peripheral (median and IQR, 16.7ug/l 
[12.5-21.0] vs 18.1ug/l [14.0-23.0], p<0.001).295 The CS Gal-3 concentrations above the pre-
set level had higher sensitivity (18%) and specificity (90%) for predicting CRT response than 
peripheral samples.295 Lopez-Andres et al125 observed Gal-3 did not predict CRT response. 
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No significant change in Gal-3 concentration was noted between baseline and long-term 
follow-up for both CRT-p and OMT groups.125 No difference was noted between follow-up 
concentrations between both groups.125 Lopez-Andres et al125 demonstrated baseline Gal-3 
concentration >30ug/l predicted death or hospitalization for worsening HF (OR 2.98, 95% CI 
1.43-6.22, p=0.004). 
 
4.4 DISCUSSION  
The Cardiac ECM is a highly dynamic structure that is integral to myocardial structure and 
function which detrimentally remodels following cardiac injury leading to the altered 
turnover, replacing contractile tissue with collagen rich connective tissue and ultimately the 
development of myocardial fibrosis.113 Myocardial fibrosis is characterised by adverse 
remodelling which contributes to systolic and diastolic HF.113,296 PINP, PICP and PIIINP are 
released into the circulation during conversion and deposition of procollagen to collagen 
and are up-regulated during myocardial fibrosis and associated with adverse HF 
outcomes.113,124,137,296 Mechanistically higher up-regulation of collagen deposition would 
challenge a CRTs ability to reverse remodel and for the patient to respond. Umar et al119 
supported this hypothesis observing significantly lower baseline PINP expression predicted 
echocardiographic response. Dong et al244 did observe lower baseline PIIINP predicted 
echocardiographic response on univariate analysis, but not on multivariable analysis. In a 
recent observation study, Sokal et al127 supports these observations with their published  
sub-study of the Triple Site Versus Standard Cardiac Resynchronization (TRUST CRT) trial297 
examining ECM biomarkers (PINP, PIIINP, MMP-2 & MMP-9) ability to predict 
echocardiographic CRT response (↑>10% LVEF at 6 months). This study was not identified 
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through the systematic review as it was published in January 2016; outside the defined 
search window for the review.127 The TRUST-CRT trial297 was a single-centre, randomised, 
parallel observation study which was powered for differences in response (composite 
endpoint: survival free from HF or heart transplantation and ↑≥10% LVEF and ↑≥10% peak 
VO2max and ↑≥10% 6MWD at 6 months) between triple site (two leads on LV) and 
standard (biventricular) pacing (randomised 1:1) for HFrEF patients (n=100) meeting criteria 
for a complex device. The TRUST CRT trial297 identified triple site pacing improved functional 
response. Sokal et al127 observed lower PIIINP concentration pre-implant independently 
predicted response (OR 3.6, 95% CI 1.2-10.2, p=0.017) supporting the findings of Dong et 
al244 and Umar et al.119 Furthermore, higher PIIINP pre-implant was observed to predict 
MACE (OR 3.6, 95% CI 1.5-9.2, p=0.007).127  Lopez-Andres et al,125 in a larger cohort 
demonstrated higher baseline PIIINP predicted worse cardiovascular outcomes.125 Sokal et 
al127 observed no difference in baseline expression between RvsNR for MMP-2 and MMP-9. 
This study offers further insights into the cardiac ECM remodelling in HFrEF patients 
undergoing CRT implantation and their potential as predictors of response. However the 
study has limitations that should be considered; the response definition changed between 
the TRUST CRT trial297 and the subsequent sub-study had less participants (n=74)  than the 
original study. The two interventions were not statistically accounted for in analysis.127 In 
contrast, Garcia-Balao et al,126 observed higher baseline expression of PICP in responders 
and PICP:CITP ratio (type-I-collagen turnover) of  >14.4 had >2 fold increased chance of 
predicting functional response, driven by PICP. Critically, echocardiographic and 
clinical/functional response criteria correlate poorly,1 so could not be contrasted. 
Importantly, Lopez-Andres et al125 the largest study included in the review, did not observe 
up-regulation of collagen synthesis predicting echocardiographic non-response, which does 
Dr Christopher J. McAloon 
 
220 
 
challenge the Umar et al119 and Dong et al244 observations; however, the cohort 
characteristics and study designs were different. The observations of collagen synthesis 
following CRT implantation conflict with each other. Umar et al119 reported a significant 
increase in PINP and decrease in PIIINP expression in responders at six months. In contrast 
Garcia-Bolao et al126 observed PICP levels decreased for responders and increased for non-
responders at one year, which would be expected, but is based upon a functional response 
definition. In contrast to collagen synthesis, degradation biomarkers (ICTP or CITP) did not 
predict CRT response.119,125,126  Furthermore, no significant change in ICTP or CITP 
expression was observed at follow-up across all 3 studies.119,125,126 Alteration in collagen 
synthesis rate is observed to be more powerful at predicting response than collagen 
degradation. Different patterns of collagen synthesis biomarkers predicting response have 
been observed; lower expression predicted LV reverse remodelling119,244 whereas higher 
rates predicted functional response.126 The variation in these patterns is explained by the 
different response definitions and cohort characteristics. The study cohort for Umar et al119 
had a higher proportion of men and ischaemic cardiomyopathy than Garcia-Bolao et al.126 
The heterogeneities between these studies make drawing conclusions difficult. Lopez-
Andres et al125 also challenge any observations due to the size of cohort and no prediction 
value to collagen turnover observed. Overall collagen synthesis is observed to be important 
in predicting CRT response, especially LV reverse remodelling, with results replicated in two 
studies that lower rates predict LV reverse remodelling.10,26  
 
MMP-1,-2 and -9 perform a critical role in myocardial collagen degradation and have been 
identified as being important prognostic markers in HF.120,134,136 Predictive value for CRT 
non-response (death or LVEF ≤35% at 18months) was only demonstrated in baseline MMP-1 
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expression <3ug/l125 supporting an observation by Jordan et al134 that lower MMP-1 inferred 
worse HF prognosis. MMP-2 had large variations observed between the included 
studies,125,294 but was not demonstrated to predict response. MMP-9 was only observed in 
one included study showing no predictive value,126 however recently Dini et al136 
demonstrated  raised levels (>238 ng/ml) predicted worse HF outcomes. MMP activity was 
not considered in any of these studies as a predictor but would be important to consider in 
the future. Current evidence suggests MMPs, especially -2 and -9, have not yet had their 
potential fully evaluated. 
 
TIMP-1 regulates the endogenous proteolytic MMP system involving discordant inhibition 
and in chronic inflammatory states stimulating collagen synthesis and myocardial 
fibrosis.113,294 Tolosana et al,294  observed a significant baseline difference in RvsNR 
expression with lower TIMP-1 in responders. Tolosana et al,294 demonstrated baseline TIMP-
1 ( >248ug/l) predicted CRT non-response. Trucco et al,298 in long-term follow-up of the 
same cohort demonstrated the same threshold independently predicted mortality at 
60±34months, (sensitivity 80% and specificity 71%). Tolosana et al294 also demonstrated 
statistically significant lower TIMP-1 is found in participants that do LV reverse remodel 
(LVESV reduction ≥10%). Umar et al119 and Garcia-Bolao et al126 observed no difference 
statistically at baseline. Variation between the reported literature in the magnitude of 
association of TIMP-1 exists, however Tolosana et al294 offers a well-designed prospective 
observational study which is powered giving strength to the conclusions drawn.  
 
Galectin-3 stimulates fibroblasts to release TIMPs and MMPs that regulate collagen 
turnover, resulting in myocardial fibrosis.138 Elevated levels are independent predictors of 
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adverse outcomes in HF.138 Evaluation of Gal-3 as a predictor of response was limited, as 
RvsNR was not reported in either of the 2 studies.125,295 Truong et al,295 demonstrated 
peripheral baseline Gal-3 >25.9ug/l had specificity for predicting CRT response. Lopez-
Andres et al,125 observed Gal-3 baseline expression >30ng/l had nearly 3-fold increased risk 
of death or hospitalization for worsening HF following CRT. Though not demonstrated to be 
a strong predictor the evidence suggests that Gal-3 is a good biomarker for predicting poor 
outcomes in HF and needs further evaluation.  
 
The greatest challenge for research into CRT response and one that this systematic review 
demonstrated is lack of an accepted response definition. Differing definitions rarely 
correlate,1 which our review clearly demonstrates. Echocardiographic and clinical/functional 
definitions correlate very poorly and should never be compared or applied in a composite 
definition; 1 LV reverse remodelling should be considered separately.1,93  
 
Heterogeneity among included studies was widespread despite a rigorous eligibility and 
screening criteria. The variations in study design, cohort characteristics and response 
definitions made pooling data in a meta-analysis impractical. Multiple cardiac ECM 
biomarkers were being explored in this review to examine what research into ECM 
biomarkers and CRT had been done looking at their predictive strength. This offered a broad 
research question and there were a small number of studies eligible. Each was on small 
patient numbers and had differing study design and most importantly used incomparable 
response definitions. All these factors together meant a met-analysis was not feasible. CRT 
implantation techniques and indications have evolved over the last 15 years and offer 
another source of heterogeneity. Furthermore differences in laboratory techniques account 
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for some variation among biomarker results. All the included studies lacked individual 
power and had limited participant numbers making achieving any consensus conclusion very 
difficult. These limitations are particularly important to consider in future research studies. 
 
Collagen synthesis biomarkers have shown the most potential, particularly PINP and PIIINP, 
but will require further study. MMP-2 and -9 have no conclusive predictive value, and need 
further investigation. The studies to date have been too small to offer conclusive evidence 
they can’t predict response following CRT. Heterogeneity is the greatest challenge for 
research in this field and needs to be minimised in future studies, for instance focusing on 
one particular mechanism of injury e.g. hypertension, so the expression pattern of ECM 
biomarkers is similar in HF patients. Another step would be for an accepted definition of CRT 
response to be produced, to allow direct comparison to be undertaken.  
 
4.5 Contribution of Authors 
Dr Christopher McAloon had the original concept, designed methodology, performed 
literature search, article screening, data extraction, quality assessment, results analysis and 
drafted the manuscript. Dr Danish Ali performed article screening, data extraction and 
quality assessment. Mr Thomas Hamborg reviewed statistical interpretation. Professor 
Pritwash Banerjee, Dr Paul O’Hare and Dr Harpal Randeva reviewed methodology and 
critically edited manuscript. Dr Faizel Osman reviewed methodology, eligibility and critically 
edited manuscript. 
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Chapter Five 
 
PRE-IMPLANTATION PREDICTORS  
AT A UK TERTIARY CENTRE 
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5.1 INTRODUCTION 
Non-response remains one of the largest challenges in management of patients undergoing 
CRT implantation. The current rate of non-response remains at 20-40% of all CRT 
implantations performed.103 Several variables have been associated with predicting 
response. These variables are can be summarised as pre-implant, implant and post-implant.  
Unfortunately many of these variables are not proven to be robust in the prediction of 
response.  
 
Debatably the pre-implantation variables are the most important to the patient as these 
may inform their decision to proceed. Multiple ‘pre-implantation’ variables; clinical 
background, resting ECG, echocardiography and procedural factors have been suggested as 
predictors of response.38,39,65-68 Several studies (Table 1.3) have indicated that aetiology, 
gender, QRS duration/morphology, left atrial dimensions and LV dimensions can predict 
response, but these findings have not been reproducible in all study cohorts.38,39,65-68 The 
most consistent predictor of response and cardiovascular outcomes is QRS duration on 
ECG.39,68 A recent meta-analysis of five Medtronic randomised control trials (n=4317) found 
increasing QRS duration in patients having CRT vs. Controls (OMT/ICD/Back-up pacing) 
predicted all-cause mortality or HF hosptilisation (Figure 1.2).39 Cleland et al,39 identified 
several potential ‘pre-implantation’ predictors that might predict cardiovascular outcomes 
in a multivariable logistic regression model, but when treating the presence of a CRT as an 
interaction term, the only variable that remained a predictor was QRS duration.39 The meta-
analysis could not include individual particpants data from non-Medtronic randomised 
control trials, specifically COMPANION22 and MADIT-CRT.27 Broadly, both these trials22,27 
support Cleland et al,39 that increasing baseline QRS duration infers less chance of having an 
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adverse cardiovascular outcome. Interestingly several smaller observational studies have 
not replicated these findings.64-67 However, the limitations of these studies in terms of 
design and numbers of patients observed contributed to the lack of reproducibility.39,63 A 
recurring theme with weaknesses in this field is the inconsistently applied definition of 
response and the challenge this poses in comparing variables and pooling data1; a challenge 
encountered during our conduct of a systematic review into ECM biomarkers to predict CRT 
response (Chapter 4).  
 
International guidelines are informed by the patient cohorts from the large multi-centre 
randomised control trials.17,22,23,27,47,56 The strongest pre-implant predictor of response has 
been demonstrated to be QRS duration and is reflected in the international guidelines,17,47,56 
yet non-response remains a persistent issue.234 
 
5.2 AIMS (Chapter 2) 
 
The aim of this chapter is to examine reported pre-implant predictors of response and 
cardiovascular outcomes in the literature within our heterogeneous single centre CHF 
population. This analysis will inform the selection of pre-implant variables that are examined 
in the phase II prospective observation study with the specified biomarkers.   
 
5.3 CONCISE METHODS 
5.3.1 Study design 
A single-centre, retrospective study of all consecutive CRT implants at UHCW performed 
over five years (January 2009 to December 2013). Figure 3.3 summarises the patient 
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selection and study design. All implants met national and international implantation 
guidelines.17,47,234 All CRT-p and CRT-d implants were included, both de novo and upgrade 
implants to reflect all patients getting a biventricular pacing device. Pulse generator only 
changes were excluded. Procedures were excluded from analysis if LV lead implant failed or 
there was an immediate complication that prevented >90% biventricular pacing, as the CRT 
would be deemed to not be working correctly. Exclusions were applied if clinical response 
status at baseline or follow was not determinable from the records. Cardiovascular outcome 
data were collected for all patients until 31st December 2014 (minimum one year).Due to 
the outcome definition used, the low number of patients and the high percentage of non-
response, this study was not powered. Approval was provided by our local Research, 
Development and Innovation department. Chapter 3.4 summarises in detail the 
retrospective observational study design. 
 
5.3.2 Data Collection  
Detailed methodology applied to data collection for included patients is summarised in 
Chapter 3.4. Electronic (Clinical Results Reporting Systems, University Hospital Coventry and 
Warwickshire, Coventry, UK) and paper case notes were reviewed for patients meeting 
eligibility, including all correspondence from local referral centres. Hospital coding data was 
also reviewed for each participant. Two reviews of case records were performed to 
maximise recorded data quality and minimise bias. Baseline echocardiograms (EchoPac, GE 
Healthcare, Horten, Norway) and ECGs prior to CRT implant were reviewed and had LVEF, 
QRS duration and BBB morphology measured.  
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5.3.3 Implant Procedure  
A detailed description of the CRT implant procedure and aftercare is outlined in Chapter 3.2. 
 
5.3.4 Potential Pre-implant Predictors Model (Chapter 3.4) 
Potential clinical predictors were considered prior to assessment and pre-selected based on 
previous reports. Predictors identified were age and gender,38 device type (CRTp/CRTd) and 
upgrade status,235 clinical aetiology,38,65,68 CKD,236-238 diabetes mellitus,236 BBB 
morphology,38,66,68 QRS duration,38,39,68 and LV ejection fraction on echocardiography.38,67 
CKD status at implant was defined as a GFR <60ml/min/1.73m2 using the modification of 
diet in renal disease equation.237,239,240 Time from implant to determination of response was 
considered likely to be wide, therefore, time between implant and assessment was included 
as a confounding variable in the clinical predictor model. Baseline NYHA status was not 
included as a predictor due to the direct association with clinical response.  
 
5.3.5 Outcomes: Clinical Response and Cardiovascular Outcomes (Chapter 3.4) 
Primary outcome was the overall clinical response assessed at the latest cardiology/HF 
consultation. The criterion for clinical response was a decrease in NYHA classification >1 
symptoms from baseline. The latest consultation was defined as the closest to the final 
observation date (31st December 2014). Secondary outcomes were acute (<12weeks), long-
term (>12weeks) clinical response and MACE (all-cause mortality or first HF admission). 
Mortality rates were generated from hospital coding data; HF admissions were defined as a 
hospital admission requiring intravenous diuretics.  
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Determination of NYHA class was performed by reviewing all recorded consultations. The 
latest NYHA classification available was used to determine response. Clear documentation 
of NYHA score by the clinician was used to determine symptom classification. Where no 
clear scoring was made, the content of the recorded consultation was reviewed by three 
clinicians (blinded to each others review) to determine NYHA class. Where consensus was 
not reached the patient was excluded from final analysis.  
 
5.3.6 Statistical Analysis (Chapter 3.8) 
Categorical variables were reported as frequency and percentage. Comparison analysis for 
categorical data was performed using Chi-Squared and where required Fisher’s Exact test. 
Continuous data underwent histogram plots for assessment of normality. Normally 
distributed data were reported as mean±SD and comparative analysis performed using 
independent t-tests. Non-normally distributed data were reported as median (range) and 
compared using a Mann-Whitney U test. Univariate logistic regression analysis was 
performed on all pre-identified variables; those achieving p-value <0.15 were pooled as 
covariates for multiple logistic regression analysis. A stepwise entry method was applied 
with forward selection and backward elimination to ensure duplication of findings. The 
accuracy of the model was verified with Hosmer-Lemeshow goodness-of-fit test. Survival 
analysis for each categorical variable was performed on MACE, all-cause mortality and first 
hospital admission separately using Kaplan-Meier survival curves and assessed visually and 
for statistical significance using the log-rank test. Multivariate Cox proportional hazards 
regression analyses were performed, for potential predictor variables, on their ability to 
predict MACE, with mortality and first hospital admission considered separately. A forward 
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selection and backward elimination method was applied using the Wald statistic with 
p<0.15. A p-value <0.05 was considered statistically significant. 
 
5.3.7 Missing Data  
Missing data were anticipated given the method of data collection. Sequential searches of 
multiple sources were performed by two investigators to minimise data loss. A missing data 
analysis was performed to determine patterns of ‘missingness’ for selected predictors 
(Table 5.1). Absent demographic and medical background variables were assessed to 
demonstrate a MCAR pattern and continuous potential predictor variables (LVEF and QRS 
duration) have a MAR pattern. Precise LVEF measurments were not always possible due to 
specific patient factors, the main example being patients having a large body habitus. QRS 
duration could not always be measured as an ECG and was not available for a small minority 
of patients, (due primarily to its unavailability with external centres referals). Multiple 
imputation was performed to compensate for the small amount of missing data. Logistic 
regression analysis and proportional hazards Cox regression analysis models utilised 
multiple imputation data sets. Complete case analysis was performed to confirm multiple 
imputation models. Absence of electrocardiographic data represented the lack of availability 
of the baseline trace for those particular patients in their records.  
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Table 5.1 Selected ‘Pre-Implant’ Predictors Missing Data.  
  
Missing 
(n,%) 
Valid 
N 
Complete Case 
Mean±SD 
Age at Implant 0 (0.0%) 300 71.5±10.1 
Gender 0 (0.0%) 300  
CRT Device 0 (0.0%) 300  
Upgrade Status 0 (0.0%) 300  
Aetiology 10 (3.3%) 290  
Diabetic Status 10 (3.3%) 290  
CKD 8 (2.7%) 292  
BBB Morphology 41 (13.7%) 259  
QRS duration (msec) 40 (13.3%) 260 157.3±25.3 
LVEF (%) 71 (23.7%) 229 24.1±5.3 
 
5.4. RESULTS 
5.4.1 Patient Characteristics 
During the period of study 376 implants were performed; 11 (2.9%) were excluded because 
biventricular pacing was not possible at the end of implant and 65 (17.8%) excluded due to 
lack of clinical response data at follow up, leaving 300 patients (Figure 5.1). The overall 
response rate was 52.7% (n=158). Baseline characteristics of the cohort and comparison 
between overall clinical responders vs non-responders is shown in Table 5.2.  
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Figure 5.1 Screening and selection of all CRT implantations eligibile for study.  
 
 
 
  
Total CRT = 376 
Jan 2009 – Dec 2013 
Successful CRT Implant = 365 
CRT-p=145, CRT-d=142, Upgrade CRT-p = 39, 
Upgrade CRT-d=39 
Eligible CRT Implants = 300 
CRT-p=116, CRT-d=118, Upgrade CRT-p=31, 
Upgrade CRT-d=35 
Excluded Procedure = 11 
Failed Procedure = 9 
High LV lead threshold = 1 
Immediate LV displacement = 1 
Incomplete response data = 65 
CRT-p=29, CRT-d=24, Upgrade 
CRT-p = 8, Upgrade CRT-d=4 
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Table 5.2. Baseline characteristics of overall clinical responders vs non-responders. 
  
Total 
Cohort  
N=300 
Responders     
N= 158 
Non-Responders 
N= 142 
P-value 
 
Demographics 
Age (years, mean±SD) 
Male (n,%) 
71.5±10.1 
227 (75.7%) 
69.9±10.7 
119 (75.3%) 
73.3±9.1 
108 (76.1%) 
<0.001 
0.98 
Device 
CRT-D (n,%) 
Upgrade (n,%) 
153 (51.0%) 
66 (22.0%) 
87 (55.1%) 
27 (17.1%) 
66 (46.5%) 
39 (27.5%) 
0.17 
0.04 
Aetiology≠ 
Ischaemic (n,%) 
Non-ischaemic (n,%) 
171 (59.0%) 
119 (41.0%) 
93 (60.8%) 
60 (39.2%) 
78 (56.9%) 
59 (43.1%) 
0.58 
Co-morbidities 
Prev-MI (n,%)≠ 
CABG (n,%)≠ 
Prev-PCI (n,%)≠ 
Diabetes Mellitus (n,%) 
CKD (n,%) 
 
126 (45.0%) 
67 (24.1%) 
55 (20.5%) 
75 (25.9%) 
103 (35.3%) 
 
71 (48.6%) 
38 (26.2%) 
28 (20.4%) 
37 (24.2%) 
46 (29.7%) 
 
55 (41.0%) 
29 (21.8%) 
27 (20.6%) 
38 (27.7%) 
57 (41.6%) 
 
0.24 
0.47 
1.00 
0.58 
0.05 
NYHA (n,%) 
I 
II 
III 
IV 
 
4 (1.3%) 
24 (8.0%) 
246 (82.0%) 
26 (8.7%) 
 
2 (1.3%) 
8 (5.1%) 
127 (80.4%) 
21 (13.3%) 
 
2 (1.4%) 
16 (11.3%) 
119 (83.8%) 
5 (3.5%) 
<0.01 
Electrocardiogram 
AF (n,%) 
QRS duration (msec), 
median (range))≠ 
LBBB (n,%)≠ 
72 (28.0%) 
154 (88-
278) 
 
186 (71.8%) 
33 (25.4%) 
157 (88-278) 
 
102 (75.0%) 
39 (30.7%) 
154 (88-230) 
 
84 (68.3%) 
0.42 
0.77 
 
0.29 
Echocardiogram 
LVEF (%, mean±SD)≠ 
24.10±8.30 23.70±8.60 24.97±8.01 0.15 
Medications 
ACEi/ARB (n,%) 
Beta-blocker (n,%) 
MRA (n,%) 
237 (82.0%) 
215 (73.9%) 
129 (51.4%) 
126 (81.0%) 
108 (71.1%) 
66 (50.8%) 
111 (82.9%) 
107 (77.0%) 
63 (52.1%) 
0.79 
0.31 
0.94 
LV Lead Position (n,%) 
Anteroseptal 
Anterior 
Anterolateral 
Lateral 
Posterolateral 
Posterior 
 
1 (0.3%) 
15 (5.0%) 
32 (10.7%) 
194 (64.7%) 
56 (18.7%) 
2 (0.7%) 
 
0 (0.0%) 
5 (3.2%) 
17 (10.8%) 
101 (63.9%) 
33 (20.9%) 
2 (1.3%) 
 
1 (0.7%) 
10 (7.0%) 
15 (10.6%) 
93 (65.5%) 
23 (16.2%) 
0 (0.0%) 
0.30 
≠ Based upon avaliable data 
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5.4.2 Implant details  
Of the total cohort, 147 (49.0%) had CRTp and 153 (51.0%) CRTd implants; of the latter 103 
(67.3%) had primary prevention and 50 (32.7%) secondary prevention indication for 
defibrillator implantation. There were 227 (75.7%) elective and 73 (24.3%) urgent CRT 
implants performed. Overall clinical response vs non-response in elective implants (52.9% vs 
47.1%) and urgent implants (52.1% vs 47.9%) was not statistically different (p=1.0).Vascular 
access was cephalic vein with either one (n=140, 46.7%) or two (n=158, 52.6%) venous 
punctures. The RV lead was already in-situ in 46 (15.3%) cases. New RV leads were placed 
most commonly via the cephalic vein (n=177, 69.7%). There were 254 new RV leads placed, 
and they were deployed either at the RVA (n=239, 94.1%) or RV septum (n=13, 5.1%). 
Overall clinical response vs non-response was no different between different RV pacing sites 
(RVA: 55.6% vs 44.4% and RV septum: 69.2% vs 30.8%, p=0.16). A new RA lead was not 
placed if there was one already in-situ (n=34, 11.3%) or the patient was in permanent AF 
(n=52, 17.3%). RA leads were placed at the RAA (n=177, 82.7%) or RA free wall (n=36, 
16.8%). The LV lead was most commonly placed via the axillary vein (n=184, 61.3%). The LV 
lead distal lead circumferential position is shown in Table 5.2 with no statistical difference 
noted when evaluating overall clinical response. The LV lead axial position was basal (n=57, 
19.0%) or mid-cavity (n=236, 78.7%) in the majority with only a few apical (n=7, 2.3%). There 
was no statistical difference demonstrated with overall clinical response (p=0.56). 
 
There were 66 (22.0%) device upgrades to CRT within the cohort (Figure 5.1): 30 
pacemakers upgraded to CRT-p (n=23 dual, n=7 single lead), 1 single lead ICD upgraded to 
CRT-p, 16 pacemakers upgraded to CRT-d (n=9 dual, n=7 single lead) and 19 ICDs (n=15 dual, 
n=4 single lead) upgraded to CRT-d. Upgrade status was significantly different between 
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overall clinical responders and non-responders (Table 5.2). The index cardiac device was 
compared with overall clinical response vs non-response with no significant difference 
found (p=0.082): single chamber pacemaker (14.8% vs 25.6%), dual chamber pacemaker 
(51.9% vs 46.2%), single lead ICD (33.3% vs 15.4%) and dual chamber ICD (0% vs 12.8%).  
 
5.4.3 Clinical response 
Overall there were 158 (52.7%) responders and 142 (47.3%) non-responders with a median 
(range) time to assessment of 12.0 (0.02-68.2) months. In the overall cohort older age, 
presence of device upgrade and CKD were significantly more common in the non-
responders (Table 5.2).  
 
Acute response was definable for 247 patients: 153 (61.9%) responders and 94 (38.1%) non-
responders. Table 5.3 provides the baseline characteristics of the cohort where an acute 
response was definable. The median (range) follow-up to acute response assessment was 
1.4 (0.02-3.0) months. There were no significant differences in characteristics between 
acute responders and non-responders. 
 
Long-term response was determined for 238 patients with 116 (48.7%) responders and 122 
(51.3%) non-responders; the median (range) follow-up was 15.2 (3.1-68.2) months. Table 
5.4 demonstrates baseline characteristics of these patients. Long-term response cohort 
characteristics were similar to the overall cohort. The two variables that demonstrated 
statistical significance between clinical responders and non-responders were older age 
(68.9±10.68 vs 72.9±9.40, p<0.01) and presence of CKD (27.0% vs 41.5%, p=0.03). Presence 
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of device upgrade showed a significant difference for overall response between responders 
and non-responders, but did not reach statistical significance for long-term response. 
 
5.4.4 Predictors of Clinical Response  
Table 5.5 demonstrates increasing age was an independent predictor of overall clinical 
response. Age at implant was demonstrated to be the strongest predictor with an OR of 
0.96 (p=0.002, CI 0.94-0.99), representing a 4% decreased chance per year of age of having a 
clinical response. Increasing time from implant to assessment was observed to be an 
important confounder for predicting non-response (OR 0.99, p=0.03, CI 0.99-1.00). 
Upgrading devices to CRT was also suggestive of predicting non-response, but did not reach 
statistical significance (OR 0.57, p=0.05, CI 0.32-1.01). Complete case analysis verified the 
findings for the imputed analysis. QRS duration as a predictor in the cohort was evaluated 
by performing quadratic and logarithmic transformation as it was a non-normally 
distributed variable. These analyses did not demonstrate that QRS duration had the ability 
to predict clinical response. The limited numbers in the cohort may explain the associations 
that are seen as chance observations and do not rule out roles as predictors. 
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Table 5.3 Baseline characteristics acute response (<12 weeks) response vs non-responders 
 
Total Cohort   
N= 247 
Responders     
N= 153 
Non-Responders  
N= 94 P-value 
Demographics 
    
Age (years, mean±SD) 71.4±10.2 70.7±10.8 72.4±9.2 0.22 
Male (n,%) 186 (75.3%) 115 (75.2%) 71 (75.5%) 1.00 
Device 
    
CRT-D (n,%) 128 (51.8%) 80 (52.3%) 48 (51.1%) 0.97 
Upgrade (n,%) 53 (21.5%) 33 (21.6%) 20 (21.3%) 1.00 
Aetiology≠ 
    
Ischaemic (n,%) 139 (58.4%) 60 (41.1%) 39 (42.4%) 
0.95 
Non-ischaemic (n,%) 99 (41.6%) 86 (58.9%) 53 (57.6%) 
Co-morbidities 
    
Prev-MI (n,%)≠ 96 (42.1%) 60 (43.2%) 36 (40.4%) 0.79 
CABG (n,%)≠ 52 (22.8%) 31 (22.1%) 21 (23.9%) 0.89 
Prev-PCI (n,%)≠ 43 (19.5%) 24 (18.0%) 19 (21.6%) 0.52 
Diabetes Mellitus (n,%) 63 (26.4%) 36 (24.7%) 27 (29.0%) 0.55 
CKD (n,%) 81 (33.8%) 31 (33.7%) 50 (33.8%) 1.00 
NYHA (n,%)   I 
II 
III 
IV 
2 (0.8%) 
20 (8.1%) 
205 (83.0%) 
20 (8.1%) 
0 (0.0%) 
9 (5.9%) 
127 (83.0%) 
17 (11.1%) 
 
2 (2.1%) 
11 (11.7%) 
78 (83.0%) 
3 (3.2%) 
0.01 
Electrocardiogram 
    
AF (n,%) 63 (29.7%) 32 (25.0%) 31 (36.9%) 0.09 
QRS (msec, median (range))≠ 152 (88-230) 154 (95-206) 150 (88-230) 0.26 
BBB (n,%)≠ 155 (72.1%) 98 (73.1%) 57 (70.4%) 0.78 
Echocardiogram 
    LVEF (%, mean±SD)≠ 23.9±8.3 23.3±8.2 25.0±8.5 0.20 
Medications 
    ACEi/ARB (n,%) 199 (82.9%) 75 (81.5%) 124 (83.8%) 0.78 
BB (n,%) 179 (74.3%) 107 (71.8%) 72 (78.3%) 0.34 
MRA (n,%) 107 (51.2%) 69 (53.5%) 38 (47.5%) 0.48 
LV Lead Position (n,%) 
    Anteroseptal 1 (0.4%) 0 (0.0%) 1 (1.1%) 
0.50 
 
Anterior 13 (5.3%) 7 (4.6%) 6 (6.4%) 
Anterolateral 28 (11.3%) 16 (10.5%) 12 (12.8%) 
Lateral 163 (66.0%) 105 (68.6%) 58 (61.7%) 
Posterolateral 41 (16.6%) 25 (16.3%) 16 (17.0%) 
Posterior 1 (0.4%) 0 (0.0%) 1 (1.1%) 
  ≠ Based on available data 
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Table 5.4 Characteristics long-term (>12 weeks) response vs non-responders.  
  
  
Total Cohort   
N= 238 
Responders     
N= 116 
Non-Responders  
N= 122 
P 
value 
Demographics 
    Age (years, mean±SD) 71.0±10.22 68.9±10.68 72.9±9.40 <0.01 
Male (n,%) 179 (75.2%) 87 (75.0%) 122 (51.3%) 1.00 
Device 
    CRT-D (n,%) 119 (50.0%) 62 (53.4%) 57 (46.7%) 0.36 
Upgrade (n,%) 50 (21.0%) 20 (17.2%) 30 (24.6%) 0.22 
Aetiology≠ 
    Ischaemic (n,%) 137 (59.3%) 69 (60.5%) 68 (58.1%) 
0.81 
Non-ischaemic (n,%) 94 (40.7%) 45 (39.5%) 49 (41.9%) 
Co-morbidities 
    Prev-MI (n,%)≠ 105 (45.9%) 56 (49.6%) 49 (42.2%) 0.33 
CABG (n,%)≠ 51 (22.5%) 25 (22.3%) 26 (22.6%) 1.00 
Prev-PCI (n,%)≠ 50 (22.6%) 28 (25.9%) 22 (19.5%) 0.32 
Diabetes Mellitus (n,%) 58 (25.2%) 27 (23.9%) 31 (26.5%) 0.80 
CKD (n,%) 80 (34.3%) 31 (27.0%) 49 (41.5%) 0.03 
NYHA (n,%)   I 
     II 
     III 
                        IV 
4 (1.7%) 
17 (7.1%) 
198 (83.2%) 
19 (8.0%) 
2 (1.7%) 
4 (23.5%) 
95 (81.9%) 
15 (12.9%) 
2 (1.6%) 
13 (10.7%) 
103 (84.4%) 
4 (3.3%) 
<0.01 
Electrocardiogram 
    AF (n,%) 59 (28.1%) 26 (26.0%) 33 (30.0%) 0.62 
QRS (msec, median 
(range))≠ 155 (88-278) 160 (88-278) 154 (88-230) 0.82 
LBBB (n,%)≠ 149 (71.6%) 102 (74.5%) 73 (68.9%) 0.45 
Echocardiogram 
    LVEF (%, mean±SD)≠ 25.0±8.48 23.1±8.2 25.1±8.7 0.10 
Medications 
    ACEi/ARB (n,%) 199 (85.4%) 101 (88.6%) 98 (82.4%) 0.24 
BB (n,%) 179 (76.2%) 85 (74.6%) 94 (77.7%) 0.68 
MRA (n,%) 108 (51.9%) 52 (51.0%) 56 (52.8%) 0.90 
LV Lead Position (n,%) 
    Anteroseptal 1 (0.4%) 0 (0.0%) 1 (0.8%) 
0.26 
 
 
 
Anterior 13 (5.5%) 4 (3.4%) 9 (7.4%) 
Anterolateral 28 (11.8%) 14 (12.1%) 14 (11.5%) 
Lateral 153 (64.3%) 72 (62.1%) 81 (66.4%) 
Posterolateral 41 (17.2%) 24 (20.7%) 17 (13.9%) 
Posterior 2 (0.8%) 2 (1.7%) 0 (0.0%) 
    ≠ Based on available data 
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Table 5.5 Univariate and Multivariate Logistic Regression Analysis of Potential Predictors of Overall Clinical Response (Pooled Multiple 
Imputation Model).  
  Univariate  Regression Multivariate Regression 
Clinical Variable 
Odds 
Ratio 
P-
Valve  
Confidence 
Interval (95%) 
Odds 
Ratio P-Valve  
Confidence 
Interval (95%) 
Age at implant  0.97 <0.01 0.94 – 0.99 0.96 <0.01 0.94 - 0.99 
Gender 0.96 0.88 0.57-1.63       
Device 1.41 0.14 0.90 - 2.22       
Upgrade Status 0.54 0.03 0.31 - 0.95 0.57 0.05 0.32 - 1.01 
QRS Duration 0.87 1.00 0.99 - 1.01       
LBBB 1.42 0.20 0.84 - 2.42       
LVEF 0.98 0.21 0.95 - 1.01       
Aetiology 1.18 0.50 0.74 - 1.87       
Diabetes Mellitus  0.84 0.53 0.50 - 1.43       
CKD 0.60 0.04 0.37 - 0.97       
Days from Implant 
to Response 
Assessment  1.00 0.13 0.99 - 1.00 0.99 0.03 0.99-1.0 
 
  
Dr Christopher J. McAloon 
 
240 
 
8.4.5 Predictors of Cardiovascular Outcomes  
During the observation period there were 72 (24.0%) deaths at a median of 19.0 months 
(0.0-56.5). The number of first HF hospital admissions was 40 (13.3%) at a median of 7.4 
months (0.6-50.6). The overall MACE event rate was 85 (28.3%) at median of 16.4 months 
(IQR 0.0-56.5). Analysis of individual pre-selected categorical variables using Kaplan-Meier 
survival curves (table 5.6) demonstrated that CKD was associated with significantly worse 
time-to-event rate for all-cause MACE (p<0.001), all-cause mortality (p<0.001) and first HF 
admission (p=0.03) (figure 5.2: Panel A, B and C ). The presence of a cardiac device at 
implant that was to be upgraded was associated with a significantly worse survival curve for 
all-cause mortality (p=0.03) (figure 5.3), but was not significant for any other cardiovascular 
outcome measure. however, this association was not present when a Cox regression model 
was used (table 5.7). No other variables were identified on survival analysis as being 
associated with cardiovascular outcomes (table 5.7).  
 
Multivariate Cox regression was performed for all clinical outcome measures on complete 
cases and multiple imputation models. Comparing both models demonstrated similar 
findings and supported the use of the multiple imputation model. Presence of CKD was the 
only variable demonstrated to predict cardiovascular outcomes following CRT implantation. 
CKD at implant inferred increased risk of MACE (HR 2.10, p=0.001, 95% CI: 1.23-3.19), all-
cause mortality (HR 2.06, p=0.001, 95% CI: 1.22-3.46), and first HF admission (HR 1.95, p 
=0.036, CI: 1.05-3.63) (Table 5.7, 5.8 and 5.9). There were no other variables that predicted 
any defined cardiovascular outcomes.  
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Figure 5.2CKD status at implant and time to MACE (A), all-cause mortality (B) and first HF hospitalisation (C) 
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Table 5.6 Log-rank (P-value) of Kaplan-Meier Curves  
Clinical Variable MACE All-Cause Mortality First HF Admission 
Gender 0.61 0.21 0.98 
Device 0.74 0.96 0.29 
Upgrade  Status 0.09 0.03 0.79 
LBBB 0.86 0.86 0.73 
DM 0.89 0.95 1.00 
CKD <0.001 <0.001 0.03 
Ischaemic Aetiology 0.11 0.19 0.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Upgrade device status at implant and time to all-cause mortality 
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Table 5.7 Univariate and Multivariate Proportional Hazards Cox Regression for MACE (Pooled imputation model)  
 
Univariate  Regression Multivariate Regression 
Hazard Ratio P-Valve  Confidence Interval (95%) Hazard Ratio P-Valve  Confidence Interval (95%) 
Age at implant  1.01 0.31 0.99-1.04    
Gender 1.14 
0.63 
0.66-1.96    
Device 1.10 0.72 0.65-1.88    
Upgrade Status 0.83 0.50 0.49-1.41    
QRS Duration 1.00 0.49 0.99-1.01    
LBBB 
1.02 
0.93 0.59-1.77    
LVEF 0.99 0.58 0.96-1.02    
Ischaemic 0.69 0.21 0.39-1.23 0.73 0.19 0.46-1.17 
Diabetes Mellitus  1.16 0.58 0.69-1.93    
CKD 1.92 0.001 1.22-3.00 2.10 0.001 1.23-3.19 
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Table 5.8 Univariate and Multivariate Proportional Hazards Cox Regression for all-cause mortality (Pooled imputation model)  
 
 
 
 
 
  Univariate Regression Multivariate Regression 
 
Hazard Ratio P-Valve Confidence Interval (95%) Hazard Ratio P-Valve Confidence Interval (95%) 
Age at implant  1.02 0.10 0.99-1.05 1.03 0.06 1.00-1.06 
Gender 1.51 
0.19 
0.82-2.80 1.58 0.14 0.87-2.79 
Device 0.80 0.44 0.45-1.41    
Upgrade Status 1.30 0.36 0.74-2.27    
QRS Duration 1.00 0.50 0.99-1.01    
LBBB 
1.10 
0.77 0.59-2.03    
LVEF 0.98 0.24 0.95-1.01    
Ischaemic 1.28 0.45 0.68-2.40    
Diabetes Mellitus  0.84 0.53 0.48-1.47    
CKD 2.167 0.001 1.33-3.54 2.06 0.001 1.22-3.46 
Dr Christopher J. McAloon 
 
245 
 
Table 5.9 Univariate and Multivariate Proportional Hazards Cox Regression for first HF Hospitalisation  (Pooled imputation model)  
  
  Univariate  Regression Multivariate Regression 
 
Hazard Ratio P- Valve Confidence Interval (95%) Hazard Ratio P-Valve Confidence Interval (95%) 
Age at implant  1.01 
0.65 
0.97-1.04    
Gender 
0.96 
 
0.92 
 
0.45-2.05    
Device 1.17 0.71 0.52-2.59    
Upgrade Status 1.02 0.97 0.46-2.27    
QRS Duration 
1.00 
 
0.69 
 0.98-1.01    
LBBB 
1.21 
0.66 0.53-2.74    
LVEF 1.01 
0.78 
 0.96-1.05    
Ischaemic 1.54 0.34 0.64-3.72 1.72 
0.13 
0.86-3.45 
Diabetes Mellitus  0.92 0.83 0.44-1.92    
CKD 1.92 0.05 1.00-3.71 
1.95 
 
0.04 
1.05-3.63 
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5.4.6 Chronic Kidney Disease 
CKD status was available in hospital coding data for 292 patients (97.3 %) at the time of CRT 
implantation. A recorded set of renal function blood tests were available at the time of 
implant for 194 patients (64.7%) of the cohort. These tests were performed at a mean ± SD 
of 5.7±9.4 weeks before CRT implantation. Blood results were available for 193 (66.1%) 
patients who had coding data available. Calculated GFR matched the coding categorisation 
in 74.6% of cases. There were 78 (86.7%)  patients in  CKD stage 3 (30-59 ml/min/1.73m2)239 
with an estimated GFR  46.0±8.5 ml/min/1.73m2. There were  11 (12.2%) patients in stage 
4(15-29 ml/min/1.73m2)239  with a mean GFR of 25.4±3.6 ml/min/1.73m2. Moreover there 
was only one patient in stage 5 (<15 ml/min/1.73m2)239 and they had a GFR of 14.7 
ml/min/1.73m2. The calculated GFR questioned the reliability of hospital coding data  as a 
method for defining CKD status in a small number of cases. The difference between the 
biochemical and coding data may be accounted for by the patient’s condition at the time of 
the blood sampling. An analysis was performed on the complete data set for patients with 
calculated GFR and it showed GFR did not show any statistical difference overall in clinical 
responders and non-responders. Those patients whom had CKD based upon calculated GFR 
had a  significantly higher MACE rate; 36.7% vs 23.1% (p=0.001). These results support the 
prediction models utilising hospital coding data. Moreover a significant proportion of 
patients had missing blood test results, which may have weakened the analysis.  
 
5.5 DISCUSSION 
Non-response to CRT remains a significant problem for patients, healthcare providers and 
the wider society, despite implanted patients meeting international criteria.234 Poor 
response has been linked to several factors; pre-implant, procedure and post implant.  The 
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focus is now on patient selection prior to CRT implantation and the predictors that have 
shown some strength as predictors of response or cardiovascular outcome. There is often 
inconsistency reported in the literature regarding potential predictors (Table 1.3). A 
substantial contributor to the inconsistency in the literature is the lack of consensus on a 
definition of CRT response (Table 1.4).1 Several studies utilise MACE definitions and others 
use specific clinical/echocardiographic combination definitions.1 Importantly, definitions are 
often non-comparable producing different proportions of responders/non-responders when 
different definitions are applied to the same cohort.1 Correlation is often poor, especially 
between clinical and echocardiographic definitions.1 Ultimately, this makes comparison of 
data challenging, especially given varying study designs. Interpretation of our results has to 
be performed within this context. However, this small retrospective study does allow the 
best opportunity to examine variables that may be particularly important in our centres 
hetrogenous CHF population.   
 
Increasing age at implant was the most significant predictor of overall (OR 0.96, p=0.002, 
CI(95%) 0.94-0.99)and long-term (OR 0.96, p=0.004, CI 0.93-0.99) clinical response in our 
study. Interestingly, when examining acute response alone, age at implant was not a 
statistically significant predictor. These observed patterns seem somewhat intuitive. 
However, no other cohort studies have demonstrated increasing age at implant predicts 
response or MACE. This study represents an older population, with most other studies 
having mean age in the low sixties.38,65-67 Increasing age at implant within the study cohort 
predicted overall and long-term non-response. 
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Several patient parameters, including baseline ECG features, have been examined in 
multiple cohorts and post-hoc RCT analyses to determine their value in estimating risk 
stratification of patients undergoing CRT. QRS duration is considered one of the strongest 
predictors of response and forms a central part of implant criteria.234 Cleland et al,39 in the 
large meta-analysis previously described, demonstrated that only QRS duration added value 
in predicting cardiovascular outcomes. Improved cardiovascular outcomes in CRT patients 
increased in magnitude at QRS duration >132msec. The benefit reached a plateau beyond 
180msec for composite outcome alone.39 BBB morphology trended towards worse outcome 
for non-LBBB, but these were not statistically significant.39 Interestingly Hsu et al,38 in a 
post-hoc analysis of MADIT-CRT (trial not included in Cleland et al39 meta-analysis), 
demonstrated QRS duration >150msec predicted an echocardiographic response (top 
quartile LVEF change at 12 months) based upon best subset regression analysis. Hsu et al,38 
demonstrated that only LBBB on ECG decreased the chances of a cardiovascular outcome 
occurring (all-cause mortality or non-fatal HF) within their best-subset. Lin et al,66 in a single 
centre retrospective cohort study identified the only feature on baseline ECG that predicted 
echocardiographic response was LBBB morphology on multivariate regression analysis. 
Several single centre cohort studies, including this study, did not demonstrate any 
association between QRS duration or morphology and response or cardiovascular outcome 
on multivariate analysis.65,67 The observation that QRS duration and/or BBB morphology in 
this cohort study did not predict response was unexpected. Quadratic and logarithmic 
transformation was attempted on QRS duration to see if data distribution was impacting the 
predicting ability of the variable. The ECG variable suffered from a degree of missing data 
and that was recorded in patient records tended to be non-specific. Repeat measurements 
were performed of available data, yet no association was observed. The missing data is the 
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likely reason why this variable was demonstrated to be a predictor of CRT response. Most 
importantly the study had very small numbers and is the likely reason why this association 
was not seen, even though it is well described in the literature.   
 
Patient specific variables vary in their significance in predicting response to CRT in the 
literature. Cleland et al,39 determined that no specific background clinical factor predicted 
cardiovascular outcome in those benefitting from CRT. Hsu et al,38 determined that three 
background factors predicted echocardiographic response: female gender, body mass index 
<30kg/m2 and no previous MI.38 Importantly, these same factors did not predict 
cardiovascular outcomes within the same post-hoc analysis of MADIT-CRT. Gender was not 
shown to be a predictor of response within this study. Several other studies examined 
gender and did not demonstrate statistical significance for predicting response or outcome 
(Table 1.3).67 Consistently amongst all cohort studies, females are under-represented 
including in this study.  Body mass index was not examined within this study, due to absence 
of this specific baseline data in the clinical records. Several studies have commented on the 
importance of non-ischaemic aetiology (Table 1.3). Shanks et al,65 demonstrated ischaemic 
aetiology increased the chance of non-response significantly.65 This study did not 
demonstrate any significance of aetiology as a predictor of response or MACE, which is 
supported by several other studies.39,66  
 
CKD status (eGFR <60ml/min/1.73m2) present in a patient pre-CRT implant was shown in 
our study to infer a 2-fold increased risk of MACE (HR 2.10, p=0.001, CI(95%) 1.23-3.19) and 
all-cause mortality (HR 2.06, p=0.001, CI(95%) 1.23-3.46). These results replicate several 
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other studies, which show CKD status predicts worse cardiovascular outcomes for patients 
undergoing CRT. Hoke et al,300 observed in a small prospective cohort study that patients 
with CKD stage 4 undergoing CRT had only a 30% echocardiographic response (>15% 
reduction LVESV at 6 months), much lower than is traditionally reported. However, 
cardiovascular outcomes were reported to be better than patients with CKD stage 4 having 
an ICD implant alone. Hoke et al,300 therefore demonstated an improvement in renal 
function in patients who had a CRT implanted with CKD stage 4.300 Seperately Lin et al,237 in 
a large retrospective cohort study demonstrated CKD status inferred an increased risk (OR 
1.61, p<0.01, CI (95%) 1.2-2.3) of long-term cardiovascular events (all-cause mortality and 
heart transplantation). Furthermore, Bogdan et al,238 undertook an observational cohort 
study (n=179) of all CRT implants at a single centre and identified CKD 
(GFR<60ml/min/1.73m2) strongly predicted all-cause mortality (HR 2.03, CI (95%)1.14–3.61, 
p=0.01) but did not predict 1 year functional response (composite of change in NYHA, QoL 
and 6MWT) (HR: 0.74; CI(95%): 0.38–1.43; p=0.37). We also observed CKD status did not 
predict non-response in our multivariate model, although the univariate analysis suggested 
it did. 
 
CHF patients with CKD are well known to have poor cardiovascular outcomes,301 which is 
also reflected in higher event rates in patients with  eGFR <60ml/min/1.73m2 undergoing 
CRT.237,238 The increased risk of poor cardiovascular outcomes following CRT implantation in 
patients with CKD stage 3 or above does not appear to be related to adverse cardiac 
remodelling. Lin et al237 observed patients with and without CKD at implant had 
improvement in LVEF and LV end diastolic dimensions. This observation is somewhat 
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unexpected considering advancing CKD has previously been observed to be associated with 
maladaptive LV hypertrophy and increased myocardial fibrosis, causing diastolic 
dysfunction.302 However, these particular observations were made on patients in end stage 
renal failure on dialysis302 unlike  Lin et al.237 CRT causes reverse remodelling of the LV in 
patients with and without advancing CKD, however the poor cardiovascular outcomes rates 
remain unchanged. This suggests that poor cardiovascular outcomes in CHF patients 
undergoing CRT with advancing CKD is not completely related to the degree of adverse 
cardiac remodelling. Whether the mechanism for poor cardiovascular outcomes in these 
patients is related to the coronary artery disease risk burden or an alternative mechanism is 
not clear.  
 
Interestingly, CKD status in several studies238 including ours demonstrates a strong ability to 
predict poor cardiovascular outcomes, but not functional/symptomatic response. This is 
partly because functional response poorly correlates with reverse remodelling, but also 
suggests there is a lack of relationship between these two factors. An additional reason 
which needs to be considered is that GFR is calculated by more variables than just serum 
creatinine. The modification of diet in renal disease equation is used in our study accounts 
for multiple variables; age, gender, serum creatinine, ethinicity, serum urea, serum albumin 
and body surface area.239 Therefore all these variables may be having an important 
influence on CKD stage/GFR as a predictor of cardiovascular outcomes. Age at implant has 
already been discussed a possible determinant of functional response and this may 
influence GFR as a variable. Body composition is also discussed in chapter 10 as a potential 
important variable in CHF and following CRT. 
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Comparative analysis of lead positions within our study demonstrated a statistically 
significant difference between RV lead position in the overall clinical response. 
Proportionally more responders had the RV lead at the septum than RV apex; however, only 
a small proportion of patients had leads placed at the RV septum, but the statistical 
difference was an interesting observation. Lead position was not included in the logistic 
regression model as it was not a pre-defined variable. A small pilot study has suggested 
adjustment in RV lead position can enhance acute haemodynamic CRT response.303 Right 
heart lead position does pose an interesting question in predicting response but requires 
further study. 
 
5.5.1 Study Limitations 
Our study was retrospective and performed in a single-centre, which reflected a relatively 
small number of patients across a five year period. This study was not powered for the study 
outcomes, which importantly means absolute conclusions, cannot be drawn from the 
results of this study. There was a degree of missing data, which may have influenced the 
associations that were reported. The echocardiographic data had a significant proportion of 
missing data which was due to the lack of availability of external centres scans. Specific 
measurements were not performed on the baseline scan due primarily to scan quality, 
which can be influenced by body habitus. ECG reporting was not always correct and not all 
baseline traces were available. The availability of an ECG was generally related to where a 
patient was referred from. Both these factors represent selection bias for these particular 
variables. Repeat measurements of all echocardiograms and ECGs were performed 
independent of the original reports, this minimised reporting bias, but could be only 
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performed if the information was available.   The response criteria utilised was based upon 
NYHA classification during the latest review; this is one of the most consistently used clinical 
response measures,304 however poorly correlates with other established definitions.1 
Assessment on NYHA class was based upon recorded findings and consensus of three clinical 
reviewers, though blinded to each others assignments, a reporting bias cannot be 
completely removed. 
 
5.5.2 Informing Prospective Cohort Study 
The first stage of this research thesis was to understand the HF population dynamics that is 
served by our implantation centre. The Arden Cardiac Network (figure 5.1) region 
represents a diverse population in both ethnicity and socio-economic status. Our 
retrospective study was a complete analysis of all implants performed since th service 
began. Firstly our study demonstrated the heterogeneity of our local HF population having 
CRT implantations. Secondly our study demonstrates the challenge of using only change in 
NYHA class as a definition and on reflection a more robust measure of functional response 
was required. Thirdly, this study has partially informed the selection of pre-implant variables 
for the planned prediction model for the phase II proof of concept study. Age at implant and 
CKD status have proven to be the most useful variables in this study for predicting clinical 
response and cardiovascular outcomes respectively. However, other variables have proven 
more robust at predicting response and cardiovascular response in the literature. The 
prospective study prediction models will account for these variables, in particular resting 
ECG QRS duration and BBB morphology.38,39  
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5.6 CONCLUSION 
In this real world heterogeneous cohort retrospective observation study increasing age at 
implant was associated with poor overall clinical response. It was also observed CKD status 
predicted long-term non-response and strongly predicted future MACE and all-cause 
mortality. These variables will be used to inform the planned prediction model for the phase 
II proof of concept study. Important variables including QRS duration and BBB morphology 
were not observed in this cohort to predict clinical response and this is likely due to the 
degree of missing data. This study also highlights the challenge of using a single metric as 
the definition of response. These factors have informed the planning and performance of 
the phase II study 
 
5.7 PUBLICATIONS 
The work in this chapter has been produced into two publications and several conference 
abstracts. Data from this chapter has been presented at several national and international 
conferences including the American Cardiology Congress, San Diego March 2015 and British 
Cardiovascular Society Conference June 2016 (Appendix R). This cohort also formed part of a 
study examining same-day complex cardiac device implantation224, which was submitted 
and published in The American Journal of Cardiology on the May 2016 (Appendix S). 
Furthermore a smaller study was conducted on the long-term follow-up of the epicardial 
lead placements,305 which formed a small part of this cohort. This article was published in 
the PACE journal August 2016 (Appendix S). 
  
Dr Christopher J. McAloon 
 
255 
 
 
 
 
 
 
 
 
Chapter Six 
 
THE CHARACTERISATION OF CIRCULATING 
BIOMARKERS BEFORE AND AFTER CRT IN 
PATIENTS WITH CHF AND THEIR ROLE IN 
PREDICTING RESPONSE:  
THE COVERT-HF STUDY 
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6.1 INTRODUCTION 
HFrEF is characterised by adverse cardiac remodelling resulting in a progressive reduction in 
LVEF and poor cardiovascular outcomes.22,23,31 CRT has revolutionised the treatment of 
HFrEF patients with dyssynchrony refractory to optimal medical therapy by demonstrating a 
consistent reduction in mortality and morbidity.22,23,31 Reverse cardiac remodelling has also 
been shown to be induced by CRT.31,306 Unfortunately, no functional improvement is 
observed in 20-40% of HFrEF patients following CRT implantation.22,23,26,27,60  
 
Maladaptive processes of neurohumoral activation, cardiac ECM remodelling, pro-
inflammatory changes and myocardial wall stress are central mechanistically to the 
development and progression of HFrEF.94 Altered ECM turnover in HFrEF is directly 
associated with adverse cardiac remodelling113 and biomarkers of collagen synthesis 
(PINP,PICP and PIIINP)125-127 and degradation (ICTP or CITP)119,126 have been shown to be 
associated with poor HF outcomes. As key regulators of ECM turnover, matrix 
metalloproteinases (MMP-2 and -9)135,136 have also been implicated as biomarkers of HF 
diagnosis and prognosis. GDF-15 is a member of the transforming growth factor- cytokine 
superfamily involved in the regulation of cell survival, proliferation and differentiation that is 
associated with poor HF outcomes110 and has been suggested as a potential predictor of CRT 
response.112  
 
MiRNAs are short (20-22 nucleotides) endogenous non-coding ribonucleic acids that have 
been attracting much interest as key regulators of gene expression, including the 
cardiovascular system.139,140 MiRNAs are readily measured in blood plasma and serum, and 
several circulating miRNAs have been shown to be dysregulated in cardiovascular disease, 
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suggesting potential use as biomarkers. 139,160,197  Specifically, miR-21, -30d199, -122173,180, -
133a181,183, and -210149  have been demonstrated to be dysregulated in adverse cardiac 
remodelling and HFrEF.139 
 
Markers of collagen turnover have previously been studied to establish their value as 
predictors of CRT response, but outcomes have thus far been inconsistent;119,125,126,244,294 
miRNAs are implicated as a novel set of biomarkers with variation reported in HFrEF,139,188 
but limited information is available on their ability to predict CRT response.197,199 MiR-30d in 
particular has been proposed to be mechanistically related to LV wall stress and to predict 
cardiac remodelling following CRT implantation.199  
 
6.2 AIM AND OBJECTIVES (Chapter 2) 
This proof-of-concept prospective observational study principle aim was to evaluate the 
ability of a panel of potential predictor variables including novel ECM and miRNA 
biomarkers to predict functional response of HFrEF patients who meet CRT implantation 
criteria to respond long-term.  
  
Secondary aims and objectives are to examine and characterise specific ECM and miRNA 
behaviour in HFrEF patients undergoing and following CRT implantation. Furthermore to 
examined the differences between systematic and CS expression in specifically defined ECM 
and miRNA biomarkers at the time of CRT implantation. Moreover to correlate biomarker 
expression overtime with functional and echocardiographic variables.  
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6.3 METHODOLOGY (Chapter 3.5) 
The COVERT-HF study is a proof-of-concept prospective observational study of unselected 
HFrEF patients undergoing CRT implantation at a single tertiary centre between November 
2013 and June 2015. The trial was registered at clinicaltrials.gov under reference 
NCT02541773 (Appendix F). Participants were eligible if they met the NICE17,51 criteria for 
resynchronisation therapy in HF patients (LVEF<35% on OMT>3/12; NYHA I with QRS 
>150msec or NYHA II-IV with QRS >150msec or QRS 120-149msec and LBBB). Patients in AF 
or requiring a cardiac device upgrade (LVEF<35% and ventricular pacing >40%) were also 
included in the study to reflect clinical practice.17,56 The NICE CRT guidelines were updated 
(TA120) in 2014 and the inclusion criteria were updated at this time accordingly. Patients 
were excluded if there was a recent acute coronary syndrome or acute heart failure 
decompensation event (<6 weeks), end-stage renal disease (on renal replacement therapy), 
significant cognitive impairment or a terminal illness unlikely to have a survival greater than 
a year. Post-implantation exclusions were applied in case of procedure failure or 
complications resulting in unsuccessful biventricular pacing (e.g. lead displacement/ non-
avoidable phrenic nerve pacing). 
 
Each participant underwent a pre-implantation visit and two follow-up visits at 6 weeks and 
6 months post-implantation. Participants underwent clinical assessment (NYHA class), 
MLHFQ, 6MWT, transthoracic echocardiography, resting 12-lead ECG and blood sampling at 
all research attendances. All follow-up study visits coincided with routine CRT device checks. 
All participants provided written informed consent. The study was conducted in accordance 
with the 1975 Declaration of Helsinki and was approved by the South Birmingham Regional 
Ethics committee (13/WM/0355).  
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6.3.1 Study Outcomes (Chapter 3.5) 
The primary outcome measure for the study was the patients’ functional response status. 
Functional responders were defined as those whom survived, did not undergo heart 
transplantation and achieved two out of three response criteria (↓>1 NYHA, ↑>10% 6MWT 
distance, ↓MLHFQ score>5) at 6 months follow-up. Secondary outcomes were categorised 
as echocardiographic response, defined as a >15% reduction in LV end-systolic volume at 6 
months, and major adverse cardiovascular events (MACE), defined as a composite of all-
cause mortality and first HF hospital admission.  
 
6.3.2 Device Implantation (Chapter 3.2) 
CRT devices were implanted at UHCW according to local standard operating procedures.  
 
6.3.3 Transthoracic Echocardiography (Chapter 3.5) 
All participants underwent transthoracic echocardiography (Vivid 7, GE Healthcare, Horten, 
Norway) examination for LV volumetric assessment. Each echocardiogram was performed 
on the same machine by the same nationally accredited operator for each study visit. Grey-
scale two dimensional images were obtained in the standard parasternal (long and short 
axis) and apical (2, 3, 4 chamber) view to allow LV volumetric assessment according to 
published guidelines.201 All measurements were analysed offline (EchoPac, GE Healthcare, 
Horten, Norway). LV ejection fraction was estimated using the biplane method of discs 
(modified Simpsons method).201 A blinded inter-rater study was conducted on all scans of a 
randomly selected 20% of the study participants. The inter-rater study for available 
comparative measures demonstrated a strong correlation between rater measurements 
(r2=0.90, p<0.01). Paired measurements were not significantly different between both raters 
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when compared with a paired T-test (p=0.90). Bland-Altman limits of agreement were 
calculated to be 20.7%. 
 
6.3.4 Blood Sampling and Laboratory Analysis (Chapter 5.5 and Chapter 6) 
Peripheral venous sampling of blood was performed following two hours of fasting and one 
hour of rest, using EDTA as anticoagulant. Serum and plasma was prepared by single 
centrifugation at 3500 RPM for 10 minutes, followed by storage at -80 oC until analysis.  
Peripheral samples at implantation were taken the morning of the implant. CS sampling was 
performed in half the cohort (n=26) during CRT implantation upon cannulation of the CS. 
Clinical laboratory measurements were performed according to standard hospital 
procedure. ECLIA analysis for NT-pro-BNP and hs-TnT were performed in the local 
laboratory.  
 
Plasma levels of PINP and CTx were determined using an ECLIA Cobas ®8000 modular 
analyser (Roche Diagnostics, Basel, Switzerland). The immunoassays inter and intra assay of 
precision for P1NP is <3.0%, and for CTx was <2.5%. The assays manufacturer calculated 
measures and were locally validated according to the validated international Clinical and 
Laboratory Standards Institute EP05-A3 protocol.271  
 
Sandwich ELISA were used to determine plasma levels of GDF-15, MMP-2 and -9 (R&D 
Systems Inc, Minneapolis, Minnesota, USA) and PIIINP (Cusabio, Wuhan, Hubei, China) 
according to the manufacturers’ protocol. The inter-assay and intra-assay coefficient of 
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variability was calculated for each assay: GDF-15 (7.7% and <4.8%); MMP-2 (4.5% and 
<5.6%); MMP-9 (10.3% and <12.9%); PIIINP (5.1% and <7.2%).  
 
MiRNA profiling was undertaken for MiR-21, -30d, -122, -133a, -210 and -486 using 
previously described methods.277 MiR-486, being highly enriched in erythrocytes307, was 
used as a marker for sample quality with regards to hemolysis.308 In brief, total RNA 
including small RNA was extracted using the miRNeasy Mini kit (Qiagen, Hilden, Germany). 
An exogenous miRNA (cel-miR-39-3p) was added to the plasma prior to the extraction 
procedure to serve as a spike-in normalization control. MiRNA’s were reverse-transcribed 
using the TaqMan® MicroRNA Reverse Transcription Kit and RT MegaplexTM Primer pools 
(Human Pools A v2.1 and B v2.0, Applied Biosystems®, Darmstadt, Germany) and further 
amplified using TaqMan PreAmp Master Mix and MegaplexTM PreAmp Primers (Primers A 
v2.1 and B v2.0, Life Technologies, Massachusetts, USA). TaqMan® miRNA assays (Applied 
Biosystems) and TaqMan® Universal PCR Master Mix, no AmpErase® UNG were used for 
quantitative real-time polymerase chain reaction (qPCR) of specified miRNAs on a ViiA7 
Real-Time PCR System (Life Technologies). Relative quantification was performed using the 
2-ΔΔCt method.309 Hemolytic samples were excluded from the analysis.  
 
6.3.5 Statistical Analysis (Chapter 3.8) 
Statistical analysis was performed using SPSS, version 22.0 (IBM, Chicago, Illinois). 
Categorical variables were reported as frequency and percentages. Comparison analyses for 
categorical data were performed using the Chi-Squared or Fisher’s Exact tests, dependent 
on appropriateness. Continuous data and the residuals save from the appropriate analyses 
underwent histogram plots for assessment of normality. Normally distributed data were 
Dr Christopher J. McAloon 
 
262 
 
reported as mean ±SD and comparative analysis was performed using independent t-tests. 
Non-normally distributed data were reported as median (full range) and were compared 
using a Mann-Whitney U test. Paired continuous data were analysed with a paired t-test or 
Wilcoxon Signal Rank test, as appropriate. Non-normally distributed ECM biomarkers, NT-
pro-BNP, GDF-15 and hs-TnT circulating biomarker data was transformed logarithmically. 
Fold change was calculated using the mean (responder/non-responders) cohort value when 
comparing two datasets. Variation in continuous variables over three time periods was 
analysed using either one-way analysis of variance (ANOVA) or Friedman test, respectively. 
Mixed between-within subjects analysis of variance was used to compare variation in 
continuous data in functional responders and non-responders over 6 months of 
observations. Bivariate correlation analysis either Pearson (parametric) or Spearman rank 
(non-parametric) estimators was performed between two continuous variables to explore 
relationships. Univariate logistic regression analysis was performed for functional response 
for pre-defined circulating biomarkers and established clinical variables. Those variables that 
achieved a p-value <0.20 were pooled as co-variants for multiple logistic regression. A high 
alpha was set on the basis of the clinical response definition. A stepwise entry method was 
applied with forward selection and backward elimination to ensure duplication of findings. 
The accuracy of the model was verified with a Hosmer-Lemeshow goodness-of-fit test. A p-
value <0.05 was considered statistically significant. Detailed discussion on the statistical 
methods employed in the prospective study was provided in Chapter 3.8.  
 
6.4 RESULTS 
A total of 58 patients consented to participation in the study, of which 52 participants were 
included in the study. Figure 6.1 provides an overview of participant selection and 
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functional response categorisation. Follow-up research visits occurred at 1.7±0.3 and 
5.7±0.7 months respectively. There were 27 (59.1%) responders and 22 (44.9%) non-
responders after 6 months follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Patient recruitment, flow and outcomes. 
 
6.4.1 Baseline Clinical Characteristics 
Baseline characteristics of the study population and functional response rate are provided in 
Table 6.1. There were 43 (82.7%) males in the cohort with an average age of 72.4±9.4. with 
no significant difference between responders and non-responders. In the cohort, 30 (57.7%) 
had an ishaemic aetiology and 22 (42.3%) had a non-ischaemic cause, which did not 
significantly vary by response status.  The median (range) QRS duration was 164.0 msec 
Recruited & Consented = 58    
Nov 2013 – June 2015 
Participants = 52 
CRT-p=14, CRT-d=24,  
Upgrade CRT-p=5, Upgrade CRT-d=9 
Six month follow-up= 49 
Responders = 27 (55.1%) 
Non-responders = 22 (44.9%) 
Mortality = 4 (mean 4.0 months) 
1 Arrhythmic, 3 HF 
HF Death (before assessment) = 1 
Baseline LVEF >35% = 1 
Post Procedure Exclusions = 4 
(1 Failed Procedure, 1 Phrenic Nerve 
Stimulation, 2 Lead Displacements)    
Lost to Follow-up = 2 
(1 at 6 weeks & 1 at 6 months)  
Post Procedure Exclusion = 1 
(after 6 week FU) 
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(120.0-240.0) and 39 (75.0%) had Left Bundle Branch Block on the resting ECG at baseline. 
The QRS duration (168.0 msec vs 159.0 msec, p=0.11) and LBBB morphology (85.2% vs 
63.6%), p=0.16) did not vary significantly between responders and non-responders 
respectively. However a trend for a wider QRS and presence of left bundle branch block 
morphology was observed more frequently in responders.  The three patients lost in follow-
up did not change the cohort characteristics.  
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Table 6.1 Baseline Characteristics 
  Total Cohort=52 Responders=27 Non-
Responders=22 
p-value 
Demographics         
Age (years, mean±SD) 72.4±9.4 72.0±10.4 73.0±8.5 0.74 
Male (n,%) 43 (82.7%) 23 (85.2%) 17 (77.3%) 0.74 
Device         
ICD: Primary Prevention (n,%) 26 (78.8%) 16 (88.9%) 9 (64.3%) 0.22 
Upgrade (n,%) 14 (26.9%) 5 (18.5%) 9 (40.9%) 0.16 
Aetiology         
Ischaemic (n,%) 30 (57.7%) 15 (55.6%) 13 (59.1%) 
1.00 
Non-ischaemic (n,%) 22 (42.3%) 12 (44.4%) 9 (40.9%) 
Co-morbidities         
History of Atrial Fibrillation (n,%) 28 (53.8%) 14 (51.9%) 12 (54.5%) 1.00 
Diabetes Mellitus (n,%) 15 (28.8%) 5 (18.5%) 9 (40.9%) 0.16 
COPD (n,%) 10 (19.2%) 3 (11.1%) 6 (27.3%) 0.28 
CKD (n,%) 23 (44.2%) 11 (40.7%) 12 (54.5%) 0.5 
NYHA (n,%)         
II 20 (38.5%) 11 (40.7%) 8 (36.4%) 
0.25 III 27 (51.9%) 15 (55.6%) 10 (45.5%) 
IV  5 (9.6%) 1 (3.7%) 4 (18.2%) 
Routine Blood Markers         
eGFR (mL/min/1.73 m2, median, 
range) 
61.5 (25.0-
130.0) 
59 (25.0-130.0) 58.0 (26.0-99.0) 0.36 
Haemglobin (g/dl, mean±SD) 134.4±13.5 136.6±14.1 132.5±12.5 0.28 
NT-pro-BNP (pmol/L, median, range) 248.7 (53.0-
4138.0) 
207.0 (53.0-
4138.0) 
255.5 (67.0-
547.0) 
0.37 
hs-TnT (ng/L, median, range) 26.5 (6.5-233.0) 26.4 (8.5-
233.0) 
27.6 (6.5-61.8) 0.78 
Medications         
ACEi/ARB (n,%) 50 (96.2%) 26 (96.3%) 21 (95.5%) 1.00 
BB (n,%) 44 (84.6%) 22 (81.5%) 21 (95.5%) 0.24 
MRA (n,%) 34 (65.4%) 17 (63.0%) 14 (63.6%) 0.96 
Aspirin (n,%)  24 (46.2%) 13 (48.1%) 9 (40.9%) 0.83 
Clopidogrel (n.%) 6 (11.5%) 3 (11.1%) 3 (13.6%) 1.00 
Prasugrel (n,%) 1 (1.9%) 1 (3.7%) 0 (0.0%) 1.00 
Electrocardiogram         
Atrial Fibrillation (n,%) 19 (36.5%) 9 (33.3%) 8 (36.4%) 0.5 
QRS duration (msec, median, range) 164.0 (120.0-
240.0) 
168.0 (146.0-
240.0) 
159.0 (120.0-
210.0) 
0.11 
LBBB (n,%) 39 (75.0%) 23 (85.2%) 14 (63.6%) 0.16 
QoL Score (mean±SD) 48.5 (8-101) 50 (9-86) 48.5(8-101) 0.77 
6MWT (M,mean±SD) 238.8±130.6 237.6±130.5 239.4±127.4 0.95 
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Echocardiogram         
LVIDD (mm, mean±SD)≠ 61.7±10.1 62.9±11.2 60.2±9.0 0.4 
LVESV (ml,median,range)≠ 111.5 (49.4-
219.3) 
119.3 (49.4-
268.7) 
110.2 (56.0-
169.4) 
0.41 
LVESV_BSA (ml,mean±SD)≠ 61.3±21.5 65.7±25.8 56.6±16.3 0.26 
LVEF (%, mean±SD)≠ 24.3±8.0 24.1±7.9 24.4±8.7 0.91 
LV Lead Circumferential Position 
(n,%) 
      
0.64 
Anterior 5 (9.6%) 2 (7.4%) 3 (13.6%) 
Anterolateral 3 (5.8%) 2 (7.4%) 1 (4.5%) 
Lateral 28 (53.8%) 13 (37.0%) 13 (59.1%) 
Posterolateral 16 (30.8%) 10 (37.0%) 5 (22.7%) 
LV Axial Lead Position (n,%) 
Basal (n,%) 
 
29 (55.8%) 
 
15 (55.6%) 
 
11 (50.0%) 0.7 
Mid-Cavity (n,%) 23 (44.2%) 12 (44.4%) 11 (50.0%) 
 
6.4.2 Baseline Biomarker Levels 
Table 6.2 shows baseline levels of the ECM biomarkers and miRNA panel for the total cohort 
and by functional response status. There was no significant difference in expression of ECM 
biomarkers of collagen synthesis or degradation between functional responders and non-
responders at baseline. CTx were observed to be more highly expressed in responders than 
non-responders, but did not reach statistical significance (0.48 ug/L (0.14-1.14) vs 0.31 ug/L 
(0.16-0.73), p=0.07)). The biomarker of myocardial stress GDF-15 was not demonstrated to 
have significant variation in expression between responders and non-responders (1.12 ug/L 
(1.12-10.29) vs 1.20 ug/L (2.75-5.95), p=0.42). MiRNA biomarker expression profiles were 
not observed to vary significantly between functional responders and non-responders, 
although a trend for changes in miR-133a was observed (fold change 0.65, p=0.08). MiR-486 
was found to have no significant difference between responder and non-responders at 
baseline (fold change 1.16, p=0.76). 
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Table 6.2 Baseline Biomarker Levels for Functional Responders and Non-Responders 
 
Total Cohort=52 Responders=27 Non-Responders=22 p-value 
 PINP (ug/L, median, range) 40.0 (15.0-141.0) 43.0 (22.0-141.0) 38.0 (15.0-113.0) 0.53 
CTx (ug/L, median, range) 0.40 (0.14-1.14) 0.48 (0.14-1.14) 0.31 (0.16-0.73) 0.07 
PIIINP (ug/L,mean±SD) 1.02±0.39 1.09±0.35 0.94±0.43 0.11 
MMP-2(ug/L, median, range) 277.3 (155.3-789.5) 258.8 (157.0-789.5) 323.5 (155.3-543.4) 0.13 
MMP-9 (ug/L, median, range) 73.5 (13.6-254.1) 71.8 (13.6-254.1) 80.8 (13.6-254.1 0.47 
GDF-15 (ug/L, median, range) 2.66 (1.12-10.29) 2.66 (1.12-10.29) 2.75 (1.20-5.95) 0.42 
miR-21 (RQ, median, range) 0.8 (0.3-2.4) 0.77 (0.3-1.9) 0.82 (0.5-2.4) 0.72 
miR-30d (RQ, median, range) 0.7 (0.2-2.55) 0.81 (0.2-2.55) 0.68 (0.29-2.27) 0.35 
miR-122 (RQ, median, range) 0.50 (0.06-3.60) 0.45 (0.08-3.60) 0.69 (0.06-2.48) 0.27 
miR-133a (RQ, median, range) 0.78 (0.01-4.52) 0.34 (0.01-4.52) 1.28 (0.01-3.79) 0.08 
miR-210 (RQ, median, range) 0.76 (0.03-5.12) 0.57 (0.17-5.12) 0.79 (0.03-3.61) 0.36 
miR-486 (RQ, median, range) 0.76 (0.17-3.14) 0.87 (0.17-3.14) 0.73 (0.21-2.48) 0.76 
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6.4.3 Effects of CRT on Cardiac Function and Biomarker Expression  
The impact of implanting a CRT on functional variables, LV geometry and biomarker 
expression over 6 months was examined. Trends between functional responders and non-
responders were compared. Table 6.3 summarises all the changes during follow-up. Figure 
6.2 demonstrates the most significant changes (6MWT, LVEF, PINP and MMP-2) over the 
period or follow-up for changes over time and between groups. Quality of life scores and 
LVESV both improved following CRT implantation for responders and non-responders 
(p<0.01). MMP-9 was observed to have decreased expression in both groups over the 
follow-up period (p=0.01). MiR-122, a liver-specific miRNA’ was the only miRNA to 
demonstrate significantly higher initial expression in non-responders compared to 
responders (p=0.03). MiR-486 expression trended towards a significant decrease in 
expression in   both responders and non-responders (p=0.05).  
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Table 6.3 Behaviour of Functional LV Geometry and Circulating biomarkers Following CRT Implantation. Interaction between responders 
status and over time analysed.  
  Responders Non-Responders 
Response  
P-value 
Time P-
value 
Interaction    
P-Value Parameter Baseline 6 weeks 6 months Baseline 6 weeks 6 months 
6MWT (M,mean±SD) 237.6±130.5 304.8±129.0 325.1±147.5 239.4±127.4 265.5±127.7 194.9±159.1 0.16 <0.01 <0.01 
QoL Score (median, range) 50 (9-86) 19 (0-64) 21 (0-72) 48.5 (8-101) 28.5(0-73) 32 (0-83) 0.3 <0.01 0.01 
LVEF (%, mean±SD) 24.1±7.8 29.5±8.9 33.4±10.8 24.5±8.7 30.4±9.6 33.1±7.1 0.66 <0.01 0.93 
NT-pro-BNP (pmol/L, median, 
range) 
207.0 (53.0-
4138.0) 
173.0 (27.0-
3848.0) 
116.0 (15.0-
1690.0) 
255.5 (67.0-
547.0) 
265.5 (49.9-
896.0) 
184.0 (30.9-
1437.0) 
0.59 0.96 0.27 
Hs-TnT (ng/L, median, range ) 
26.4 (8.5-233.0) 
24.0 (6.7-61.9) 23.1 (6.5-63.2) 
27.6 (6.5-61.8) 
29.2 (8.4-77.3) 31.2 (14.5-83.1) 0.84 0.82 0.35 
PINP (ug/L, median, range) 43.0 (22.0-141.0) 48.0 (29.0-136.0) 53.0 (13.0-107.0) 38.0 (15.0-113.0) 39.0 (16.0-69.0) 41.0 (14.0-94.0) 0.04 0.02 0.41 
CTx (ug/L,, median, range) 0.48 (0.14-1.14) 0.43 (0.08-1.06) 0.38 (0.07-1.30) 0.31 (0.16-0.73) 0.27 (0.16-0.59) 0.30 (0.10-0.79) 0.05 0.33 0.36 
PIIINP (ug/L,mean±SD) 1.09±0.35 1.10±0.32 1.01±0.36 0.94±0.43 0.65±0.50 0.87±0.47 0.13 0.10 0.44 
MMP-2(ug/L, median, range) 
258.8 (157.0-
789.5) 
241.3 (163.9-
695.2) 
243.2 (159.8 
(159.8-625.4) 
323.5 (155.3-
543.4) 
295.1 
(162.0(512.3) 
299.8 (162.4-
515.9) 
0.51 <0.01 0.19 
MMP-9 (ug/L, median, range) 71.8 (13.6-254.1) 52.3 (5.6-192.9) 61.3 (8.8-126.1) 80.8 (13.6-254.1 65.2 (29.5-129.6) 58.3 (16.9-143.3) 0.77 0.01 0.66 
GDF-15 (ug/L, median, range) 2.66 (1.12-10.29) 2.69 (0.97-6.27) 2.34 (0.99-5.68) 2.75 (1.20-5.95) 3.06 (1.09-5.54) 3.63 (1.32-8.49) 0.20 0.41 0.08 
miR-21 (RQ, median, range) 0.77 (0.3-1.9) 0.65 (0.31-1.98) 0.71 (0.32-1.85) 0.82 (0.5-2.4) 0.83 (0.53-2.31) 0.66 (0.34-1.41) 0.39 0.15 0.75 
miR-30d (RQ, median, range) 0.81 (0.2-2.55) 0.72 (0.35-1.85) 0.76 (0.37-1.28) 0.68 (0.29-2.27) 0.99 (0.4-1.84) 0.61 (1.78-1.65) 0.56 0.9 0.14 
miR-122 (RQ, median, range) 0.45 (0.08-3.60) 0.33 (0.10-2.61) 0.43 (0.10-2.07) 0.69 (0.06-2.48) 0.84 (0.10-2.18) 0.44 (0.20-5.74) 0.03 0.12 0.53 
miR-133a (RQ, median, range) 0.34 (0.01-4.52) 0.46 (0.01-15.45) 0.64 (0.01-3.75) 1.28 (0.01-3.79) 0.29 (0.01-2.42) 0.30 (0.01-2.75) 0.5 0.49 0.16 
miR-210 (RQ, median, range) 0.57 (0.17-5.12) 0.85 (0.05-4.05) 0.61 (0.13-3.08) 0.79 (0.03-3.61) 0.63 (0.02-3.59) 0.78 (0.04-4.01) 0.85 0.85 0.81 
miR-486 (RQ, median, range) 0.87 (0.17-3.14) 0.69 (0.32-3.15) 0.56 (0.33-1.59) 0.73 (0.21-2.48) 0.93 (0.36-1.89) 0.60 (0.17-1.01) 0.51 0.05 0.63 
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 Figure 6.2 Trends in functional variables, LV geometry and biomarker expression following CRT implantation in 
responders and non-responders. Trends represent the mean value of responders or non-responders. Differences over time 
and between response status tested 
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6.4.4 Correlation between change in biomarker expression and cardiovascular variables 
following CRT 
Correlation analyses of relative change (follow-up - baseline/baseline) over the short and 
long-term were undertaken between pre-specified biomarkers and functional, 
echocardiographic and NT-pro-BNP parameters. Figure 6.3 demonstrates the strongest 
associations demonstrated in the exploration of the relationship between changes in 
parameters following CRT. Further significant associations in short term relative changes 
following CRT implantation were observed between LVESV/PIIINP (r=0.39, p=0.04) and NT-
pro-BNP/miR-133a (r=-0.34, p=0.03). Moreover, additional associations were also observed 
between relative long-term changes in NT-pro-BNP with miR-133a (r=-0.50, p=<0.01) and 
MMP-9 (r=-0.32, p=0<0.03). 
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Figure 6.3 Bivariate correlation analyses of short and long-term changes following CRT 
between biomarkers versus functional and echocardiographic variables. Relative change 
applied to short (6 weeks) and long-term (6 months) reviews compared to the baseline 
assessments. Relative change was calculated by follow-up-Baseline/Baseline. Parametric or 
non-parametric bivariate correlation analysis performed dependent of continuous data 
distribution. Specific variables all pre-specified biomarkers compared to were 6MWT, QoL 
score, NT-pro-BNP, LVESV and LVEF. 
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6.4.5 Predicting Functional Response 
Pre-specified baseline ECM, GDF-15 and miRNA biomarkers, alongside established clinical 
parameters underwent logistic regression modelling to build a prediction model for 
functional response. Figure 6.4 demonstrates the univariate and multivariate model for pre-
implant parameters ability to predict functional response. There were two variables on 
multivariate modelling trended towards being able to predict long-term functional 
response; increasing baseline CTx expression and presence of LBBB morphology on resting 
12 lead ECG.  
 
  
Dr Christopher J. McAloon 
 
274 
 
 
Figure 6.4 Univariate and Multivariate Regression Model of Pre-CRT implant variables for prediction of functional response at 6 months. 
Forrest plot demonstrated the odds ratio and 95% confidence interval for parameters in univariate analysis. The table demonstrated the final 
step in the multivariate analysis. ECM, GDF-15 and NT-pro-BNP were logarithmically transformed for the prediction model. 
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6.4.6 Echocardiographic response and baseline biomarker expression 
Echocardiographic response was established in 28 participants, due to limitations in the 
ability to perform paired LV volumetric assessments due to image quality, body habitus and 
ability to have a scan. There were 12 (42.9%) responders and 16 (57.1%) non-responders 
who did not. Baseline comparison of biomarker expression was performed between these 
echocardiographic responders and non-responders (Table 6.4). MMP-2 baseline expression 
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Table 6.4 Comparison of Baseline Biomarker Expression between with and without >15% 
Reduction in LVESV at 6 Months Following CRT Implantation.  
Biomarkers 
Responders = 12 
Non-Responders = 
16 
p-value 
PINP (ug/L, median, range) 39.5 (24.0-69.0) 48.0 (26.0-141.0) 0.14 
CTx (ug/L, , median, range) 0.47 (0.14-1.14) 0.48 (0.18-0.90) 0.94 
PIIINP (ug/L,mean±SD) 1.05±0.43 1.08±0.46 0.87 
MMP-2(ug/L,median, range) 
247.5 (155.3-671.5) 
342.5 (194.0-
789.5) 
0.05 
MMP-9 (ug/L, median, range) 77.5 (24.7-182.3) 70.4 (13.6-204.2) 0.51 
GDF-15 (ug/L, median, range) 1.96 (1.12-4.28) 2.46 (1.20-10.29) 0.24 
miR-21 (RQ, median, range) 0.86 (0.50-1.40) 0.77 (0.60-2.30) 0.63 
miR-30d (RQ, median, range) 0.64 (0.34-1.68) 0.91 (0.35-1.86) 0.39 
miR-122 (RQ, median, range) 0.46 (0.06-3.28) 0.84 (0.09-3.60) 0.16 
miR-133a (RQ, median, range) 0.53 (0.01-3.79) 0.80 (0.08-2.26) 0.66 
miR-210 (RQ, median, range) 0.42 (0.17-2.05) 0.85 (0.06-5.12) 0.15 
miR-486 (RQ, median, range) 0.81 (0.17-1.93) 0.72 (0.21-2.48) 0.98 
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6.4.7 MACE and Baseline Biomarker Expression  
During the observation one year period following CRT implantation therewere 8 (15.4%) 
MACE’s at a median of 2.8 (0.1-11.9) months. There were 4 (7.7%) all-cause mortality events 
at a median of 3.7 (0.1-9.6) months. There were 6 (11.5%) hospital admissions for first heart 
failure event after CRT implantation which occurred at a median of 2.8 (1.3-11.9) months. 
Baseline characteristics for those with and without a MACE were not significantly different 
for any parameter. Table 6.5 compares baseline biomarker expression dependent on MACE 
occurrence in the following year.  
Table 6.5 Comparison of Baseline Biomarker Expression for Participants with and without 
MACE at 12 Months Following CRT Implantation. 
Biomarkers MACE = 8 No MACE = 44 p-value 
PINP (ug/L, median, range) 50.0 (17.0-113.0) 40.0 (15.0-141.0) 0.36 
CTx (ug/L, median, range) 0.43 (0.29-0.56) 0.38 (0.14-1.14) 0.41 
PIIINP (ug/L,mean±SD) 1.25±0.49 1.01±0.37 0.15 
MMP-2(ug/L, median, range) 
332.3 (164.2-
434.5) 
281.9 (155.3-
789.5) 0.63 
MMP-9 (ug/L, median, range) 82.3 (45.1-145.5) 70.7 (13.6-254.1) 0.27 
GDF-15 (ug/L, median, range) 2.82 (1.2-4.55) 2.64 (1.05-10.29) 0.76 
miR-21 (RQ, median, range) 0.79 (0.50-1.0) 0.75 (0.30-2.40) 0.86 
miR-30d (RQ, median, range) 0.53 (0.35-0.87) 0.71 (0.20-2.55) 0.05 
miR-122 (RQ, median, range) 0.60 (0.14-1.38) 0.50 (0.06-3.60) 0.54 
miR-133a (RQ, median, range) 1.23 (0.02-3.35) 0.53 (0.01-4.52) 0.47 
miR-210 (RQ, median, range) 0.79 (0.06-1.43) 0.68 (0.17-5.12) 0.61 
miR-486 (RQ, median, range) 0.77 (0.28-1.90) 0.76 (0.17-3.14) 0.57 
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6.4.8 Coronary Sinus Biomarker Profile  
Coronary sinus and peripheral venous sampling was conducted on a subset of the COVERT-
HF study cohort (n=26) on the day of CRT implant (only paired samples were compared). 
Haemolysed samples were excluded from the respective analyses. Figure 6.5 shows those 
biomarkers that demonstrated significant variation in their expression. Expression was 
higher in the coronary sinus for hs-TnT (p<0.01) miR-30d (fold change 1.29, p=0.05) and -
133a (fold change 3.36, p<0.01). Notably miR-486 had significantly higher expression in the 
coronary sinus (fold change 1.43, p<0.01), which is in keeping with the higher haemolysis 
rate observed in the coronary sinus sampling. PINP, PIIINP and MMP-2 all had significantly 
higher expression in peripheral samples than in the coronary sinus (p<0.01), this was 
observed for both responders and non-responders (p<0.01).The hs-TnT demonstrated 
significantly higher expression in non-responders in the coronary sinus than peripheral 
samples (28.8 ng/L (6.5-61.6) vs 38.4 ng/L (10.3-60.6), p<0.01) No statistical difference in hs-
TnT levels for responders was observed between peripheral and coronary sinus samples 
(23.4 ng/L (8.5-68.2) vs 27.5 ng/L (17.7-64.7), p=0.14). 
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Figure 6.5 Variation between biomarker expression in peripheral and coronary sinus blood. PIIINP is expressed as mean±SD and underwent 
parametric comparison.PINP, MMP-2, hs-TnT, miR-30d, miR-133a and miR-486 were reported as median (range), and underwent non-
parametric comparison. Comparisons were undertaken on the number of paired datasets available (n given for each comparison).   
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6.5 DISCUSSION 
The COVERT-HF study is the first, prospective observational study to examine cardiac 
fibrosis biomarkers and dysregulated miRNA in HF patients undergoing CRT as to determine 
their potential to predict functional response. It is the first study, to our knowledge, to 
profile specific miRNAs that are known to be dysregulated in HFrEF patients. Selected 
baseline biomarkers and clinical variables did not demonstrate the ability to predict 
functional response, although CTx and LBBB morphology trended towards significance. 
However, levels of PINP and miR-122 following CRT implantation were shown to vary 
significantly between responders and non-responders. Expression over time in both groups 
was shown to alter for MMP-2,-9 and hs-TnT. Furthermore, specific changes in biomarker 
expression have shown to be associated with changes in functional, neurohormonal and LV 
geometry parameters both in short and long-term follow-up. The study also observed higher 
expression of cardiac fibrosis biomarkers systemically and higher expression of miRNAs in 
the CS.   
 
Cardiac fibrosis biomarkers are known to be strongly associated with poor HF 
outcomes.94,123,136 Alteration in cardiac ECM turnover is a key feature of cardiac fibrosis and 
is strongly associated with the development and progression of HFrEF.113,134,136 Over the last 
decade ECM biomarkers have been associated with poor HF outcomes134,136 and have 
shown the ablity to predict response to CRT.127 Alteration in collagen synthesis and 
deposition, demonstrated by PINP/PICP for type I and PIIINP for type III have been observed 
to predict response in several observational studies for both functional and 
echocardiographic criteria. The exact behaviour and significance of collagen turnover has 
not been consistently replicated. 119,126,127,244 This inconsistency is principally due to the 
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variation in response definitions used. No synthesis, deposition or degradation biomarkers 
observed in our observational study demonstrated the ability to predict response. CTx 
trended towards the ability to predict response in a multivariable model, but it was not 
significant. No statistically significant differences in ECM biomarker expression was 
demonstrated between echocardiographic responders or those participants with or without 
a MACE. The CARE-HF trial23 sub-study was the largest (n=260) to examine ECM biomarkers 
(PINP, PIIINP, ICTP, MMP-1) as potential predictors of response (survival and LVEF >35% at 
18 months) and their findings observed that none of the biomarkers could predict response, 
supporting our observations.125 Short-term changes in PINP, MMP-2 and PIIINP expression 
have been observed to correlate with 6MWT, NT-pro-BNP and LVESV changes respectively. 
Moreover, long-term changes in MMP-2 and PIIINP have been shown to correlate with NT-
pro-BNP and 6WMT changes respectively. However, PINP in the short-term had a direct 
correlation with change in 6MWT distance, whereas PIIINP has a negative correlation with 
6MWT distance change over the long-term, suggesting an association between collagen 
type I and III and functional response, which changes with time. These results imply greater 
increase in PINP expression correlates with the ability to increase the 6MWT test distance 
following CRT implantation, which reflects greater ECM turnover. This observation is made 
by Garcia-Balao et al in their observation study over 12 months.126 Our observations 
however, demonstrate that a reduction in PIIINP expression at 6 months is associated with a 
greater 6MWT distance from baseline, suggesting reversal of cardiac fibrosis is associated 
with an improved functional status. PIIINP is observed to be more sensitive to changes in 
cardiac modelling, meaning this may represent a more long-term remodelling pattern. 
However in the long-term these markers do not correlate with LV geometry parameters, 
therefore it remains unclear the precise relationship between collagen turnover and 
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response to CRT. The ECM behaviour observations from the COVERT-HF study and the wider 
literature represent a heterogeneous response, which is likely to relate to the variety of 
factors causing the geometric changes seen in HFrEF. 
  
Interestingly it is observed that PINP, PIIINP and MMP-2 expression are detected at higher 
levels in peripherally sampled blood compared to samples from the CS. These observations 
are in line with previous findings of Tolsana et al,294 reporting that MMP-2 was more highly 
expressed systemically than in the CS. Multiple difference cell types have been 
demonstrated to secrete pro-MMP-2 that are not exclusive to the heart.116 The implications 
of these particular observations are that HF modifies systemic expression of MMP-2 
alongside that of the heart. Furthermore, greater expression is seen systematically, exerting 
that potentially modification of cardiac ECM in HF is contributed to by non-cardiac sources.  
 
GDF-15 is a marker of myocardial stress and its ability to predict poor HF outcomes is well 
described.110 Previously GDF-15 has been demonstrated to be a robust predictor of 
mortality following CRT implantation.112 However, GDF-15 did not demonstrate the ability to 
predict functional response (survival & no HF hospitalisations, ↓>1 NYHA class or ↑>25% 
6MWD at 1 year).112 Our observations support these conclusions that GDF-15 cannot predict 
response, however we did not observe any difference in baseline expression in those 
participants with and without MACE.  
 
There is maladaptation of complex cardiovascular biological systems in HF. This 
maladaptation involves dysregulation of specific miRNAs which regulate and control these 
systems.139,148 MiRNA dysregulation has been demonstrated recently to occur and be 
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associated with the development of the adverse cardiac remodelling in HFrEF.139 Marfella et 
al197 were the first to observe altered expression in miRNA profiles between responders and 
non-responders using a miRNA microarray. Melman et al199 more recently in a validation 
and translational study identified miR-30d was overexpressed in responders and had the 
ability to predict response status (increase LVEF >10% at 6 months). Neither study replicated 
the results of the other, however the studies significantly differed in the methodology 
employed. Marfella et al197 and Melman et al199 both used small cohorts with different 
characteristics, and different quantification methods (microarray and quantitative PCR 
respectively). In our study we selected six specific miRNAs that have been demonstrated to 
be dysregulated in HFrEF including miR-30d. MiRNAs were individually profiled by 
quantitative PCR methods, which is the gold standard for quantification.310 None of the 
miRNAs were observed to be predictors of functional response and no variation at baseline 
was observed for echocardiographic responders. However, it was observed that miR-30d 
had statistically higher expression in patients with no MACE at 12 months. This observation 
has not previously been made, and implies increased LV wall stress is protective; however, 
this observation has not been tested in a prediction model against other variables. Over the 
observation period miR-122 expression was found to be statistically lower in functional 
responders. Recently miR-122 has been shown to be expressed in the liver due to 
congestion, which would support the observation there is lower expression in responders 
after CRT implantation.311 Higher expression of miR-30d and -133a was observed in the 
coronary sinus compared to the peripheral circulation. These observations replicate 
previous findings that demonstrated these miRNAs to be enriched.181 MiR-486 
demonstrated higher expression in the coronary sinus than peripherally, potentially 
reflecting the higher haemolysis rate of samples taken via the catheter.  
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The overall cohort behaved as expected following CRT implantation.22,23,31,126,294  Overall, the 
patients had a significantly improved NYHA classification and 6MWT distances alongside 
reducing QoL scores. Interestingly the entire cohort showed a statistically significant 
improvement in LV geometry and reduction in hs-TnT over the observation period, without 
any difference between responders and non-responders being observed. The pattern 
observed in overall improvement in LV geometry has been well described following CRT 
implantation23,31 but the pattern not being replicated in functional responders only 
emphasises the known poor correlation between echocardiographic and clinical response 
criteria.1 Variation in different definitions used for response remains a major limitation of 
research in this field.1 
 
6.5.1 Study Limitations 
There are several limitations to our prospective study that should be reflected upon during 
the interpretation of our results. Firstly, this was a small single-centre proof-of-concept 
study. Secondly, transthoracic echocardiography was limited in several participants due to 
body habitus and illness, resulting in the inability to perform paired standardised modified 
Simpson’s biplane assessments on all scans. Thirdly, the NICE 201417 guidance was released 
during the trial period reflecting a change in the guidelines moving away from mechanical 
dys-synchrony on echocardiography and towards QRS duration and morphology. The study 
inclusion changed to reflect the real world circumstances of the study, but this may have 
altered the cohort characteristics. Fourthly, the numbers of MACE events was low in the 12 
months observed and results must be interpreted cautiously. Finally, coronary sinus samples 
were taken on the second half of the cohort following permission to perform the 
assessment being granted. This was a logistical limitation of the study and formed a practical 
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problem of extrapolating the implication of the results from such small numbers, in what 
formed essentially a sub-study. Continous sampling of CS samples was performed on the 
second half of the cohort; however the total numbers of participants in the sub-study was 
low. Caution must be applied when interpreting these specific results.  
 
6.6 CONCLUSION 
In conclusion, our proof-of-study, did not demonstrate that ECM biomarkers, GDF-15 or 
specific miRNAs can predict functional response in a heterogeneous HFrEF patient 
population undergoing CRT. We observed LBBB morphology and the biomarker CTx did 
show a trend towards predicting response and warrant further study. 
 
6.7 PUBLICATIONS  
This chapter formed the basis of a poster presentation at the Sankey Cliinical Competion 
(University Hospitals Birmingham) which won best poster presentation. The paper has been 
recently submitted for consideration for publication with Heart Rhythm at the time of 
submission of this thesis. .  
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Chapter Seven 
 
BODY COMPOSITION IN HEART FAILURE AND 
IMPACT OF CARDIAC RESYNCHRONISATION 
THERAPY 
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7.1 INTRODUCTION 
There is a complex relationship between HF, body composition and metabolism with the 
interplay altering with the development and progression of HF.218 The development of HF 
causes neurohormonal activation, a pro-inflammatory state and endothelial 
dysfunction.206,207 The degree of metabolic systems shifting into a pro-catabolic state in HF is 
heavily influenced by the patient’s body composition.218 Presence of obesity makes the 
development of HF more likely,212 but the presence of higher adiposity is protective.213 This 
counterintuitive observation is referred to as the ‘obesity paradox’.212,214  Higher adiposity is 
inversely related to neurohormonal activation and is observed to be protective against 
progression of HF.208,209  
 
More complex relationships between different body composition components and HF have 
been observed. Sarcopenia is associated more with HFrEF and a more pro-inflammatory 
state211 and neurohormonal signalling.209 CC reflects the body composition of the pro-
catabolic state seen in HF and is an important and reproducible variable in predicting poor 
HF outcomes.207,212,213 All body components have been shown to be affected by CC and 
regulated by elevated neurohormonal and inflammatory signals.207,208 The presence of CC 
represents a critical step in the pro-catabolic transition of the body’s metabolism and body 
composition in advancing HF.218 Our own detailed peer-reviewed article summarises the 
literature on the complex interplay between HF, BC and metabolism, highlighting the 
importance on outcomes, but also the very limited evidence currently.218 
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CRT implantation provides a unique opportunity in the study of HFrEF to see how reverse 
remodelling and improvement in the patient alters the patient’s body composition. Cai et 
al216 observed in a retrospective cohort study of 219 Chinese HFrEF (LVEF<35%) that 
overweight (24.0-28.0 kg/m2) and obese (>28.0 kg/m2) BMI predicted response to CRT and 
improved survival at 6 months. This observation represents the potential importance of 
body composition in predicting response to CRT, although there are limitations in drawing 
any significant conclusions from this study. Firstly it was based on a far eastern population 
and is not directly applicable to western populations.216 Secondly, no account of specific 
body composition components was made or whether CC was present.216 Thirdly, the study 
demonstrated obese population better tolerated OMT, which may have contributed to the 
improved response and outcomes.216 This study is the only one study examining body 
composition and CRT. Treatment of HFrEF with CRT and the potential response including 
cardiac remodelling is an potential opportunity to examine impact on body composition 
component and whether there are any changes.  
 
7.2 AIM AND OBJECTIVES (Chapter 2) 
To examine the impact of body composition in patients with HFrEF and dys-synchrony 
undergoing CRT. 
 
7.3 METHODOLOGY (Chapter 3.5)  
A small physiological pilot as part of the COVERT-HF prospective observational study (sub-
study) was undertaken on unselected HF patients undergoing CRT implantation meeting 
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NICE (TA120)17 criteria between September 2014 and December 2015. In July 2014 a 
substantial amendment to the regional ethics committee approved performance of air-
displacement plethysmography assessment. All participants recruited beyond this point 
were asked to participate in the sub-study as part of the informed consent process. Air 
displacement tomography was conducted at all three defined research visits (pre-implant, 
post-implant: 6 weeks and 6 months) alongside NYHA classification, 6MWT, 
echocardiography, MLHFQ, ECG and blood sampling.  The methods employed in the 
COVERT-HF prospective cohort study are outlined in detail in Chapter 5.5 and Chapter 6. 3. 
This sub-study is the first to examine body compostion alterations following CRT 
implantation. It is a small sub-study, which may be hypothesis generating. The recruitment 
was a small number of participants and was not powered being a pilot study.    
 
7.3.1 Device Implantation (Chapter 3.2) 
Device implantation was undertaken as a day-case procedure according to local protocol.312  
 
7.3.2 Transthoracic Echocardiography (Chapter 3.5) 
All participants underwent transthoracic echocardiography (Vivid 7, GE Healthcare, Horten, 
Norway) examination for LV volumetric assessment. LV volumetric assessment according to 
the prescribed literature201 by the same nationally accredited200 operator on the same 
machines. All measurements were analysed offline (EchoPac, GE Healthcare, Horten, 
Norway).  
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7.3.3 Air-Displacement Plethysmography (Chapter 3.5) 
Whole body air-displacement plethysmography (BOD POD® Life Measurement Inc, Concord, 
California, USA) reliably and reproducibly measures body composition.261 The BOD POD® is 
comparable with more traditional methods of measuring body composition.261 Participants 
were required to starve and not exercise two hours prior to the test. The participant had a 
height measurement performed and was weighed on the calibrated scales attached to the 
BOD POD®. All participants were asked to enter the BOD POD® wearing a lycra swim cap and 
their underwear only for standardisation of the measurements. Two serial measurements 
were performed for body composition and the average was taken as the result, where 
measurements between tests varied significantly the operator was asked to perform a third 
test.  
 
7.3.4 Blood Sampling and Laboratory Analysis (Chapter 3.5) 
Peripheral venous sampling of blood was performed following two hours of fasting and one 
hour of rest. Peripheral samples at implantation were taken the morning of the implant. 
Clinical laboratory measurements were performed according to standard hospital procedure 
including NT-pro-BNP.  
 
7.3.5 Study Outcomes (Chapter 3.5) 
The primary outcome measure for the study was the patients’ functional response status. 
Functional responders were defined as those whom survived, did not undergo heart 
transplantation and achieved two out of three response criteria (↓>1 NYHA, ↑>10% 6MWT 
distance, ↓MLHFQ score>5) at 6 months follow-up  
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7.3.6 Statistical Analysis (Chapter 3.8) 
Categorical variables were reported as frequency and percentages. Comparison analyses for 
categorical data were performed using the Chi-Squared or Fishers Exact tests dependent on 
appropriateness. Continuous data underwent histogram plots for assessment of normality. 
Normally distributed data were reported as mean ± SD and comparative analysis was 
performed using independent t-tests. Non-normally distributed data were reported as 
median (full range) and were compared using a Mann-Whitney U test. Variation in 
continuous variables over three time periods was analysed using either one-way analysis of 
variance (ANOVA) or Friedman test, respectively. Mixed between-within subjects analysis of 
variance was used to compare variation in body composition data in functional responders 
and non-responders over 6 months of observations. Bivariate correlation analyses ( Pearson 
(parametric) or Spearman rank (non-parametric) estimators) was performed between 
change in body composition and functional, echocardiographic and neurohormonal 
parameters. A p-value <0.05 was considered statistically significant.  
 
7.4 RESULTS 
There were 27 participants enrolled in the sub-study, however only 25 were able to 
undertake baseline body composition assessment. One participant was excluded from the 
sub-study due to being unable to undertake assessment in the BOD POD®. The other 
participant had significant erroneous body composition baseline measurements despite 
repeated tests. These exclusions made no difference to sub-study cohort characteristics. 
Figure 7.1 demonstrates the recruitment and flow of patients through the sub-group within 
the COVERT-HF study. 
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Figure 7.1 Recruitment and Flow of Participants through body composition sub-study. 
7.4.1 Baseline Sub-Group Characteristics 
The sub-groups characteristics are summarised in table 7.1. Functional responders and non-
responders characteristics were compared within the sub-group. Response status at 6 
months was determined in 23 participants with body composition measurements. The two 
others in the group could not have a 6 month response status performed (one post 
procedure exclusion and one lost to follow-up). Comparatively three participants whom did 
have a functional response status were unable to have a 6 month body composition 
assessment performed (1 death during follow-up and two not well enough to undergo 
assessment).The first follow-up occurred at a mean(±SD) 1.7±0.3 months and the final 
research visit was at 5.8±0.5 months.  
  
COVERT-HF = 52 → Sub-study = 25 
CRT-d = 12, Upgrade-CRT-d = 6,  
CRT-p = 4, Upgrade CRT-p = 3 
Six month BOD POD® assessment= 20 
Responders = 12 (52.2%) 
Non-responders = 11 (47.8%) 
Mortality = 1  3.1 months)  
 HF Death = 1 
Post procedure LV lead displacement = 1 
Couldn’t have FU BOD POD ® assessment = 2 
Lost to FU (HF Hospital admission) = 1 
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Table 7.1 Baseline Characteristics 
  Total Cohort =25 Responders=12 
Non-Responders 
=11 p-value 
Demographics         
Age (years, mean±SD) 73.4±10.0 68.1±14.4 76.0±7.4 0.19 
Male (n,%) 23 (92.0%) 12 (100.0%) 9 (81.8%) 0.42 
Device         
CRT-D (n,%) 18 (72.0%) 8 (66.7%) 9 (81.8%) 0.73 
Upgrade (n,%) 9 (36.0%) 2 (16.7%) 7 (63.6%) 0.06 
Aetiology         
Ischaemic (n,%) 16 (64.0%) 6 (50.0%) 8 (72.7%) 
0.49 
Non-ischaemic (n,%) 9 (36.0%) 6 (50.0%) 3 (27.3%) 
Co-morbidities         
Diabetes Mellitus (n,%) 6 (24.0%) 2 (16.7%) 4 (36.4%) 0.55 
CKD (n,%) 13 (52.0%) 7 (58.3%) 6 (54.5%) 1.00 
NYHA (n,%)II 10 (43.5%) 5 (41.7%) 5 (45.5%) 
0.52                      III 12 (52.2%) 7 (58.3%) 5 (45.5%) 
                     IV 1 (4.3%) 0 (0.0%) 1 (9.1%) 
Electrocardiogram         
AF (n,%) 9 (36.0%) 4 (33.3%) 4 (36.4%) 1.00 
LBBB (n,%) 17 (68.0%) 9 (75.0%) 6 (54.5%) 0.56 
QRS (msec, median, range) 162(120-212) 168 (138-212) 160 (138-194) 0.60 
6MWT (M, mean±SD) 252.6±132.0 291.9±133.3 215.3±147.4 0.29 
QOL Score (median, range) 48.0 (8.0-85.0) 55.5 (9.0-85.0) 29.0 (8.0-68.0) 0.11 
Laboratory Tests         
eGFR (ml/min/1.73m2, 
median,range) 
52.0 (25.0-130.0) 52.5 (25.0-130.0) 52.0 (26.0-79.0) 0.61 
NT-pro-BNP (pmol/L, median, 
range) 
267.0 (75.0-
4138.0) 
237.0 (75.0-
4138.0) 
273.0 (133.0-
547.0) 
0.33 
Medications         
ACEi/ARB (n,%) 25 (100.0%) 12 (100.0%) 11 (100.0%) 1.00 
BB (n,%) 21 (84.0%) 10 (83.3%) 10 (90.9%) 0.62 
MRA (n,%) 14 (56.0%) 7 (58.3%) 5 (45.5%) 0.38 
Echocardiography≠         
LVESV (ml,median,range) 125.8 (62.9-268.7) 136.7(80.7-268.7) 110.9(62.9-169.4) 0.29 
LVESV_BSA(ml,median,range) 58.9 (38.7-128.0) 66.1 (42.7-128.0) 59.1 (38.7-85.8) 0.35 
LVEF (%, median,range) 25.6 (9.7-35.4) 24.4 (10.0-34.4) 28.6 (9.7-35.4) 0.40 
Body Composition         
BMI (kg/m2, median, range) 28.7 (22.4-41.9) 29.3 (22.4-37.3) 27.8 (23.9-40.8) 0.85 
Fat Mass (kg, median, range)~ 31.4 (18.1-61.2) 31.3 (19.3-56.4) 29.7 (18.1-58.7) 0.81 
Relative FM (median, range)~ 0.38 (0.23-0.54) 0.35 (0.28-0.50) 0.42 (0.23-0.54) 0.29 
Lean Mass (kg, median, range) ~ 52.3 (30.9-73.3) 52.6 (40.3-73.3) 50.5 (30.9-62.5) 0.48 
Waist circ (cm, median,range)~ 98.2 (84.6-131.0) 97.5 (84.6-120.8) 98.2 (85.0-114.5) 0.79 
≠ based on available data, FM = Fat Mass 
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Both responders and non-responders shared similar characteristics with no statistical 
differences observed. This observation included all the baseline body composition 
components. As expected there were no differences in patient symptoms, function, QoL and 
LV geometry characteristics over the 6 months of follow-up.  
 
7.4.2 Effect of CRT on Cardiac Function and Body Composition 
Table 7.2 demonstrates the impact of CRT over 6 months on body composition and cardiac 
function variables. One participant at 6 weeks and two participants at 6 months (including 
the same one at 6 weeks) could not/did not want to undertake the BOD POD® assessment; 
however they were able to complete the other assessments as part of the research visit. The 
data observed a significant improvement in MLHFQ scores and a decrease in QRS duration. 
Total and percentage fat mass demonstrated a trend towards a reduction 6 months after 
CRT implantation. There was also an expected trend in improvement in LVEF as is 
demonstrated in the wider COVERT-HF study. The clinical, functional, laboratory results in 
the sub-group correspond with those in the larger COVERT-HF study. 
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Table 7.2 Changes in Sub-Group Characteristics Over 6 Months 
  Baseline 6 weeks 6 months p-value 
Clinical, Functional, 
Laboratory∆      
QOL Score (median,range) 48.0 (8.0-85.0) 33.5 (0.0-73.0) 23.5 (0.0-0.83) 0.06 
QRS (msec, median,range) 162(120-212) 145 (102-194) 159 (112-214) 0.02 
6MWT (M, mean±SD) 252.6±132.0 277.1±145.2 242.4±178.8 0.29 
eGFR (ml/min/1.73m2, 
median,range) 
52.0(25.0-130.0) 47.0(24.0-105.0) 52.7(20.0-90.0) 0.34 
NT-pro-BNP (pmol/L, 
median,range) 
267.0 (75.0-
4138.0) 
236.5 (27.0-3848.0) 
272.5 (15.0-
1690.0) 
0.87 
Body Composition (median, 
range)     
BMI (kg/m2) 28.7 (22.4-41.9) 28.5 (22.0-34.4) 28.0 (22.4-35.7) 0.39 
Fat Mass (kg)~ 31.4 (18.1-61.2) 29.0 (18.9-61.2) 29.1 (18.6-50.3) 0.12 
Relative Fat Mass ~ 0.38 (0.23-0.54) 0.34 (0.25-0.51) 0.39 (0.28-0.52) 0.09 
Lean Mass (kg)~ 52.3 (30.9-73.3) 53.9 (31.9-75.0) 50.5 (31.9-75.0) 0.19 
Waist circ (cm)~ 98.2 (84.6-131.0) 99.3(76.0-119.4) 100.1(78.9-120.9) 0.53 
Echocardiography≠ 
    
LVESV (ml, median,range) 125.8 (62.9-268.7) 112.7 (52.8-210.8) 95.2 (57.8-315.6) 0.26 
LVESV_BSA(ml,median,range) 58.9 (38.7-128.0) 56.8(28.2-118.7) 49.5(30.6-131.5) 0.26 
LVEF (%, median,range) 25.6 (9.7-35.4) 29.4(13.6-43.6) 32.7(14.4-41.7) 0.14 
∆ based on patients able to have clinical, functional and laboratory assessments 
(baseline=25, 6 weeks=24, 6 months=22), ~based on participants able/available to have BOD 
POD ® assessment (baseline=25, 6 weeks=23, 6 months=20), ≠based upon complete series 
of echocardiograms with biplane measurements 
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7.4.3. Effects of CRT on Body Composition by Response Status. 
The changes over time in body composition for functional responders and non-responders 
were analysed. Table 7.3 demonstrates the trends in the changes in the body composition 
components for 6 months after CRT implantation. There were no significant differences 
between responders and non-responders observed. Furthermore there were no statistically 
significant changes in body composition over the 6 month observation period. However, 
there was a trend that was observed where relative fat mass was higher at baseline for non-
responders and had a large decrease after 6 weeks following CRT implantation, compared to 
responders (Figure 7.2). Following the 6 week observation period the relative fat mass 
proportion returned to similar baseline levels at 6 months for non-responders. The trend 
towards there being a significant change in fat mass over time was driven by the amount of 
decrease in fat mass for non-responders in the first 6 weeks following CRT. Responders were 
observed to have minimal variation over the three observation points and to have lower 
levels of relative fat mass than non-responders (Figure 7.2). There was a trend towards a 
difference between responders and non-responders over time for fat mass.   
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  Responders Non-Responders P-Value 
Body Composition 
(median, range) Baseline  6 weeks 6 months  Baseline  6 weeks 6 months  
Response Time Interaction 
BMI (kg/m2) 29.3 (22.4-37.3) 29.7 (22.0-37.4) 28.8 (22.4-35.0) 27.8 (23.9-40.8) 27.3 (23.9-35.9) 27.6 (23.8-35.7) 0.98 0.28 0.71 
Fat Mass (kg)  31.4 (19.3-56.4) 29.5 (18.9-61.2) 30.3 (18.6-50.3) 29.7 (18.1-58.7) 27.6 (19.6-47.7) 29.1 (24.5-45.6) 0.74 0.11 0.68 
Relative Fat Mass ~ 0.35 (0.28-0.50) 0.34 (0.28-0.50) 0.36 (0.28-0.44) 0.42 (0.23-0.54) 0.35 (0.25-0.51) 0.40 (0.32-0.52) 0.18 0.13 0.47 
Lean Mass (kg)~ 52.6 (40.3-73.3) 51.7 (43.6-75.0) 51.2 (42.5-74.4) 50.5 (30.9-62.5) 53.9 (31.9-62.4) 48.4 (32.5-62.3) 0.25 0.25 0.48 
Waist circumference 
(cm)~ 97.5(84.6-120.8) 98.8(85.6-114.5) 99.3(84.2-113.8) 98.2(85.0-114.5) 96.7(76.0-119.4) 103.2(78.9-120.9) 0.55 0.96 0.33 
Figure 10.2 Change in Relative Fat Mass in Functional Responders and Non-Responders over 6 Months. . The median (CI 95%) is 
represented. 
Time p=0.13 
Group p=0.18 
Table 7.3 Behaviour of Body Composition Following CRT Implantation. Interaction between responder status and over time 
analysed. 
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7.4.4 Correlations Analysis between Relative change in Body Composition and Cardiac 
Function  
Bivariate correlation analysis for relative change (follow-up-baseline/baseline) in the short 
and long-term were undertaken between body composition components and cardiac 
function variables (functional, LV geometry and neurohormonal). Figure 7.3 demonstrates 
the strongest associations demonstrated in the exploration of the relationship between 
body composition and cardiac function variables following CRT. A strong inverse correlation 
was demonstrated between LVESV volume index and relative fat mass (Figure 7.3 A). The 
strength of this association was reflected in the strength of the correlations between fat 
mass and LVESV (both measurements with and without volume indexing). A strong inverse 
correlation was observed between fat mass and NT-pro-BNP (Figure 7.3 B).There was an 
observed medium association between Fat Mass and eGFR (r=0.41, p=0.06) that trended 
towards significance at 6 weeks observation. Long-term the strongest inverse correlation 
was observed between fat mass and eGFR (Figure 7.3 C). A significant association was also 
observed between eGFR and lean mass (r=0.47, p=0.04) at 6 months after CRT implantation.  
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Figure 7.3 Bivariate correlation analysis of short and long-term changes following CRT between biomarkers versus functional and 
echocardiographic variables. Relative change applied to short (6 weeks) and long-term (6 months) research visits compared to the 
baseline assessments. Relative change was calculated by follow up-Baseline/Baseline. Parametric or non-parametric bivariate 
correlation analysis was performed dependent of continuous data distribution. All body composition components were compared in 
bivariate correlation analysis to MLHFQ, QRS duration, 6MWT, eGFR, NT-pro-BNP, LVESV, LVESV Volume indexed and LVEF. Fat 
Mass vs LVESV Volume indexed (A). Fat Mass vs Log10 NT-pro-BNP (B). Fat Mass vs eGFR (C). 
A B C 
Dr Christopher J. McAloon 
 
     
  299 
 
7.5 DISCUSSION  
This small physiological pilot is the first study as a proof-of-concept to examine body 
composition before and after CRT implantation, a sophisticated technology to resynchronise 
the dyssynchronous heart in advanced cardiac failure. This study examines the differences 
between patients who are functional responders and non-responders. We observed that 
there was an association between changes in fat mass and LV geometry shortly after CRT 
placement. Relative short-term changes in LVESV and LVESV volume indexed measurements 
were strongly inversely correlated with fat mass and relative fat mass over the first 6 weeks 
of observation. The long term relative change correlations however did not reflect the 
strength of the short term associations. There was no difference in body composition at 
baseline between responder and non-responders. The entire cohort demonstrated no 
statistical change in body composition components over 6 months, however there was a 
trend towards statistical significance for change over time for lean mass, fat mass and 
relative fat mass. Lean mass  was observed to decrease following CRT implant. Fat mass and 
relative fat mass were observed to have a large decrease in levels at the first follow-up visit 
and then return to similar baseline levels at six months. This trend was observed to be 
driven by non-responders primarily. Importantly air-displacement plethysmography 
interprets body water as fat mass; therefore this will potentially exert an influence on the 
changes in body compostion as fluid retention improves following CRT. Moreover, there is 
no data examining the reporting of the reliability of air-displacement plethysmography in HF 
patients,261 meaning the exact impact of body water is not clear. Finally renal function, 
specifically eGFR was found to be significantly inversely correlated with relative change in 
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fat mass at 6 months. Moreover this association was trending towards significance at the 
initial follow-up assessment at 6 weeks post implant.  
 
The observed association between LV geometry and fat mass relative change following CRT 
implantation has not been observed previously. The relationship potentially reflects that 
increased fat mass is associated with reverse cardiac remodelling, in other words if fat mass 
is lost following CRT implantation, this is associated with progression in LV dilation. The 
mechanism of this potential relationship is not demonstrated in this study. The 
neurohormonal system would appear to be implicated though given the well described 
reduction in circulating natriuretic peptides in the presence of increased adiposity.206,218 
Adipocytes are sensitive to natriuretic peptides, activating lipolysis and enhancing 
expression of brown adipocyte genes, increasing thermogenesis, favouring the metabolic 
shift towards a pro-catabolic state in progressive HF.206 Naturetic peptides critical role also 
known to stimulate the release of adipokines (specifically adiponectin and leptin) which 
increase energy utilisation and weight reduction.206 The comparison of NT-pro-BNP and fat 
mass demonstrated a moderate strength inverse correlation; reflecting increasing levels of 
NT-pro-BNP immediately after CRT implantation is associated with decreasing levels of fat 
mass. The association is not reproduced when comparing relative change between pre-
implant and 6 months follow-up measures. This observation supports the inverse 
association between natriuretic peptides and BMI/fat mass that has previously been 
described in the literature.206,209 The observed correlations reflect those seen between fat 
mass and LV geometry. The observations are only seen over a short period post CRT 
implantation. There is also no significant association seen between changes in free fat mass 
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and LV geometry and neurohormonal variables. Suggesting that fat mass is intertwined with 
LV dysfunction and the neurohormonal systems and this is affected by the implantation of a 
CRT device. There is extensive evidence of the interplay between body composition, 
metabolism and HF and the critical role that adiposity plays in regulation of the pro-
catabolic state. Higher levels of adiposity are protective from poor outcomes in HF, slowing 
progressive towards a pro-catabolic state. The precise mechanisms involved are not entirely 
clear with the limited evidence in this area. The impact of adiposity on the neurohormonal 
system reduces the circulating levels of natriuretic peptides and their ability to drive the 
metabolic shift in HF.  The interplay between metabolism, bidy composition and HF is far 
more complex and interwined than the natruteic peptide system.218 Fat mass specifically 
may influence the CRTs ability to induce reverse cardiac remodelling. This is a hypothesis 
that requires further investigation. 
 
Limited evidence is available on the impact of CRT on body composition. The only study 
indirectly measuring of body composition was a retrospective analysis (n=219) of Chinese 
patients with severe LV systolic dysfunction with a wide spread of BMIs undergoing CRT 
implantation.216 This study focused on initial BMI predicting response and cardiovascular 
outcomes at 6 months.216 Cai et al216 observed that overweight (24-28 kg/m2) and obese 
(>28 kg/m2) patients before implant had better responses and improved cardiovascular 
outcomes. There are limitations around drawing major conclusions on body composition 
and CRT from this study; firstly is it is based purely on a Chinese population where obesity is 
defined at different levels to Western population’s, therefore the results are not particularly 
applicable to our population in the UK. Secondly, the study also observed that obese 
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patients better tolerated OMT, than non-obese patients and this may be partially the 
explanation for why these patients had better outcomes. Obesity has been observed to 
contribute to maintaining systolic blood pressure and preserving renal function, which 
physiologically explains why obese patients better tolerate OMT.212 Thirdly, this study does 
not account for specific body composition components and uses BMI which is a very crude 
measure of body composition and cannot comment on the relative contribution of fat or 
lean mass.212  Given these limitations and the potential impact of body composition on the 
success of CRT further study is required, especially into the specific role of fat mass and 
metabolic shifts in HF.  
 
Deterioration in renal function and the presence of CKD stage 3 (eGFR <60ml/min/1.73m2) 
and above is consistently and reproducibly finding that predicts non-response and poor 
cardiovascular outcomes following CRT implantation.237,238,300 Our own retrospective study 
of all CRT implants 2009-2013 observed that CKD stage 3 and above was observed to be the 
strongest predictor of MACE and all-cause mortality in a multivariate prediction model 
(chapter 7). Importantly the prospective study demonstrated that eGFR when treated as a 
continuous variable in a multivariable logistic regression did not predict function response.  
Mechanistically progressive deterioration in eGFR is linked to progressive adverse cardiac 
remodelling.302  The observations of the inverse correlation between eGFR and fat mass 
relative change during the 6 months observations suggests increasing fat mass is associated 
with deteriorating renal function. This is a paradoxical observation as obesity is thought to 
preserve renal function.212 This evidence is related to BMI and does not account for fat mass 
exclusively. There was no association described between lean mass and BMI in this study. 
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Caution is advised in interpreting these results as eGFR is calculated using the modification 
of diet in renal disease equation239 which utilises body surface area as a parameter. This 
means eGFR is not a completely independent variable and this may be the reason for the 
findings observed. 
   
The sub-groups were very similar to the COVERT-HF cohort characteristics. The baseline 
characteristics were marginally different, with the subgroup having slightly more men, less 
ischaemic aetiology and LBBB. The clinical symptoms, 6MWT, MLHFQ and LV geometry 
variables did not vary at baseline between the COVERT-HF cohort and this sub-study. 
Proportionally the sub-group had similar levels of responders and non-responders to the 
larger cohort. The trends in the entire cohort over the three observation points, across six 
months demonstrated a significant decrease in MLHFQ and QRS duration. The significance 
of the QRS duration decrease is driven principally by the initial decrease from pre-implant to 
the 6 week observation point. The 6MWT did not show a significant change during follow-
up, which initially might be expected. It however is an important discriminator between 
responders and non-responders. When responders and non-responders 6MWT are 
examined separately over 6 months the non-responders demonstrate no significant change 
in 6MWT (p=0.16) and the responders demonstrate a significant increase in 6MWT distance 
over 6 months (p<0.01), reflecting behaviour observed in the COVERT-HF cohort.  
 
In the sub-study only observations on the overall trends for responders and non-responders 
could be made due to the small numbers of participants. This has allowed for hypothesis 
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generation. The next step in analysis would be to stratify patients by percentage fat mass 
and examine their behaviour and outcomes following CRT implantation. An additional 
consideration in further studies that could not be performed in this study was to catergorise 
patients by the presence of CC and see how a CRT implantation affects outcomes in these 
patients. The literature suggests this is a particularly critical step in the switching of body 
metabolism to a pro-catabolic state and infers particularly poor cardiovascular 
outcomes.207,213,214 Both lean and fat mass are implicated in CC and examining these 
following CRT implantation would be a particularly important next step.  
 
7.5.1 Study Limitations  
This prospective study has several limitations that should be accounted for when 
interpreting these results. Firstly it is a sub-group analysis on a small number of participants 
from a single centre prospective cohort study, therefore conclusion generation will be 
limited. However, the study is hypothesis generating. Secondly, two participants completed 
research assessments, but were unable to have a BOD POD® assessment, both being graded 
as non-responders. This produces a participant selection bias. Thirdly, air-displacement 
plethysmography does not account for body water and measures it as fat mass, which 
means dependent on how oedematous the patient was, the results may be inaccurate. This 
potential bias was minimised as participants were recruited when well and not in 
decompensated HF (Appendix Q). Fourthly, though air-displacement tomography is 
validated in healthy populations, it has not yet been validated in HF patients. This poses a 
limitation in the accurancy of the body compensation measurments taken. The next step in 
body composition in HF patients using this mrthodology is a validation study. Fifthly, the 
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study was unable to account for the presence of CC, which has been demonstrated to be a 
critical variable in indicating advancing HF.218 Finally not all patients undergoing BOD POD® 
were able to have a complete echocardiogram performed, limiting the ability to perform 
volumetric assessment of the LV. An important reason for this was body habitus, with 
participants being more obsess generally being the more challenging to perform a full 
echocardiogram. This issue offers an obvious reporting bias in the study. 
 
7.6 CONCLUSION 
This is the first prospective study to examine body composition components before and 
after CRT implantation. The observations suggest there is an overall trend towards 
reduction in fat mass in non-responders, which potentially forms part of the HF progression. 
CRT success appears to be linked to maintenance of fat mass status at implant. The 
neurohormonal appears integral to this system. This is the principle hypothesis that should 
be investigated further. 
 
7.7 PUBLICATIONS 
This chapter has formed the basis of a conference poster presentation at the Heart Rhythm 
UK conference in October 2016 (Appendix R). A review publication was published in the 
British Journal of Hospital Medicine in June 2016 sumarising the literature presented in the 
discussion and chapter 1.7 (Appendix S). 
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Chapter Eight 
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8.1 DISCUSSION 
HF remains one of the greatest challenges to cardiovascular medicine for both the patient 
and wider society. The prevalence continues to increase and continues to be associated with 
poor outcomes.2,313 Several pharmacological agents, specifically angiotensin receptor 
blockers314, beta-blockers13, mineralocorticoid receptor antagonists11 and angiotensin 
receptor neprilysin inhibitors315 have been shown to significantly improve morbidity and 
mortality. However, despite advances in medications the incidence and prevalence of HF 
continues to rise and confers a poor prognosis.2,313 CRT has revolutionised management of 
HFrEF patients with cardiac dyssynchrony by improving mortality, reducing hospitalisation 
rates and inducing cardiac reverse remodelling.22,23,26-28,31 However, a significant minority of 
patient 20-40% of patients who meet the implantation criteria fail to respond to CRT 
implantation. 
 
Non-response is one of the greatest challenges of CRT. Predicting a response prior to CRT 
has remained a challenge despite extensive research in this field. The most important 
predictor of success has been shown to be QRS duration >132msec with a magnitude of 
increase in benefit for increasing duration, which is based on a large meta-analysis of five 
Medtronic RCTs.39 Ruschitzka et al41 in a RCT of CRT devices in patients with a QRS duration 
<130msec demonstrated a higher mortality in those with CRT devices on, to the point that 
the trial was stopped early. These observations have informed the new European Society of 
Cardiology 2016 implantation criteria to increase the lower boundary of QRS duration 
resting ECG for when to consider CRT implantation.316 The evolving evidence is changing as 
to which patients are perceived to benefit from CRT. Bundle branch morphology of the QRS 
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complex on the resting 12 lead ECG has also been observed (in a recent meta-analyses) to 
predict response following CRT implantation.44,45 Separating out the individual prognostic 
valve of bundle branch morphology from QRS duration is difficult as they appear to closely 
related to each other; LBBB is observed to be associated with a broader QRS durations.39 
Multiple other variables have been observed to predict response in different observational 
or post-hoc RCT studies (Table 1.3). However these observations are often not replicated. 
Predicitng non-responders remains an important goal for both the patient and society, given 
the cost and risk involved in implanting a CRT device. 
 
Research into predicting response has been beset with challenges. Firstly there is no 
accepted definition, with many different definitions being used.1 Fornwalt et al1  observed 
that there was poor correlation amongst most definitions and no correlation between 
echocardiography and clinical definitions. Secondly, the majority of research in this field is in 
small observational studies, often not powered for the observations being made. The 
systematic review undertaken in Chapter 4 highlights this particular limitation. Thirdly, the 
heterogeneity of the different HFrEF study population’s means direct comparison between 
different analyses is often difficult. The limitations of the research in this field make study 
observations challenging to examine and validate. Success thus far in testing variables has 
only come when testing RCT datasets in a meta-analysis setting, but these still make 
response difficult to assess.  
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HFrEF is a heterogeneous condition, which develops as a result of myocardial injury from a 
several different potential (ischaemia, volume and pressure overloads etc) mechanisms 
which potentially result adverse cardiac remodelling.113 Adverse cardiac remodelling leads 
to neurohormonal activation, pro-inflammatory changes, ECM remodelling and myocardial 
apoptosis.94 Circulating biomarkers are abundant and reflect the changes that are 
undertaken in these systems during HF.94 Alteration in circulating biomarker levels reflect 
the development and progression of HF and many have demonstrated the ability to predict 
cardiovascular outcomes.  
 
The cardiac ECM is a highly dynamic support structure and actively remodels during the 
development and progression of HF.94,113  Turnover of ECM alters with a pathological insult 
that leads to adverse remodelling of the myocardium. There is increased turnover with 
more degradation of exisiting collagen and deposition of newly constructed collagen, 
forming new ECM. The mechanism of injury to the myocardium determines the precise 
dynamic response of the ECM.113 Spinale et al113 summarises how specifically the ECM 
turnover increases in verying injury mechanisms. Broadly this varies between an ischaemic, 
pressure or voume overload injury mechanism. Degradation increases, allowing for the 
formation and deposition of new collagen. This process significantly contributes to the 
development and progression in HF. The MMP’s are key regulatiors of the degradation of 
collagen, with many being specific for certain types. In HF ,MMP levels and activation have 
been shown to increase.94,113,135  Progressively increased turnover of collagen leads to the 
development of cardiac fibrosis 113  Cardiac fibrosis development is a signficiant contributor 
to the adverse remodelling of the myocardium during HF. Increased turnover of the ECM 
Dr Christopher J. McAloon 
 
     
  310 
 
with progression to cardiac fibrosis leads to stiff ventricles, decreased relaxation and 
complicnace. 94,113   In turn these lead to the development of diastolic dysufunction, which 
in turn relates to systolic dysfunction.113 The development of cardiac fibrosis respresents a 
poor prognostic feature for HF.94,113  Specific circulating biomarkers reflect the cardiac ECM 
turnover of collagen, reflecting altered deposition (e.g. PINP and PIIINP) and degradation 
(e.g. CTx).113 Increased PINP and PIIINP represent increased degradation of type I and III 
collagen respectively.  More CTx in the circulation represents increased deposition of newly 
formed type I collagen. Cardiac ECM turnover is performed by specific enzymes (e.g. MMPs.-
1,-2 and -9) and these are regulated by TIMPs (e.g. TIMP-1). Alterations of these specific 
circulating biomarkers have been shown to associated with adverse cardiac remodelling of 
HF and have been shown tp habe the ability to predict HF outcomes.124,134,136,317  We 
hypothesised that certain levels of circulating cardiac ECM biomarkers reflect changes in 
collagen turnover in HF patients, therefore potentially have the ability to predict a patient’s 
ability to respond to CRT implantation.  
 
In Chapter 4, a systematic review was undertaken to examine all the cardiac ECM 
biomarkers that had been studied to test their ability to predict CRT response. A total of 6 
studies, which researched a total of 9 biomarkers, met the criteria to be included in the 
systematic review. These included 5 observational studies318 and 1 sub-study119,125,244,294,295 
of the CARE-HF23 RCT. A meta-analysis was originally planned; however all the studies 
demonstrated large heterogeneity. There were 3 functional and 3 echocardiography 
response definitions in use within the included studies. The study designs and patient 
population’s also contrasted with each other making amalgamation of the studies difficult. 
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All the studies were small in terms of participant numbers and none were powered. The 
studies reported differences in the behaviour of these biomarkers and differences in 
expression predicting response (table 4.6). The literature to date demonstrates that no 
consistent pattern of behaviour of the ECM has been demonstrated to predict response.  
The definition used is different between each study; therefore the circulating biomarker 
expression level is being compared to different response definitions. However, even in the 
studies where changes in ventricle volumes and function are made the definition, there are 
different reported patterns of ECM circulating biomarker expression. This means no clear 
pattern of behabviour on HF patients has been determined to date. These studies with 
common respond definitions are often not comparable because os study design and cohort 
characteristics differences. To exert real consistent valve in these observational studies a 
common definition should be applied to a specific population. Logistically, however this 
would pose a real challenge as it would be more difficult to recuit participants and would 
require more centres being involved.  
 
MiRNA’s are short endogenous non-coding RNA which regulate protein expression at the 
post transcriptional level.139 MiRNA’s are recognised as regulators of complex biological 
systems and many are tissue specific.139 They are stable in the circulation and considered to 
have great potential as biomarkers.143 Multiple miRNA have been observed to be 
dysregulated in HF and have potential as biomarkers.158,188,191 Chapter 1 summarises the 
miRNA that have been studied in HF. Variability in study designs, laboratory techniques, HF 
patient’s characteristics and small participant numbers have meant that observations are 
often not replicated consistently.139 Marfella et al197 and Melman et al199 have observed 
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miRNA’s potentials as biomarkers in predicting response in patients undergoing CRT. There 
remains limited evidence to validate their use in clinic prwctive. The current evidence is 
limited by studies only on small cohorts, variation in quanitification technique and 
hetrogenity of study populations. 
 
Predicting non-response in patients undergoing CRT implantation is important to both the 
patient and society. Building a prediction model that improves our prediction rate is 
important to these HF patients to allow them to make better informed decisions. What the 
research to date has shown us is many variables are important on an individual basis, but 
predicting a populations chances of a response is difficult due to the heterogeneity of the 
condition. Building a model involves examining several important variables and examining 
those that have potential. We hypothesised alongside certain clinical variables that ECM 
biomarkers and specific miRNAs that have shown dysregulation in HF may be important 
predictors that have not been fully assessed. This body of research aimed to undertake a 
small observational study to test this hypothesis as a proof of concept study. 
 
In, Chapter 5 all the implant data from out single centre was examined (2009-2013) to 
explore our potential cohort and examine variables that may be important to account for in 
our prediction model when examining the selected circulating biomarkers. Certain variables 
based on the literature outlined in Chapter 1 would be included in the prediction model to 
account for factors that are known to predict response. Examining the characteristics of our 
heterogeneous group of patients we have implanted at UHCW reflects a unique population 
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(Table 5.2), which will vary from other centres. These characteristics were important to 
understand when planning study II (COVERT-HF) to examine circulating biomarkers. The 
retrospective cohort study also allowed us to examine clinical (symptoms only) response 
and to see if any pre-defined variables (Chapter 3) were important within our cohort. The 
only variable that was shown to predict a clinical response was age at implant, reflecting a 
4% chance for every year older at time of implant (Table 5.5). These findings are driven by 
those patients who had their clinical response assessed over 12 weeks following implant. 
Importantly QRS duration and bundle branch morphology were not shown to be predictors 
of response, which is somewhat surprising given the previous reported strength to predict 
response/outcomes. These results are due to the small numbers of patients and the 
response definition being assessed over a wide period of time. There was also a proportion 
of missing data, accounted for some patients being referred from other centres in the Arden 
Cardiac Network and availability of information. Pre-defined clinical variables were also 
analysed to test their ability to predict cardiovascular outcomes (MACE and/or first HF 
hospital admissions). The presence of CKD at baseline (estimated GFR <60 ml/min/1.73m2) 
predicted the composite cardiovascular outcome following CRT implantation (HR 2.10, CI 
(95%) 1.23-3.19, p=0.001) in a multivariate regression model (Table 5.7). The CKD findings 
replicated previously reported poor outcomes for CKD patients following CRT 
implantations.238,300 Both age and CKD status were important in our cohort and would be 
accounted for in the prospective study prediction model. 
 
In Chapter 6, we report the ability of ECM (PINP, CTx, PIIINP, MMP-2 and MMP-9) and miR (-
21,-30d,-122,-133a,-210 and -486) circulating biomarkers to predict a single HFrEF patients 
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ability to have a functional response following CRT implantation (Figure 6.4). Alongside 
these biomarkers six important variables (QRS duration,39 BBB morphology,45 CKD,238 
gender306 and aetiology306) were analysed for their predictive ability. GDF-15112 and NT-pro-
BNP100 biomarkers were also included in the prediction models given their previous 
reported abilities to predict response. These results that none of the biomarkers actually 
predict functional response are supported by the observations reported by Lopez-Andres et 
al.125 
 
Our proof-of-concept prospective observational study recruited a small heterogeneous 
cohort (82.7% male, 72.4 mean age, 57.7% ischaemic aetiology, 51.9% NYHA III, 36.5% AF 
and 75.0% LBBB) over two years (Nov 2013- June 2015). The multivariate logistic regression 
model did not observe that any variables could predict functional response in participants 
undergoing CRT (Figure 6.4). The result indicated that increasing baseline CTx expression 
and LBBB morphology trended towards predicting functional response. The CTx results 
indicate that increased turnover at baseline may reflect the increased ability to respond to 
CRT if there is more dynamic turnover of the ECM. Mechanistically, this suggests those 
patient’s further along in the development of cardiac fibrosis have the greatest potential to 
improve when a CRT is implanted. Therefore, potentially if these changes are seen across 
the entire left ventricle, the diastolic function might improve compliance and decrease 
stiffness allowing for an improvement in symptoms (NYHA) and exercise tolerance (6MWT 
distance). CRT implantation may be able to exert a greater influence on those patients 
whom are still actively remodelling at the molecular level with increased ECM turnover. 
Therefore, patients with increased formation and deposition of collagen may have the 
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greatest potential chance to benefit from CRT implantation. The correlations between 
changes in PINP and PIIINP with 6MWT distance at 6 weeks favours this conclusion. PINP has 
also been observed to have increased expression in functional responders following CRT 
implantation (Figure 6.2). Highlighting the influence CRT implants has on ECM turnover. 
However, contrary to this observation no difference is seen between responders and non-
responders for the other tested circulating biomarkers. 
 
Our results however do not completely support this mechanistic conclusion. The PINP and 
PIIINP baseline results showed no difference between responders and non-responders. 
There would be an expectation that CTx levels would vary between those that reverse 
remodelled (↓ >15% LVEDV at 6 months) on echocardiography following CRT implantation 
as reversal of ECM turnover would lead toventricular reverse remodelling. However, no 
difference between echocardiographic responders and non-responders were observed for 
any of the studies circulating biomarkers.  
 
The study (Chapter 6) did not indicate any variation in the expression of ECM or miRNA 
biomarkers patients with and without MACE events (Table 6.5). No definitive observation 
can be made that ECM expression or miRNA dysregulation predicts functional response 
based upon the COVERT-HF study. Higher expression was noted of ECM biomarkers 
systemically than in the coronary sinus, whereas the specific miRNA selected for study were 
found to have higher expression in the coronary sinus (Figure 6.5). The regulation of cardiac 
ECM turnover has systemic involvement, but the dysregulations of miRNA appears to occur 
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in the heart. There are however suggestions that alterations in ECM turnover on type I 
collagen may be an important observation between responders and non-responders, 
whether this may be useful in future clinical studies requires further and more refined 
studies. 
 
In Chapter 7, consideration was given to body composition and CRT in HFrEF patients in a 
small physiological pilot study (COVERT-HF sub-study). There is a complex interplay between 
body composition, metabolic processes and HF (Chapter 1).218 These have been extensively 
studied and describe the influence of body composition on metabolic dysregulation that 
occurs during HF development and progression.218 Advancing HF favours the development 
of a pro-catabolic metabolic state and this is demonstrated by the changes in the 
neurohormonal, inflammatory and ECM pathways previously discussed. The progression 
towards a catabolic state favours poorer cardiovascular outcomes.218  Body composition has 
been shown to exert influence on the development and progression of HF through these 
metabolic pathways. The presence of adiposity in established HF exerts a protective effect 
on patients.206,218 The understanding of this complex interplay is not fully understood. There 
is limited research about body composition behaviour and its influence on HFrEF patients 
following CRT implantations. Only a Chinese observational study to date has examined the 
impact differing BMI at implantation has on response and cardiovascular outcomes, 
suggesting the presence of adiposity at the time of CRT implantation favours a better 
response/outcome.216   
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Chapter 7 reported the observtaions of the effects the implant of a CRT in a HFrEF patient 
had on body composition and and whether there was any difference between functional 
responders and non-responders. No differences were observed between functional 
responders and non-responders at implant (Table 7.1). Following CRT implantation, body 
composition did not significantly vary for the entire cohort over 6 months (Table 7.2). 
Furthermore no significant difference was observed between responders and non-
responders (Table 7.3 and Figure 7.2). However, there was a trend towards a reduction in 
fat mass immediately following CRT implantation. There was also a strong correlation 
between changes in fat mass and LV geometry, suggesting that a reduction in fat mass was 
related to an increase in LV dilation over the first 6 weeks following CRT implantation 
(Figure 7.3). This observation supports those previously reported in the literature about the 
protective effect of adiposity on HF patients. Due to the size of the study, these 
observations can only be hypothesis generating, but certainly pose an area of further 
research. However, they may also overstate the relationship due to the limited available 
data. The correlations curves are likely to more heavily impacted by outliers, due to the low 
number of data points.  
 
8.2 LIMITATIONS 
This body of work has several key limitations that must me acknowledged when drawing 
conclusions on our observations and utilising them to inform the next steps of research into 
predicting response following CRT implantation. Initially the challenges of research in this 
field should be discussed as our research did not escape them. The greatest challenge is the 
inconsistency in definitions applied throughout research in this field for a response to CRT. 
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Fornwalt et al1 has identified when comparing the commonest definitions there is often very 
poor correlation. Our own critical evaluation in the systematic review (Chapter 4) of the 
research into ECM biomarker potential as predictors of CRT response demonstrated the 
wide variation in definitions used (Table 4.2). This research informed the decision to use a 
composite functional definition rather than also utilising an echocardiographic criterion for 
the prospective study. Making the decision for the best definition for the prospective study 
meant our retrospective study (Chapter 5) was not directly comparable to the prospective 
observational study (Chapter 6). In the wider literature our primary results are only directly 
comparable to those with functional definitions, which ultimately further highlight the 
challenge of not having a universal response definition. 
 
The systematic review (Chapter 4) was a critical review of the literature that informed the 
decision behind the selection of the cardiac ECM biomarkers. The initial aim was to 
undertake a meta-analysis and pool the analyses. Unfortunately, this was not possible given 
the heterogeneity of the research studies included. Firstly, the studies represented a wide 
HFrEF population that varied between the studies. Secondly the study designs differed 
significantly between each other, including the period of time the participants were 
observed for. Thirdly, the definitions of response differed so significantly (Table 4.2) that 
response assessments were not comparable. Finally the studies included were all small and 
not powered. Critical appraisal was undertaken however a complete amalgamation of the 
results and a meaningful meta-analysis was not possible.  
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The retrospective registry (Chapter 5) had several critical limitations which are important to 
address. The number of anonymous patients involved was limited, though comparable to 
similar studies.64,65 There was a small degree of missing data due to incomplete records or 
patients having limited information available as they were referrals from outside UHCW. 
Information was requested and collected from these sites, but despite strenuous efforts it 
was often incomplete. Multiple imputation techniques were used to overcome these 
limitations, but they may account for QRS duration and BBB morphology not being shown to 
be predictors when this is clearly the case if the literature. The study was also under-
powered for the findings that were identified. There was also a possible reporting bias, due 
to the fact the two clinicians assessing clinical response were colleagues, despite stringent 
efforts being made to avoid collusion. 
 
The COVERT-HF study had several limitations that need to be explored. Firstly, during 
participant recruitment the NICE 200751 implantation guidelines were altered in 2014. An 
echocardiographic metric of dyssynchrony was removed from the 200751 guidelines. 
Recruitment occurred under both the 200751 and 201417 guidelines. The inclusion criteria for 
COVERT-HF reflected the NICE implantation criterion. We aimed to produce a cohort as 
close to ‘real world’ as possible, so altered the inclusion criteria to reflect the 2014 
guidelines. However, this alteration may reflect a change in the cohort recruited before and 
after this point. Secondly, there have also been developments in the pharmacological 
therapy for HF recently with the introduction of angiotensin receptor neprilysin inhibitors 
(ARNI) following the ‘Prospective comparison of ARNI and ACEi to Determine Impact on 
Global Mortality and morbidity if Heart Failure trial’ (PARADIGM-HF), which showed a 16% 
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relative risk reduction in all-cause mortality.315 This new therapy may impact outcomes and 
response rates for CRT therapy, which means our results, may not be as current as they do 
not include any patients on ARNIs. Thirdly, the study was single centred, with small 
participant numbers and it was not powered, which means the observations made should 
be questioned and may represent statistical chance. This may also mean that just because 
an observation is not made in the COVERT-HF study it does not mean it does not exist. 
Fourthly, not all patients were able to have a complete echocardiogram performed, due to 
either missing a visit or having poor quality images. This may produce a reporting bias for 
the echocardiographic results. Fifthly, ECM biomarkers altered expression is attributed to 
HF, however the cohort was older and had other health issues, which may affect the 
systemic expression of these biomarkers. Finally, the CS samples could only be taken in the 
latter half of the cohort. There were a reduced number of paired results due to a high 
haemolysis rate of the CS samples. The CS sample results must be scrutinised due the small 
number of results made.  
 
The body composition analysis examined the hypothesis that body composition is effected 
by CRT implantation in HFrEF patients. It then explored whether there was a difference 
between responders and non-responders to the degree it might be a potential predictor. 
Therefore, the value of this sub-study to the prediction model is limited, but it adds value 
for the future work to be considered. The sub-study occurred in a small sub-set of the 
cohort study. The participant numbers were not large enough to stratify patients by a body 
composition metric, an option that should be considered for the next area of study. Air-
displacement plethysmography is a non-invasive option of measuring body composition that 
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was acceptable with an implanted cardiac device. The limitation of this body composition 
measurement method is it is not validated in HF patients and the presence of body water is 
interpreted as fat mass. This means that patients with fluid retention are measured as 
having a higher fat mass. A further limitation of this sub-study was the reporting bias of 
patients having incomplete echocardiograms performed. The most frequent reason for sub-
optimal images was a large body habitus, meaning that participants with larger fat masses 
were more likely to have absent useable echocardiography data. This is likely to represent a 
reporting bias.  
 
8.3 FUTURE WORK 
Our research demonstrates that predicting response involves multiple factors and their 
interactions. Predicting response is likely to take a more individual approach focusing on a 
variety of potential risk predictors. Our body of research reviews the evidence behind well-
established predictors like QRS duration and BBB morphology. However, these observations 
have not changed the significant non-response rate. Tailoring the prediction model is the 
direction the research in this field has been moving.  
 
Our research replicated in our retrospective registry that CKD status is an important variable 
in predicting outcomes following CRT implantation. Together with the review of the 
previous literature, important potential predictors were accounted for in a prediction model 
that focused in the COVERT-HF study on pre-selected ECM and miRNA biomarkers as 
important variables. Informed and critical reviews identified biomarkers that had potential 
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to predict a response. This potential model was applied to every participant undergoing CRT 
implantation. This meant the cohort was very heterogeneous and reflected the broad 
swathe of different patients suffering from HFrEF. Our results did not show a definitive 
predictive value to the ECM and miRNA biomarkers tested, but there was a suggestion Type 
I Collagen turnover maybe important. However, the COVERT-HF study did not demonstrate 
this.  
 
For a future direction of research, a larger scale multi-centre should be considered to test 
whether baseline type I Collagen turnover biomarkers (PINP and CTx) are predictors of 
response to CRT.  To demonstrate a significant difference between baseline concentrations 
in PINP and CTx as predictors of response (non-response rate 42.3%) a sample size of N=430 
HRrEF patients was required. Assuming an 80% power and a significance level of p=0.05.  
However, a more focused strategy should also be considered for predicting response. 
Minimising the heterogeneity of the study population is more likely to reveal important 
predictors. For example focusing on a patients HF aetiology and studying only ischaemic or 
non-ischaemic patients might yield a more consistent pattern of ECM biomarker behaviour. 
The ECM remodelling following a similar cardiac injury would be more likely to behave and 
respond more consistently following CRT implatation.113 A study examining patients who 
meet CRT implantation criteria and who have the same aetiology for there HF would be 
required to minimise heterogeneity, however it would take more time to recruit the same 
number of participants. A multicentre approach would overcome this challenge, but require 
more funding.  
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The body composition sub-study has produced the physiological hypothesis that more 
adiposity favours improved reverse cardiac remodelling following CRT implantation. This 
hypothesis needs to be tested to see if body composition should be considered before 
implanting a CRT. Further observation studies should be undertaken, that are powered to 
observe differences in participants response and outcomes based on their baseline relative 
fat mass or lean mass. If proven to be important, these body composition metrics should 
then be tested as potential predictors of response. CC should also be observed to see the 
differences following CRT implantation on response/outcomes in those where is present or 
absent. Prior to implantation CC should be screened for and participants stratified based on 
its presence and absence. Furthermore, if it transpires to be important, CC should be tested 
as a potential predictor of response.  
 
8.4 CONCLUSIONS 
CRT is a game-changing development in the management of HF patient’s refractory to OMT 
that improves survival and decreases morbidity. Unfortunately, non-response occurs in a 
significant minority, impacting individuals and wider society. Important work has taken 
place examining potential predictors of response, the most important of which is QRS 
duration and BBB morphology, which have now altered the implantation criterion.316 
However, non-response remains one of the greatest challenges in HF management. Specific 
ECM and miRNA biomarkers which have been observed to be important in HF have not 
demonstrated the ability to predict functional response. However, circulating biomarkers of 
type I collagen turnover are observed to have the potential to predict functional response. A 
larger cohort study could potentially test this hypothesis. The key achievement of this body 
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of research is to highlight the heterogeneity that challenges research into testing potential 
CRT predictors, especially ECM and miRNA biomarkers. Adapting research designs to 
compensate for heterogeneity will go some distance to being able to absolutely test a 
biomarkers ability to test potential to predict CRT response. Furthermore, body composition 
maybe important in prediction models and further study is required. In combination with 
other predictors involved in systematic remodelling it may be an important predictor of CRT 
response and outcomes.   
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1.0 Introduction 
CHF is a common, costly and disabling condition affecting almost 1 million people in the UK.2 CRT is 
one of the most effective heart failure therapies to emerge in the last 25 years and is applicable to a 
third of all symptomatic heart failure patients.234 It involves implantation of pacemaker leads to pace 
the right atrium, right ventricle and left ventricle (via the CS) to resynchronise cardiac contraction. 
Several prospective randomised studies have shown that CRT is associated with a significant 
reduction in hospitalization rates for heart failure and improved long-term survival.22,23,28 
Consequently, CRT has gained widespread acceptance as a safe and effective therapeutic strategy.  
Recently indications for suitable patients have been broadened based on more focused evidence of 
patients that may benefit from CRT implantation.17,38,319  The new guidance requires a LVEF≤35%, 
optimal medical therapy, in either sinus rhythm or atrial fibrillation (where satisfactory level of 
biventricular pacing can be achieved). All NYHA symptoms classification can be considered; I 
(QRS>150msec on resting ECG), II/III/IV (QRS>150msec or 120-149msec with LBBB)17,47,56. Patients 
undergoing pacemaker implantation or upgrade should be considered for CRT if LVEF<35% and likely 
to be pacing dependent >40% of the time47. However, despite these indications, a significant 
proportion of patients (approximately 20-30%) remain unresponsive and have recurrent 
hospitalisations for heart failure with no improvement or even deterioration in symptoms with CRT 
pacing.23,27,28,31,41,250,319 As such, better identification of suitable patients would be of great benefit to 
the NHS.  
 
Multiple biomarkers have been associated with different disease processes within CHF and have 
been examined for their clinical value. Van Kimmende et al, outlined the multiple circulating 
biomarkers that have been associated with CHF and alter with development and progression of the 
condition, highlighting their potential clinical value. 94 Table 1 demonstrates the circulating 
biomarkers highlighted by Van Kimmende et al as altering in CHF. Currently only N-terminal pro-
brain natriuretic peptide (NT-pro-BNP), a neurohormone is utilised clinically in diagnosis and 
prognostication of CHF. 2,100,320  
 
ECM is of particular interest in heart failure development and progression, given the dynamic nature 
of its structure and function. 113 Implications for ECM in the major injury mechanisms of the 
myocardium in the development of all types of heart failure have been examined. 113 Critically the 
implication on the signalling of progression has been described and the potential development of 
myocardial fibrosis.113 Changes in structure and function of ECM have been associated with clinical 
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outcomes.94,113,115,132 Surrogate markers are available for the key structural collagens and the 
metabolic processes involved in regulating ECM in the blood stream and these have been highlighted 
as potential biomarkers of the development and progression of heart failure. 94 Table 1 
demonstrated ECM biomarkers, that have previously been studied in HF.94 
 
CRT therapy for patients outlined in national guidelines has been demonstrated to improve LV 
geometry and clinical outcomes for CHF patients.17 Reverse remodelling of the LV occurs in many 
CHF patients following CRT, which is demonstrated by improved LVEF, decreasing LVEDV and 
functional mitral regurgitation.22,23 LV reverse remodelling is associated with changes in ECM 
structure and function. 119,120,126,263,298 ECM remodelling offers a potential marker of prognosis 
following CRT and much work has been done to determine the potential clinical value of circulating 
biomarkers of ECM on predicting CRT response and/or MACE.119,120,126,244,321 These studies have 
tended to be small observational studies or post-hoc RCT trial analyses and do not collectively 
demonstrate a clear pattern. ECM and its surrogate markers have the potential to demonstrate the 
LV’s future ability to reverse remodel and future clinical response to CRT implantation.  
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Table 1: Emerging Biomarkers in Heart Failure. Van Kimmende et al (2012)94 
Inflammation  Myocyte stress 
Extracellular-matrix 
remodelling  
Neurohormones 
CRP Norepinephrine 
BNP, NT-proBNP, 
MR-proANP 
MMPs Norepinephrine 
TNF-  sST2 TIMP1  Renin 
TWEAK (TNF-like 
weak inducer of 
apoptosis) 
Growth 
Differentiation 
Factor 15 
IL-6  Angiotensin II 
IL-1, 6, 10, and 118 
Extracardiac 
involvement 
Collagen propeptides Aldosterone 
LP-PLA2 RDW 
N-terminal collagen 
type I/III peptide 
Arginine 
vasopressin, 
copeptin 
Soluble TNF 
receptors 1 and 2  
Cystatin-C, -trace 
protein 
Myostatin Endothelin-1 
YKL-40 Urocortin 
NGAL, NAG [N-
acetyl--(D)-
glucosaminidase] 
Syndecan-4 Urocortin 
IL-1 receptor 
antagonist  
KIM-1 (kidney 
injury molecule-1) 
Galectin-3 
Chromogranin A 
and B 
Midkine  ß2-microglobulin   MR-proADM 
Leucine-rich 2-
glycoprotein  
Urinary albumin-
to-creatinine ratio   
 
PTX3  Triiodothyronine    
CA-125  
Myocyte injury and 
apoptosis 
Oxidative stress  
S100A8/A9 complex   Troponins I and T Oxidized LDLs  
Osteoprotegerin 
Creatine kinase MB 
fraction 
 
Myosin light-chain 
kinase I 
MPO  
Serine protease PR3   
Heart-type fatty-
acid–binding protein 
Urinary biopyrrins  
Soluble endoglin   
Creatine kinase MB 
fraction 
Urinary and plasma 
isoprostanes  
Adiponectin   
sFAS (soluble 
apoptosis-stimulating 
fragment) 
Urinary 8-hydroxy-
2-deoxyguanosine  
  
 Heat shock protein 60 
Plasma 
malondialdehyde  
Adapted from van Kimmenade et al 94 
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2.0. Objective Systematic Review 
The objective of this systematic review is to consolidate all studies relating to ECM surrogate 
circulating biomarkers (table 1) on their ability to predict response (clinical/echocardiographic) and 
MACE in CHF patients undergoing CRT implantation with the following. The primary objective of this 
systematic review is: 
 
1. What is the value of the ECM biomarkers van Kimmenade et al 94 listed at predicting patient 
response (clinical/echocardiographic) to CRT? 
 
Secondary objectives for this systematic review are:  
 
1. What is the value of the ECM biomarkers van Kimmenade et al 94 listed at predicting patient 
MACE following CRT implantation? 
2. To report the definitions of ‘response’ used within the ECM biomarker and CRT literature. 
3. Does the pattern of ECM biomarker expression following influence response and MACE 
prediction? 
 
3.0 METHODOLOGY 
This systematic review protocol has been produced according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis Protocol [PRISMA-P 2015]288. The review is registered with 
the systematic review website PROSPERO [25864]. The systematic review will be conducted in-line 
with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
guidelines.287 
 
3.1. Eligibility Criteria  
Study selection for inclusion in the systematic review must meet these strict eligibility criteria. 
 
3.1.1. Target Population 
CHF patients that meet specific CRT implantation criteria outlined in the international guidance.17 
47,234  
 
3.1.2. Circulating biomarker 
All ECM circulating biomarkers outlined by van Kimmenade et al 94 (table 1)  will be included in the 
systematic review as an association with CHF has previously been described.94 Biomarkers must be 
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taken peripherally when the patient is clinically stable, up to seven days prior to implantation. 
Principle focus of the articles included in the review will on pre-implant ECM biomarkers. Post CRT 
implantation ECM biomarker analysis will only be included if the pre-implant are examined for their 
predictive value. 
 
3.1.3. Outcomes 
Multiple clinical/echocardiographic response and MACE definitions have been used in literature as a 
metric of CRT success.1 Correlations between different definitions is often poor.1,100 Comparison 
between different studies of a particular biomarker or intervention is often difficult due to the 
different response/MACE definitions used. It is recognised that this is a limiting factor of performing 
a systematic review within this field. Application of a clinical response definition will be undertaken 
as the primary outcome measure of the systematic review for ECM biomarkers listed in table 1. To 
be included in the analysis,  the articles must measure clinical and/or functional and/or quality-of-
life data at baseline and final follow-up (>6months post implant).  Separately the degree of 
echocardiographic change in LV geometry between implant and follow-up (>6months post implant) 
will form a separate response definition to be evaluate in the review.  MACE will be defined as all-
cause mortality and/or first heart failure hospital admission during observation period. Absence of 
secondary outcome data will not exclude an article from being included in the systematic review. 
 
3.1.4. Selection of Articles 
All types of cohort and randomised control trials (including post-hoc analysis) will be included in the 
systematic review. The study must be on adults only (ages >18) and performed principally to 
examine clinical value/outcome measures. Translational research will not be included. Review 
articles will be excluded.  
 
3.2. Database Search Strategies 
Detailed searches will be conducted on PubMed, Ovid SP MEDLINE, Cochrane Library (CENTRAL) and 
TRIP.  The search strategy will be designed and undertaken by one author [CM] and reviewed by 
another independently [DA].  The bespoke search strategy will search for the specific terms ‘cardiac 
resynchronization therapy’/’cardiac pacing’/’extracellular matrix’ in combination, within titles/ 
abstracts or Medical Subject Headings (MeSH).  Moreover the specific circulating biomarkers (‘TIMP’ 
‘MMP’ ‘collagen’ ‘Myostatin’ ‘Syndecan-4’ and ‘Galectin-3’) will be included in the search strategy. 
Specific TIMP, MMP and Collagen circulating biomarkers will not be searched for as these will be 
identified using the broader classification terms. Clinical Trials (www.clinicaltrials.gov) will be 
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searched for ongoing or unpublished work relating to the systematic review.  The largest 
international cardiology conferences (European Society of Cardiology, American Heart Association 
and the American College of Cardiology) will undergo a manual search of abstracts. A paper sift 
search will be performed on all papers taken forward to full review. A date limitation of the last 15 
years (31/12/1999 – 31/12/2015) will be applied to the search strategy to coincide with the advent 
of CRT as a mainstream therapy. No language restrictions will be applied to the search strategy.   
Title/Abstract reviews will be performed independently [CM and DA] and those that meet eligibility 
criteria will be taken forward for full paper review. Consensus must be reached to take abstract 
forward to full paper review, any conflicts will be adjudicated by a third independent reviewer [FO]. 
Duplications of articles will be identified and only one will be taken forward to full paper review. It is 
anticipated that several conference abstracts will be identified as articles separately. Articles in this 
instance will only be taken forward. Each article will undergo full paper review to ensure 
compatibility with the eligibility criteria. Full article reviews will be undertaken using the Criticial 
Appraisal Skills Programme checklist dependent on study design to ensure quality of assessment to 
match the eligibility criteria for the systematic review.289 Consensus must be reached on full paper 
review to take study forward into data extraction, any conflicts will be adjudicated by a third 
independent reviewer [FO]. 
 
3.3. Data Extraction and Management  
Full texts of the articles included in the analysis will be retrieved. A standardised data extraction will 
be piloted on two separate articles and then reviewed for its robustness [CM, DA, FO, PB]. The 
standardised data extraction form will collect data on study design (number of participants, eligibility 
criteria, study design, assessment period), patient population (age, gender, aetiology, ECG, LV 
geometry, quality of life, NYHA, functional assessment), circulating biomarker / predictor (specific 
ECM surrogate circulating biomarkers; units measure, conditions taking samples, laboratory 
assessment, statistical assessment) and outcome (response definition and MACE. Data extraction 
will be performed by two independent reviewers [CM and DA]. A third independent reviewer [FO] 
will resolve any disagreement. All authors of papers taken forward to each review will be contacted 
for further details and available data. In situations where more than one article is published off the 
back of one dataset, no direct comparison will be performed between the articles, but will be 
included if different ECM biomarkers are examined in each article. 
 
3.4. Risk of Bias Assessment 
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The risk of bias for each study will be assessed by two reviewers [CM and DA] independently utilising 
either the Cochrane Collaboration ‘Risk of Bias’ assessment tool or the Risk of Bias Assessment Tool 
for Nonrandomised Studied [RoBANS], whichever is the most appropriate per the particular study 
290,291. Both these standardised risk assessment tools have established criteria to examine selection 
bias, exposure measurement, blinding and completeness of outcome data.   
 
3.5. Data Synthesis and Analysis 
Individual trials data will be presented summarising findings for each ECM biomarker. Datasets will 
be sought from the corresponding authors. Distribution of outcome measures will be summarised. 
Overall cohorts for each ECM biomarker will be compared too. When a different studies use the 
same outcome definitions at similar time-points a comparative analysis will be performed. The broad 
definition of outcomes is recognised as being a limitation of the study. 
   
4.0  Discussion 
CHF as a condition carries a high mortality as it progresses following diagnosis. Changes in LV 
geometry are a hallmark of progression and poor outcomes in CHF. Medical treatments for heart 
failure have significantly improved outcomes. 2 CRT is an effective therapy for treating CHF and 
improves outcomes and reverse remodels the LV. 22,23,38 Despite improvements in CHF with CRT, 30% 
continue not to respond to treatment. 235,322 The focus of research at the moment is examining ways 
to better predict response clinically, with several options demonstrating promise, but not quite 
changing practice. 
 
ECM surrogate circulating biomarkers represent changes in a dynamic structure that remodels with 
continued myocardial injury, altering cardiac structure and function.113 In particular this causes LV 
geometry alterations, associated with poor outcomes. ECM surrogate markers have been associated 
with diagnosis and progression of CHF. 94  
 
Several biomarkers have been examined to determine clinical value in CHF patients undergoing CRT 
implantation, but none have demonstrated a clear benefit clinically. ECM surrogate markers have 
been particularly scrutinised and offer a potential tool to predict outcome following CRT treatment. 
Unfortunately the narrative is not clear with evidence not quite supporting each other. 119,120,126 One 
particular observed issue is that the studies tend to be small observational studies using different 
outcome definitions to determine response. Other studies are post-hoc analysis of big randomised 
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control trials. Study design is subtly different, making direct assessment difficult. Thus analysing ECM 
surrogate makers clinical is truly challenging.  
 
This protocol outlines the proposed mechanism to bring all the evidence together to determine the 
clinical utility of these markers on ECM circulating biomarkers. The application of the protocol will be 
robust and clear.  
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APPENDIX B  
Literature Search for Systematic Review 
PubMed 15th February 2016 
The search algorithm is given below, alongside the first two abstracts identified. The rest of 
the abstracts found in this search are not given in this appendix. If they are needed to be 
reviewed, they are available on the PROPSERO website.  
73 results generate  
Sent on: Mon Feb 15 07:22:57 2016  
Search: ((((((tissue inhibitor of metalloproteinase) OR Matrix metalloproteinase) OR 
collagen) OR Myostatin) OR Syndecan-4) OR Galectin-3) OR ((extracellular matrix[MeSH 
Terms]) OR extracellular matrix[Title/Abstract]) AND ((((((((cardiac resynchronization 
therapy[MeSH Terms]) OR cardiac resynchronization therapy[Title/Abstract])) OR ((cardiac 
pacing, artificial[MeSH Terms]) OR cardiac pacing[Title/Abstract]))))))  
Search restricted 31/12/1999 – 31/12/2016 
PubMed Results 
Items 1 - 91 of 91    (Display the 91 citations in PubMed) 
 
1.  Heart Rhythm. 2016 Jan 8. pii: S1547-5271(15)01671-9. doi: 
10.1016/j.hrthm.2015.12.036. [Epub ahead of print] 
Prognostic value of collagen turnover biomarkers in cardiac resynchronization 
therapy: A subanalysis of the TRUST CRT randomized trial population. 
Sokal A
1
, Lenarczyk R
2
, Kowalski O
2
, Mitrega K
3
, Pluta S
2
, Stabryla-Deska J
2
, Streb W
2
, 
Urbanik Z
2
, Krzeminski TF
4
, Kalarus Z
2
. 
CONCLUSION:  
Low PIIINP levels are associated with favorable echocardiographic response and long-term 
survival in CRT recipients. 
. 
   
  
  
  
  
 
APPENDIX C 
Dr Christopher J. McAloon 
 
     
  399 
 
 
Applied Medical Definitions 
Ischaemic Aetiology 
Aetiology of reduced ejection fraction heart failure will be defined as ischaemic or non-
ischaemic cardiomyopathy.  Ischaemic cardiomyopathy will be defined as either: previous 
myocardial infarction, previous coronary bypass grafting, significant ischemic disease with 
previously treated stenosis of ≥50% of lumen diameter in ≥1 major epicardial coronary 
artery or cardiac magnetic resonance imaging defining ischaemic aetiology. Non-ischaemic 
aetiology are all those HFrEF patients that do not meet the above criteria. 
 
Cardiomyopathy  
Cardiomyopathies are defined by structural and functional abnormalities of the ventricular 
myocardium that are unexplained by flow-limiting coronary artery disease or abnormal 
loading conditions.323 
 
Diabetes Mellitus  
Diabetes will be defined as either patients on therapy [anti-diabetic therapy or insulin], a 
random venous plasma glucose concentration >11.1 mmol/l, a fasting plasma glucose 
concentration > 7.0 mmol/l (whole blood >6.1mmol/l), a two hour plasma glucose 
concentration >11.1 mmol/l two hours after 75g anhydrous glucose in an oral glucose 
tolerance test (OGTT) or HbA1c >48 mmol/mol (6.5%) 324. 
 
 
Chronic Kidney Disease 
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Chronic kidney disease was defined as a GFR of ≤60 mL/min/1.73 m2 (estimated by 
modification of diet in renal disease equation).237,239 Table C1 outlines Stages of Chronic 
Kidney Disease based upon estimated eGFR.239  
 
Table C1 Chronic Kidney Disease Stage. (Adapted239) 
Stage GFR*(ml/min.1.73m2) Description 
1 >90 Normal kidney function 
2 60-89 Mildly reduced kidney function 
3 30-59 Moderately reduced kidney function 
4 15-29 Severely reduced kidney function 
5 <15 or on dialysis Very severe or end-stage kidney failure 
 
 All GFR values are normalised to an average surface area of 1.73m2 
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APPENDIX D 
 
Retrospective Cohort Study I Data Collected. 
 
Pre-Procedure 
Demographics 
1. Age at implant 
2. Gender 
Medical History 
1. Aetiology Cardiomyopathy 
2. Previous Myocardial Infarction 
3. Previous PCI 
4. Presence previous Coronary Artery Bypass Grafting 
5. Angina 
6. Diabetes Mellitus  
7. Chronic Kidney Disease 
8. Atrial Fibrillation 
Medication (Pre-Procedure) 
1. Heart Failure Medication  
Pre-Procedure Electrocardiogram 
1. QRS duration (msec) 
2. BBB 
Pre-Procedure Transthoracic Echocardiogram 
1. LVEF (Modified Simpson’s Biplane Method) 
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Procedure 
1. Elective or Urgent Procedure 
2. Type of CRT device 
3. De novo or Upgrade device 
a. If upgrade what the index device was?  
4. LV Lead circumferential position 
5. LV Lead axial position 
6. RV lead position (anatomical) 
7. RA lead position (anatomical) 
8. Failed Procedure (and reason) 
9. Complications 
Latest Review /Outcomes  
1. MACE  
2. Hospitalisations 
3. All-Cause Mortality  
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APPENDIX E 
 
Ethical Approval 
 
Approval Letter 
 
30 October 2013 
 
Dr Faizel Osman 
University Hospitals Coventry and Warwickshire (UHCW) NHS Trust 
Clifford Bridge Road 
Coventry 
CV2 2DX 
 
Dear Dr Osman, 
Study title: The characterisation of circulating biomarkers before and after 
 cardiac resynchronisation therapy in patients with heart failure 
 and their role in predicting response 
REC reference: 13/WM/0355 
IRAS project ID: 135985 
 
Thank you for your letter of 28 October 2013, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chair. 
We plan to publish your research summary wording for the above study on the NRES 
website, together with your contact details, unless you expressly withhold permission to do 
so. Publication will be no earlier than three months from the date of this favourable opinion 
letter. Should you wish to provide a substitute contact point, require further information, or 
wish to withhold permission to publish, please contact the REC Manager, Helen Wakefield, 
NRESCommittee.WestMidlands-Edgbaston@nhs.net. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as  
Ethical review of research sites 
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NHS sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see "Conditions of the favourable opinion" below). 
Non-NHS sites 
The Committee has not yet been notified of the outcome of any site-specific assessment 
(SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion does 
not therefore apply to any non-NHS site at present. We will write to you again as soon as 
one Research Ethics Committee has notified the outcome of a SSA. In the meantime no 
study procedures should be initiated at non-NHS sites. 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
Sponsors are not required to notify the Committee of approvals from host organisations 
Registration of Clinical Trials 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
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There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process. 
To ensure transparency in research, we strongly recommend that all research is registered 
but for non clinical trials this is not currently mandatory. 
If a sponsor wishes to contest the need for registration they should contact Catherine 
Blewett (catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be 
made. Guidance on where to register is provided within IRAS. 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document Version 
 
Date  
Advertisement     
    
Covering Letter  13 August 2013 
    
GP/Consultant Information Sheets 2.0 02 September 2013 
    
Investigator CV Dr Faizel Osman 13 August 2013 
     
Investigator CV Dr Christopher McAloon    
    
Letter of invitation to participant 4 22 October 2013 
    
Participant Consent Form 5 07 October 2013 
    
Participant Information Sheet 5 07 October 2013 
    
Protocol 4 14 July 2013 
    
Questionnaire 2 03 September 2013 
    
REC application 135985/488787/1/948 13 August 2013 
    
Response to Request for Further 
Information  26 September 2013 
    
Response to Request for Further 
Information  28 October 2013 
     
    
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
After ethical review 
Reporting requirements 
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The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
Feedback 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the website. 
Further information is available at National Research Ethics Service website > After Review 
13/WM/0355   Please quote this number on all correspondence 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
With the Committee’s best wishes for the success of this project. 
Yours sincerely, 
 
 
Mr Paul Hamilton 
Chair 
Email:NRESCommittee.WestMidlands-Edgbaston@nhs.net 
Enclosures: “After ethical review – guidance for researchers” 
Copy to: Dr Christopher McAloon 
Mrs Ceri Jones, University Hospitals Coventry & Warwickshire NHS Trust 
Isabella Petrie  
Dr Christopher J. McAloon 
 
     
  407 
 
Amendments Summary 
Three substantial amendments were sent to the REC committee in April, July 2014 and May 
2015. The first amendment requested local laboratory blood tests at follow-up assessments. 
This routinely occurred in normal clinical practice, but formal adoption in protocol was 
required. The second amendment updated the eligibility criteria to be better aligned with 
the recently published NICE June 2014 CRT implantation guidelines, which had broadened 
the national criteria for patient selection [TA120].17 The July 2014 amendment included a 
sub-set study on body composition assessment and CS sampling, reflecting recent changes 
in the literature. More discussion on these sub-set studies can be found later in this chapter. 
MACE observation extension was requested for 12 months, given the likelihood of a low 
number of outcome events within the study population in six months. The alteration to 
eligibility criteria was essential to reflect the real world cohort we hoped to create. The 
additional changes did not affect study design or have any undue bias upon the cohort 
study. The final amendment allowed for a blinded intermittent biomarker analysis; however 
this was actually never undertaken. 
Four minor amendments were requested in September 2015, October 2015, February 2016 
and March 2016 regarding clarification of definitions in the protocol, statistical analysis, and 
adding metabolic biomarkers and specifically hs-TnT to the analysis respectively. All these 
respective amendments were approved by the REC. None of these amendments altered the 
study design and were performed before outcome allocation and analysis. HS-Troponin was 
requested to strengthen translational assessment of cardiac source of biomarkers; it did not 
form part of the prediction of outcome models. All amendments were granted permission 
by the UHCW Research, Development and Innovation department.  
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APPENDIX F 
Clinical Trials Registration Form 
https://clinicaltrials.gov/ct2/show/NCT02541773?term=COVERT&rank=11 
Novel Circulating biomarkers Behaviour and Clinical 
Value in Heart Failure and CRT (COVERT-HF) 
 
Verified by Dr Christopher McAloon, University Hospitals Coventry and Warwickshire NHS Trust, September 
2015 
 
Sponsor: University Hospitals Coventry and 
Warwickshire NHS Trust 
 
 
Collaborators: Medtronic 
  
Information provided by 
Dr Christopher McAloon, University 
Hospitals Coventry 
(Responsible Party): and Warwickshire NHS Trust 
  
ClinicalTrials.gov Identifier: NCT02541773 
  
 
 Purpose 
The purpose of this study is to understand the behaviour of certain blood markers in 
patients with heart failure who undergo a cardiac device implantation procedure called 
cardiac resynchronization therapy (CRT). CRT is an effective treatment for heart failure, but 
up to 30% of people do not respond and have poor outcomes (1,2). Despite extensive 
investigation, identifying these patients continues to be a challenge. The study intends to 
describe the changes in these blood markers before and after CRT and to examine any 
potential clinical value. 
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APPENDIX G 
Patient Information Sheet 
 
 
The Role of Circulating biomarkers in Heart Failure patients undergoing CRT 
(The characterisation of circulating biomarkers before and after cardiac resynchronisation 
therapy in patients with heart failure and their role in predicting response) 
 
Summary Page 
(For more detailed information, please see the following pages) 
You are invited to take part in a clinical research study that is conducted at the University 
Hospital, Coventry and Warwickshire (UHCW). The study is organised by the University of 
Warwick (Warwick Medical School) and is funded by research grants from the UHCW 
Research and Development and the company Medtronic Ltd. It is important that you 
understand why this research is being carried out and what it will involve for you. A member 
of the study research team will go through the Information Sheet with you and answer any 
questions that you have. Please take the time to read the following information carefully, 
and discuss it with your GP and others if you wish. Ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether or not you wish to take 
part. Your participation in this study is entirely voluntary. Please start by reading the study 
summary pages. If you think that you might be interested in taking part in this study, then 
please go on to read the remainder of this Information Sheet.  
Part 1 of this Information Sheet explains the purpose of this research study and describes 
what will happen to you if you take part. Part 2 gives you further detailed information about 
the conduct of the study. 
 
If you decide to take part, you would be free to withdraw from the study at any time 
without giving a reason. If you decide not to take part, your treatment and Device implant 
will not be affected in any way by your decision. 
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Summary Page 
(For more detailed information, please see the following pages) 
The decision has been made by your cardiology team that you will benefit from a special 
heart failure pacemaker. This is called a biventricular pacemaker or ‘cardiac 
resynchronisation therapy’ (CRT). This CRT is used in patients whom have heart failure that 
meet certain criteria outlined by the health organisation ‘National Institute of Clinical 
Evidence’ or NICE. Current evidence suggests that some patients with heart failure will 
benefit from CRT. The decision has been made that you will benefit from this procedure.  
Despite strong evidence that people should get better after the procedure, about 30% of 
people do not improve. The reasons for this are not clear. 
 
Our study plans to see if we can predict those people who will not respond. Recently, new 
blood markers (circulating biomarkers) have been shown to be different in certain heart 
conditions, including heart failure. We believe these blood markers may differ in patients 
that respond and those that do not to CRT. There is currently very little evidence in this 
particular area of heart failure.  
 
We would like to follow you up before and after the insertion of your CRT. There will be an 
initial assessment using a short questionnaire about your symptoms and medical history. A 
heart scan (echocardiogram) will be performed (you will already have had one of these 
performed). We will perform a walking test which will involve you walking for a few minutes 
and measuring the distance you can walk. A heart trace (ECG) will be performed as you 
would normally have at a routine hospital visit. A simple assessment of body fat content 
(body composition) will be performed using a machine you sit in for two minutes.  Finally, 
we would like to take several blood samples to look at routine blood tests and circulating 
biomarkers.  
 
After the CRT is inserted we would like to perform two other check-ups at roughly 2 and 6 
months after the CRT is implanted. These check-ups would involve exactly the same 
assessments as your initial assessment. These will be planned to occur at the same time as 
your routine assessments at UHCW. We would like to take some information about the CRT 
at the time of implantation and collect some blood when the device is implanted. Finally we 
would like to review your clinical records over the year after the implant to see what 
happens to you.   
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Part 1 
 
Part 1 of this Information Sheet explains the purpose of this study and describes what will 
happen to you if you take part.  
 
Part 2 gives you further detailed information about the conduct of the study. 
 
 
What is the purpose of the study?  
The purpose of the study is to examine your response to the CRT  you will have implanted 
by the cardiology team. By examining your response through our assessments and scans we 
want to assess if this can be predicted by new blood markers (circulating biomarkers).  
 
 
Why have I been chosen?  
You have been chosen because the doctors feel that your heart failure may be improved 
with the CRT implantation. All patients having one put in at UHCW may be asked to join the 
study.   
 
Do I have to take part?  
It is entirely up to you whether or not you take part in this research study. If you decide not 
to take part, you do not have to give a reason. A decision not to take part in this study will 
not affect in anyway the standard of care that you receive either at our hospital or from 
your GP. You will be asked to sign the attached consent form only when you are satisfied 
that you have been given enough information both verbally and in writing about the study 
and have decided that you want to participate. You will be given a copy of this patient 
information sheet and the signed consent form. You should not participate in any other 
research studies where you are given an experimental treatment or procedure, for the 
period of this study.   
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Can I change my mind about taking part? 
You are free to withdraw from the study at any time, including after having signed the 
consent form. This will not impact your normal follow-up after having had a pacemaker 
implanted.  
 
What will happen to me if I take part?  
If you decide to take part in this study, you will have an initial assessment before the 
pacemaker is implanted and then follow-up for six months after the device is implanted. 
There will be two further visits to hospital for assessments and scans to try and coincide 
with your normal follow ups. The follow-up assessments take place at approximately two 
and six months. Finally we would like to record anything that happens to you in the year 
after the CRT is implanted by looking at your medical records and providing you with a 
follow-up phone call a year after your implant.  
 
Study Schedule 
 
Recruitment: You receive your ‘patient information sheet’ and will be asked to sign a 
consent form to participate in the study after you have read the information and had time 
to think it through. You will only be asked to sign the consent form when you are happy all 
your questions have been answered. 
 
First Assessment (morning of implant): Clinical assessment, quality of life questionnaire, 
echocardiogram, ECG, simple walking test, body composition assessment, and blood 
samples. 
 
Pacemaker device Implantation:  Information about the pacemaker and procedure are 
recorded. Blood samples during the procedure will be taken (explained later). 
 
Two and six months follow-up after implant (days of pacemaker check): Clinical 
assessment, quality of life questionnaire, echocardiogram, simple walking test, body 
composition assessment, and taking blood samples 
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What do the assessments involve? 
 
Clinical Assessment: Questionnaire about symptoms and medical history 
 
Quality of Life Questionnaire: Standardised questionnaire to assess quality of life 
 
Echocardiogram: An ultrasound scan of the heart (you should have had this done before) 
 
ECG: A heart trace (you would normally have this done on routine hospital visits) 
 
Walking Test:  A walking test to see how far you can walk on the flat in six minutes 
 
Body Composition Assessment:  A machine that measures for body composition (muscle 
and fat content) by sitting in a chamber for two minutes.  
 
Blood Samples:  Several blood samples will be taken with one blood test and this will be 
repeated at all three assessment periods. Some of these blood samples will be sent to our 
local laboratory for routine blood tests on kidney function, full blood count, long term 
glucose control (HBA1c) and Brain Naturetic Peptide (Blood test used to look for heart 
failure). The remaining blood samples will be stored to test for these circulating biomarkers.  
 
Procedure Blood Samples: During a routine CRT procedure a tube is placed into a vein in the 
heart to help insert one of your leads into the heart. This is all routine as part of the 
procedure. We would like to take some blood from that vein via the tube to look at 
circulating biomarkers directly coming from the heart.  
 
What do I have to do? 
During the study you will need to follow the instructions of your study doctor. It is very 
important that you attend all scheduled visits, so please let your study doctor know if this is 
not possible.  
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What does body composition (BodPod) assessment involve? 
The BodPod is a very accurate method of measuring your body composition. It does this by 
calculating your weight and volume (measured by air displacement) to determine body 
density. Your body fat percentage is determined from density and other measurements. 
 
You will first be asked to change into close fitting underwear. There is a screen and a couch 
provided to change in private. Once you are changed you will be asked to stand on a set of 
weighing scales for a few seconds.  We will then get you to sit in the BodPod (a chamber to 
measure air displacement), where we will ask you to sit still for two minutes while the 
measurements are done. 
 
 Is Bod Pod safe? 
Yes Bod Pod is very safe. An experienced operator will be present throughout the 
measurements. There is an emergency button if you want the door to open at any time.  
 
What are the possible inconveniences and risks of taking part?  
There is little risk with the walk test because you are briefly exerting yourself.  This test is 
performed routinely in heart and lung patients to assess exercise capacity.  You can stop at 
any point and a cardiology doctor will be present throughout the test. 
 
It is possible that some discomfort or bruising may occur when blood samples are taken.  
However, all care will be taken to minimise this. 
 
Taking blood during the procedure carries no risk at all to you during the procedure. 
 
What are the possible benefits?  
To be a part of the assessment of a new blood test to see if they will help identify those 
patients that will definitely benefit from CRT insertion.  It may also help other patients avoid 
an unnecessary procedure (despite it having a low complication rate).  
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What happens when the research study stops?  
Once you have completed the follow-up for six months no further research appointments 
will be made. We will continue for the next six months (months 6-12 after CRT implantation) 
to record anything that happens to you. We will do this by reviewing your medical records 
and we may phone you at 12 months. You will continue with routine follow-up for the CRT 
after the study finishes.  
 
What happens if you withdraw from the study before the end of the follow-up period? 
You would be free to withdraw from the study at any time without giving a reason and a 
decision to withdraw from this study will not affect in any way the standard of care that you 
receive either at our hospital or at your GP. If you decide to no longer take part in the study, 
we will ask you if we can keep the information (including blood) you have already provided 
us. However, if you want all information (including blood) removed from storage we will 
delete it all at your request. 
 
What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any possible 
harm you might have suffer will be addressed. The detailed information on this is given in 
Part 2 of this Information Sheet. 
 
Will my taking part in the study be kept confidential?  
Yes. All information about your participation in this study will be kept strictly confidential. 
The details are included in Part 2 of this Information Sheet. 
 
 
Contact Details:  
If you have any questions regarding your rights as a study participant or about the way this 
study is conducted please contact your study doctor or nurse. They will be happy to answer 
them.  
 
Name:   Dr Christopher McAloon/ Dr Faizel Osman  
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Address:  University Hospitals Coventry and Warwickshire (UHCW) NHS Trust,  
Clifford Bridge Road, Coventry, CV2 2DX  
 
Tel.:   02476 96 5813 
 
 
This completes Part 1 of the Information Sheet. If the information in Part 1 has interested 
you and you are considering participation, please continue to read the additional 
information in Part 2 before making any decision. 
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Part 2  
 
What if new information becomes available?  
Sometimes during the course of a clinical study, new information may become available 
about blood markers and so the study procedures may be changed or a new analysis may be 
planned. If any of this happens your study doctor will inform you about it, answer any 
questions you may have and discuss whether or not you want to continue in the study. If 
you decide to withdraw from the study, your CRT follow-up will continue as normal. If you 
decide to continue in the study, you will be asked to sign an updated consent form 
containing the new information.  
 
At any point during the study you can ask your study doctor for the results of the tests that 
have under taken.  
 
What will happen if I don't want to carry on with the study?  
You are free to withdraw your consent to participate in this study at any time and without 
giving a reason. This will not affect in any way the standard of care you receive. No further 
assessments in the study will be arranged but follow-up for your pacemaker will continue as 
normal. We will ask you if the information and samples you have already provided can still 
be used in the study. You are entitled to request the destruction of your laboratory samples 
and that no further laboratory samples are taken.  
 
What if there is a problem?  
Complaints:  
If you have a concern about any aspect of this study, you should ask to speak to your study 
doctor or nurse who will do their best to answer your questions (see Part 1 above for 
contact details). If you remain unhappy, you can contact the UHCW Patient Advice Liaison 
Service or ‘PALS’ 
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Patient Advice Liaison Service 
University Hospitals Coventry and Warwickshire NHS Trust 
Clifford Bridge Road 
Coventry 
CV2 2DX 
Telephone:  0800 028 4203 
 
Will my taking part in the study be kept confidential?  
All information about you will be kept and handled in a strictly confidential manner, in 
accordance with applicable laws and/or regulations. All study participants will be given 
coded study numbers, and no names will be used for the storage of information and 
samples. Any information that leaves the hospital will not have any identifiable personal 
data attached to it.  All information collected during the course of the study will be 
accessible only to the researchers participating in the study and will be kept on 
hospital/university computers that can only be accessed by the study researchers using a 
password. By signing the study consent form you consent to the collection and use of your 
personal data for the study. This may include sensitive personal data about your age, ethnic 
origin and health. You may withdraw your consent at any time. If you consent to take part in 
this study, your medical records will be accessed by members of the study team for the 
purpose of checking study procedures and data. Your medical records may also be looked at 
by representatives from national and international regulatory authorities to check that the 
study is being or has been carried out properly. However, your name and identity will not be 
recorded or disclosed outside the study clinic.  
 
Your study doctor is responsible for the code list by which you can be identified. The code 
list may be reviewed by representatives from regulatory authorities, but it will not be 
disclosed outside the study clinic. Apart from this, the information about you will be given 
the usual confidentiality that all National Health Service patients can expect.  
 
What will the results of the study be used for? 
The results of the study may be published in medical literature, but you will not be 
identified and the confidentiality of all study participants will be respected. You have the 
right to request information about your study data and to be provided with a copy of them. 
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You also have the right to request that any inaccuracies in such data be corrected. If you 
wish to make a request, then please contact Dr. Osman at UHCW. If there is important new 
information about the study we will inform you. 
 
The study data will also form the basis of the lead investigators research degree (PhD).  The 
results will be used in the lead investigator’s thesis (research project).  All information used 
will be anonymous and kept confidential. 
 
Involvement of the General Practitioner/Family Doctor (GP)  
Your study doctor/nurse is obliged to inform your GP and other specialist doctors who are 
involved in your healthcare about your participation in the study. You will be asked to give 
your consent for that when you sign the attached consent form. 
 
What will happen to any samples I give?  
Some of the blood samples will be tested by our local laboratory for routine tests that the 
hospital does daily. The likelihood is that you will have had these blood tests performed 
previously. These samples will be sent to the laboratory and be tested within 24 hours. The 
routine blood tests have to be performed at a set time so the results can be compared to 
the other information that have been recorded for the research at that time. 
  
The other blood samples will be stored at the University Hospitals of Coventry and 
Warwickshire and at the University of Warwick and analysed for the research purposes of 
this study.  We hope that there will be some samples left over and we hope to store these 
for future research relating to heart failure.  However, you may say that you only want your 
samples used for this study and no others, therefore any samples not used will be destroyed 
(you are expressly asked about this in the consent form). 
 
Some of the samples will be sent to Kings College London for a specific test that we want to 
perform as part of the study.  Unfortunately, we are unable to perform this test at UHCW or 
the University of Warwick.  These samples will be transferred securely to Kings College 
London.  Each sample will have a unique identifying number and no personal details 
attached to them. 
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All samples will be coded to make sure that your identity remains confidential.  The results 
of these research investigations are unlikely to have any implications for you personally. 
 
If you withdraw from the study at any time, you are entitled to request the destruction of 
your laboratory samples and that no further laboratory samples are taken.  
 
Will I get the results of my routine blood tests? 
The routine blood tests will be sent to the principle investigation and recorded in the 
research notes. The results will be given to you when they are available. 
 
Will I get the results of my echocardiogram? 
The images taken at the time of the assessment need to be assessed by the investigator and 
this can take a short time. The results will not be immediately available, but if requested 
they will be available. A formal report will go on to your electronic clinical record which is 
available to any doctor or nurse. 
 
What happens if there is an abnormal result? 
Firstly the results will be given to you by a clinician (likely the lead investigator). If required 
these results will be sent to the Cardiology consultant looking after your care. Most likely 
any abnormal results will not be serious and can be fed back to your general practitioner to 
be actioned. In the unlikely event that a serious problem is identified a management plan 
will be implemented at the time to remedy the problem, which may involve the hospital 
team. 
 
Will any genetic tests be done?  
No genetic tests will be performed within this study. 
 
What will happen to the results of the research study?  
Once the study is complete the results will be published and a final report will be written. 
Information relating to the study may be communicated in scientific meetings. You will not 
be identified in any reports or publications. 
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Who is organising and funding the research?  
You are invited to take part in a clinical research study that is conducted at the University 
Hospitals of Coventry and Warwickshire (UHCW). The study is organised by the UHCW and 
University of Warwick (Warwick Medical School) and is funded by UHCW research, 
development and innovation department and the device company Medtronic Ltd. The 
doctors and nurses responsible for your treatment will not receive any personal payments.  
 
Will I receive any expenses for taking part in this study? 
Unfortunately there will be no money available for expenses (travel costs etc).  To limit this 
impact we are attempting to perform all assessments at your routine hospital 
appointments.  For instance we will do your initial assessment on the morning of your 
implant.  On occasions, it might not be possible to do your assessment on the day of your 
routine appointment and you will be invited to attend at another occasion (at your 
convenience). 
 
Who has reviewed this study?  
Before any research is carried out, it has to be thoroughly checked by an ethics committee. 
The committee makes sure that the research is appropriate to do in accordance to Good 
Clinical Practice (GCP) principles, regulations and guidelines. This study has been reviewed 
and approved by the local Research Ethics Committee which is entirely independent of any 
hospital trust. 
 
If you wish to take part in the study you will be asked to sign the consent form overleaf. A 
copy of your signed consent form and this patient information sheet will be given to you 
to keep.  
 
Thank you for taking the time to read this information sheet. 
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APPENDIX H 
 
Concent Form 
Patient ID Number:  ____________________ 
Trial:  The Role of Circulating biomarkers in Heart Failure Patients Undergoing CRT 
Chief investigator:  Dr Faizel Osman 
Please Initial box 
1- I confirm that I have read and understand the information sheet dated 
14th July 2014 for the above study. I have been given sufficient time 
to consider the information and to seek other advice.  I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
2- I understand that I am being invited to take part in a research study.  
I am not taking part in any other clinical trial at this time.  I 
understand the risks and benefits and I freely give my informed 
consent to participate in the research study described in the 
information sheet, under the conditions stated in it. 
 
3- I understand that my participation is voluntary and that I am free to 
withdraw at anytime, without giving any reason, without my medical 
care or legal rights being affected. 
 
4- I understand that relevant sections of any of my medical notes and 
data collected during the study may be looked at by the study 
researchers where it is relevant to my taking part in this study.   
 
5- I give consent that my GP and specialist doctors involved in my 
healthcare may be contacted and access given to my medical notes 
held by my GP and at other hospitals. 
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6- I am aware that I will receive a signed copy of this Patient Information 
Sheet and Informed Consent Form, which is mine to keep. 
 
 
7- I agree to donate blood samples for this study.  I understand that 
samples will be stored at UHCW and the University of Warwick and 
analysed for the research purposes of this study and for future 
research, with relevant ethical approval, relating to heart failure.  I 
understand that the results of these research investigations are 
unlikely to have any implication for me personally. 
 
8- I agree to my samples that are not being used in this study to be kept 
by Warwick Medical School and Kings College London for future 
analysis, in projects related to heart failure.  (This is optional and 
samples will be destroyed if you do not want them kept in storage). 
 
Please tick the box to tell us your decision 
 
 
Yes     No  
  
 
9- I agree to take part in the above study. 
 
 
  
Name of person giving consent  Date   Signature 
 
 
…………………………..   …………..  ……………………… 
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APPENDIX I  
Research Protocol 
The Characterisation of Circulating 
biomarkers before and after Cardiac 
Resynchronisation Therapy in patients 
with Chronic Heart Failure and their 
Role in Predicting Response 
 
 
Version 11 and  8th March 2016  
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STUDY SUMMARY 
TITLE  
The Characterisation of Circulating biomarkers before and after Cardiac Resynchronisation 
Therapy in patients with CHF and their role in predicting response. 
DESIGN  
A prospective, non-randomised, self-control trial examining novel circulating biomarkers in 
CHF patients undergoing CRT implantation.  
AIMS 
To evaluate whether novel vascular markers [ECM and miRNA] maybe predictive of CRT 
response and major adverse cardiovascular outcomes. Furthermore to characterise the 
behaviour of these novel circulating biomarkers and body composition in CHF patients 
before and after CRT implantation and examine their potential clinical value.  
OUTCOME MEASURES  
Primary outcome measure is clinical response to CRT implantation. The secondary 
outcomes are major adverse cardiovascular events (mortality and heart failure 
hospitalisation).  
POPULATION  
Local population of Coventry and Warwickshire with chronic heart failure selected to undergo 
CRT implantation. 
ELIGIBILITY  
All patients being implanted for CRT who meet NICE criteria(specific criteria below). 
DURATION  
Two and a half years. 
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1. INTRODUCTION 
1.1 BACKGROUND 
CHF is a common, costly and disabling condition affecting almost 1 million people in the 
UK2. CRT is one of the most effective heart failure therapies to emerge in the last 25 years 
and is applicable to a third of all symptomatic heart failure patients234. It involves implantation 
of pacemaker leads to pace the right atrium, right ventricle and left ventricle (via the coronary 
sinus) to resynchronise cardiac contraction. Several prospective randomised studies have 
shown that CRT is associated with a significant reduction in hospitalization rates for heart 
failure and improved long-term survival 22,23,28.Consequently, CRT has gained widespread 
acceptance as a safe and efficacious therapeutic strategy.  
 
Recently indications for suitable patients have been broadened 17 based on more focused 
evidence of patients that may benefit from CRT implantation 38,319. The new guidance 
requires a left ventricular ejection fraction ≤35%, optimal medical therapy, in either sinus 
rhythm or atrial fibrillation (where satisfactory level of biventricular pacing can be achieved). 
All  NYHA symptoms classification can be considered; I (QRS>150msec on resting ECG), 
II/III/IV (QRS>150msec or 120-149msec with LBBB)17,47,56. Patients undergoing pacemaker 
implantation or upgrade should be considered for CRT if LVEF <35% and likely to be pacing 
dependent >40% of the time47. However, despite these indications, a significant proportion of 
patients (approximately 20-30%) remain unresponsive and have recurrent hospitalisations 
for heart failure with no improvement or even deterioration in symptoms with CRT 
pacing23,27,28,31,41,250,319. As such, better identification of suitable patients would be of great 
benefit to the NHS. 
 
Novel circulating biomarkers of CHF (miRNA, ECM remodelling markers and GDF 15) have 
demonstrated that their expression is altered on implantation of CRT and alters significantly 
between responders and non-responders112,119,120,126,197. MiRNA are small non-coding RNAs 
that modify gene expression at the post-transcriptional level and have emerged as key 
regulators of cardiac growth, vascular development, and angiogenesis191,276. Altered levels 
have been reported in patients with heart failure, coronary artery disease, and 
diabetes155,188,197. Recently miRNA has been profiled in CHF patients undergoing CRT 
implantation and demonstrated that there is alteration in expression between responders 
and non-responders in the peripheral blood samples197. Only a small number of miRNA were 
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examined and potentially these markers offer very stable and durable biomarkers of CRT 
response 164,197. 
 
Extracellular matrix remodelling is implicated in myocardial fibrosis, which directly correlated 
with left ventricular adverse remodelling and ultimately adverse outcomes 119. Controversy 
on the response of specific ECM markers exists and exactly how they alter in responders 
119,126.  Clarification is required to delineate their role and whether they are potential 
predictors of response and adverse outcomes.  
 
GDF 15 is a marker of myocardial stress demonstrated to associated with heart failure and 
can be used for risk stratification325. Recently higher levels of GDF15 prior to CRT have been 
shown to predict non-response and higher occurrence of adverse outcomes 112. The levels 
of GDF 15 correlate with the behaviour of brain naturetic peptide (BNP) and together they 
are synergistic for predicting response and outcome 112.  
 
Profiling novel circulating biomarkers in CHF demonstrated the alterations that occur in the 
body as a result of adverse remodelling of the ventricles. The common pathway for the 
deterioration in CHF from a given aetiology is the activation of the neurohormonal pathway, 
inflammation, extracellular matrix remodelling and ultimately cardiac fibrosis. Biomarkers 
allow this process and the particular stage to be identified. Endothelial dysfunction and body 
composition alterations are hallmarks of this adverse remodelling systemically. Cardiac 
cachexia (defined as >5% non-oedematous weight reduction over six months) is directly 
linked to adverse outcome and inversely linked to BNP 206,214. This allows a systemic 
measure of the deconditioning that the body goes through with adverse remodelling 208. 
Certain biomarkers may have a role in this that has not yet been linked. CRT moreover 
offers the opportunity to examine what happens in reverse remodelling and whether there is 
a link to potential novel circulating biomarkers. 
 
A robust examination of the selected biomarker profiles requires a precise cardiac measure 
of their expression. Blood samples from the coronary sinus allow a direct measure of 
biomarker release from the heart to be measured 263,326. The profiling of biomarkers [miRNA, 
GDF 15, and ECM] directly from the heart and comparing them to systemic blood allows 
differences to be identified and explored.  
 
Characterisation and profiling of these novel biomarkers in CHF, before and after 
implantation, is important and could help clarify their role in identifying those who may 
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benefit from such therapy. Understanding biomarker behaviour in the heart and in the 
periphery will allow the robustness of these markers to be challenged. Charting these 
markers with important correlation to echocardiographic and body composition markers will 
challenge the real valve of these markers and their behaviour. This would enable effective 
use of limited health-care resources, especially in the current financial climate, to target 
those most likely to benefit and have an enormous clinical impact. This project will generate 
novel pilot data for a competitive research grant application at the end of the study. 
 
The study will evaluate circulating biomarkers in heart failure patients before and after CRT, 
in collaboration with Dr Harpal Randeva (University of Warwick) and Professor Manuel Mayr 
(Kings College London).  
 
1.2 RATIONALE FOR CURRENT STUDY 
The study rationale is to determine the clinical and predictive value of novel circulating 
biomarkers (ECM, miRNA) in determining CRT response (clinical and echocardiographic) 
and major adverse cardiovascular outcomes. The further rationale is to characterise 
behaviour of specific novel circulating biomarkers on implantation of CRT devices.  
 
1.3HYPOTHESIS 
 
‘The profiling and characterisation of novel circulating biomarkers (miRNA, ECM markers, 
GDF15) in CHF patients undergoing CRT implantation will provide potential indicators of 
patient response and major adverse cardiovascular outcomes’ 
 
2. STUDY OBJECTIVES 
 
2.1 PRIMARY OBJECTIVE 
To examine if novel circulating biomarkers [GDF-15, ECM remodelling markers, miRNA] 
may predict response and major adverse cardiovascular outcome’s in CHF patients 
undergoing CRT implantation  
 
2.2 SECONDARY OBJECTIVE 
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1. To characterise novel biomarkers in CHF patients undergoing CRT. 
2. To characterise miRNA expression in patients with severe left ventricular systolic 
dysfunction. 
3. To correlate CRT response and body composition alterations 
a) To correlate novel circulating biomarker behaviour and body composition 
changes in CRT responders and non-responders 
4. To compare novel circulating biomarker expression systemically (peripheral blood) 
and from the heart (coronary sinus). Does the alteration in expression delineate the 
role of these novel biomarkers in adverse remodelling of the heart?  
 
3.1 STUDY DESIGN  
 
3.1 PARTICIPANTS SELECTION 
A prospective, non-randomised, self-control study of unselected heart failure patients 
undergoing CRT implantation, all recruited within two years (~82 CRT implanted 2012 at 
UHCW). All participants having CRT implantation at UHCW will be screened using the 
eligibility criteria (section 4).  
 
Participants will have three assessments within six months (baseline, 6 weeks and 6 
months). All visits coincide with routine clinical visits for CRT implantation and interrogation. 
Assessments at all three time points will  include clinical data (including NYHA functional 
class), quality of life measurements (Minnesota Living with Heart Failure questionnaire), 
echocardiography data (left ventricular volumetric assessment, ejection fraction, 
dyssynchrony measurements), electrocardiograph, functional capacity (6 minute walk test) 
and body composition assessment (air displacement). Peripheral blood samples will be 
taken to examine novel circulating biomarkers and to examine renal function, full blood 
count, diabetic control (HBA1c – only diabetics) and heart failure control (Brain Naturetic 
Peptide). 
Aetiology of heart failure will be defined as ischaemic or non-ischaemic cardiomyopathy.  
Ischaemic cardiomyopathy will be defined with either previous myocardial infarction, 
previous coronary bypass grafting, significant ischemic disease with previously treated 
stenoses of ≥50% of lumen diameter in ≥1 major epicardial coronary artery and cardiac MRI 
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defining ischaemic aetiology. Diabetes will be defined as either patients on therapy [anti-
diabetic therapy or insulin], a random venous plasma glucose concentration > 11.1 mmol/l, a 
fasting plasma glucose concentration > 7.0 mmol/l (whole blood > 6.1mmol/l), a two hour 
plasma glucose concentration > 11.1 mmol/l two hours after 75g anhydrous glucose in an 
oral glucose tolerance test (OGTT) or HbA1c of 48 mmol/mol (6.5%) is recommended as the 
cut point for diagnosing diabetes 324. 
 
3.2 BLOOD SAMPLING AND LABORATORY ANALYSIS 
Participants are asked to starve for two hours and rest for one hour before blood sampling. 
Coronary sinus blood sampling occurs at the time of coronary sinus cannulation before 
contrast is injected. Blood samples (serum/plasma) are taken in citrate and EDTA  
tubes. The samples stand at room temperature for a minimum of 30 minutes and undergo 
centrifugation within an hour. Centrifugation (3500rpm for 10 minutes) occurs at room 
temperature. Samples are then stored in -80 freezer.  
 
Samples will undergo final analysis at the University of Warwick (Dr Harpel Randeva 
laboratory) and Kings College London (Professor Manual Myer). Novel circulating 
biomarkers of heart failure that exist as proteins in the serum will analysed using ELISA 
techniques previously outlined in publications 119,120,126,318. The specific novel circulating 
biomarkers represent different aspects of adverse ventricular remodelling; myocardial stress 
(GDF-15) and ECM remodelling (MMP-2,-9, PINP, PIIINP, ICTP). These markers will 
undergo level quantification using ELISA techniques that have previously described in the 
literature 131,265.  MiRNA profiling will be undertaken in coronary sinus and peripheral 
samples and will be compared to those taken after CRT implantation. Responders will be 
compared to non-responders to determine variation in profile between these two distinct 
groups. Profiling will be performed by extraction of RNA amplifying it and quantifying by 
polymerase chain reaction as outlined in previous publications 147,276. High-sensitive-
Troponin is a specific biomarker produced in the heart and it will be utilised to examine the 
production source (cardiac vs peripheral) of the respective biomarkers outlined above.   
 
Participants that have undergone body composition assessment will have blood samples 
assessed for metabolic and insulin related markers to explore the relationship between heart 
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failure and the body’s metabolism. Quantification of these markers will further strengthen the 
secondary aim of understanding the physiological changes to the body in heart failure 
patients and how these alter with CRT placement.     
 
3.3 DEVICE IMPLANTATION 
CRT devices (pacemaker of defibrillator) are implanted by two independent operators at our 
single centre in a standard fashion. CRT is implanted traditionally in the left deltropectroal 
groove. Venous access is via the cephalic>axillary>subclavian veins (all operators can 
cannulate either vein based on individual patient). Right ventricular lead for the majority of 
patients will be implanted at the right ventricular apex. Right atrial leads will be planned to be 
implanted in the right atrial appendage. Patients in permanent Atrial Fibrillation will not have 
a right atrial lead implanted. Coronary sinus will be cannulated and angiography performed 
to roadmap anatomy for lead deployment site. The most lateral position will be favoured in a 
basal/ mid-cavity position. At the point of coronary sinus cannulation blood samples 
(plasma/serum will be taken). Post procedure patients undergo targeted echocardiography 
and a chest x-ray film. Post procedure on the day of implant patients will undergo CRT 
interrogation and optimisation of programming.  
 
3.4 ECHOCARDIOGRAPHY 
A full standard echocardiographic examination will be performed at all three assessments 
including grey-scale images optimised for 2D and colour tissue doppler imaging (TDI) from 
the 3 standard apical views (2, 3, 4 chamber). All echocardiograms will be performed on the 
same machine by the same operator for each participant in line with current 
echocardiographic guidelines 327. The left ventricular end systolic and diastolic volume will be 
measured and LVEF will be calculated using the Simpson’s biplane method. 
 
3.5 INTER- AND INTRA-OBSERVER VARIABILITY ECHOCARDIOGRAPHY STUDY  
An inter- and intra-observer variability study will be performed to ensure standardisation of 
echocardiographic examinations. Twenty percent of echocardiograms will be randomly 
selected to have measurements and conclusions reviewed. An independent cardiologist/ 
cardiac physiologist (accredited by the British Society of Echocardiography) will be blinded to 
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selected echocardiograms and will validate reporting and measurements of these 
examinations.  
 
3.6 BODY COMPOSITION ASSESSMENT 
Air-displacement plethysmography (Bod Pod) is an easily accessible and safe tool to 
measure body composition 261. The assessment is reproducible and is comparable to other 
measures of body composition 261. The major advantage of Bod Pod is that it is safe for 
patients who have had a CRT implanted. Bioelectrical impedance another accurate measure 
of body composition is not recommended by manufacturers of CRT to be used after 
implantation, despite evidence demonstrating it is safe 260. The University of Warwick has 
one of the few facilities in their Human Metabolic Unit to perform Bod Pod quickly and 
effectively. The assessment will take place at all time points and only require a few minutes 
to get a full set or results.  
 
3.7 DEFINITION OF RESPONSE 
The criteria for CRT clinical and echocardiographic response will be applied short-term [six 
week review] and long-term [six months]. Overall response will be determined on the final 
review. The clinical definition of CRT response will be a two out of three criteria [↓>1 NYHA, 
↑>10% 6MWT distance, ↓MLHFQ score>5] (Table One). Echocardiographic response will be 
defined as >15% reduction in LVESV.  Continous echocardiogram data will be correlated 
with novel circulating biomarkers and body composition variables. 
 
Participants will be defined as a non-responder if during the six months follow-up they die or 
undergo a heart transplantation. Hospitalisation will not influence response criteria. 
 
Table 1. Clinical and echocardiographic response criteria 
Clinical Response at Six 
Months  
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Two out of Three:   
↓> 1 NYHA    
↓MLHFQ score > 5   
↑> 10% 6MWT distance    
    
Echocardiographic Response at Six 
Months 
    
↓> 15% LVESV 
  
↓= reduction, ↑= increase 
 
3.8 MAJOR ADVERSE CARDIOVASCULAR OUTCOMES 
MACE will be calculated as a composite [mortality and first heart failure hospital admission] 
over a 12 month period from CRT implantation. Individual event rates for mortality and heart 
failure admissions will be calculated. Heart failure hospital admissions will be defined as 
overnight stays with intravenous diuretics treatment.   
 
3.9. STUDY OUTCOME 
The primary outcome for the study will be clinical response at 6 months. The secondary 
outcomes for the study will be echocardiographic response and MACE. 
 
4. PARTICIPANT ENTRY 
 
4.1 PRE-REGISTRATION EVALUATIONS 
Participants must have clinical investigations to allow assessment under the clinical criteria 
of the NICE guidance for CRT implantation. Left ventricular ejection fraction can be originally 
evaluated by echocardiography, cardiac magnetic resonance imaging and nuclear 
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myocardial perfusion scanning (this does not replace baseline echocardiographic 
evaluation). 
 
4.2 INCLUSION CRITERIA 
  
7. Age > 18 years  
8. Left ventricular ejection fraction ≤35% on echocardiography 
9. NYHA Class III/IV symptoms or milder symptoms with: 
c) NYHA I (LVEF <35% and QRS>150msec on resting ECG) 
d) NYHA II (LVEF <35% with either QRS>150msec or QRS 120-149msec with 
Left Bundle Branch Block on resting ECG) 
10. Optimal medical therapy for heart failure that the patient tolerates (ACEi, Beta-
Blocker, Mineralocorticoid) for > 3 months 
11. QRS duration ≥120-149msec with LBBB on resting ECG or QRS duration >150msec 
on resting ECG 
12. Patient consent to participation in the study 
 
4.3 EXCLUSION CRITERIA 
 
6. Acute heart failure decompensation < 6/52 before implant  
7. Significant cognitive impairment 
8. Acute coronary syndrome < 6/52 before implant  
9. Chronic kidney disease stage V (requiring dialysis) 
10. Terminal illness with likely survival < 1 year after implant  
 
4.4 PROCEDURE AND POST PROCEDURE STUDY EXCLUSIONS 
3. Failure of procedure (e.g. coronary sinus anatomy) 
4. Complication resulting in poor/ none biventricular pacing (e.g. phrenic nerve 
stimulation, lead displacement/ damage) 
 
4.5 ECHOCARDIOGRAPHY 
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Imaging quality is essential for the study to determine volumetric assessments and perform 
Simpsons biplane assessment for left ventricular ejection fraction. Biplane assessment will 
be the standard, but single plane assessment will be accepted dependent  on image quality. 
Participants that have poor overall images (e.g. High Body Mass Index) then patients will be 
excluded from echocardiographic response analysis but included in clinical response and 
major adverse cardiovascular outcome assessment. 
 
All participant images will be stored on the local institution echocardiography database and 
available to all users. All images will be subject to  inter- and intra-observer validation study. 
Twenty percent of all images will be reviewed by an independent cardiologist /cardiac 
physiologist blinded to patient outcomes. 
 
5. ADVERSE EVENTS 
This is an observational study, without intervention. Definitions of adverse and serious 
adverse events are unlikely to have a need to be applied. Clinical events in a CHF 
population undergoing CRT implantation are expected in the natural history of the period of 
observation. Only directly attributable events to the study will be logged as adverse events 
and will be graded depending upon situation. Specifically hospital admissions or deaths 
related to heart failure or another cardiac cause will not be graded as an adverse event. 
Procedural issues (including complications) will not be designated at adverse events as the 
study does not influence the decision to implant CRT or the procedure itself. All clinical 
events will be logged and if it meets MACE criteria will be logged as a MACE event.  
 
5.1 DEFINITIONS 
Adverse Event (AE): any untoward medical occurrence in a patient or clinical study subject. 
 
Serious Adverse Event (SAE): any untoward and unexpected medical occurrence or effect 
that: 
1. Results in death 
2. Is life-threatening – refers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event which hypothetically might have 
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caused death if it were more severe 
3. Requires hospitalisation, or prolongation of existing inpatients’ hospitalisation 
4. Results in persistent or significant disability or incapacity 
5. Is a congenital anomaly or birth defect 
 
Medical judgement should be exercised in deciding whether an AE is serious in other 
situations.  Important AEs that are not immediately life-threatening or do not result in death 
or hospitalisation but may jeopardise the subject or may require intervention to prevent one 
of the other outcomes listed in the definition above, should also be considered serious. 
 
5.3 REPORTING PROCEDURES 
All adverse events will be reported. 
 
5.3.1 Non serious AEs 
All such events, whether expected or not, will be recorded. 
 
5.3.2 Serious AEs 
An SAE form will be completed and faxed to the Chief Investigator within 24 hours. However, 
relapse and death due to heart failure and hospitalisations for elective treatment of a pre-
existing condition do not need reporting as SAEs. Complications from the CRT implant does 
not need to be reported as SAE. It is anticipated that there will be no SAE’s as there is no 
intervention being undertaken directly by the study.  
 
Reports of related and unexpected SAEs should be submitted within 15 days of the Chief 
Investigator becoming aware of the event, using the NRES SAE form for non-IMP studies. 
 
Local investigators will report any SAEs as required by their Local Research Ethics 
Committee, Sponsor and/or Research, Development & Innovation Office. 
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ASSESSMENT AND FOLLOW-UP 
Patients will be screened once CRT implantation decision is made, based on national 
guidelines (eligibility criteria above). Screening will be performed in patients attending weekly 
arrhythmia clinic (main portal for CRT referral to UHCW). Ward based patients may be listed 
directly for CRT implantation and will be screened. These patients need to be well before 
enough for elective (non-urgent) implantation (as per eligibility criteria). A local district 
general hospital (George Eliot, Nuneaton) refers patients directly for CRT implantation and 
these patients will be screened once a decision is made to implant. Patients screened and 
who meet eligibility criteria will have the study mentioned to them by the clinician making the 
decision to implant the CRT. Each patient undergoing elective CRT implantation attends a 
pre-operative clinic (minimum 3 days before procedure) the researcher will approach the 
patient and provide the patient information sheet at this attendance. A follow-up phone call 
will be offered to clarify any outstanding questions. Consent will be obtained on the morning 
of implantation (before assessment). In the rare situation that a patient attends as an 
unplanned (non-urgent e.g. due to cancellation), the patient will be given the patient 
information sheet or asked if it can be posted to them a minimum of 48 hours before the 
procedure.  
 
At the time of procedure, data will be collected on the device and the implantation. These will 
be two further follow-up reviews after the device implantation. These will correspond with the 
CRT follow-up. Approximately these will take place at two and six monthly intervals.  
 
7. STATISTICS AND DATA ANALYSIS 
Statistical analysis will be performed with IBM SPSS Statistics 22 (USA) software package. 
Categorical variables will be reported as numbers and percentages. Comparison analysis for 
categorical data will be performed using the Chi-Squared test. Where smaller than expected 
values are derived Fishers Exact test will be performed.  Continuous data will undergo 
histogram plots and Kolmogorov-Smirnov tests of normality. Normally distributed data will be 
reported as mean ± standard deviation (SD). Non-normally distributed data will be reported 
as median ± interquartile range (IQR). Comparison analysis for independent and dependent 
normally distributed continuous data will be performed using unpaired or paired t-tests 
respectively. Where paired and unpaired continuous data is non-normally distributed a 
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comparison analysis will be performed using Mann-Whitney U test or Wilcoxon Signed Rank 
test respectively. ANOVA or Friedman test will be used to perform comparative analysis of 
multiple continuous data sets with normal and non-normal distribution respectively. A value 
of p<0.05 was used for statistical significance. 
 
Based on response, patients will be categorised as a responder or a non-responder [clinical 
and echocardiographic]. Univariate analysis will be performed using logistic regression on all 
individual biomarkers and known predictors of response [LBBB, gender, aetiology, QRS 
duration]. Multivariate logistic regression analysis will be performed correcting for known 
cofounders. Survival analysis will be conducted on those free from MACE based on grouping 
above or below the median individual biomarker level, these groupings will be used to 
predict risk of MACE.  
 
Sequence of individual biomarker levels will have a t-test performed to assess the difference 
between baseline and follow-up [six weeks and six months]. A correlation analysis of 
biomarker levels at baseline and follow-up with CRT response and MACE will be performed. 
Correlation coefficient will be presented depending on distribution.    
 
Paired t-test will be performed to compare individual biomarker levels in peripheral venous 
and coronary sinus samples. Receiver operating characteristics (ROC) curves will be 
created. ROC curve coefficients will be statistically compared for peripheral venous and 
coronary sinus biomarkers.  
 
Correlation matrix will be performed to compare multiple continuous variables (biomarker 
levels, echocardiography, clinical, body composition] to explore the possible relationships 
between variables in responders and non-responders.  
8. REGULATORY ISSUES 
 
8.1 ETHICS APPROVAL 
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Ethical approval for the study was obtained from the South Birmingham Regional Ethics 
Committee in October 2013. University Hospital Coventry and Warwickshire is the only 
participating site.  
 
8.2 CONSENT 
Consent to enter the study must be sought from each participant only after a full explanation 
has been given, an information leaflet offered and time allowed for consideration. Signed 
participant consent should be obtained. The right of the participant to refuse to participate 
without giving reasons must be respected. After the participant has entered the study the 
clinician remains free to give alternative treatment to that specified in the protocol at any 
stage if he/she feels it is in the participant’s best interest, but the reasons for doing so should 
be recorded. In these cases the participants remain within the study for the purposes of 
follow-up and data analysis. All participants are free to withdraw at any time from the 
protocol treatment without giving reasons and without prejudicing further treatment. 
 
8.3 CONFIDENTIALITY 
The Chief Investigator will preserve the confidentiality of participants taking part in the study 
and is registered under the Data Protection Act. 
 
8.4 INDEMNITY 
Indemnity for the study is provided by the sponsor the University Hospital of Coventry and 
Warwickshire. 
 
8.5 SPONSOR 
The study is sponsored by the University Hospital of Coventry and Warwickshire. 
 
8.6 FUNDING 
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The study is funded by the research and development department of the University Hospitals 
of Coventry and Warwickshire. Further funding has been provided by Medtronic Ltd. This 
funding is confirmed and in place.  
 
The funding principally funds the wages of the principle investigator and the resources 
needed for performing the study. Funding will be needed for the analysis of the blood 
samples to look at the circulating biomarkers including possible purchase of a centrifuge. 
Agreements are otherwise in place analysis of samples to be done in collaborators 
laboratories. Patient assessments will be performed using UHCW resources which the 
principle investigator will perform. Cost basis will be low for delivery of the study. Patients will 
not be paid for participation or travel as review points are arranged to correspond with 
routine checks. 
 
8.7 AUDITS AND INSPECTIONS 
The study will be subject to inspection and audit by the Sponsor and other regulatory bodies 
to ensure adherence to GCP. 
 
9. STUDY MANAGEMENT 
The day-to-day management of the study will be co-ordinated through UHCW Cardiology 
Department by Dr Christopher McAloon. 
 
10. PUBLICATION POLICY 
The intention for the study is to publish the anonymous results and analysis in a peer review 
cardiology journal and present the data to international conferences.  
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APPENDIX J 
Clinical and Procedure Data Collected 
1.Clinical Baseline Data  
The following section outlines the specific clinical data recorded at the baseline study visit.  
 
Baseline Data Collection 
Demographic information was collected at the baseline assessment; age, gender, ethnicity, 
device type. There is overlap with the information captured in study I 
 
Medical History 
1. Aetiology Cardiomyopathy 
2. Heart Disease of another cause 
3. Previous Myocardial Infarction 
4. Presence previous Coronary Artery Bypass Grafting 
5. History of Hypertension 
6. Diabetes Mellitus (Type, Complications) 
 
Other conditions were noted in other comments if observed. These included previous PCI 
for coronary artery disease, presence of current angina, a history of or current atrial 
fibrillation and a history of chronic obstructive pulmonary lung disease. Any previously 
inserted cardiac device (Pacemaker or ICD) was recorded under ‘Heart Disease of another 
cause’. The specific device was recorded with the number of leads in-situ. If the device was 
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an ICD it was noted whether any previous therapies (anti-tachycardia pacing and/or delivery 
of a shock).  
 
Clinical Assessment of Symptoms 
During the clinical assessment, data was entered on to a specific form (Appendix K). 
Participants were initially assessed to see if they had HF symptoms. NYHA symptom 
classification was assessed at each study visit. Specific symptoms and exercise tolerance was 
assessed at every study visit: 
Dyspnoea at rest 
1. Dyspnoea with minimal effort 
2. Dyspnoea with moderate effort 
3. Nocturnal dyspnoea 
4. Ankle Oedema 
5. Dyspepsia 
6. Syncope/Pre-syncope 
7. Palpitations 
8. Fatigue  
 
Medication History 
All medications which the participant was taking at the time of assessment were recorded. 
The dose, route and frequency of each medication were also recorded. HF medications for 
addressed in particular: 
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1. ACEi 
2. Angiotensin Receptor Blocker 
3. Beta-Blockers 
4. MRA 
5. Diuretics 
The doses, frequency and route were all recorded. Optimal HF and stability of treatment will 
have already been established in the screening process. Where the above optimal medical 
treatments for HF were not prescribed, a reason as part of the screening process was 
required to be recorded. Broad reasons were contraindicated, intolerant or not applicable 
(i.e Angiotension Receptor blocker not prescribed as on ACEi or NYHA I symptoms therefore 
MRA indicated2). Between study visits any medication changes were noted. Specific 
Diabetes medication was recorded alongside the type of therapy (diet, oral hypoglycaemics, 
insulin, DDP inhibitor or GLP-1 inhibitor). Allergy status was also specifically recorded.  
 
2.Procedure Data Collection 
The CRT implantation was performed in a standard way as per UHCW standard operating 
procedure.  
1. Type of CRT device (de novo vs upgrade) 
2. Anatomical position of pocket 
3. Model of pulse generator (model and company) 
4. Vascular Access (veins, number of leads, number of punctures) 
5. CS image recorded  
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6. RA lead ( type, anatomical lead deployment position, lead fixation) 
7. RA lead (type, anatomical lead deployment  position, lead fixation) 
8. LV Lead (type, lead fixation) circumferential position 
a. LV Lead  position in CS (axial and circumferential position) 
9. RA lead position (anatomical) 
10. Immediate Complication (type and management)  
 
For participants having a CRT-d, the reason for a defibrillator (primary or secondary 
prevention) was recorded.  
 
Follow-up Study Visit Clinical Assessment 
Overall the clinical data recorded during both follow study visit was the same as the baseline 
visit with the addition of examining CRT functional parameters and assessing for MACE . The 
clinical data capture form can be found in Appendix K.  
 
Clinical Follow-up Data Collection 
The clinical information collected was the same as the baseline study.  
 
Medication History 
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The medication being taken at the time of the study visit is recorded in the same way as laid 
out in the baseline study visit. The emphasis during the follow-up study visits is to identify 
any changes to medication in the intervening periods. 
 
Cardiovascular Outcome Data 
Each follow-up visit was used to evaluate the patient for MACE. Specifically for HF  
hospitalisation episodes as defined in the projects MACE criteria.  
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APPENDIX K 
 
Data Collection Forms 
 
 
 
Initial Assessment 
 
Participant  Number: _____________________________ 
 
Assessment Date: ____/____/______ 
 
Consent Date: ____/____/______ 
 
Demographics     
Date of Birth __/___/___ 
Gender Male □ Female □ 
Background     
Ischaemic Cardiomyopathy: Yes □ No □ 
Dilated Cardiomyopathy: Yes □ No □ 
Heart Disease of other causes: ______________________________ 
Previous Myocardial Infarction Yes □ No □ 
Previous CABG: Yes □ No □ 
History of Hypertension Yes □ No □ 
Diabetes Yes □ No □ 
Clinical Information     
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Current NYHA Class:  _________   
Does the participant have heart failure  Yes □ No □ 
related symptoms? 
 
  
If Yes then please apply: Dysponea at rest □   
  Dysponea with minimal effort □ 
  Dysponea withmoderate effort □ 
  Nocturnal dysponea □ 
  Ankle oedema □   
  Dyspepsia □   
  Syncope/ Pre-syncope □ 
  Palpitations □   
  Fatigue □   
  Other, please specify:_________________ 
Drug History     
Allergies: _______________________________________________ 
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Implantation Data 
 
Participant  Number: ____________________________________ 
 
Implant Date: __________________________________________ 
 
Implant Data   
Procedure Performed: _______________________________________________________ 
Pocket Position: ____________________________________________________________ 
Device Implanted: __________________________________________________________ 
Puncture One Access:_______________________________________________________ 
Puncture Two Access:_______________________________________________________ 
Puncture Three Access:______________________________________________________ 
Device Type:_______________________________________________________________ 
Right Atrial Lead Type: _______________________________________________________ 
Lead Fixation:                  Active  □               Passive □ 
Right Atrial Lead Position: ____________________________________________________ 
Right Ventricular Lead Type: __________________________________________________ 
Right Ventricular Lead Position: _______________________________________________ 
Lead Fixation:                  Active  □               Passive □ 
Left Ventricular Lead Type: ___________________________________________________ 
Left Ventricular Lead Position in Coronary Sinus: 
 
Dr Christopher J. McAloon 
 
     
  449 
 
 
 
Follow-up Assessment 
 
Participant Number: _____________________________ 
 
Assessment Date: ____/____/______  Follow-up:   2 month □          6 month  □ 
 
Consent Date: ____/____/______ 
 
Clinical Information     
Current NYHA Class:  _________   
Does the participant have heart failure  Yes □ No □ 
related symptoms? 
 
  
If Yes then please apply: Dysponea at rest □   
  Dysponea with minimal effort □ 
  Dysponea withmoderate effort □ 
  Nocturnal dysponea □ 
  Ankle oedema □   
  Dyspepsia □   
  Syncope/ Pre-syncope □ 
  Palpitations □   
  Fatigue □   
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  Other, please specify:_________________ 
CRT Follow-up   
Complication                                                               Yes □                                   No □  
If Yes , please specify:__________________________________________________________ 
 
Hospital admissions since CRT implantation?       Yes □                                   No □  
If Yes , please specify:__________________________________________________________ 
 
Percentage Biventricular Pacing:                                                                          % 
Battery Longevity:_____________________________________________________________ 
 
Re-programmed?                                                        Yes □                                   No □                                         
If Yes , please specify:__________________________________________________________ 
 
Repeat Echocardiogram organised?                        Yes □                                   No □                                         
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Echocardiogram Data Collection Worksheet 
 
 
Participant Number: _____________________________ 
 
Assessment Interval:  Initial  /  2 months  /  6 months 
 
Assessment Date: ___________________________ 
 
Parameter Valve Units 
Height   cm 
Weight 
 
kg 
Body Service Area 
 
m2 
Heart Rate 
 
bpm 
LV Dimensions    
LV internal end diastolic diameter (LVIDD) 
 
mm 
LV internal end systolic diameter (LVIDS)  cm 
LV Volumes and Ejection Fraction     
End-diastolic volume (4-Chamber) 
 
ml 
End-systolic volume (4-Chamber) 
 
ml 
Ejection Fraction (LVEF) (4-Chamber)  % 
End-diastolic volume (2-Chamber)   ml 
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COVERT-HF: Body Composition Assessment 
 
Participant  Number: _____________________________ 
 
Assessment Date: ____/____/______ 
 
Assessment:  Initial  □  2 months  □  6 months   □ 
 
 
Body Composition Value Units 
Age   
Height   cm 
Weight   Kg 
BMI   Kg/m2 
Body Fat Percentage   % 
Muscle Mass       Kg 
Bone mass   Kg 
Total Body Water Percentage   % 
Visceral Fat Level     
Dietary Calorie Intake (DCI)   Kcal 
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Metabolic Age     
      
 
 
Signature: __________________________________  
 
Date: ____/____/______
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APPENDIX L 
Six Minute Walk Methods 
Prior to the 6MWT, participants do not exercise or eat/drink for two hours prior to the test. 
A wheel chair was utilised to transport the participant between research equipment sites 
without requirement for performing exercise. A standard and clear explanation was 
provided to participants at each assessment according to the American Thoracic Society 
2002 guidelines.241 Opportunity was given to ask any questions. A 30 metre section of quiet 
flat corridor was marked out with two chairs at each end. Prior to starting the test heart rate 
and blood pressure were recorded. Participants were also required to rate symptoms of 
breathlessness and tiredness using the Borg scale (Table L1) Participants were required to 
walk between the chairs (figure 5.6). A continuous six-minutes was timed, and the 
participant was allowed to stop and rest as many times during the test as they required. The 
clock continued to run during any stops the participant made. During the test minimal 
communication was performed with the participant as per the American Thoracic Society 
2002 guidelines.241 Time checks were given every minute that elapsed The test was 
terminated on exactly 6 minutes, where the patient stopped and sat down. Immediate 
observations (as above) and symptoms were checked. Total distance walked is calculated 
based upon laps walked and final distance when stopped walking using a calorimeter. The 
participant was then asked to sit quietly for 15 minutes and was offered a glass of water.  
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Table L1. The Borg Symptoms Scale. Taken from American Thoracic Society; Am J Respir Crit Care 
Med 2002;.241 
0  Nothing at all 
0.5  Very, very slight (just noticeable) 
1  Very slight 
2 Slight (light) 
3  Moderate 
4  Somewhat severe 
5  Severe (heavy) 
6 
7  Very severe 
8 
9 
10  Very, very severe (maximal) 
 
The change in 6MWT between pre-implant/baseline assessment and follow-up assessments 
is the measure of improvement and contributes to the functional composite response 
definition. A definition that has been used extensively to represent improvement following 
intervention on CHF patients and in particular CRT implantation is an improvement >10% 
6MWT baseline distance.1 This particular definition applied has been applied in a number of 
observational trials as being a criteria for a significant response/improvement in functional 
exercise capacity 
.
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APPENDIX M 
LeftVentricle Dimensions and Function Quantification 
Table M1. Left Ventricular Dimensions and Function Quantification. *LVEF catergorisation of severity reflects the British Society of 
Echoardiography measures.200. (Adapted253) 
 
  Women Men 
  
Reference 
Range Mild Moderate Severe 
Reference 
Range Mild Moderate Severe 
LV Dimension                 
LVEDD (mm) 39-53 54-57 58-61 >62 42-59 60-63 64-68 >69 
LV Volume                 
LVEDV (ml) 56-104 105-117 118-130 >131 67-155 156-178 179-201 >202 
LVEDV/BSA (ml/m2) 35-75 76-86 87-96 >97 35-75 76-86 87-96 >97 
LVESV (ml) 19-49 50-59 60-69 >70 22-58 59-70 71-82 >83 
LVESV/BSA (ml/m2) 12-30 21-36 37-36 >43 12-30 31-36 37-42 >43 
LV Function Two 
Dimensional Method 
                
                
LVEF (%)* >55 45-54 36-44 <35 >55 45-54 36-44 <35 
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APPENDIX N 
 
Participant Questionnaires 
 
 
 
Participant Questionnaire: ‘The characterisation of circulating biomarkers before and 
after cardiac resynchronisation therapy in patients with heart failure and their role in 
predicting response’ (COVERT-HF) 
 
Initial Assessment Questionnaire  
 
Participant  Number: 
 
Please complete participant questionnaire: 
Please circle the appropriate option where applicable: 
 
Date of Recruitment: Date of Assessment: 
 Age:  Gender:     Male/ Female 
Ethic Origin (Please circle appropriate)   
White  British  Indian 
White Irish Pakistani 
White other (please specify)  
Black African Bangladeshi 
Black Caribbean Chinese 
Black British Asian British 
Black other (please specify)  
Asian other (please specify)   
    
Past Medical History: Current Drug History: 
1 1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
10 10 
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APPENDIX O 
Minnesota Living with Heart Failure ® Questionnaire Description 
MLHFQ scoring has proven to have high reliability at baseline measurements.328 Internal 
consistency, measured using Cronbach’s alpha coefficient have also been shown to be 
consistently high.328 The challenge with high internal consistency is a high score reflects a 
single construct, in the case of the MLHFQ the interrelated effects of CHF on an 
individual’s QoL. However, the more inter-related the questionnaire the higher the 
internal consistency score will be, challenging the degree of validity. To overcome this 
challenge, comparing a questionnaire, to other constructs provides a bench mark to test 
the questionnaires validity. Gorkin et al,328demonstrated the Functional Status score 
(physical limitations) (r=0.75), Dysponea scale (r=0.52) and the Clinician perceptions of 
patients health (r=0.44) correlated highly with the MLHFQ score. Increasing NYHA 
classification has consistently demonstrated a strong and direct correlation with 
increasing MLHFQ scores.28,258,328,329 The 6MWT distance reasonable correlates with the 
MLHFQ score (r=0.39).330 Interestingly the MLHFQ score does correlates with LVEF 
poorly.258,328  
 
The MLHFQ is a questionnaire designed to measure the impact of heart failure and its 
IMPACT on QoL.258,259 Contained within the MLHFQ are key physical, emotional, social 
and mental dimensions, which are effected by heart failure and its treatment. There are 
21 facets that are specifically explored; physical symptoms (shortness of breath, fatigue, 
peripheral oedema and difficulty sleeping), psychological impact (anxiety and depression) 
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and physical/social functioning (walking, climbing stairs, household work, need to rest, 
working to earn a living, going place places away from home, doing things with friends or 
family, recreational activities, sexual activities, eating and mental and emotional 
functions of concentrations, memory, loss of self-control and being a burden to 
others).258,259 Each facet/question has the same six –point scale, between 0 and 5, where 
0 means not at all and 5 means very much. The MLHFQ provides a total score (range 0–
105, from best to worst QoL).258,259 Furthermore, two QoL dimensions are measured;  
physical (8 items, range 0–40) and emotional (5 items, range 0–25).258,259  The eight 
remaining facets are only considered for the calculation of the total score.258,259 A 
‘clinically meaningful’ difference is the change in score between tests that indicates a 
large enough change for physicians and patients to consider using a new treatment, if 
risks and costs were acceptable.257 A score change of five-points is the minimum needed 
to define a significant change in QoL.331 MLHFQ has been extensively used in 
pharmcology332,333 and CRT23,28,250 intervention randomised control trials and proven to 
be robust measure of total QoL in CHF intervention trials.  
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APPENDIX P 
 
Minnesota Living with Heart Failure Qestionnaire® 
 
The following questions ask how much your heart condition has affected your life during 
the past month (4 weeks). After each question, circle the 0, 1, 2, 3, 4 or 5 to show how 
much your life was affected. f a question does not apply to you, circle the 0 after that 
question. 
 
Has your heart condition prevented you from living as you wanted during  the last 
month (4 weeks) by  
                     Very       Very      
         No        Little                   Much 
       
1.  Causing swelling in your ankles or legs?           0            1        2        3        4        5 
2.  Making you sit or lie down to rest during    
     the day?        0            1        2        3        4        5 
3.  Making walking about or climbing      
   stairs difficult?       0            1        2        3        4        5 
4.  Making working around the house    
       or garden difficult?       0            1        2        3        4        5 
5.  Making going places away from           
     home difficult?       0            1        2        3        4        5 
6.  Making sleeping well at night 
     difficult?        0            1        2        3        4        5 
7.  Making doing things 
    with your friends or family difficult?            0            1        2        3        4        5 
8.  Making working to earn a living 
     difficult?        0            1        2        3        4        5                                                               
9.  Making your recreational pastimes, sports 
     or hobbies difficult?              0            1        2        3        4        5 
10.  Making sexual activities difficult?    0            1        2        3        4        5 
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Has your heart condition prevented you from living as you wanted during  the last 
month (4 weeks) by  
                     Very       Very      
                         No         Little                  Much  
11.  Making you eat less of the foods you  
        like?         0            1        2        3        4        5 
12.  Making you short of breath?             0            1        2        3        4        5 
13.  Making you tired, fatigued, or low on 
       energy?        0            1        2        3        4        5 
14.  Making you stay in a hospital?     0            1        2        3        4        5 
15.  Costing you money for medical care?    0            1        2        3        4        5 
16.  Giving you side effects from treatments? 0            1        2        3        4        5 
17.  Making you feel you are a burden to your  
       family or friends?          0            1        2        3        4        5 
18.  Making you feel a loss of self-control 
       in your life?              0            1        2        3        4        5  
19.  Making you worry?             0            1        2        3        4        5 
20.  Making it difficult for you to concentrate 
       or remember things?      0            1        2        3        4        5  
21.  Making you feel depressed?     0            1        2        3        4        5 
 
Thank you taking the time to complete the questionnaire. Any questions 
please do not hesitate to contact Dr Christopher McAloon on 02476 965 
813.  
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APPENDIX Q 
 
Air-Displacement Plethysmography (BOD-POD®) 
 
BOD POD® is comparable with other more  traditional body composition methods include 
hydrostatic weighing and dual energy X-ray absorptiometry.261 Components of body 
composition measured are FM, FFM and body fat percentage. BOD POD® has been 
demonstrated to be a reliable measure of body composition. When measuring the same 
50 litre cylinder 20 times consecutively, the reliability is excellent; demonstrated by a 
coefficient variant of 0.025%.261 Reported reliability of serial measurements on the same  
in humans demonstrated a coefficient variant ranging from 1.7% to 4.5% for body fat.261 
Measurements performed between days ranged from 2.0-2.3%.261Comparing repeated 
measurements of body fat percentage on different days between BOD POD® and 
hydrostatic weighting showed there was no significant difference.261 The BOD POD® has 
also been demonstrated to have higher precision in measurements of body volume than 
hydrostatic weighting techniques.261 Variations when using BOD POD® have been 
observed between genders, body habitus and age.261 However, no data to date has been 
undertaken to validate BOD POD® use in HF patients.261 Importantly BOD POD® has no 
contraindications to use in patients with a CRT in situ. Overall BOD POD® is a reliable and 
well validated measure of body composition. 261 BOD POD also measures body water as 
fat mass, which in HF patients is an important confounder in the assessment of body 
composition. However, patients in the study were stable and decompenstated patients 
were not enrolled in the study. 
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APPENDIX R:  
 
Selection of Published Abstracts 
 
Arrhythmias and Clinical EP
A461
JACC March 17, 2015
Volume 65, Issue 10S
CoMparison of upgradEd VErsus dE-noVo CardiaC rEsynChronisation thErapy (Crt) 
dEViCEs on CardioVasCular outCoMEs and rEsponsE: a 5 yEar rEgistry
Poster Contributions
Poster Hall B1
Monday, March 16, 2015, 9:45 a.m.-10:30 a.m.
Session Title: Outcomes and Cardiac Device Therapy
Abstract Category: 6. Arrhythmias and Clinical EP: Devices
Presentation Number: 1253-248
Authors: Christopher James McAloon, Domonic P. Heining, Jethro J. Barker, Benjamin Anderson, Gavin Atherton, Faizel Osman, University 
Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, Warwick Medical School, University of Warwick, Coventry, 
Coventry, United Kingdom
background:  CRT is an effective therapy in HF. Pacemakers and defibrillators are implanted for arrhythmogenic indications. Pacing 
dependency can induce HF and is an established CRT upgrade criterion [LVEF<35% and ventricular pacing >40%]. We aimed to compare 
cardiovascular outcomes between upgraded and de-novo CRT’s.
Methods:  A retrospective study of all consecutive CRT implants over five years (Jan 2009 - Dec 2013) in a UK tertiary centre. Data 
was collected on baseline demographics, co-morbidities and indications (NYHA class, ECG, echocardiogram). Comparisons were made 
for these outcomes: acute response [2mths], all-cause mortality and first hospitalisation. CRT response was defined as >1 NYHA class 
increase.
results:  373 CRT implants were performed (79 upgrades). Upgrade and de-novo patients were matched for all comorbidities. Table 1 
demonstrates baseline demographics, indications and CRT response. A Kaplan-Meier analysis was performed on all-cause mortality and 
time to first hospitalisation, with three year rates demonstrated in the table. A significantly worse long-term response (p0.002) and all-cause 
mortality (p0.043) was demonstrated for upgrade patients.
Conclusion:  Upgraded CRT patients have a worse long-term response and higher all-cause mortality. The potential worse outcome for 
upgrade patients should be considered before implant.
HF = Heart Failure, NYHA = New York Heart Association, LVEF = left ventricular ejection fraction, ECG = Electrocardiogram
Table 1
 
Total Cohort
N=373
Upgrades
N= 79
De Novo Implants 
N=294 P value
Age (mean+/-SD) 72.0+/-10.4 74.0 +/- 10.6 71.44 +/- 10.4 0.055
Gender (male n,%) 287 (76.9%) 69 (87.3%) 218 (74.1%) 0.013
Device (CRT-D n,%) 182 (48.8%) 39 (49.4%) 143(48.6%) 0.909
NYHA Class 3/4 (n,%)* 324 (91.5%) 74(98.7%) 250 (90.0%) 0.028
LVEF <35% (n,%)* 364 (98.4%) 76(97.4%) 288(98.6%) 0.458
QRS >150msec (n,%)* 272 (77.1%) 55 (78.6%) 217 (76.7%) 0.634
Acute Response (n,%) 132 (61.4%) 23 (59.0%) 109 (61.9%) 0.731
Long-term Response (n,%) 101 (47.0%) 11 (25.6%) 90(52.3%) 0.002
All-Cause Mortality Rate
(36 months) (%+/-SE) 21.1%+/-2.6% 25.6%+/-5.8% 19.2%+/-2.9% (Log-Rank) 0.043
All-Cause First Hospitalisation (36 months) 
(%+/-SE) 42.9%+/-3.3% 46.7%+/-3.7 % 41.9%+/-4.2 % (Log-rank)0.096
*Percentage represents all recorded data
Downloaded From: http://content.onlinejacc.org/ on 03/19/2015
bradyarrhythmias, loss of pacing function when pacing-depend-
ent or inappropriate defibrillator shocks. The were no device-
related deaths or complications requiring ITU level care.
Conclusion Same day discharge appears safe in an unselected
population of patients undergoing elective primary implanta-
tion of a CRM device at a high-volume cardiothoracic unit.
Procedural difficulties, symptoms or signs suggestive of a
potential complication should prompt further evaluation, and
all patients should undergo device interrogation and chest
radiography prior to discharge.
54 MEASURES OF ENDOTHELIAL DYSFUNCTION PREDICT
RESPONSE TO CARDIAC RESYNCHRONISATION
THERAPY
1David Warriner*, 2Ryan Crapper, 1Patricia Lawford, 3Paul Sheridan. 1Sheffield University;
2Sheffield Teaching Hospitals; 3Chesterfield Royal Infirmary; *Presenting Author
10.1136/heartjnl-2016-309890.54
Background Cardiac resynchronisation therapy (CRT) improves
morbidity and mortality in heart failure (HF). Impaired endo-
thelial function, as measured by flow mediated dilation (FMD)
is associated with increased morbidity and mortality in heart
failure (HF) and may help to differentiate responders from
non-responders.
Methods FMD was measured at baseline and 12 months fol-
lowing CRT. The patient group were 94% male, mean age 69
± 8 years, New York Heart Association (NYHA) functional
class II-IV, QRSd 173 ± 21 ms and had a left ventricular
ejection fraction (LVEF) 26 ± 8%.
Results 70% of patients were found to have responded at 12
months. Responders had significant improvements in VO2
(12.6 ± 1.7 to 14.7 ± 1.5 ml/kg/min, p < 0.05), quality of
life score (43 ± 23 to 24 ± 22, p < 0.01), left ventricular
end diastolic volume (210 ± 125 ml to 173 ± 125 ml, p <
0.01), NT-proBNP (2422 ± 829 ml to 1732 ± 976 ml, p <
0.01 and 6 min walk distance (379 ± 117 m at baseline to
418 ± 105 m, p < 0.05). Baseline FMD in responders was
2.9 ± 1.9% and 7.4 ± 3.73% in non-responders (p < 0.05).
Conclusions This confirms that FMD identifies response to
CRT, due to endothelium dependent mechanisms alone.
55 EVALUATION OF POTENTIAL CLINICAL RESPONSE AND
CARDIOVASCULAR OUTCOMES PREDICTORS IN A
TERTIARY CARDIAC RESYNCHRONISATION THERAPY
IMPLANTATION CENTRE
Christopher McAloon*, Dominic Heining, Gavin Atherton, Benjamin Anderson,
Harpal Randeva, Paul O’Hare, Faizel Osman. University Hospital Coventry and Warwickshire;
*Presenting Author
10.1136/heartjnl-2016-309890.55
Background Cardiac Resynchronisation Therapy (CRT) is an
effective treatment for dys-synchronous chronic heart failure
(CHF), however there is a significant non-response rate. Clinic
predictors of response and cardiovascular outcome are often
inconsistently reported. The aim of the study was to examine
previously reported clinical predictors of response and cardio-
vascular outcomes in a heterogeneous CHF patients under-
going CRT implantation at a UK tertiary centre.
Methods A retrospective single-centre cohort study of all con-
secutive CRT implantations (147 (49.0%) CRT-p; 153 (51.0%)
CRT-d) performed over 5 years (Jan 2009–Dec 2013).
Implants had to meet eligibility criteria; successful implant,
follow-up case records availability and clinical response deter-
mination. Clinical response was defined by three independent
reviewers as a New York Heart Association classification symp-
tom reduction > 1 class or class I maintenance from pre-
Abstract 53 Table 1 Device implantation according to device
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implant to the most recent cardiology/heart failure consulta-
tion. Major Adverse Cardiovascular Events (MACE), defined
as all-cause mortality or first heart failure hospital admission,
was recorded independently of clinical response. Pre-identified
potential clinical predictors (Table 1) were analysed to deter-
mine ability to predict response and MACE.
Results A cohort of 300 (mean age 71.5 years ± 10.1; 227
(75.7%) males) had clinical response definable (158 (52.7%)
responders; 142 (47.3%) non-responders) at a median of 12.0
( ± (IQR) 4.38–25.5) months. Baseline cohort characteristics
were: 171 (59.0%) ischaemic aetiology; 72 (28.0%) AF; 75
(25.9%) Diabetes; 103 (25.3%) Chronic Kidney Disease
(CKD); Electrocardiogram: QRS 154mesc (± 144–172); 186
(71.8%) LBBB; Echocardiogram 24.1% (± (SD)8.3) LVEF.
Multivariate logistic regression (Table 1) of pre-defined param-
eters of overall clinical response demonstrated increasing age
at implant predicted a poorer response (OR 0.96, p0.002, CI
(95%) 0.94–0.99). CKD status trended towards predicting
long-term (>12 weeks) clinical response (OR 0.58, p0.06, CI
(95%) 0.33–1.01). Figure 1 shows the survival curve demon-
strating significantly higher all-cause mortality rate for those
with CKD at implant (p < 0.001). Multivariate Cox regres-
sion demonstrated that CKD status predicted increased MACE
(HR 2.10, p0.001, CI (95%) 1.23–3.19) and all-cause mortal-
ity (HR 2.06, p < 0.007, CI (95%) 1.22–3.46) following
CRT implantation.
Conclusion Increasing age at implant predicts poorer overall
clinical response. CKD status predicts increased MACE and
all-cause mortality events following CRT.
Abstract 55 Table 1 Univariate and multivariate logistic
regression of potential predictors of overall clinical response
Univariate Regression Multivariate Regression
Predictor Odds
Ratio
p
Valve
Confidence
Interval
(95%)
Odds
Ratio
p
Valve
Confidence
Interval
(95%)
Age at implant 0.97 0.00 0.94–0.99 0.96 0.002 0.94–0.99
Gender 0.96 0.88 0.57–1.63
Device 1.41 0.14 0.90–2.22
Upgrade Status 0.54 0.03 0.31–0.95 0.57 0.05 0.32–1.01
QRS Duration 0.87 1.00 0.99–1.01
LBBB 1.42 0.20 0.84–2.42
LVEF 0.98 0.21 0.95–1.01
Aetiology 1.18 0.50 0.74–1.87
Diabetes Mellitus 0.84 0.53 0.50–1.43
CKD 0.60 0.04 0.37–0.97
Days from Implant to
Response Assessment
1.00 0.13 0.99–1.00 0.99 0.03 0.99–1.0
Abstract 55 Figure 1 Survival curve for CKD status at CRT implantation and all-cause mortality (p < 0.001)
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TROUBLESHOOTING LV LEAD IMPLANTATION - NOVEL “UNIRAIL  
TECHNIQUE” 
 
S. Honarbakhsh, P.D. Lambiase, M.D. Lowe, R.J. Hunter, R.J. Schilling, and M. Finlay 
 
Barts Heart Centre, Barts Health NHS trust, London 
 
Introduction: Lack of guide catheter support and difficulty accessing the coronary sinus (CS) are frequently cited 
as reasons for difficulty in placing CS pacing leads. We present a new “unirail” technique whereby a femorally 
placed catheter provides the support for guide-catheter placement at the os of a target vessel.  
Method and results: A 69 year old female was referred for device upgrade. She was pacing dependent, had mod-
erate left ventricular (LV) impairment, and had NYHA class III symptoms. Despite utilizing a range of 
established techniques (including balloon anchoring), it was impossible to pass a CS lead into any target vessel 
due to lack of guide-catheter support. She was rescheduled for a further procedure where a combination of 
subclavian and femoral access was used. A CS hook guide was advanced from the subclavian vein, whilst a 
quadripolar electro-physiology catheter (quad) was simultaneously advanced through a femoral SL1 sheath, 
which remained within the low right atrium. A gooseneck snare passed from the CS hook lassoed the quad and 
the quad was then advanced into the CS (figure 1A). The CS hook sheath was advanced, tightening the snare 
around the quad at the CS os position. The SL1 sheath was then advanced over the quad, railing the lassoed snare 
and CS hook up the path of the CS to the os of the target vein (figure 1B). The quad was then withdrawn, 
releasing the snare. A Starfix LV lead was then easily positioned into the target vessel without complications 
(figure 1C and D). At four month follow-up pacing parameters were stable. Patient was NYHA class I and LV 
function had improved to mildly impaired.  
Discussion: This case illustrates a novel technique of accessing complex coronary anatomy. Minor variations of 
this method would allow the guide-cath to be supported from the femoral vessel whilst placing a lead if required. 
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SUBCLINICAL ATHEROSCELEROSIS AND COGNITIVE  
IMPAIRMENT 
 
Sevara Tairova, Gulnara Rakhimbaeva, and Nigora Akramova 
 
Tashkent Medical Academy, Tashkent 
 
Purpose: To determine associations between subclinical atherosclerosis, cognitive screening 
and white matter hyperintensities on MRI.  
Method and materials: The study consisted of 124patients from the department of neurology 
of Tashkent Medical Academy(mean age 44 + 10 years, 56% female and 44% male) without 
cardiovascular disease who underwent carotid and brain MRI at 3 Tesla. Semi-automated 
tech-niques were used to define wall contours of the internal and common carotid arteries 
(ICA and CCA) and white matter hyperintensity volume (WMH). Subjects also underwent 
Montreal Cognitive Assessment (MoCA) testing and muHidetector CT for measurement of 
coronary artery calcium (CAC) using the Agatston method. A MoCA score less than 26 was 
used to indi-cate the presence of at least mild cognitive impairment.  
Results: ICA and CCA wall areas correlated with WMH and MoCA score (all p , .001) in 
unadjusted models. After adjusting for traditional risk factors, ICA wall area remained asso-
ciated with MoCA(¼0.02, p , .05) and CCA wall area remained associated with WMH (0.002, 
p ¼ 0.04). Increasing ICA wall area predicted MoCA score ,26 (OR 1.12 per SO change, 95% 
Cl 0.99-1.26, p ¼ 0.04) after multivariable adjustment, but increasing CCA wall area did not 
predict MoCA score ,26 ( p ¼ 0.5). After adjusting for traditional risk factors, CAC was 
associated with WMH (¼0.013, p ¼ O.OOOB). Increasing CAC score predicted large WMH 
(OR 1.19 per SO change, 95% Cl 1.03-1.38, p ¼ 0.02). 
Conclusion: Subclinical coronary and carotid atherosclerosis are predictors of poorer cognitive 
function as measured by MoCA score and white matter hyperintensity volume on MRI. 
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EFFECT OF LOZARTANE ON DEVELOPMENT OF THE ELECTRICAL  
INSTABILITY OF THE MYOCARDIUM 
 
N.V. Getman
1
, and T.V. Getman
2 
 
1
National Medical University named after Bogomolets, Kiev; and 
2
Governmental institution NNC “Institute of 
cardiology named after Stragesko, N.D”, Kiev 
 
Aim: to study the effect of Lozartane on the morphologically functional characteristics of the patients with  
various dysfunctions of the heart rhythm.  
Materials and methods: The study included 62 patients aged 50 to 70. (57.4 + 1.82 years) with following diag-
noses: ischemic heart disease (stable pressure angina, types I-III) (80.7% of patients), heart failure of types I-IIA 
(90.3% of patients), hypertonic heart disease of types I-II (87.1% of patients), myocardial fibrosis (12.9% of 
patients). Changes to the heart rhythm were identified in all of the patients: 36% of patients suffered from 
ventricu-lar beats, 29.6% with supraventricular beats, 44.8% with paroxysmal and persistent forms of atria l 
fibrillation and 27.4% with constant form of atrial fibrillation. All patient received the basic therapy, which 
included Lozartane. The research was conducted twice: with admission of the patient to the hospital and 4 weeks 
after the Lozartane-consisting treatment. The following methods were used: clinical observation; ECG-control 
with measurement of the QT interval; Holter monitoring; 24-hour monitoring of AD and echocardigraphy. 
 
Results of the study 
 
Factor Initial value After the treatment P 
       
Mean HR (bpm) 78,06 + 2,57 71,71 + 3,84 0,00001 
Maximum HR (bpm) 125 + 4,44 102,43 + 8,44 0,00001 
Minimum HR (bpm) 51,6 + 2,86 46,71 + 2,78 0,00001 
Ventricular beats (absolute quantity) 443,4 + 205,84 169,35 + 103,94 0,00001 
Supraventricular beats (absolute quantity) 417,97 + 133,26 216,78 + 122,9 0,00001 
FP runs (absolute quantity) 32,35 + 26,3 16,38 + 14,93 0,0006 
SDNN (ms) 99,26 + 9,25 127,37 + 12,86 0,00001 
SDANN (ms) 123,32 + 11,77 127,95 + 11,1 0,0555 
SDNNi (ms) 59,06 + 6,12 61,6 + 7,89 0,2273 
RMSSD (ms) 48,82 + 8,83 58,38 + 14,95 0,0003 
pNN50 (%) 15,79 + 3,89 18,05 + 5,06 0,0189 
LF (ms
2
) 2124,74 + 708,82 1322,0 + 517,06 0,00001 
HF (ms
2
) 1641,32 + 620,52 1281,5 + 614,77 0,0064 
QTc (ms) 418,4 + 14,95 414,08 + 40,28 0,00001 
DQT (ms) 17,26 + 1,68 16,48 + 2,15 0,0518 
       
 
Conclusions: Significant difference in the decrease of the corrected QT interval and dispersion of QT interval,  
along with positive effect of Lozartane on the values of variable heart rhythm, allow to correlate the antiarrhyth-
mic effect of the medication with its positive effects on the vegetative regulation of the heat tone, as well as with 
the independent antiarrhythmic activity of the Lozartane metabolite, EXP3174. 
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THE INTERPLAY BETWEEN BODY COMPOSITION AND LEFT  
VENTRICULAR REMODELLING IN CARDIAC  
RESYNCHRONISATION THERAPY 
 
C.J. McAloon
1
, T. Hamborg
2
, J.P. O’Hare
2
, H. Randeva
2
, and F. Osman
1 
 
1
University Hospitals Coventry and Warwickshire, Coventry; and 
2
University of Warwick, Coventry 
 
Background: Body composition (BC) alters in heart failure (HF) patients. Cardiac resynchronisation therapy 
(CRT) improves left ventricular (LV) geometry, but impact on BC is unknown.  
Purpose: To examine BC changes in HF patients undergoing CRT and interplay with clinical, neurohormonal and 
echocardiographic parameters.  
Method: Prospective cohort study of HF patients undergoing CRT [meeting ESC guidelines] between Sept14-
Dec15. Each participant underwent 3 assessments [ pre-CRT, 6 weeks, 6 months] for BC parameters [air-
displace-ment plethysmography], New York Heart Association (NYHA), echocardiographic parameters [LV End 
Systolic/ Diastolic volume (LVESV/LVEDV), LVESV index (LVESVi), LV ejection fraction (LVEF)], 
electrocardiog-raphy, Minnesota Living with HF Questionnaire (QOL), and N-terminal pro-brain natriuretic 
peptide (NT-pro-BNP). Repeated Measures Analysis of Variance was performed to assess parameter’s change 
over time and corre-lations of parameters explored.  
Results: 25 participants recruited; 73.4 + 10.0 years (mean + standard deviation), 23 males, 18 CRTd, 16 
Ischaemic, 6 Diabetes, 17 LBBB and 10 Atrial Fibrillation. During follow-up there was 1 HF mortality, 2 unable 
to attend (1 HF hospital admission), 1 LV lead displacement and 1 unable to undertake BC assessment after CRT. 
Table 1 demonstrates the trend in the change in parameters over 6 months follow-up. Alterations between other 
BC and LV parameters in first 6 weeks also strongly correlated; Fat Mass (FM) and LVESVi (r ¼ -0.76,p , 
0.001), Lean Mass vs LVESVi (r ¼ 0.63, p ¼ 0.008), FM vs LVEDV (r ¼ -0.66, p ¼ 0.005) and FM vs LVEF (r 
¼ 0.49, p ¼ 0.06). 
Conclusion: This is the first study to demonstrate interplay between BC and LV geometry alterations following 
CRT. A trend in overall FM reduction is also suggested. BC in CRT requires further study.  
Table 1. 
c device. 
Dr Christopher J McAloon 
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i.org/1implantation improve morbidity and mortality in selected patients. Many centers still admit
patients overnight. We evaluated the safety, feasibility, and cost savings of same-day CRT/
ICD device implantation by performing a retrospective study of all consecutive elective
CRT/ICD implants at a tertiary center from January 2009 to April 2013. All emergency
and/or inpatient cases were excluded. Data were collected on baseline demographics, im-
plantation indication, procedure details, complications (categorized as immediate
[£24 hours], short term [24 hours to 6 weeks], medium term [6 weeks to 4 months], and long
term [>4 months]), and mortality (30 day and 1 year). Comparisons were made between
those having planned same-day versus overnight stay procedures. A cost analysis was
performed to evaluate cost savings of the same-day policy. A total of 491 devices were
implanted during this period: 267 were elective (54 planned overnight, 213 planned same-
day) of which 229 were CRT pacemakers or CRT deﬁbrillators and 38 ICDs. There were 26
total overall complications (9.7%) with no signiﬁcant differences between planned same-day
versus planned overnight stay cohorts (9.4% vs 11.1%, p [ 0.8) and speciﬁcally no dif-
ferences in immediate, short-, medium-, and long-term complications at follow-up. The 30-
day and 1-year mortality rates did not differ between the two groups. An overnight stay at
our hospital costs $450 (£300); our cost saving during this period was $91,800 (£61,200).
Same-day CRT/ICD implantation is safe, feasible, and associated with signiﬁcant cost
savings. It provides signiﬁcant advantages for patients and health care providers, especially
given the current ﬁnancial climate.  2016 Elsevier Inc. All rights reserved. (Am J
Cardiol 2016;-:-e-)Cardiac resynchronization therapy (CRT) and the
implantable cardioverter deﬁbrillator (ICD) are known to
improve morbidity and mortality in selected patients.1e3
CRT has been shown to reduce mortality and hospitaliza-
tion in selected patients with heart failure on optimal medical
therapy.2,4,5 ICDs implanted for primary and secondary
prevention have become the cornerstone in the prevention of
sudden cardiac death in selected patients.3,4 Recent changes
to international guidelines reﬂect the success of these devices
and are now offered to a wider range of patients6,7 with
implantation rates continuing to rise year on year.8 The cost-
effectiveness of such procedures has been an important issue
of discussion.9,10 Many centers in Europe and North America
keep patients overnight after implantation, driven mainly byf Medicine, Warwick Medical School, University of
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0.1016/j.amjcard.2016.02.019the assumed risk of device-related complications. With
increasing health care costs and the current worldwide
ﬁnancial climate, the costebeneﬁt ratio of such a strategy is
now being reconsidered. We have previously reported that
same-day bradycardia pacemaker implantation is safe and
cost-effective with signiﬁcant cost savings for health care
providers.11 The aim of the present study was to evaluate the
safety and feasibility of this same-day policy by comparing
outcomes with those routinely kept overnight; we also
performed a cost-saving analysis for the period of study.Methods
A retrospective study of all consecutive elective CRT
pacemaker (CRTp), CRT deﬁbrillator (CRTd), or ICD
(single/dual chamber) implants performed at University
Hospital Coventry, UK, from January 2009 to April 2013.
This included all de novo and upgrade cases but excluded all
having a pulse generator change only (as these patients are
not usually admitted overnight). Elective implants were
those seen in the outpatient clinic and subsequently admitted
with a planned date. We excluded all who had a device
implanted during an acute emergency hospital admission.
Electronic patient records and case notes were reviewed forwww.ajconline.org
2 The American Journal of Cardiology (www.ajconline.org)all cases. Data were collected on patient demographics,
implant indication, procedure details, and outcomes.
Patients were divided into 2 cohorts: planned same-day
implants (following commencement of our same-day
policy in 2010) and those planned to be kept overnight
(patients implanted before same-day policy). Patients were
seen routinely at 6 weeks and 4 months after the implant.
Approval for the study was provided by our Local Audit and
Research Department. The study applied the principles of
the declaration of Helsinki. Complications were categorized
overall and by time of occurrence: immediate (24 hours),
short term (24 hours to 6 weeks), medium term (6 weeks to
4 months), and long term (>4 months, median 30 months,
interquartile range 20 to 42 months). Mortality was exam-
ined at 30 days and 1 year after the procedure and classiﬁed
as due directly to the device implant, cardiac cause (heart
failure, myocardial infarction, arrhythmia, sudden cardiac
death), and non-cardiac causes. Types of complication
recorded were cardiac arrest, cardiac chamber perforation,
tricuspid valve injury, pneumothorax or hemothorax, stroke,
myocardial infarction, pericardial effusion or tamponade,
major bleeding (deﬁned as decrease in hemoglobin 20 g/l
and/or blood loss requiring blood transfusion), wound
hematoma (with or without reintervention), coronary sinus
(CS) dissection or perforation (for CRT implants), proce-
dure- or device-related infections, lead displacement,
phrenic nerve stimulation postoperatively for CRT cases,
and device erosion. Failed procedures due to patient factors
(such as poor CS anatomy, poor patient tolerance) were also
recorded. Both upgrade and de novo device implants were
evaluated because of the deﬁned increase in complication
rates reported in upgraded devices.12
All implants during the period of study were performed
by a consultant cardiologist with specialist interest in
EP/Devices alone or scrubbed with a Devices Fellow.
Patients on oral anticoagulation were asked to discontinue
it 3 days before operation and resume it the same day
after operation. Conscious sedation (mostly midazolam
0.1 mg/kg intravenously) and local anesthesia (1% lido-
caine) was used in all patients with a left deltopectoral
groove incision in most. Venous access was mainly cephalic
and axillary veins with subclavian vein used only if the ﬁrst
2 routes failed. The right ventricular lead for most patients
was implanted at the right ventricular apex and right atrial
lead at the right atrial appendage. Patients in permanent
atrial ﬁbrillation did not have an atrial lead implanted. For
left ventricular (LV) lead implantation, the CS was cannu-
lated, and angiography was performed in all with the most
lateral and basal/midcavity position favored; redundant
leads were capped and left in situ. The pulse generator was
placed into a prepectoral pocket. Deﬁbrillation safety
margin testing was not performed. All were given pre-
procedural intravenous antibiotics using 1-g ﬂucloxacillin
and 1.5-mg/kg gentamicin (maximum dose 150 mg) and
3 days after procedural oral antibiotics (ﬂucloxacillin
500 mg 4 times a day). Patients with penicillin allergy were
given intravenous teicoplanin 600 mg preoperatively, and
oral doxycycline 200 mg/day for 3 days postoperatively. All
had postimplant chest x-ray to check lead position and
exclude pneumothorax. Patients were taken back to the ward
and kept overnight for observation before our same-dayprotocol. Following the same-day protocol, patients were
taken to our cardiology day-case unit and observed for 3
to 4 hours before being discharged if all checks were
satisfactory. If for any reason there were concerns about
same-day discharge, patients were admitted overnight and
discharged the following day. Those discharged were
instructed not to undertake strenuous physical activity for
1 week after and advised to keep the wound dry for 3 days
postoperatively. In case of problems, patients were instruc-
ted to contact our day-case unit or cardiology ward imme-
diately. Those living farther away were listed earlier than
those living closer to allow timely discharge. Age and
geography were not speciﬁcally used to exclude patients.
The costing for an overnight stay in a cardiology bed was
obtained from our ﬁnance department. We calculated actual
cost savings that occurred during the period of study for
those patients who were discharged home the same day only.
Statistical analysis was performed using Statistical
Package for Social Sciences [SPSS], version 22.0 (IBM,
Chicago, Illinois). Categorical variables were reported as
numbers and percentages. Comparison analysis for cate-
gorical data was performed using the chi-square test. Where
smaller than expected values were derived, Fisher’s exact
test was performed. Continuous data underwent histogram
plots and KolmogoroveSmirnov tests of normality.
Normally distributed data were reported as mean  SD.
Non-normally distributed data were reported as median
 interquartile range. Comparison analysis for independent
normally distributed continuous data was performed using
the unpaired t test. Independent continuous data that were
not normally distributed underwent comparison analysis
using the ManneWhitney U test. A value of p <0.05 was
used for statistical signiﬁcance.
Results
There were 491 patients who underwent a complex
device procedure during the period of study (Figure 1). Of
these, 224 (53 CRTd, 40 CRTp, 131 ICD) were done during
an acute hospital admission and were excluded from anal-
ysis leaving 267 elective procedures (114 CRTd, 115 CRTp,
38 ICD). Of these, 54 (20%) were planned overnight and
213 (80%) planned same-day cases. Baseline characteristics
of the 2 cohorts are summarized in Table 1 with no sig-
niﬁcant differences noted. In the same-day cohort, there
were 9 (4.2%) unplanned overnight hospital admissions:
8 CRT (CRTp ¼ 5, CRTd ¼ 1, CRTp upgrade ¼ 2) and
1 single chamber ICD. Three were kept in because of a
complication (pneumothorax, wound hematoma); the
remaining were kept in at the operators discretion (late
ﬁnish ¼ 2, multiple co-morbidity/social reasons ¼ 2,
generally unwell after procedure with no speciﬁc
complication ¼ 2). These patients were analyzed as part of
the same-day cohort when comparing groups; however, they
were excluded from analysis of actual cost savings as they
were admitted overnight.
Successful device implantation (satisfactory lead and
device implantation) occurred in 260 (97.3%) of the entire
cohort. The 7 failed implants were all CRT (CRTp ¼ 2,
CRTp upgrade ¼ 3, CRTd ¼ 1, CRTd upgrade ¼ 1) with
reason for failure in all being inability to securely implant an
Figure 1. Figure showing the overall study cohort.
Table 1
Table showing baseline characteristics of the same-day versus overnight
cohorts
Characteristics Total Cohort
(n ¼ 267)
Same-day
(n ¼ 213)
Overnight
(n¼ 54)
P
Value
Age (yrs) median  SD 73.015.0 73.0-15.0 73.513.0 1.0
Men 196 (73%) 157 (74%) 39 (72%) 0.8
Device Type:
CRT-D 114 (43%) 91 (43%) 23 (43%)
CRT-P 115 (43%) 89 (42%) 26 (48%) 0.3
ICD 38 (14%) 33 (16%) 5 (9%)
NYHA class
1 23 (9%) 19 (9%) 4 (8%)
2 21 (8%) 17 (8%) 4 (8%) 0.4
3 199 (78%) 159 (78%) 40 (76%)
4 13(5%) 8 (4%) 5 (9%)
Ischemic etiology 146 (56%) 115 (56%) 31 (57%) 0.9
Non-Ischemic etiology 105 (42%) 83 (43%) 22 (42%) 0.9
Atrial ﬁbrillation/ﬂutter 70 (26%) 56 (26%) 14 (26%) 0.96
Previous MI 117 (47%) 92 (47%) 25 (48%) 0.9
CABG 53 (21%) 43 (22%) 10 (19%) 0.7
Hypertension 113 (42%) 92 (49%) 21 (47%) 0.8
Diabetes Mellitus 57 (23%) 49 (25%) 8 (16%) 0.2
Chronic Kidney Disease 76.0 (34%) 57 (33%) 19 (37%) 0.6
Electrocardiogram:
Q
QRS Duration
<120msec 35 (14%) 28 (141%) 7 (14%)
120-149msec 48 (20%) 42 (22%) 6 (12%)
150msec 161 (66%) 125 (78%) 36 (22%) 0.3
LBBB morphology 144 (54%) 111 (52%) 33 (61%) 0.4
Echocardiography:
Q
LVEF 35% 249 (94%) 195 (92%) 54 (100%) 0.2
Medication:
Q
Warfarin 87 (38%) 66 (37%) 21 (43%) 0.5
Aspirin 127 (56%) 101 (57%) 26 (53%) 0.8
Q
Percentage based on available data.
NYHA ¼ New York Heart Association; LBBB ¼ left bundle branch
block; LVEF ¼ left ventricular ejection fraction.
Heart Failure/Safety of Same-Day CRT/ICD Implantation 3LV lead through the CS. Reasons were CS occlusion (n ¼
2), inability to cannulate the CS because of difﬁcult anatomy
(n ¼ 2), and no usable CS branches to place the LV lead(n ¼ 3). Table 2 summarizes the complications rates of the
2 cohorts. There were no signiﬁcant differences in the
overall complication rate between the same-day versus
overnight stay cohorts and no differences at any prespeciﬁed
time points. The most common complication was LV lead
displacement (n ¼ 10): 3 successfully repositioned percu-
taneously and 7 had successful epicardial LV leads through
a surgical minithoracotomy. Two developed diaphragmatic
pacing immediately after operation because of LV lead
microdisplacement: 1 had successful LV lead reprogram-
ming, the other needed LV lead repositioning. One patient
developed a small pneumothorax immediately after opera-
tion, which was managed conservatively and discharged
home the next day. There were 4 immediate bleeding
complications: 3 wound hematomas and 1 wound oozing;
3 of these patients were on warfarin (stopped preopera-
tively) and 1 on aspirin (not stopped preoperatively). All
were treated conservatively with pressure dressings; no
reintervention or blood transfusions were required. Two LV
leads failed to capture at short-term follow-up (no macro-
displacement on chest x-ray): 1 had reprogramming of
threshold and the other required LV lead repositioning. Two
patients developed wound infections (1 short-term and
1 medium-term follow-up). Both were treated successfully
with antibiotics and required no further intervention. Wound
site pre-erosion occurred in 1 patient at short-term follow-up
and required pulse generator reburial. There were no
differences in complications between the 2 cohorts. Three
patients (1.1%) died at 30 days of device implantation;
2 from cardiovascular causes unrelated to the procedure
(1 acute myocardial infarction, 1 heart failure). There were
24 patients (9.0%) who had died 1 year after device
implantation; 12 from cardiovascular causes: 8 heart failure,
2 sudden cardiac death, and 2 acute myocardial infarction.
No deaths were device implantation related. Two deaths had
no cause identiﬁed, from primary or secondary care medical
records. A cause related to device implantation was ruled
out. All mortalities 1 year after implant occurred in
CRT implants only. There were no signiﬁcant differences in
30-day or 1-year mortality rates between the 2 cohorts
(Table 2).
Table 2
Table showing outcomes (complications and mortality) of same-day versus
ovenight cohorts
Outcomes Total Cohort
(n¼267)
Same-day
(n ¼ 213)
Overnight
(n¼54)
P
Value
Failed Procedure 7 (2.6%) 7 (3.3%) 0 0.4
Unplanned overnight stay 9 (4.3%)
Total Complications 26 (9.7%) 20 (9.4%) 6 (11.1%) 0.8
Immediate (24hrs) 9 (3.4%) 7 (3.3%) 2 (3.7%) 1.0
RV Lead Displacement (n) 2 1 1
Diaphragmatic
Stimulation (n)
2 2 0
Pneumothorax (n) 1 1 0
Hematoma (n) 3 2 1
Wound bleeding (n) 1 1 0
Short term (>24hrs-6 wks) 6 (2.2%) 4 (1.9%) 2 (3.7%) 0.4
LV Lead displacement (n) 2 1 1
RA Lead displacement (n) 1 0 1
LV Lead not capturing (n) 1 1 0
Wound infection (n) 1 1 0
Pre-erosion (n) 1 1 0
Medium term (6 wks-4 mths) 4 (1.5%) 4 (1.9%) 0 (0.0%) 0.6
LV Lead Displacement (n) 2 2 0
RV Lead Displacement (n) 1 1 0
Device Infection (n) 1 1 0
Long term (>4mths) 7 (2.6%) 5 (2.3%) 2 (3.7%) 0.6
LV Lead Displacement (n) 6 5 1
LV Lead Not Capturing (n) 1 0 1
Mortality:
Mortality  30 days 3 (1.1%) 2 (0.9%) 1 (1.9%) 1.0
Mortality 1 years 24 (9.0%) 17 (8.0%) 7 (13.0%) 0.5
Table 3
Comparison of same-day versus overnight stay CRT implantation
Characteristics CRT total
(n ¼229)
Same-day
(n ¼ 180)
Overnight
(n¼49)
P
Value
Age (median  SD) 74.014.0 74.514.0 74.013.0 0.4
Men 168 (73%) 134 (74%) 34 (69%) 0.5
Device type:
CRT-D 89 (39%) 70 (39%) 19 (38%)
Upgrade CRT-D 25 (11%) 21 (12%) 4 (8%) 0.2
CRT-P 90 (39%) 66 (37%) 24 (49%)
Upgrade CRT-P 25 (11%) 23 (13%) 2 (5%)
CRT-D Indication:
Primary prevention 87 (78%) 67 (75%) 20 (87%) 0.3
Secondary prevention 25 (22%) 22 (25%) 3 (13%)
NYHA Class
3 192 (88%) 152 (89%) 40 (83%) 0.3
4 12 (6%) 7 (4%) 5 (10%)
Electrocardiogram:
QRS Duration
120-149ms 44 (20%) 38 (22%) 6 (14%) 0.4
150ms 161 (75%) 125 (73%) 36 (82%)
LBBB 142 (62%) 109 (61%) 33 (67%) 0.6
Echocardiography:
Q
LVEF 35% (n, %) 225 (99%) 176 (98%) 49 (100%) 1.0
RA Lead Position:
Q
RA Appendage 127 (56%) 97 (54%) 30 (63%)
RA Free Wall 28 (12%) 20 (11%) 8 (17%) 0.4
No lead [due to AF] 41 (18%) 35 (20%) 6 (13%)
Lead-in-situ 27 (12%) 23 (13%) 4 (8%)
RV Lead Position:
Q
RV Apex 173 (76%) 134 (75%) 39 (81%)
RV Septum 14 (6%) 11 (6%) 3 (6%) 0.7
Lead-in-situ 37 (16%) 32 (18%) 5 (10%)
LV Lead Position:
Q
Anterior 15 (7%) 13 (8%) 2 (4%)
Antero-lateral 23 (10%) 19 (11%) 4 (8%) 0.1
Lateral 129 (58%) 105 (61%) 24 (490%)
Postero-lateral 53 (24%) 34 (20%) 19 (39%)
Posterior 1 (0.6%) 0 1 (0.5%)
LV Lead Displacement 10 (4.4%) 8 (4.4%) 2 (4.1%) 1.0
Mortality
Mortality  30 days 3 (1.3%) 2 (1.1%) 1 (2.0%)
Mortality  1year 24 (10.4%) 17 (9.4%) 7 (14.3%)
Q
Percentage based on available data.
NYHA ¼ New York Heart Association; LBBB ¼ left bundle branch
block; LVEF ¼ left ventricular ejection fraction.
4 The American Journal of Cardiology (www.ajconline.org)There were no differences in baseline characteristics,
implant data, complications, or mortality between the same-
day versus overnight stay patients undergoing CRT
implantation (Table 3). Vascular access for the right atrial
and ventricular leads was mostly cephalic vein (70%), for
LV lead was predominantly axillary vein (55%) with the
remainder through the cephalic (23%) or subclavian (21%)
veins. There were no differences in the axial LV lead
position at the midcavity level in both cohorts (79.4% vs
69.4%, p ¼ 0.6). There were 50 (19%) cardiac device
upgrades, all of which were CRT upgrades. The original
device was either a dual-chamber pacemaker (n ¼ 25, 50%),
single-chamber pacemaker (n ¼ 6, 12%), dual-chamber ICD
(n ¼ 4, 8%), or single-chamber ICD (n ¼ 15, 30%). There
were more failed procedures in the upgraded group
compared with de novo implant group (8% vs 1.2%,
p ¼ 0.04). However, there were no signiﬁcant differences in
complications between the 2 groups. There was a trend
toward higher 1-year mortality rate in the upgrade group
compared with de novo group (18% vs 9%, p ¼ 0.07).
An overnight stay on our cardiology ward (excluding
further procedures) costs $450 (£300). A similar overnight
stay on our coronary care unit costs $525 (£350). Given that
most stayed on our cardiology ward, we used $450 (£300)
for overnight stay in our analysis. The cost was determined
by the total ward budget divided by bed-days plus an
allowance for supporting medical staff and services. Our
same-day policy over this period resulted in 204 patients
(213 planned same-day minus 9 unforeseen admissions)going home the same day. This resulted in a cost saving to
our hospital of approximately $91,800 (£61,200).
Discussion
Complex cardiac device implant rates continue to rise in
Europe and North America with resultant increase in
costs.8,13 Complication rates for CRT/ICD implantation
have repeatedly been shown to be low.14 Several studies
have demonstrated same-day ICD implantation is safe and
effective but have been limited by time and speciﬁc indi-
cation.15,16 International guidelines still do not currently
recommend same-day device implantation.13
Complex device implantation has a low overall compli-
cation rate with high overall success for ICD (99%) and
CRT (93%).14 The rate of pneumothorax was found to be
Heart Failure/Safety of Same-Day CRT/ICD Implantation 5low (0.9%), and lead displacement rates were low in ICD
implants (1.8%) and tended to occur early.14 Lead
displacement was greater in CRT implants (5.9%), driven
mainly by LV lead displacement (6.8%); right atrial (1.0%)
and right ventricular leads (0.6%) had low displacement
rates.14 Postprocedural hematoma rates were similar for both
CRT (2.4%) and ICD (2.2%) implants, although this is
likely to have been underestimated. Our overall total
complication rate of 9.7% was low compared with published
data, and speciﬁc complication rates were within published
data14; this was despite including 50 CRT upgrades, which
are associated with higher complication rates.12 In addition,
our median follow-up of 30 months was greater than several
previous CRT trials. The commonest complication in our
study was LV lead displacement (4.4%) and was below the
rate reported in a systematic review (6.8%).14 Our study
demonstrated that complication rates for same-day implants
did not differ from those staying overnight with no differ-
ences in immediate, short-, medium-, or long-term compli-
cations and applied equally to both CRT and ICD implants.
Our study reﬂects real-world practice and has a high
proportion of upgraded devices, speciﬁcally CRT upgrades.
Patients having device upgrade have higher complication
rates12; however, in our study, only procedure failure was
greater compared with de novo CRT implants (8.0% vs
1.7%, p ¼ 0.04). Upgrading simple pacemakers and ICDs to
complex devices is becoming more common, although
speciﬁc data on their procedural risk are limited. Poole
et al.12 demonstrated in a large multicenter prospective
study of >1,700 upgraded pacemakers and ICDs over
6 months that complication rates were higher in transvenous
lead replacement upgrades versus lone box changes (15.3%
vs 4.0%). Hematoma formation and bleeding are common
and expensive complications in terms of hospital stay.17 The
prevalence of hematoma or bleeding in our study was low
(1.5%) with no difference between the same-day and over-
night groups; none required reintervention or blood trans-
fusion. Increasingly, patients have device implants on
continuing oral anticoagulation. These patients may poten-
tially require longer monitoring postoperatively because of a
greater risk of bleeding. Device infection may range from
superﬁcial to deep and involve the intravascular lead.18 Two
patients in our study developed pocket infection at follow-
up that was successfully treated with antibiotics; the inci-
dence of ICD infection is estimated at 0.7% to 1.2%.19,20
Patients most commonly present with erythema and
swelling at the pocket site.18 The time delay between device
implantation and presentation with pocket infection typi-
cally ranges from 1 to 16 months after implantation.21e23 In
our study, the 2 wound or device infections occurred within
the 6-week to 4-month follow-up. Three patients were kept
in because of a complication (1 pneumothorax, 2 wound
hematomas). No other major short-term complications were
noted. Theses complications, except on rare occasions, are
usually recognized and reported during or soon after the
postoperative period because of their immediate hemody-
namic cosequences24; we noted none of these following
implant. Our immediate complication rate for the entire
cohort was 3.4%, which is consistent with recently reported
registry data.15,25 Certain characteristics can play a major
role in acute device complications such as advanced age,co-morbidity (diabetes, hypertension, renal impairment),
and anticoagulant or antiplatelet therapy.15,26 In our study,
we noted 3 of 4 wound hematomas or bleeds had been on
warfarin; however, none were on warfarin at implant (1 on
aspirin), and all settled with conservative measurements.
Signiﬁcant bleeding requiring transfusion or need for pocket
reexploration has been associated with use of dual-
antiplatelet therapy or periprocedural heparin bridging
therapy.27 Another recent study on same-day ICD implan-
tation demonstrated a low rate of short-term complications
with 1 patient developing a delayed pneumothorax on the
contralateral side.16 However, this was a small study in
patients at very low risk. Contrary to our study, they
excluded patients who lived >50 miles from an emergency
department and those who were pacemaker dependent; our
day-case protocol had no such restrictions and included
CRT implants. At a time of increasing ﬁnancial pressure on
the UK health care system, efﬁciency savings such as
demonstrated are greatly welcomed. With increasing device
implants seen in Europe and North America, potential cost
savings with this strategy are signiﬁcant.
Limitations of our study were that it was a single-center,
non-randomized, retrospective study and based in a tertiary
urban center. Additionally, some patients may have had
minor complications (wound hematoma/superﬁcial infec-
tion), that resolved between follow-ups and for which no
medical advice was sought or been given antibiotics and not
mentioned at follow-up resulting in under-reporting of mi-
nor complications. Our same-day policy started in 2010, and
we were comparing patients before and after this time frame.
There have been advances in implant technology during this
period that could introduce a time-speciﬁc bias. Some
centers still perform deﬁbrillator threshold testing which can
have implications for postprocedural monitoring and
discharge. Also, cost savings for patients living in remote
regions that need readmission within 24 hours may be
signiﬁcantly impacted.Acknowledgment: The authors thank University Hospital
Coventry and Warwickshire NHS Trust Research and
Development Department for their support.
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H
eart failure is a common and disabling condition, 
defined as an abnormality in cardiac structure 
and/or function that is unable to meet the 
metabolic demands of the body. Heart failure 
affects 800 000 people in the UK and ultimately 
carries a high mortality (McMurray et al, 2012). There 
is strong evidence of the impact of obesity and overall 
body composition on the development and progression of 
heart failure. Understanding of this complex interplay is 
limited, but has clinical value given the recognized impact 
of adiposity and weight loss on predicting heart failure 
outcomes. This article summarizes the current evidence 
and importance of this interplay between heart failure, 
metabolism and body composition.
Heart failure metabolism
Under normal physiological circumstances there is a 
balance between anabolic and catabolic metabolism and 
its regulation. The development and progression of heart 
failure is associated with activation of neurohormonal 
systems, the development of a pro-inflammatory state 
and endothelial dysfunction (McMurray et al, 2012; 
Melenovsky et al, 2013; Christensen et al, 2014). The 
imbalance in metabolism that favours a pro-catabolic state 
is associated with progression of heart failure and alters 
skeletal and adipose tissue metabolism (Christensen et 
al, 2014). 
Natriuretic peptides (e.g. N-terminal prohormone of 
brain natriuretic peptide; NT-pro-BNP) are released in 
response to the haemodynamic changes in heart failure 
and convey diagnostic and prognostic value (McMurray 
et al, 2012). An inverse relationship is well established 
between levels of natriuretic peptides and body mass 
index (Christensen et al, 2013). In a small cross-sectional 
study, Christensen et al (2014) observed that high levels 
of NT-pro-BNP were associated with low total fat mass 
(ß=-0.3, P<0.05). 
Adipocytes are sensitive to natriuretic peptides, 
activating lipolysis and enhancing the expression of brown 
adipocyte genes; increasing energy use and thermogenesis 
(Christensen et al, 2014). Natriuretic peptides stimulate 
the release of adipokines, specifically adiponectin and 
leptin, which increase energy use and weight reduction 
(Christensen et al, 2014). Adipokines are involved in 
whole body energy metabolism, and adiponectin is 
particularly involved in the regulation of skeletal muscle 
metabolism and weight loss in patients with heart failure. 
In a cross-sectional study of elderly males with stable 
heart failure and no cardiac cachexia, Loncar et al (2013) 
observed that adiponectin was independently associated 
with muscle mass and strength. In a pivotal prospective 
observational study of right ventricular dysfunction 
and cardiac cachexia (n=408), Melenovsky et al (2013) 
identified that adiponectin levels were significantly raised 
in both patients with right ventricular dysfunction who 
were cachectic. Furthermore, adiponectin was one of the 
few variables (alongside NT-pro-BNP, right ventricular 
dysfunction and neurohormonal antagonist therapy) to 
independently predict cardiac cachexia (Melenovsky et 
al, 2013). 
Serum adiponectin levels are associated with severity 
of heart failure and adverse outcomes (Loncar et al, 
2013). Paradoxically, adiponectin has been observed to 
have beneficial effects on lipid and glucose metabolism, 
alongside myocardial inflammation, hypertrophy and 
The interplay between heart failure, 
metabolism and body composition
A complex interplay exists between heart failure, metabolic status and body composition. The idiosyncrasies 
of these relationships are poorly understood, but they offer prognostic value and potential clinical utility. 
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fibrosis (Okamoto, 2009). It has been identified as a well-
placed potential biomarker for the cross-talk in heart failure 
metabolism (Okamoto, 2009). 
Pro-inflammatory signals from cytokines and 
interleukin-6 (IL-6) are increased in patients with heart 
failure (Christensen et al, 2014). Proteolysis in muscle 
occurs predominantly via the ubiquitin–proteasome 
system, which has increased activation in patients with 
heart failure as a result of stimulation from these increased 
pro-inflammatory signals (Fülster et al, 2013). Christensen 
et al (2014) described a trend towards an association 
between high IL-6 levels and fat free mass. Adiponectin 
and leptin have receptors in skeletal muscle which have 
acute and chronic effects on local metabolism (Loncar et 
al, 2013). 
Adiposity and heart failure
Obesity, defined as a raised body mass index (>30.0 kg/m2), 
is recognized as a risk factor for heart failure. The risk of 
developing heart failure increases for men and women by 
5% and 7% respectively for every one unit rise in body mass 
index, independent of other important co-variables (Clark 
et al, 2014). A graded increase in risk of developing heart 
failure is recognized for increasing body mass index in both 
males and females in different population groups (Clark 
et al, 2014). Furthermore, Clark et al (2014) describe the 
increased risk of heart failure from other raised adiposity 
surrogate metrics, for example waist circumference and 
waist–hip ratio. 
Counterintuitively, those with a raised body mass index 
and established heart failure have been observed to have 
improved outcomes (Oreopoulos et al, 2008; Pocock et 
al, 2008; Futter et al, 2011; Clark et al, 2014). In a large 
meta-analysis of 28 209 patients with heart failure who 
were obese or overweight (25.0–29.9 kg/m2), Oreopoulos 
et al (2008) found an all-cause mortality of -19.0% and 
-40.0% and cardiovascular mortality of -16.0% and 
-33.0% respectively compared to those without a raised 
body mass index (<24.9 kg/m2) at >2years follow-up. The 
relationship between body mass index and mortality has a 
U-shaped curve with the lowest rates associated with those 
overweight and obese and the higher rates associated with 
leanness and severe obesity (>35.0 kg/m2) (Pocock et al, 
2008), although not all datasets have replicated this finding 
(Futter et al, 2011). 
The inverse relationship of NT-pro-BNP and 
adiponectin with body mass index and total percentage 
body fat suggests that a higher fat content protects against 
the catabolic activity of these neurohormonal signalling 
pathways, and supports the observation that fat mass is 
preserved in patients with cardiac cachexia (Christensen 
et al, 2013; Loncar et al, 2013). In a retrospective cohort 
study of 219 Chinese patients with severe left ventricular 
systolic dysfunction (ejection fraction <35%), Cai et al 
(2014) demonstrated that overweight (24.0–28.0 kg/m2) 
and obese (>28.0 kg/m2) predicted response to cardiac 
resynchronization therapy and improved survival at 
6 months. Notably in this study the defined body mass 
index ranges were lower than those used in other studies 
because the Chinese population has a lower average body 
mass index than western populations. Furthermore, this 
study demonstrated that the obese population better 
tolerated optimal medical therapy, an observation noted 
in other studies (Melenovsky et al, 2013; Cai et al, 2014).
The paradoxical observations that an overweight or 
obese body mass index predicts development of heart 
failure but offers improved survival once established is 
referred to as the ‘obesity paradox’ (Pocock et al, 2008; 
Clark et al, 2014). Several explanations and hypotheses 
have been offered to explain the obesity paradox. First, 
lower levels of natriuretic peptides are seen in obese 
patients, therefore symptoms may present earlier (Clark et 
al, 2014). Second, patients with lower levels of circulating 
natriuretic peptides are thought to have a more attenuated 
renin–angiotensin–aldosterone system (Clark et al, 2014). 
Despite this, obesity also contributes to maintaining 
systemic blood pressure, preserving renal function, 
which allows patients to better tolerate anti-heart failure 
medication (Clark et al, 2014). Third, body mass index is 
a crude metric of body composition, with some patients 
classified as overweight or obese actually containing a high 
proportion of muscle; body mass index does not account 
for the different body composition components (Clark 
et al, 2014). Finally, obesity is a heterogeneous condition 
with various fat mass distributions. These can include 
visceral fat deposits or subcutaneous or gluteofemoral 
obesity, each of which have differing metabolic profiles 
(Clark et al, 2014). 
Body composition and heart failure
Muscle wasting is common in patients with heart failure. 
Sarcopenia, defined as reduced muscle mass and limited 
mobility, occurs naturally with aging at a rate of 1–2% 
per annum over 50 years of age. Fülster et al (2013) 
recruited 200 patients with heart failure at a single centre 
and observed that 19.5% of the cohort had sarcopenia, 
a higher proportion than would be expected through 
natural aging. Significantly patients with heart failure 
with both reduced (68.8%) and preserved (31.2%) 
ejection failure were recruited to this study (Fülster et 
al, 2013). Heart failure patients with sarcopenia had 
a higher incidence of reduced left ventricular ejection 
fractions, reduced muscle strength, worse functional 
capacity and significantly higher IL-6 levels (Fülster et 
al, 2013). Elevated levels of pro-inflammatory signals in 
patients with heart failure, including cytokines and IL-6, 
stimulate catabolic pathways, for example the ubiquitine-
protease pathway, and cause sarcopenia (Fülster et al, 
A graded increase in risk of developing 
heart failure is recognized for increasing 
body mass index in both males and females 
in different population groups. 
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Long-Term Follow-Up of Isolated Epicardial Left
Ventricular Lead Implant Using a Minithoracotomy
Approach for Cardiac Resynchronization Therapy
CHRISTOPHER J. McALOON, M.B.CH.B., M.R.C.P., P.G.C.M.E.,*
BENJAMIN M. ANDERSON, M.B.CH.B., M.R.C.P.,* WADIH DIMITRI, M.D., F.R.C.S.,*
JONATHAN PANTING, PH.D., F.R.C.P.,† SHAMIL YUSUF, PH.D., M.R.C.P.,†
SUNIL K. BHUDIA, M.D., F.R.C.S.,* and FAIZEL OSMAN, M.D., F.R.C.P., F.E.S.C.*
From the *Department of Cardiology, University Hospital Coventry, Coventry, UK; and †Department of Cardiology,
Good Hope Hospital, Heart of England NHS Trust, Birmingham, UK
Background: Transvenous left ventricular (LV) lead placement for cardiac resynchronization therapy
is unsuccessful in 5–10% of reported cases. These patients may benefit from isolated surgical placement
of an epicardial LV lead via minithoracotomy approach.
Aim: To evaluate the success of this approach at long-term follow-up.
Methods: Retrospective evaluation of all consecutive patients undergoing isolated epicardial LV lead
placement after failed transvenous attempt over a 6-year period. Data collected on baseline parameters,
procedural details, and outcome at follow-up (hospital stay, complications, mortality, and clinical
response).
Results: Forty-two patients underwent epicardial lead implant. Five died within 1 year (11.9%): two
(4.8%) died within 30-days post op (one from intraoperative hemorrhage, the other from multiple organ
failure); 39 (95.1%) were admitted to the high dependency unit and transferred to the ward <24 hours.
Median hospital stay was 3.4 ± 1.9 days. The overall complication rate was 17.5% (n = 7): 15.0% (n =
6) short term and 2.5% (n = 1) long term; these included three (7.5%) LV noncapture events all treated
with reprogramming. There were two (5.0%) wound infections requiring oral antibiotics and two (5.0%)
device infections requiring intravenous antibiotics (one had device resiting, the other developed septic
shock requiring intensive care admission). Assessment of clinical response was possible in 34 (81.0%)
at follow-up: 21 (61.8%) were responders and 13 (28.2%) nonresponders with no significant differences
between these groups; no clinical predictors of response were identified.
Conclusion: Isolated epicardial LV lead implant using minithoracotomy is relatively safe and effective
at successful LV pacing. Response rate and postoperative recovery at long-term follow-up are reasonable
in these high-risk patients. (PACE 2016; 39:1052–1060)
cardiac resynchronization therapy, epicardial LV lead, minithoracotomy
Introduction
Cardiac resynchronization therapy (CRT) is
a highly successful treatment option for chronic
heart failure with cardiac dyssynchrony that
is refractory to medical therapy.1,2 Successful
placement of the left ventricular (LV) lead is
essential in order to achieve resynchronization.
The initial approach is via the transvenous route
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utilizing the coronary sinus. However, LV lead
placement at an optimal site can be challenging
due to anatomical or pathological factors (such
as the presence of myocardial scar). Failure of
LV lead delivery via the transvenous route has
been reported in 5–10% of cases.3–5 Epicardial
LV lead placement is an important second-line
option to allow these patients to benefit from
CRT.4,5 Current national and international guide-
lines on CRT have resulted in ever-increasing
numbers of patients being offered this therapy,
resulting in a higher demand for alternative LV
lead placement options if the transvenous route
fails.6
Multiple surgical options are available for
placement of an epicardial LV lead. These
include use of a median sternotomy (such as
with coronary artery bypass grafting [CABG] or
©2016 Wiley Periodicals, Inc.
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valve repair/replacement), full left lateral thora-
cotomy, and a minimal thoracotomy approach
(minithoracotomy).5,7 The full lateral thoracotomy
offers wider access to the left lateral wall of
the left ventricle. However, the minithoracotomy
approach is less invasive and is used more
commonly because of the lower incidence of
mediastinitis or osteomyelitis.8 The reported
success of surgically placed epicardial LV leads is
variable, in terms of durability and complications,
both in the short term and long term.3,9–11 Long-
term infection of devices has been quoted to
be as high as 9.6%.9 Nonresponse among heart
failure patients undergoing CRT represents a
significant problem and has been reported to
occur in up to 30% of implants.1 Mechanical
and anatomical causes can contribute to this
burden.
The objective of this study was to report our
6-year experience of the minithoracotomy ap-
proach for isolated placement of epicardial LV
leads following failure of the traditional transve-
nous route. We report the success of this approach,
length of hospital stay, complications, and clinical
predictors of response following epicardial LV
lead placement.
Methods
Study Design
We performed a retrospective study of all
consecutive patients who underwent surgical
placement of an epicardial LV lead via a
minithoracotomy approach at University Hospital
Coventry, UK, between November 2007 and
November 2013. Eligibility for the study was that
all patients had at least one attempt at transvenous
LV lead implant via the coronary sinus as part
of a CRT-pacemaker or CRT-defibrillator (CRT-
D) implant. All patients met national criteria for
CRT implantation and both de novo and upgraded
cardiac devices were included in the study. All
surgical epicardial LV lead placements using
alternative approaches were excluded. Patient
electronic and paper case records were used to
obtain baseline patient demographics, procedu-
ral details, length of hospital stay, epicardial
lead data, and outcome measures. Approval for
the study was obtained from our hospital’s
Research, Development, and Innovation depart-
ment. The study conformed to the declaration
of Helsinki.
Approach to Performing Minithoracotomy
All procedures were performed in the operat-
ing theater under general anesthesia on the beating
heart by one of two experienced cardiothoracic
surgeons (WD, SKB); both surgeons had extensive
cardiac surgical experience as consultants (WD
30 years/SKB 10 years) and each had com-
prehensive experience of the technique. The
incision was left submammary with standard
monitoring in all cases (electrocardiogram, pulse
oximetry, invasive arterial monitoring, central
venous line, and external defibrillator pads) and
Swan-Ganz catheter used if needed. Standard
single lumen intubation was utilized. Patients
were placed in a supine position with the left
chest elevated by 30°–40°. A 3–4-cm incision
was made in the left submammary region to
enter either the 4th or the 5th intercostal space
depending on the chest x-ray. The pericardial
fat was dissected superiorly and the pericardium
opened vertically using a 1–2-cm incision. The
lateral LV wall of heart was identified and the
muscular portion approached for implantation
of a screw-on unipolar lead (Medtronic 5071,
Medtronic Inc., Minneapolis, MN, USA) in all
cases. Lead threshold measurements were taken
and data accepted if threshold was <2 V and
R-wave sensing >4 mV. The IS-1 connector of
the lead was passed through the same intercostal
space and tunneled submuscular to a left pectoral
pocket and the pacemaker pulse generator con-
nected. The incisions were closed in a layered
manner.
Device Follow-Up
Each patient was seen routinely following
LV epicardial lead placement by the cardiol-
ogy/cardiothoracic team and at the CRT pacing
clinic. Referrals from external centers were often
repatriated for continued care and follow-up
data obtained from those centers. Following
LV epicardial lead placement, routine device
check was performed initially at 2 months,
6 months, and then annually, dependent on
the local center policy and individual clinical
situation. Epicardial LV lead data (impedance and
threshold) were recorded following the first check
and annual check.
Outcomes Measures
The outcome measures reported included
hospital stay, complication rates, and mortality
at follow-up. Duration of stay on the high
dependency unit (HDU) and overall hospital
stay was reported for each patient in the study.
The overall complication rates were recorded
and defined as immediate (24 hours), short
term (>24 hours to 4 months), and long term
(>4 months to 1 year). Complications were broadly
classified as failure of procedure, epicardial LV
lead failure, infection, and hemorrhage (defined
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as >2 g/dL hemoglobin reduction requiring blood
transfusion). All-cause mortality was recorded
for all patients up to 1-year postprocedure. The
30-day mortality rate was examined separately
from complications.
Clinical Response
Clinical response was defined as a reduction
of New York Heart Association (NYHA) class 1.
NYHA symptom classification was determined
based on the first formal assessment following the
procedure. Clear documentation of NYHA score
or detailed symptom evaluation was required
for an independent reviewer to conclude NYHA
score. Where classification was unclear, a second
reviewer assessed the consultation, requiring a
consensus to determine a score. Where no clear
documentation or consensus was achievable, then
no response classification was possible.
Statistical Analysis
Statistical analysis was performed using
Statistical Package for Social Sciences (SPSS),
version 22.0 (IBM Corp., Armonk, NY, USA).
Categorical variables were reported as frequency
and percentages. Comparison analyses for cate-
gorical data were performed using the χ2 and
Fisher’s exact tests. Continuous data underwent
histogram plots for assessment of normality.
Normally distributed data were reported as mean
± standard deviation (SD) and comparative
analysis was performed using independent t-
tests. Nonnormally distributed data were reported
as median with interquartile range and were
compared using a Mann-Whitney U test. Paired
continuous data (dependent on whether distribu-
tion parametric or nonparametric) were compared
with a paired t-test or Wilcoxon signed-rank
test, respectively. Univariate logistic regression
analysis was performed on clinical response.
Those variables that achieved a P value <0.15
were pooled as covariants for multiple logistic
regression. A high alpha was set on the basis
of the clinical response definition. A stepwise
entry method was applied with forward selection
and backward elimination to ensure duplication
of findings. The accuracy of the model was
verified with a Hosmer-Lemeshow goodness-of-fit
test. A P value <0.05 was considered statistically
significant.
Results
A total of 42 patients underwent epicardial
LV lead placement using the minithoracotomy
approach. Table I demonstrates the baseline
characteristics of the cohort. The reason for
referral for epicardial LV lead placement is shown
in Figure 1. A total of 41 (97.6%) patients
Table I.
Baseline Characteristics of Overall Cohort
Baseline Characteristics N = 42
Age (median and IQR) 73.5 (64.0–76.3)
Male (n, %) 33 (78.6%)
CRT-D implant (n, %) 21 (50.0%)
CRT upgrade (n, %) 10 (23.8%)
NYHA baseline (mean ± SD) 2.95 ± 0.38
Ischemic cardiomyopathy (n, %) 29 (69.0%)
Myocardial infarction (n, %) 23 (54.8%)
Previous PCI (n, %) 10 (23.8%)
Previous CABG (n, %) 10 (23.8%)
Diabetes mellitus (n, %) 12 (28.6%)
Hypertension (n, %) 25 (59.5%)
Chronic kidney disease (n, %) 13 (31.0%)
CABG = coronary artery bypass grafting; CRT = cardiac
resynchronization therapy; CRT-D = CRT-defibrillator; IQR =
interquartile range; NYHA = New York Heart Association; PCI =
percutaneous coronary intervention; SD = standard deviation of
mean.
had successful LV lead placement, with one
mortality occurring intraoperatively. All LV lead
data at implant were accepted if LV threshold was
2.0 V with R-wave sensing >4 mV; this was
noted in all LV lead implants. No patients required
cardiopulmonary bypass. Six (14.3%) patients
had an additional procedure performed at the
same time (four had pulse generator changes,
one resitting of pulse generator pocket, and one
removal of transvenous LV lead). None of these
additional procedures were associated with any
complication or 30-day mortality. Overall success
rate was the same for both surgeons and overall
individual complication rate was not statistically
different (13.0% vs 21.1%, P = 0.78).
Hospital Stay
Postoperatively all patients were transferred
to the HDU, with the exception of one patient who
was transferred directly to the ward. A total of
39 (95.1%) patients spent 1 day on HDU before
being transferred to the ward. The remaining
patients spent 7 days on HDU before dying from
multiple organ failure. Total hospital stay for
patients discharged (n = 40) was 3.4 ± 1.9 days.
Four patients were transferred back to the referring
center for convalescence with no prolonged stay
reported at the referring centers.
Complications
The total number of complications following
the procedure within 1 year was nine (21.4%);
this included two patients who died within the
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Figure 1. Transvenous left ventricular lead failure reasons (N = 42).
Table II.
Overall Complications, Both Short Term and Long Term (N = 40)
Short Term (>24 Hours to 4 Months) Long Term (>4 Months to 1 Year)
n = 6 (15.0%) n = 1 (2.5%)
LV lead noncapture (n, %) 2 (5.0%) LV lead noncapture (n, %) 1 (2.5%)
Wound infection (n, %) 2 (5.0%)
Device infection (n, %) 2 (5.0%)
LV = left ventricular.
hospital admission (discussed separately later).
The number of complications of those discharged
from hospital (n = 40) was seven (17.5%).
Table II shows these specific complications classi-
fied by the predefined time period postprocedure.
There were three LV lead noncapture events at
follow-up with an initial attempt at reprogram-
ming made in all; this was successful in one
patient. The second patient went on to have a
reattempt at transvenous LV lead placement which
failed; the patient was referred back for a repeat LV
epicardial lead placement, but died waiting for the
lead placement from unrelated events over a year
after the initial implant. The remaining patient did
not want any further intervention and went on to
have the CRT removed and leads capped.
Infection occurred in four (10%) patients
within a year of the epicardial lead placement.
Wound infection occurred in two of these cases
and was treated successfully with one course
of oral antibiotics. Device infection accounted
for the other two patients and both required
hospital admission; one patient developed septic
shock secondary to his device infection and was
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treated with intravenous antibiotics; there was no
evidence of infection on the intravascular leads.
The patient required admission to the intensive
care unit for inotropic support. He responded well
to medical therapy and did not require further
intervention on his device. The remaining patient
required intravenous antibiotics and resiting of
the CRT pulse generator. All patients made a full
recovery from these episodes.
Upgrade versus Nonupgrade Cases
There were 32 de novo and 10 upgrade
CRT cases. All de novo epicardial LV lead
placements were successful compared with nine
upgraded CRT cases. The one patient who was not
successful had the intraoperative mortality and
was originally a CRT-D upgrade. In the de novo
group, there were four (12.4%) complications and
in the upgrade group, there were three (30.0%)
complications with no statistical difference noted
(P = 0.42). The specific complications that
occurred for CRT upgrade cases were one wound
infection, one device infection (requiring intra-
venous antibiotics and device resitting), and one
LV lead noncapture. No difference in complication
pattern was observed between both groups.
Epicardial LV Lead Data
There were 26 patients who had epicardial
LV lead data available at the first checkup (median
2.1 [1.2–3.0] months). Four deaths occurred before
the first routine device checkup. One patient
was immediately transferred to an external center
outside the region. There were 13 patients whose
epicardial LV lead data were not available despite
extensive searches at several centers. The annual
review epicardial LV lead data were available
for 23 patients; two patients were transferred to
external centers and one patient died following the
first checkup (median 13.3 [11.7–14.2] months).
Figure 2 shows there was no significant change
in epicardial LV lead threshold or impedance
between the two checks.
Mortality
There were five (11.9%) deaths within 1 year
of the epicardial procedure. The median time
to 1-year mortality was 1.3 (0.1–4.1) months.
Two patients (4.8%) died within 30 days of
the procedure: one died intraoperatively due
to catastrophic hemorrhage from a left atrial
appendage rupture. Despite operative intervention
and aggressive resuscitation, the bleeding site
extended and the situation was unfortunately ir-
reversible. The other patient died postoperatively
on HDU 7 days after the procedure. The procedure
was complicated by one episode of ventricular
tachycardia upon identifying and opening the
Figure 2. Epicardial left ventricular lead data (thresh-
old @ 1 ms and lead impedance) between first (N = 26)
and annual device check (N = 23).
pericardium; the patient had a background of
severely impaired LV systolic function due to
dilated cardiomyopathy. This was treated im-
mediately by direct current cardioversion and
administration of adrenaline. The remaining part
of the procedure was uncomplicated and the
patient remained hemodynamically stable. The
patient was transferred to the HDU for more
intensive monitoring following the ventricular
tachycardia. Initially the patient recovered well;
however, he developed paralytic ileus followed
by acute on chronic renal failure and multiple
organ failure. Vasopressor drug requirements
continued to increase without any improvement
in clinical course. The decision was taken that
the patient was unlikely to survive and was made
comfortable. The patient was at high surgical risk
prior to the procedure being performed given his
comorbidity (severe heart failure and chronic renal
impairment). Three further patients had died by
1-year postprocedure; none of these deaths were
attributable to the placement of the epicardial LV
lead.
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Table III.
Responder and Nonresponder Baseline Characteristics (N = 34)
Response n = 21 (61.8%) Nonresponse n = 13 (38.2%) P Value
Age (median and IQR) 71.0 (61.5–76.0) 72.0 (65.5–77.0) 0.52
Male (n, %) 17 (81.0%) 9 (69.2%) 0.71
CRT-D (n, %) 11 (52.4%) 6 (46.2%) 1.00
Upgrade (n, %) 6 (28.6%) 2 (15.4%) 0.64
NYHA baseline (mean ± SD) 3.0 ± 0.45 2.9 ± 0.38 0.31
NYHA follow-up (mean ± SD) 1.62 ± 0.67 2.9 ± 0.38 0.00
Ischemic cardiomyopathy (n, %) 14 (66.7%) 9 (69.2%) 1.00
Myocardial infarction (n, %) 9 (42.9%) 9 (69.2%) 0.25
Angina (n, %) 8 (38.1%) 3 (23.1%) 0.59
Previous PCI (n, %) 4 (19.0%) 4 (30.8%) 0.71
Previous CABG (n, %) 3 (14.3%) 6 (46.2%) 0.1
Diabetes mellitus (n, %) 7 (33.3%) 2 (15.4%) 0.45
Hypertension (n, %) 12 (57.1%) 7 (53.8%) 1.00
Chronic kidney disease (n, %) 5 (23.8%) 4 (30.8%) 0.96
Complication 1 year (n, %) 6 (28.6%) 1 (38.2%) 0.305
Abbreviations as in previous tables.
Table IV.
Logistic Regression Analysis for Clinical Predictors of CRT Response
Univariate Multivariate
OR P Value CI OR P Value CI
Age 0.96 0.39 0.88–1.05
Male 1.89 0.44 0.38–9.40
CRT-D 1.28 0.72 0.32–5.13
Upgrade 2.20 0.39 0.37–13.04
Ischemic cardiomyopathy 1.13 0.87 0.25–5.00
Myocardial infarction 0.33 0.14 0.07–1.44 0.46 0.33 0.10–2.17
Previous PCI 0.53 0.44 0.11–2.63
Previous CABG 0.19 0.05 0.038–1.00 0.24 0.10 0.04–1.32
Diabetes mellitus 2.75 0.26 0.47–16.0
Hypertension 0.88 0.85 0.21–3.51
Chronic kidney disease 0.70 0.65 0.15–3.31
Complication 1 year 4.80 0.17 0.51–45.5
CI = confidence interval; OR = odds ratio. Other abbreviations as in previous tables.
Clinical Response
The clinical response status of the cohort was
definable in 34 (81.0%) patients. Two patients
died before any formal follow-up could be
performed; a further six patients did not have
a follow-up NYHA classification performed or
definable. Table III compares clinical variables
between responders and nonresponders. The
median time to first cardiology/cardiothoracic
surgery follow-up was 7.3 weeks (range 0.6–61).
Specifically, the median follow-up for responders
and nonresponders was 7.9 weeks (range 3.0–
52.1) versus 6.0 weeks (range 0.6–61.0 weeks),
P = 0.1. Table IV demonstrates logistic regression
univariate and multivariate analysis. Baseline
NYHA classification was not used in the analysis
as it was used to define the clinical response
outcome measure. The multivariate analysis was
verified by the Hosmer-Lemeshow goodness-of-
fit test (P = 0.144). Significant independence
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of predictors to determine clinical response
following epicardial LV lead insertion was not
demonstrated, but a trend toward a worse outcome
was seen with previous CABG. The presence
of any previous complication demonstrated no
difference between clinical responders and non-
responders.
Discussion
Isolated surgical epicardial LV lead placement
is well established as a second-line option for
failed transvenous LV lead placement during
CRT and is increasingly being utilized.5 The
failure rate of the transvenous route for LV
lead implant has been reported between 5%
and 10%.5 Placement of a transvenous lead can
be suboptimal due to coronary venous anatomy
and presence of myocardial scar burden.5,12
Furthermore, complications can occur with the
LV lead with the most frequent displacement at
6.8%.13 Occasionally, these complications cannot
be corrected percutaneously and require surgical
placement. Our cohort represents a large regional
center for performing surgical epicardial lead
placements over 6 years and the commonest
reason for referral was failure to percutaneously
place the LV lead in the coronary sinus at CRT
implant in 59.5%. The commonest reason for
failure was the inability to access the coronary
sinus branch or achieve adequate pacing capture.
Late failure of the transvenous LV lead accounted
for referral in 40.5% of cases, which was most
common for diaphragmatic stimulation.
The surgical approach to epicardial lead
placement offers several advantages over the
transvenous approach. Overall, the surgical ap-
proach has a lower risk of lead dislodgement and
phrenic nerve stimulation.11 Moreover, placement
of the LV lead is not limited by coronary venous
anatomy.14 Despite these advantages, there are
several important disadvantages to the approach.
The general anesthesia risk is significant in a high-
risk heart failure group.5 The approach is more
invasive and can be limited by adhesions and
epicardial fat.5 Furthermore, the recovery period,
which usually involves a HDU stay, is significantly
more prolonged with a surgical approach.11
Miller et al. suggested a significantly
higher mortality in patients having isolated
surgical LV lead placement compared with
transvenous lead placement within the first
3 months postprocedure.15 In contrast, Patwala
et al. demonstrated a reasonable success in the
3–6 months following placement.10 The failure
rate for epicardial leads has been reported to
become higher and more consistent the further
away from the procedure the patient moves.5 The
superiority of transvenous LV lead placement at
the initial procedure is clear, but the surgical
approach remains the main second-line option.
Numerous surgical approaches are available
to implant an epicardial LV lead. A full left
thoracotomy approach is used primarily for CABG
and/or valve repair/replacement. This approach
offers the widest access to the LV lateral wall, but
is used less frequently for isolated lead placement
due to the prolonged recovery and potential risks.5
The minithoracotomy approach is a common
method used by many centers due to improved
survival and reduced incidence of mediastinitis
or osteomyelitis.3,8 The procedure demonstrated
long-term hemodynamic benefit, improved LV
ejection fraction, and NYHA score that can
be achieved following an LV epicardial lead
placement via a minithoracotomy approach.16
Video-assisted thoracoscopy offers direct visual
control and precise delivery of the epicardial
lead tip.5 The procedure offers fewer incisions
and is often better tolerated, though specialists
and specific technology is required.5 The novel
surgical option of robotic assisted surgery is
available and boasts a 98% technical success
rate and low complication rate.17 The greatest
restriction to the use of this technology is cost,
though extensive follow-up data are not available
to judge the success of the therapy.5
Isolated surgical delivery of an epicardial LV
lead is commonly delivered by the minithoraco-
tomy approach when the transvenous route is not
possible or has failed. Several studies have demon-
strated variable success of the minithoracotomy
approach for isolated LV lead placement.5,10,11,15
Our cohort offers a large single tertiary center long-
term experience of isolated surgical placement
of epicardial LV leads via the minithoracotomy
approach. The 1-year all-cause mortality rate for
our cohort was 11.9%, which is lower than
reported in other studies.15 In our cohort, 4.8%
died while in the hospital following the procedure,
including one patient who died intraoperatively
from a significant bleed. Mair et al. reported a
30-day mortality of 6.3%, though this relates to
one death that was not directly attributed to the
minithoracotomy procedure.3 In the cohort, 95%
were discharged from the intensive therapy unit
within 24 hours and one patient went straight
from surgical recovery to the step-down ward,
which is lower than reported by Doll et al. at
3.8 days.11 Our overall complication rate was
similar to those reported previously.3,9 Infection
postprocedure was the commonest complication,
accounting for 10% of the cohort, which is
comparable to other reported infection rates,9
all occurring at short-term follow-up. Half were
wound infections not requiring hospitalization;
the other half were device infections requiring
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T
he burden of heart failure on both the individual 
patient and wider society continues to increase 
despite optimal medical therapy. Cardiac 
resynchronization therapy has become established 
therapy for selected patients with heart failure 
who are refractory to optimal medical therapy. 
Heart failure is defined as an abnormality in cardiac 
structure and function that leads to the inability of the 
heart to deliver adequate levels of oxygen to match the 
metabolic demand of the tissues (McMurray et al, 2012). 
Patients commonly suffer from a plethora of symptoms 
including breathlessness, ankle oedema and fatigue 
(McMurray et al, 2012). Heart failure affects approximately 
800 000 people in the UK (McMurray et al, 2012), about 
half of whom have heart failure with reduced ejection 
fraction. The mortality from heart failure is estimated at 
30–40% within a year of diagnosis (Cowie et al, 2000), 
a rate that surpasses that of many malignancies. Several 
pharmacological agents, specifically angiotensin-receptor 
blockers (Swedberg and Kjekshus, 1988), beta-blockers 
(Packer et al, 1996), mineralocorticoid receptor antagonists 
(Pitt et al, 1999) and angiotensin receptor neprilysin 
inhibitors (Packer et al, 2015), significantly improve 
morbidity and mortality. Despite advances in medications 
the incidence and prevalence of heart failure continues to 
rise and confers a poor prognosis (McMurray et al, 2012). 
Cardiac resynchronization therapy has revolutionized 
management of patients with heart failure and improved 
outcomes. 
Heart failure with reduced ejection fraction 
and cardiac dyssynchrony
Many patients with heart failure with reduced ejection 
fraction develop dyssynchronous contractions of the 
heart as a result of damage to the underlying conduction 
tissue causing inefficient cardiac contraction that leads 
to symptoms. Cardiac dyssynchrony is a complex and 
multifactorial process that impacts function (Brignole et 
al, 2013). Prolongation of atrioventricular conduction 
encroaches on the starting of systole and filling of early 
diastole. With delayed ventricular contraction, the left 
ventricular diastolic pressure exceeds left atrial pressure 
during passive filling, leading to development of functional 
mitral regurgitation (Brignole et al, 2013). The impact 
of reducing ventricular pre-load leads to reduced left 
ventricular contractility, by the Starling mechanism. 
Moreover, the occurrence of intra- and inter-ventricular 
conduction delay causes asynchronous left ventricular 
contraction (so-called mechanical dyssynchrony) leading to 
reduced stroke volume, left ventricular ejection fraction and 
systolic blood pressure (Brignole et al, 2013). Ventricular 
dyssynchrony leads to dis-coordinated papillary muscle 
contraction and further contributes to development and 
progression of functional mitral regurgitation, with the 
whole process contributing to left ventricular adverse 
remodelling (Brignole et al, 2013).
Cardiac resynchronization therapy
Cardiac resynchronization therapy or ‘biventricular 
pacing’ involves implanting pacing leads into the heart 
via the transvenous route to the right and left ventricles 
(the latter through the coronary sinus) to resynchronize 
ventricular contraction. A lead is implanted to the right 
atrium to achieve atrioventricular synchrony (Figure 
1) unless the patient has permanent atrial fibrillation. 
Cardiac resynchronization therapy can ‘resynchronize’ 
cardiac contraction through restoration of inter-/intra-
ventricular and atrioventricular dyssynchrony (Brignole et 
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al, 2013). Cardiac resynchronization therapy improves left 
ventricular ejection fraction, left ventricular contractility, 
left ventricular filling time and reduces functional mitral 
regurgitation, which in turn can induce reverse left 
ventricular remodelling (Brignole et al, 2013). Cardiac 
resynchronization therapy can also be combined with a 
defibrillator function in selected patients. Implantable 
cardioverter defibrillators are designed to reduce the risk 
of sudden cardiac death caused by ventricular arrhythmias, 
by delivering anti-tachycardia pacing or shock therapy. 
This can be performed for those identified at high risk 
(primary prevention) or those who have had a malignant 
ventricular arrhythmia and survived (secondary prevention) 
(Goldenberg et al, 2011). Cardiac resynchronization therapy 
devices that have defibrillator functionality are referred to as 
cardiac resynchronization therapy-defibrillators and those 
without as cardiac resynchronization therapy-pacemakers.
Who benefits from cardiac resynchronization 
therapy?
Over the last 20 years cardiac resynchronization therapy has 
become one of the most effective treatments for heart failure 
and is appropriate for ~25–30% of heart failure patients 
(Daubert et al, 2012). Cazeau et al (1994) showed that a 
cardiac resynchronization therapy-pacemaker in a 54-year-
old patient with advancing heart failure improved New 
York Heart Association (NYHA) symptoms. Since then 
multiple randomized controlled trials have demonstrated 
the resounding benefit of cardiac resynchronization therapy 
for patients with heart failure with reduced ejection 
Table 1. Randomized control trials evaluating cardiac resynchronization therapy in sinus rhythm
Trial (reference) No Study design Inclusion Outcome Main findings
COMPANION 
(Bristow et al, 
2004)
1520 Double-blinded, randomized 
– optimal medical therapy vs 
CRT-d or CRT-p, 15 months
NYHA III–IV, left ventricular 
ejection fraction <35%, 
QRS >120 msec
Primary – all-cause mortality or 
hospitalizations, secondary – all-
cause mortality, cardiac mortality
CRT-d and CRT-p reduced 
all-cause mortality and 
hospitalization
CARE-HF 
(Cleland et al, 
2005)
813 Double-blinded randomized 
– optimal medical therapy vs 
CRT-p, 29.4 months
NYHA III–IV, left ventricular 
ejection fraction <35%, 
QRS >120 msec
Primary – all-cause mortality or 
hospitalizations, secondary – all-
cause mortality, NYHA, quality of life
CRT-p reduced all-cause 
mortality, hospitalizations and 
improved NYHA, quality of life
REVERSE (Linde 
et al, 2008)
610 Double-blinded, randomized 
– CRT-ON vs CRT-OFF, 
12 months
NYHA I–II, left ventricular 
ejection fraction <40%, 
QRS >120 msec
Primary – % worsened heart failure 
clinical composite, secondary – left 
ventricular end systolic volume 
index, heart failure hospitalizations, 
all-cause mortality
CRT-p/CRT-d did not change 
the primary endpoint, reduced 
left ventricular end systolic 
volume index, heart failure 
hospitalizations
MADIT-CRT 
(Moss et al, 
2009)
1820 Single-blinded, randomized 
– CRT-d vs internal cardiac 
defibrillator, 12 months
NYHA I–II, left ventricular 
ejection fraction <30%, 
QRS >130 msec
Primary – all-cause mortality 
or heart failure hospitalizations, 
secondary – all-cause mortality, 
left ventricular end systolic volume
CRT-d reduced the primary 
endpoint and left ventricular 
end systolic volume, CRT-d did 
not reduce all-cause mortality
RAFT (Tang et al, 
2010)
1798 Double-blinded, randomized 
– CRT-d vs internal cardiac 
defibrillator, 40 months
NYHA II–III, left ventricular 
ejection fraction <30%, 
QRS >120 msec
Primary – all-cause mortality 
or heart failure hospitalizations, 
secondary – all-cause mortality 
and cardiovascular death
CRT-d reduced primary 
endpoint CRT-d (NYHA III) 
reduced all-cause mortality
CRT-d = cardiac resynchronization therapy-defibrillator; CRT-OFF = cardiac resynchronization therapy – turned OFF; CRT-ON = cardiac resynchronization therapy – turned ON; 
CRT-p = cardiac resynchronization therapy-pacemaker; NYHA = New York Heart Association. Adapted from Brignole et al (2013).
fraction who have mechanical dyssynchrony, with reduced 
mortality and hospitalization (Bristow et al, 2004; Cleland 
et al, 2005) alongside improved quality of life (Cleland et 
al, 2005; Moss et al, 2009; Tang et al, 2010), symptoms 
(Abraham et al, 2002), functional performance (Abraham 
et al, 2002) and left ventricular volumes (Linde et al, 2008). 
Table 1 summarizes the largest randomized controlled trials 
examining cardiac resynchronization therapy in specific 
patients with heart failure with reduced ejection fraction 
Figure 1. Cardiac resynchronization therapy (CRT) device. 
CRT device
Right atrial lead
Coronary
sinus lead
Right ventricular lead
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and sinus rhythm. 
Unfortunately, not all patients who have heart failure 
benefit from cardiac resynchronization therapy. Multiple 
randomized controlled trials have informed and refined 
implantation criteria of national and international 
guidelines. Benefit has consistently been demonstrated in 
patients with severe left ventricular systolic dysfunction (left 
ventricular ejection fraction ≤35%). Those with moderate 
impairment (left ventricular ejection fraction 35–45%) can 
be offered cardiac resynchronization therapy if they have 
a bradycardia pacing indication and are likely to require 
>40% pacing (Curtis et al, 2013). 
New York Heart Association classification
NYHA symptom classification as a criterion initially 
favoured more symptomatic patients in class III or IV 
(Table 1). Interestingly, these trials consistently recruited 
a substantially lower proportion of patients with NYHA 
IV symptoms (representing 7–15%) (Brignole et al, 2013). 
More recent randomized controlled trials have included 
patients with milder heart failure symptoms (NYHA I–
II) and demonstrated improvement in cardiovascular 
outcomes and reverse left ventricular remodelling. However, 
NYHA class I patients represented a small proportion of 
the participants in all trials and no benefit was specifically 
seen for these in sub-group analyses (Linde et al, 2008; 
Moss et al, 2009). 
QRS duration
QRS duration is one of the most powerful predictors of 
benefit from cardiac resynchronization therapy. Sub-group 
analyses of MADIT-CRT (Moss et al, 2009; Hsu et al, 
2012), REVERSE (Linde et al, 2008) and RAFT (Tang et 
al, 2010) consistently demonstrated that patients with QRS 
durations ≥150 msec on resting 12-lead electrocardiogram 
have the greatest reduction in cardiovascular outcomes. 
Cleland et al (2013) performed a large meta-analysis 
(n=3782) from five Medtronic Ltd (Minneapolis, USA) 
sponsored randomized controlled trials comparing cardiac 
resynchronization therapy with no active treatment or 
cardiac resynchronization therapy-defibrillator with 
implantable cardiac defibrillators. Several pre-defined 
variables were evaluated to identify if they predicted a 
composite outcome of all-cause mortality and/or first heart 
failure hospitalization (Cleland et al, 2013). Patients with 
atrial fibrillation and NYHA I symptoms were excluded 
from analysis as they only comprised a small proportion 
of patients. Cleland et al (2013) accounted for the 
influence of having cardiac resynchronization therapy 
and treated it as a fixed effect variable in the prediction 
models. Incremental increase in QRS duration on pre-
implant electrocardiogram showed a magnitude of benefit 
for improving cardiovascular outcomes after cardiac 
resynchronization therapy implant for every additional 
millisecond. Definitive benefit was observed from 140 msec 
onwards and plateaued beyond 180 msec for composite 
outcome alone (Cleland et al, 2013). This meta-analysis 
has been an important milestone in reviewing the evidence 
behind the recommendations on QRS durations. 
Patients with narrower QRS duration (120–130 msec) 
do not benefit from cardiac resynchronization therapy 
implantation (Cleland et al, 2013). The Cardiac 
Resynchronization Therapy in Heart Failure with a Narrow 
QRS Complex (EchoCRT) trial (Ruschitzka et al, 2013) 
enrolled patients (n=855) across 115 centres. These patients 
met standard implantation criteria having a QRS complex 
≤130 msec with evidence of cardiac dyssynchrony on echo 
to CRT-ON (cardiac resynchronization therapy capability 
turned on) or CRT-OFF (cardiac resynchronization 
therapy capability turned off) following implantation. 
The primary outcome was a clinical composite of all-cause 
mortality and heart failure hospitalization. The EchoCRT 
trial demonstrated CRT-ON had a higher rate of composite 
primary end-point occurrence compared with CRT-OFF 
(28.7% vs 25.2%, P=0.15). However, all-cause mortality 
was significantly higher in the CRT-ON group compared 
with CRT-OFF (11.1% vs 6.4%, P=0.02) (Ruschitzka et 
al, 2013). The greatest benefit of cardiac resynchronization 
therapy was seen in those with the widest QRS duration.
QRS morphology: bundle–branch block 
QRS morphology is important in determining response 
to cardiac resynchronization therapy. Sub-group analyses 
of MADIT-CRT (Moss et al, 2009), RAFT (Tang et 
al, 2010) and REVERSE (Linde et al, 2008) trials all 
identified complete left bundle–branch block as having 
better outcome on all-cause mortality and hospitalization 
compared with right bundle–branch block and non-
specific intraventricular conduction delay. A meta-analysis 
by Cunnington et al (2015), including 6914 patients, 
analysed those with and without left bundle–branch block. 
Participants across all included trials had NYHA I–IV 
symptoms, left ventricular ejection fraction ≤30–40% and 
QRS duration ≥120–130 msec. The study demonstrated no 
benefit from cardiac resynchronization therapy for patients 
with non-left bundle–branch block QRS morphology for 
pooled outcome of all-cause mortality and heart failure 
hospitalization (hazard ratio 1.09, 95% confidence interval 
0.85–1.39). It should be noted that Cunnington et al 
(2015) only studied cardiovascular end-points and did 
not examine symptom, functional or echocardiographic 
outcomes. It was also acknowledged that NYHA classes 
I and IV were under represented and observations were 
driven by those with NYHA class II–III symptoms. 
The MADIT-CRT trial (Moss et al, 2009) of NYHA 
I–II patients (n=536), followed over 7 years, demonstrated 
increased risk of mortality for non-left bundle–branch 
block patients (hazard ratio 1.57, 95% confidence interval 
1.03–2.39). 
Separating QRS duration from bundle–branch 
block morphology remains a challenge for cardiac 
resynchronization therapy. Both variables are important 
for selecting suitable candidates. Different bundle–branch 
block patterns have been demonstrated on activation 
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mapping studies to have heterogeneous patterns and 
should be considered as different entities (Varma, 2009). 
In the meta-analysis by Cleland et al (2013) left bundle–
branch block was associated with broader QRS durations, 
suggesting the power of increasing QRS duration to 
infer better cardiovascular outcomes was confounded by 
bundle–branch block morphology; it also observed that 
non-left bundle–branch block had an increased trend 
towards higher mortality. However, when QRS duration 
was removed from the multivariable prediction model, 
little difference was noted between left bundle–branch 
block and non-left bundle–branch block in terms of 
impact on mortality (Cleland et al, 2013). Together these 
observations suggest that bundle–branch block and QRS 
duration are intertwined variables, which may need to be 
considered together when reviewing a patient for cardiac 
resynchronization therapy.
Atrial fibrillation
Atrial fibrillation commonly co-exists in patients with 
heart failure and its presence can reduce the success of 
cardiac resynchronization therapy (Wilton et al, 2011). 
Understanding the true influence of atrial fibrillation on 
the success of cardiac resynchronization therapy is difficult 
as patients with atrial fibrillation tend to be older, have 
more comorbidities and be more unwell. Comparison 
between sinus rhythm and atrial fibrillation is influenced 
by these confounding factors, which often infer worse 
prognosis (Brignole et al, 2013). Atrial fibrillation is 
underrepresented in randomized controlled trials of 
cardiac resynchronization therapy and so meta-analysis is 
needed. Patients with atrial fibrillation receiving cardiac 
resynchronization therapy have a similar improvement in 
left ventricular ejection fraction to those in sinus rhythm, 
but have worse symptom and functional response (Wilton 
et al, 2011). In a large (n=7495) meta-analysis of 33 
observational studies, Wilton et al (2011) compared those 
with atrial fibrillation (22.5%) to those with sinus rhythm 
receiving cardiac resynchronization therapy and observed a 
significantly higher all-cause mortality and non-responder 
rate in the atrial fibrillation group. Evidence on the precise 
recommendations for cardiac resynchronization therapy 
in patients with atrial fibrillation remains weak and is 
based on limited evidence and expert opinion. However, 
implantation is favoured if >99% biventricular pacing 
percentage can be achieved (Brignole et al, 2013).
Cardiac resynchronization therapy implantation 
criteria
The current implantation criteria have been significantly 
modified over the last 15 years as more evidence has been 
produced and collated. The previous sections have discussed 
the evolution and refinement of the current evidence, 
which reflects the current international guidelines (Daubert 
et al, 2012). These have changed to incorporate the most 
recent evidence, including patients with atrial fibrillation 
and bradycardia pacemaker indications (Brignole et al, 
2013). In June 2014 in the UK, the National Institute for 
Health and Clinical Excellence revised guidance on cardiac 
resynchronization therapy implantation that reflected 
updated international guidelines (National Institute for 
Health and Clinical Excellence, 2014) (Table 2). Current 
indications are heart failure with reduced ejection fraction 
(left ventricular ejection fraction ≤35%) with NYHA II–
IV symptoms on optimal medical therapy and with QRS 
duration on resting electrocardiogram of either: 120–
149 msec with left bundle–branch block morphology or 
≥150 msec duration (this includes NYHA class I patients). 
Patients in atrial fibrillation who can be rate controlled (by 
medication or atrioventricular node ablation) and fulfil 
cardiac resynchronization therapy implant criteria can 
be considered too. Patients with impaired left ventricular 
function who are anticipated to require ventricular pacing 
>40% of the time should also be considered for cardiac 
resynchronization therapy (Brignole et al, 2013). 
The European Society of Cardiology introduced new 
recommendations for cardiac resynchronization therapy 
implantation in August 2016 (Ponikowski et al, 2016). 
Table 2. National Institute for Health and Clinical Excellence indications for implantable cardiac defibrillator and cardiac 
resynchronization therapy in patients with left ventricular ejection fraction ≤35%
NYHA class
QRS interval I II III IV
<120 msec Internal cardiac defibrillator if there is a high risk of 
sudden cardiac death
Internal cardiac defibrillator and cardiac 
resynchronization therapy not clinically indicated
120–149 msec without left bundle–
branch block
Internal cardiac defibrillator Internal cardiac defibrillator Internal cardiac defibrillator CRT-p
120–149 msec with left bundle–
branch block
Internal cardiac defibrillator CRT-d CRT-p or CRT-d CRT-p
>150 msec CRT-d CRT-d CRT-p or CRT-d CRT-p
Adapted from National Institute for Health and Clinical Excellence (2014). CRT-d = cardiac resynchronization therapy-defibrillator; CRT-p = cardiac resynchronization therapy-
pacemaker; New York Heart Association.
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Referring to the issues raised by the strength of evidence 
about implanting cardiac resynchronization therapy into 
patients with a low QRS 120–130 msec raised by Cleland 
et al (2013) and the ECHO CRT study (Ruschitzka et 
al, 2013), these guidelines recommended that cardiac 
resynchronization therapy should now be implanted in 
patients with a QRS ≥130 msec. The National Institute 
for Health and Clinical Excellence (2014) guidance still 
remains as in Table 2, but will possibly change when 
guidelines are updated in August 2018.
Cardiac resynchronization therapy implantation 
in the UK
Over the last decade several hundred thousand cardiac 
resynchronization devices have been implanted worldwide 
(Daubert et al, 2012). In 2013 the UK was the fourth 
highest total cardiac resynchronization therapy implanter 
within western Europe (Cunningham et al, 2014). Figure 2 
demonstrates the increasing year-on-year implantation rate 
within the home nations of the UK, over the last decade. 
Figures for Scotland are not presented because the data 
are incomplete (Cunningham et al, 2014). These figures 
demonstrate the establishment of cardiac resynchronization 
therapy as a cornerstone of heart failure management. 
Implantation rates continue to increase with broadening 
of implantation guidelines and more centres starting to 
implant. 
Health economics of cardiac resynchronization 
therapy
Despite recent revision of international guidelines and 
more focused studies on cardiac resynchronization therapy 
response, evidence suggests a non-response rate of 20–30% 
(Bristow et al, 2004; Cleland et al, 2005; Moss et al, 2009). 
There is a strong focus on trying to predict and minimize 
this non-response rate. Cardiac resynchronization 
therapy implantation is a costly intervention with a 
large up-front cost of an estimated £3411 for a cardiac 
resynchronization therapy-pacemaker and £12 293 for a 
cardiac resynchronization therapy-defibrillator (National 
Institute for Health and Clinical Excellence, 2014). 
The up-front cost is larger than for many other medical 
devices, and there are also ongoing costs of monitoring and 
replacing these devices (Boriani et al, 2009). 
Randomized controlled trials have been used to 
model the quality-adjusted life year costs of a cardiac 
resynchronization therapy device. It is widely accepted 
that this falls below $50 000 per quality-adjusted life year, 
which is the accepted cost of an intervention in the USA 
(Boriani et al, 2009). Efforts have focused on minimizing 
this cost by better defining the heart failure population who 
will benefit, streamlining implantation and using remote 
monitoring to reduce patient visits to hospital (Boriani 
et al, 2009). However, the burden of cost to health-care 
systems will continue to rise with the growing population of 
patients with heart failure who might benefit from cardiac 
resynchronization therapy. More accurately defining the 
non-response rate will minimize this burden of cost. 
The challenge of non-response
Despite two decades of large randomized controlled trials, 
detailed meta-analyses and observational studies, there 
remains an unchanging minority (20–30%) of heart failure 
patients meeting cardiac resynchronization therapy implant 
criteria who fail to respond (Bristow et al, 2004; Cleland et 
al, 2005; Moss et al, 2009). QRS duration and morphology 
have consistently been shown to be the strongest predictors 
of cardiovascular outcomes. Cleland et al (2013) clearly 
demonstrated the pooled magnitude of strength of ever-
increasing QRS duration beyond >140 msec to predict 
benefit. QRS morphology does not demonstrate such clear 
strength to predict response (Cleland et al, 2013), although 
it is clear that non-left bundle–branch block morphology 
favours poorer response (Cunnington et al, 2015). 
Questions still remain around the benefit of cardiac 
resynchronization therapy in patients with QRS durations 
120–140 msec and the additional benefit that left bundle–
branch block morphology offers (Cunnington et al, 2015). 
Calls have been made for randomized control trials of 
patients with cardiac resynchronization therapy already in-
situ, who have narrow native QRS with non-left bundle–
branch block morphology on electrocardiogram, to have 
their devices deactivated for a period of observation, given 
the question over benefit (Cleland and Freemantle, 2015). 
Moreover the apparent influence of bundle–branch block 
morphology on QRS duration >150 msec remains unclear. 
Beyond current indications for cardiac resynchronization 
therapy and QRS durations and morphology many other 
predictors have been identified. Sub-studies of the large 
cardiac resynchronization therapy randomized controlled 
Figure 2. Total cardiac resynchronization therapy implant rates 2003–13 and 
release of national and international implantation criteria. Adapted from 
Cunningham et al (2014). NICE = National Institute for Health and Clinical 
Excellence.
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trials have identified multiple variables that improve 
morbidity and mortality. In a sub-study of the MADIT-CRT 
trial, Hsu et al (2012) performed a best-subset regression 
on patients who had paired echocardiograms at 12 months 
and had been assigned to have cardiac resynchronization 
therapy-defibrillator (n=752) to examine for predictors 
of echo super-responders (top quartile of left ventricular 
ejection fraction change). Six predictors were identified 
as being associated with left ventricular ejection fraction 
super-response: female gender (odds ratio 1.96, P=0.001), 
no prior myocardial infarction (odds ratio 1.80; P<0.01), 
QRS duration ≥150 msec (odds ratio 1.79, P<0.01), left 
bundle–branch block (odds ratio 2.05, P<0.01), body mass 
index <30 kg/m2 (odds ratio 1.51, P=0.035), and smaller 
baseline left atrial volume index (odds ratio 1.47, P=0.001). 
The impact of cardiac resynchronization therapy was not 
accounted for in this analysis (Hsu et al, 2012); furthermore 
this sub-study required paired echocardiograms, thereby 
favouring patients who had survived 12 months, creating 
a selection bias. 
Cleland et al (2013) examined multiple predefined 
potential predictor variables (age, gender, NYHA class, 
heart failure aetiology, QRS morphology, QRS duration, 
left ventricular ejection fraction and systolic blood 
pressure) and only QRS duration could predict cardiac 
resynchronization therapy outcomes. Cleland and 
Freemantle (2015) consistently argued that much of the 
evidence for predictors is based upon sub-group analyses. 
Moreover, in these subset studies and meta-analyses based 
upon the cardiac resynchronization therapy randomized 
controlled trials the impact of the device was not accounted 
for and confounded the results observed.
Many observational studies have been performed to 
examine the potential of different variables to predict 
cardiac resynchronization therapy response and outcome. 
These observational studies tend to be of limited value, 
often being under-powered, having flawed methodology, 
not accounting for cardiac resynchronization therapy 
implantation and using a variety of different response and 
outcome definitions. Their value shadows that of the often 
quoted cardiac resynchronization therapy randomized 
controlled trial sub-studies and more importantly meta-
analyses. However, observational studies tend to emphasize 
the value of response in terms of patient-centred criteria 
(symptoms, function and quality of life) compared 
with the composite cardiovascular outcomes of most 
cardiac resynchronization therapy trials (Table 1). Well-
conducted observational studies often generate new lines 
of hypothesis and investigation, so they still have value 
in the investigation of non-response. Table 3 summarizes 
important observational studies evaluating clinical 
predictors.
Responder definition
The consistent issue examining cardiac resynchronization 
therapy response is the variety of different definitions used 
in the literature. This makes comparing and pooling data 
for comparison difficult because of the heterogeneity of 
Table 3. Observational studies assessing predictors of non-response
Study Patients Study design Inclusion Response criteria Main findings
Shanks et 
al (2011)
581 Observational study, single centre 
(Holland), 6 months
Not clear which NYHA, 
left ventricular ejection 
fraction ≤35%, QRS 
≥120 msec
Clinical and echocardiographic: 
↓NYHA ≥1 and survival and no 
heart transplantation ↑>15% left 
ventricular end systolic volume
Predict non-response: ischaemic 
aetiology, shorter 6-minute 
walk distance at baseline, less 
baseline cardiac dyssynchrony 
and left ventricle lead position
Lin et al 
(2014)
193 Retrospective observational 
study (China), single centre, 
all consecutive cardiac 
resynchronization devices, 
12 months
NYHA II–IV, left 
ventricular ejection 
fraction ≤35%, QRS 
≥120 msec
Echocardiographic: ↑≥5% left 
ventricular ejection fraction and 
survived and being free from 
heart failure hospitalization
Predicts non-response: non-left 
bundle–branch block and 
non-optimal left ventricle lead 
position
Rinkuniene 
et al (2014)
82 Retrospective observational study, 
single centre (Lithuania), 12 months
NYHA III–IV, left 
ventricular ejection 
fraction ≤35%, QRS 
≥120 msec, left 
bundle–branch block
Clinical: ↓≥1 NYHA and ↑>15% 
6-minute walk distance 
echocardiographic: ↑≥15% left 
ventricular end systolic volume
Predicts response: non-
ischaemic aetiology (clinical) 
and left ventricular end diastolic 
diameter (≤75 mm) (echo)
Sassone et 
al (2015)
243 Retrospective observational 
study, all consecutive cardiac 
resynchronization devices, majority 
cardiac resynchronization therapy-
defibrillator, single centre (Italy), 
6 months, left bundle–branch block 
in predictor analysis 
NYHA II–IV, left 
ventricular ejection 
fraction <35%, QRS 
>120 msec
Echocardiographic: ↑>15% left 
ventricular end systolic volume. 
Clinical composite: heart failure 
hospitalization, mortality and first 
sustained ventricular tachycardia
Predict non-response: ischaemic 
aetiology and QRS duration 
(≥178 msec). Clinical composite: 
non-left bundle–branch block ↑ 
rate events
NYHA = New York Heart Association.
British Journal of Hospital Medicine, June 2017, Vol 78, No 6 7
Review
©
 2
01
7 
M
A 
H
ea
lth
ca
re
 L
td
criteria used for response. Fonwalt et al (2010) performed 
a seminal systematic review of the 26 most cited papers on 
predicting cardiac resynchronization therapy response and 
extrapolated 17 different criteria. Fifteen criteria (clinical 
and echocardiographic) were all applied to the PROSPECT 
trial cohort (two criteria could not be calculated). The 
application of these different definitions to the same cohort 
demonstrated a response rate variation between 32% and 
91% (Chung et al, 2008; Fornwalt et al, 2010). Agreement 
was poor (105 combinations) between 79 (75.2%) pairs 
of definitions (Fornwalt et al, 2010). Moreover, a strong 
association of agreement was only observed in four (3.8%) 
pairs of definitions. All echocardiographic and clinical 
definition combinations had a poor association. Removal 
of definitions applied in short-term follow up (<3 months) 
made no significant change to the analysis. Agreement 
between definitions is poor, even between similar categories 
of criteria (Fornwalt et al, 2010). 
In a paper on heart failure composite scores, Packer 
(2001) identified the pitfalls of using one individual metric 
to measure response; composite scores can minimize this 
problem. No universal response definition has yet been 
agreed upon, but the consensus is that a combination of 
composite criteria is required. Criteria should not combine 
clinical or echocardiographic variables (Fornwalt et al, 
2010).
Conclusions
Cardiac resynchronization therapy has revolutionized 
the treatment and outcomes for selected heart failure 
patients who are refractory to optimal medical therapy 
and exhibit evidence of dyssynchrony on resting 12-
lead electrocardiogram. In the correct patient, cardiac 
resynchronization therapy reverses adverse cardiac 
remodelling; the process that underpins the development 
and progression of heart failure with reduced ejection 
fraction. Refinement of evidence over the last 15 years has 
led to changes in national and international guidelines 
for cardiac resynchronization therapy. QRS duration on 
electrocardiogram remains the most important factor 
determining response to cardiac resynchronization 
therapy. Emerging evidence suggests that QRS durations 
120–130 msec do not confer any benefit. Unfortunately, 
despite refinements in implant criteria, a significant cardiac 
resynchronization therapy non-response remains (20–
30%). Research continues on being able to better identify 
and stratify patients before cardiac resynchronization 
device implantation. Cardiac resynchronization therapy 
remains one of the greatest advances in the last 20 years 
for the management of heart failure with reduced ejection 
fraction. All patients who have a significant reduction in 
left ventricular ejection fraction and have broad QRS 
duration on resting electrocardiogram should be considered 
for implantation of cardiac resynchronization therapy. 
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KEY POINTS
 ■ Cardiac resynchronization therapy should be considered in all patients 
with severe left ventricular systolic dysfunction with evidence of electrical 
dyssynchrony on resting 12-lead electrocardiogram refractory to optimal 
medical therapy. 
 ■ Cardiac resynchronization therapy significantly reduces mortality and 
hospitalizations in heart failure patients with broad QRS. 
 ■ Cardiac resynchronization therapy resynchronizes both atrioventricular and 
inter-/intra-ventricular dyssynchrony thereby promoting reverse cardiac 
remodelling, which improves left ventricular ejection fraction and reduces left 
ventricular end systolic volume and functional mitral regurgitation.
 ■ The benefit of cardiac resynchronization therapy increases incrementally with 
increasing QRS duration (with benefit beginning at QRS duration >130 msec). 
 ■ Patients with at least moderate left ventricular impairment and bradycardia 
pacing indication and likely to require >40% ventricular pacing should be 
offered cardiac resynchronization therapy.
 ■ A significant challenge of cardiac resynchronization therapy remains the 
20–30% non-response rate. 
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AbstrAct
Objective Cardiac resynchronisation therapy (CRT) is an 
effective therapy for selected patients with heart failure 
(HF); however, a significant non-response rate exists. We 
examined current evidence on extracellular cardiac matrix 
(ECM) biomarkers in predicting response following CRT.
Methods Complete literature review of PubMed, Ovid 
SP MEDLINE, Cochrane Library and TRIP, reference lists, 
international cardiology conferences and ongoing studies 
between December 1999 and December 2015 conducted 
according to prospectively registered study selection and 
analysis criteria (PROSPERO:CRD42016025864) was 
performed. All observational and randomised control 
trials (RCT) were included if they tested prespecified ECM 
biomarkers’ ability to predict CRT response. Risk of bias 
assessment and data extraction determined pooling of 
included studies was not feasible due to heterogeneity of 
the selected studies.
Results A total of 217 studies were screened; six (five 
prospective cohort and one RCT substudy) were included 
in analysis with 415 participants in total. Study sizes 
varied (n=55–260), cohort characteristics contrasted 
(male: 67.8%–83.6%, ischaemic aetiology: 40.2%–
70.3%) and CRT response definitions differed (three 
clinical/functional, three echocardiographic). Consistent 
observation in all ECM biomarker behaviour before and 
after CRT implantation was not observed between studies. 
Lower type I and type III collagen synthesis biomarkers 
(N-terminal propeptides of type I and III procollagens) 
expression demonstrated replicated ability to predict 
reverse left ventricular remodelling.
Conclusion Collagen synthesis biomarkers offer the most 
potential as ECM biomarkers for predicting CRT response. 
Heterogeneity between these studies was large and 
limited the ability to pool and compare results numerically. 
Use of different response definitions was one of the 
biggest challenges.
IntROduCtIOn
Cardiac resynchronisation therapy (CRT) 
is an effective therapy for selected patients 
with heart failure (HF).1 2 Current guide-
lines suggest that CRT is offered to those 
with a left ventricular ejection fraction 
(LVEF) ≤35% with resting 12-lead ECG QRS 
duration ≥150 ms or 120–149 ms with Left 
Bundle Branch Block (LBBB) morphology 
and refractory to optimal medical therapy 
(OMT).3 CRT reduces mortality and 
improves morbidity, underpinned by reversal 
of pathophysiological adverse cardiac 
remodelling.1 2 Unfortunately, a significant 
non-response rate of 20%–40% exists and has 
remained unchanged over the last decade, 
despite extensive research and investment.1 2
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Key questions
What is already known about this subject?
 ► Cardiac resynchronisation therapy  (CRT) is 
associated with non-response in 20%–40% of 
selected patients with heart failure (HF). Selected 
vascular biomarkers are known to be associated 
with cardiac disease but it is unknown whether 
these can be used to predict CRT response.
What does this study adds?
 ► We performed a systematic review of all studies 
examining vascular biomarkers in CRT. We 
found that collagen synthesis biomarkers have 
the most potential for predicting CRT response, 
particularly N-terminal propeptides of type I and III 
procollagens. Matrix metalloproteinases-2  and  9 
have no conclusive predictive value and need 
further investigation.
How might this impact clinical practice?
 ► Use of vascular biomarkers to predict CRT 
response could have enormous clinical benefit 
by selectively identifying those patients with 
HF who are likely to benefit. This has important 
implications for both patients and healthcare 
providers worldwide, especially given the current 
financial climate.
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The extracellular cardiac matrix (ECM) is a dynamic 
support structure that remodels following cardiac injury 
and HF.4 5 Progressive ECM remodelling is closely linked 
to HF severity and prognosis.4 5 Cardiac collagen turnover 
alterations are central to the development and progres-
sion of cardiac fibrosis and HF.5 Specific biomarkers 
of type I and type III collagen synthesis (N-terminal 
propeptides of type I and III procollagens (PINP and 
PIIINP),6 7 carboxy-terminal propeptide of procollagen 
type I (PICP))8 9 and degradation (carboxy-terminal telo-
peptide of type I collagen (ICTP or CITP))9 10 products 
are associated with poor outcomes in HF. The proteolytic 
enzyme system matrix metalloproteinases (MMPs) and 
their regulators tissue inhibitors of MMPs (TIMPs) are 
involved in collagen degradation and have been impli-
cated in HF development and progression.4 5 Specifically, 
MMP-1,11 a collagenase, MMP-212 and MMP-9,13 both 
gelatinases and TIMP-111 are associated with HF outcomes. 
Galectin-3 (Gal-3) is a beta-galactoside-binding lectin 
released by activated cardiac macrophages, which are 
upregulated in HF, causing increased fibroblast prolifer-
ation, collagen deposition and ventricular dysfunction.14 
Gal-3 is strongly associated with inflammation and fibrosis 
with raised levels strongly predict poor HF outcomes.14
Turnover of ECM alters in HF and with reverse cardiac 
remodelling following CRT implantation may offer 
potential biomarkers for response prediction.15 This 
systematic review examines the current evidence on the 
value of ECM biomarkers in predicting CRT response.
MetHOdOlOgy
Our systematic review was conducted according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) guidelines.16 It was prospec-
tively registered with PROSPERO (CRD42016025864), 
an international registry of systematic reviews. A protocol 
was designed and implemented prospectively in-line with 
PRISMA-P 2015.17
eligibility criteria
Strict eligibility criteria were applied to minimise hetero-
geneity of included articles. Observational studies 
(prospective or retrospective) and randomised control 
trials (RCTs) (including substudies) were included; basic 
science and review articles were excluded. Included 
study populations represented patients with HF meeting 
international CRT implant guidelines.3 Studies had to 
be conducted on adults (age ≥18 years). Articles were 
included if they examined an ECM biomarker previ-
ously reported to predict HF outcomes.4 Baseline ECM 
biomarkers, measured when patients were clinically 
stable prior to implantation, had to be compared with 
a predefined CRT ‘response’ criteria to evaluate their 
predictive value. Coronary sinus sampling and long-term 
trends in peripheral ECM biomarker behaviour were 
analysed if present.
A variety of clinical, functional or echocardiographic 
criteria and cardiovascular outcomes have been used to 
define CRT response in studies,18 which often correlate 
poorly. All response criteria were included in the review. 
Cardiovascular outcomes could form part of a response 
definition or be presented separately; their absence was 
not an exclusion criterion.
database search strategies
Detailed searches were conducted on PubMed, Ovid SP 
MEDLINE, Cochrane Library (CENTRAL) and TRIP 
in February 2016 by one author (CM) and reviewed by 
another independently (DA). The search strategy used 
specific terms (cardiac resynchronisation therapy/
cardiac pacing/extracellular matrix) in combination, 
within titles/abstracts or Medical Subject Headings. 
Specific vascular biomarkers (‘TIMP’ ‘MMP’ ‘collagen’ 
‘Myostatin’ ‘Syndecan-4’ and ‘Galectin-3’) were included 
in the search. A grey literature search involved searching 
the Clinical Trials database (www. clinicaltrials. gov) 
and international cardiology conferences (European 
Society of Cardiology, American Heart Association, 
American College of Cardiology) indexes for ongoing, 
abstracts and unpublished work. All included articles 
had their references searched for relevant publications. 
A date limitation of the last 15 years (31 December 1999– 
31 December 2015) was applied. No language restrictions 
were applied.
Title and abstract reviews were performed inde-
pendently (CM/DA), consensus on eligibility criteria was 
required to be taken forward to full paper review; any 
conflicts were decided by an independent reviewer (FO). 
Duplications of articles or cohort use were identified and 
only the most relevant (decided by consensus) taken 
forward. The Critical Appraisal Skills Programme check-
list (dependent on study design) was applied to full paper 
review to guide evaluation of article quality.19 Consensus 
had to be reached on full paper reviews before being 
selected for inclusion; where consensus was not reached 
a third reviewer (FO) made the final decision. Contact 
was attempted with all included article authors and any 
others at full paper review that were indicated.
data extraction and management
Full texts of included articles were obtained. Pilot data 
extraction was performed on two randomly selected 
articles and reviewed for robustness (CM, DA, FO, 
PB). A standardised data extraction form was created 
to collect data on each study’s design (eligibility 
criteria, methodology, assessment period), patient 
population (numbers, age, gender, aetiology, ECG, left 
ventricular (LV) geometry, quality of life, New York 
Heart Association (NYHA), functional assessment), 
vascular biomarker/predictor (specific ECM surrogate 
biomarkers, units, conditions of sampling, laboratory 
assessment, statistical prediction model) and outcome 
(response definition and cardiovascular outcomes). 
Data extraction was performed by two independent 
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Figure 1 Flowchart of studies screening and selection. ≠Author contacted, poster presentation sent and no baseline 
extracellular cardiac matrix biomarker sample taken.22 *Clinical trial (NCT15019908) author contacted and manuscript in 
preparation. CRT, cardiac resynchronisation therapy.
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reviewers (CM/DA), a third independent reviewer 
(FO) resolved any disagreement.
Risk of bias assessment
Risk of bias for each study was assessed by two indepen-
dent reviewers (CM, DA) utilising either the Risk of Bias 
Assessment Tool for Non-randomised Studies or the 
Cochrane Collaboration ‘Risk of Bias’ assessment tool.20 21 
Both have established criteria to examine selection bias, 
exposure measurement, blinding and completeness of 
outcome data.20 21
data synthesis and analysis
A descriptive synthesis was performed to summarise find-
ings of all selected articles. A meta-analysis of included 
study data for each specific ECM biomarker was not 
possible due to heterogeneity of outcome definitions 
and study designs. Evaluation of study designs, defined 
outcomes and cohort characteristics was performed. The 
same biomarkers compared in different included articles 
were compared. Continuous variables were summarised 
using the same units for each variable in the original text. 
Data were presented as mean ± standard deviation (SD), 
unless specified otherwise.
Results
Figure 1 shows the screening and selection of published 
articles; 110 records were excluded after the screening 
stage as they did not meet inclusion criteria. Six articles met 
the inclusion criteria. Two abstracts22 23 and one clinical 
trial entry (www. clinicaltrials. gov) (NCT15019908) were 
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taken to full review (for potential inclusion). Related arti-
cles and information were sought, including contacting 
authors (all three kindly responded). None yet had arti-
cles published and additional information provided led 
to exclusion from review (no baseline biomarkers taken22 
or study design did not test biomarkers as predictors23).
study design
Five prospective cohort studies and one RCT substudy11 
were included. Table 1 summarise the different study 
designs and CRT response outcome definitions used. 
Studies selected were published between 2008 and 2014. 
Risk of bias was assessed in each study using appropriate 
quality check tools. The lowest risk of bias was in the 
single RCT substudy.11 The prospective cohort studies 
varied minimally in their bias assessment and none were 
excluded.
Garcia-Bolao et al9 stated that 61 participants were 
consented; during the observation period there were 
four mortalities (three cardiac/one non-cardiac) and one 
functional assessment not performed at follow-up (6 min 
walk test not completed due to stroke). The cohort was 59 
but no explicit statement about the two exclusions made. 
Lopez-Andres et al11 published a substudy in 2012 of the 
‘The Effect of Cardiac Resynchronization on Morbidity 
and Mortality in Heart Failure’ (CARE-HF)1 RCT which 
itself was published in 2005; interpretation of results is 
within this context. All studies included NYHA III–IV 
patients (mostly NYHA III). Two studies recruited NYHA 
II patients24 25 with one also requiring a bradycardia 
pacing indication.24 All studies included QRS dura-
tion >120 ms, except Garcia-Bolao et al9 (QRS≥130 ms). In 
the CARE-HF trial, those with QRS duration 120–149 ms 
needed dyssynchrony on echocardiography.1 8 All trans-
venous LV leads were implanted preferably to the most 
lateral position possible. Dong et al26 performed only 
de novo CRT-defibrillator (CRT-d) implants. Three 
studies10 24 26 commented on right ventricular lead place-
ment with two26 explicitly aiming for the right ventricular 
apex. In CARE-HF (and substudy), all had CRT-pace-
maker (CRT-p) devices only.1 11 CRT response definitions 
varied between included studies. Broadly, response defi-
nitions used were classified as three clinical and three 
echocardiographic. Reported response rates varied 
between 48.9% and 71.8% (table 1).
Baseline characteristics
The baseline characteristics of the patients are shown in 
table 2.
A total of 415 patients were included. The five prospec-
tive observational studies had mean age of 67±10 years9 10 
(Lopez-Andres et al8 excluded as presented as median 
and IQR). There were 315 (75.9%) males in included 
studies, ranging 67.8%9–83.6%.25 There was large varia-
tion in frequency of CRT-d/CRT-p implants in each study 
with two not providing this data.10 25 One study included 
a high proportion of device upgrades25; the CARE-HF 
trial excluded upgrades,1 8 the remaining four studies 
did not state upgrade status.9 10 24 26 Atrial fibrillation 
(AF) was included in three prospective observational 
studies8 24 25; one did not report on AF or related publi-
cations.10 27 Precise QRS duration was not stated in two 
studies.24 26 Reporting of LV volumetric data varied 
between included studies. Three reported unadjusted 
LV end systolic volume (LVESV) and LV end diastolic 
volume (LVEDV) data which were similar to each other 
(table 3).10 24 25 Dong et al26 presented LVESV and LVEDV 
volume indexed figures only. Garcia-Bolao et al9 provided 
LVEF only. LVEF was compared between the five prospec-
tive cohorts and showed similar mean LVEF between 
25%–27%.9 10 24–26
Responder versus non-responders
Response status (responders vs non-responders (RvsNR)) 
was presented in four of the included studies.9 10 24 26 
Truong et al25 did not provide characteristics of those 
defined by response. Lopez-Andres et al8 outlined char-
acteristics by allocation to CRT-p versus OMT, however, 
not by response. There were some baseline characteristic 
differences between the four studies for RvsNR9 10 24 26; 
Dong et al26 demonstrated differences between RvsNR 
for LBBB status (15 (68.3%) vs 9 (39.1%), p=0.05) and 
ischaemic aetiology (9 (40.9%) vs 17 (73.9%], p=0.03). 
Tolosana et al24 reported lower creatinine levels in RvsNR 
(1.25±0.3 mg/dL vs 1.76±0.8 mg/dL, p=0.01). Umar et 
al10 reported that responders were older and had longer 
QRS duration than non-responders (age: 66±10 years vs 
60±11 years, p=0.03; mean± standarderror QRS: 165±3 ms 
vs 135±8 ms, p=0.001). Notably, Hessel et al published a 
study using the same cohort as Umar et al and reported 
no difference in QRS duration for RvsNR (165±2 ms vs 
153±3 ms, p=NS), suggesting one of these studies has 
recorded it incorrectly.10 27
eCM biomarkers
All ECM biomarker baseline concentrations and magni-
tude of association (if tested) are summarised in table 3. 
Lopez-Andres et al8 did not provide baseline concentra-
tions by response status, but comparison was made with 
the control group. Umar et al10 showed baseline results 
for expression of ECM biomarkers studied. However, for 
PIIINP non-responders no baseline concentration was 
reported in the article, however no statistical significance 
is reported RvsNR.10
PInP/PICP
PINP and PICP share a 1:1 stoichiometric relationship 
with the collagen molecule; therefore, they were consid-
ered together. Umar et al10 reported similar total cohort 
means values to Lopez-Andres et al8 median values (the 
skew of this data is unknown). Umar et al10 observed 
higher PINP baseline level predicted poor response. 
Garcia-Balao et al9 reported the opposite for PICP. 
Lopez-Andres et al8 observed no significant association 
of baseline PINP with CRT response or other outcomes. 
Variation in the pattern of reported levels between the 
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three studies were likely due to differences in response 
definitions and baseline characteristics. Garcia-Balao et 
al9 utilised a clinical definition of response, whereas the 
other two studies used echocardiographic criteria.8 10 All 
studies varied in duration of follow-up. Umar et al10 had 
a higher proportion of men with ischaemic aetiology 
than the other studies. Lopez-Andres et al8 excluded 
AF, whereas within the Garcia-Balao et al9 cohort it was 
present in 18.6% of participants. Garcia-Balao et al9 tested 
the predictive value of type I collagen turnover with the 
PICP:CITP ratio with a ratio ≥14.4 predicting response.
PIIInP
Variation was reported in trends of PIIINP levels at base-
line. Dong et al26 reported logarithmic figures making 
absolute figure comparison challenging. Geometric 
means could be calculated, but given small numbers 
of participants this was likely to underestimate the 
true mean.26 Higher PIIINP levels in HF versus healthy 
controls (0.88±0.21 ug/L vs 0.71±0.14 ug/L, p=0.01) were 
observed.26 Responders had significantly lower PIIINP 
baseline levels than non-responders (p=0.03).26 Umar 
et al10 demonstrated no difference in baseline levels 
between RvsNR. Lopez-Andres et al8 reported similar 
baseline levels between CRT-p and OMT, but did observe 
PIIINP (>4.7 ug/L) in univariate analysis predicted 
cardiovascular outcomes (death or HF hospitalisation at 
18 months) (OR 1.80, 95% CI 1.06 to 3.06, p=0.03).8
ICtP or CItP
Both ICTP and CITP were used to represent carbox-
yl-terminal peptides of type I collagen in three included 
studies. Umar et al13 and Garcia-Balao et al12 demon-
strated similar baseline means for ICTP/CITP for the 
entire cohort. Neither identified independent predictors 
of CRT response.9 10 Garcia-Bolao et al9 identified that 
the PICP:CITP ratio strongly predicted response but 
was driven by PICP. Lopez-Andres et al8 observed similar 
expression between CRT-p and OMT groups and showed 
no predictive value.
MMP-1, MMP-2 and MMP-9
There were variations in reported baseline concentra-
tions for MMP-1. The mean for MMP-1 in Garcia-Bolao et 
al9 was higher than median observed in CRT-p and OMT 
groups in Lopez-Andres et al,8 though the data skew is 
unknown. Garcia-Bolao et al9 examined the predictive 
value of MMP-1:TIMP-1, given their intrinsic regula-
tory role in collagen turnover,5 but showed no statistical 
significance. Lopez-Andres et al8 observed with a base-
line MMP-1 ≤3 ug/L an adjusted threefold increased risk 
of CRT non-response and an increased risk of death or 
N-terminal pro B-type natriuretic peptide >1000 ng/L 
(OR 2.23, 95% CI 1.00 to 5.00, p=0.051/0.073 adjusted 
with/without renal function).8 A precursor to MMP-1 
called pro-MMP-1 (pro-MMP-1) was studied by Umar et 
al.10 They observed no difference in baseline pro-MMP-1 
expression between RvsNR.10
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Two studies reported cohort means for MMP-2 base-
line concentration with large differences (table 3). 
Responders had lower MMP-2 baseline concentrations in 
both studies. Tolosana et al24 reported a significant differ-
ence between RvsNR (p=0.02), whereas Garcia-Bolao et 
al9 demonstrated no difference. The differences are not 
fully explained by study design, response definition or 
cohort characteristics as they showed similarities (tables 1 
and 2). Variation in levels may be due to Tolosana et al24 
using plasma and Garcia-Bolao et al9 using serum in their 
sandwich ELISAs. MMP-9 was reported by Garcia-Bolao et 
al,9 who observed a trend towards lower baseline MMP-9 
concentration for Responders. Baseline MMP-9 did not 
predict CRT response.9
tIMP-1
Tolosana et al24 observed that responders had signifi-
cantly lower concentrations at baseline of TIMP-1 than 
non-responders. Neither Umar et al10 nor Garcia-Bolao et 
al9 observed a significant difference in baseline TIMP-1 
concentration between RvsNR. Higher peripheral 
TIMP-1 was identified as an independent predictor of 
non-response by Tolosana et al24 in multivariable analysis; 
a concentration of ≥248 ug/L had a 71% sensitivity and 
72% specificity for predicting non-response. However, 
Umar et al10 did not identify TIMP-1 as a predictor. Garcia-
Bolao et al9 tested TIMP-1 in the MMP-1:TIMP-1 ratio 
and did not identify TIMP-1 as a significant predictor of 
RvsNR.
gal-3
Lopez-Andres et al8 reported higher baseline levels of 
Gal-3 than Truong et al,25 due to different response defi-
nitions and variation in cohort characteristics. Lopez et 
al8 used an echocardiographic definition at 18 months 
and Truong et al25 utilised HF clinical composite score at 
6 months. Truong et al25 has higher ischaemic aetiology 
(53.4% vs 40.2%) and included patients with AF. Neither 
study reported baseline concentrations for RvsNR.8 25 
Truong et al25 observed that peripheral baseline Gal-3 
above a preset concentration (>25.9 ug/L) had low sensi-
tivity and high specificity for predicting CRT response.
dIsCussIOn
The ECM is a highly dynamic structure that is integral 
to myocardial structure and function which detrimentally 
remodels following cardiac injury leading to the altered 
turnover, replacing contractile tissue with collagen rich 
connective tissue and ultimately the development of 
myocardial fibrosis.5 Myocardial fibrosis is characterised 
by adverse remodelling which contributes to systolic 
and diastolic HF.5 28 PINP, PICP and PIIINP are released 
into the circulation during conversion and deposition 
of procollagen to collagen and are upregulated during 
myocardial fibrosis and associated with adverse HF 
outcomes.5 7 15 28 Mechanistically, higher upregulation 
of collagen would challenge a CRT’s ability to reverse 
remodel and for the patient to respond. Umar et al10 
supported this hypothesis observing significantly lower 
baseline PINP expression predicted echocardiographic 
response. Dong et al26 did observe lower baseline PIIINP 
predicted echocardiographic response on univariate 
analysis, but not multivariable analysis. In contrast, 
Garcia-Balao et al9 observed higher baseline expres-
sion of PICP in responders and PICP:CITP ratio (type 
I collagen turnover) of ≥14.4 had greater than twofold 
increased chance of predicting functional response, 
driven by PICP. Critically, echocardiographic and clin-
ical/functional response criteria correlate poorly,18 so 
could not be contrasted. Importantly, Lopez-Andres et al,8 
the largest study included in the review, did not observe 
upregulation of collagen synthesis predicting echocardio-
graphic non-response, which does challenge the Umar et 
al10 and Dong et al26 observations; however, the cohort 
characteristics and study designs were different. The 
observations of collagen synthesis following CRT implan-
tation conflict with each other. Umar et al10 reported a 
significant increase in PINP and decrease in PIIINP 
expression in responders at 6 months; both would mecha-
nistically be expected to be lower at follow-up. In contrast 
Garcia-Bolao et al9 observed PICP levels decreased for 
responders and increased for non-responders at 1 year, 
which would be expected, but is based on a functional 
response definition. In contrast to collagen synthesis, 
degradation biomarkers (ICTP or CITP) did not predict 
CRT response.8–10 Furthermore, no significant change in 
ICTP or CITP expression was observed at follow-up across 
all three studies.8–10 Alteration in collagen synthesis rate 
is observed to be more powerful at predicting response 
than collagen degradation. Different patterns of collagen 
synthesis biomarkers predicting response have been 
observed; lower expression predicted LV reverse remod-
elling,10 26 whereas higher rates predicted functional 
response.9 The variation in these patterns is explained 
by the different response definitions and cohort charac-
teristics. The study cohort for Umar et al10 had a higher 
proportion of men and ischaemic cardiomyopathy than 
Garcia-Bolao et al.9 The heterogeneities between these 
studies make drawing conclusions difficult. Lopez-Andres 
et al8 also challenge any observations due to size of cohort 
and no prediction value to collagen turnover observed. 
Overall, collagen synthesis is observed to be important in 
predicting CRT response, especially LV reverse remodel-
ling, with results replicated in two studies that lower rates 
predict LV reverse remodelling.10 26
MMP-1, MMP-2 and MMP-9 perform a critical role 
in myocardial collagen degradation and have been 
identified as being important prognostic markers in 
HF.11 13 27 Predictive value for CRT non-response (death 
or LVEF ≤35% at 18 months) was only demonstrated in 
baseline MMP-1 expression ≤3 ug/l8 supporting an obser-
vation by Jordan et al11 that lower MMP-1 inferred worse 
HF prognosis. MMP-2 had large variations observed 
between the included studies,8 24 but was not demon-
strated to predict response. MMP-9 was only observed 
in one included study showing no predictive value9; 
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however, recently Dini et al13 demonstrated raised levels 
(>238 ng/mL) and predicted worse HF outcomes. MMP 
activity was not considered in any of these studies as a 
predictor but would be important to consider in the 
future. Current evidence suggests that MMPs, especially 
MMP-2 and MMP-9, have not yet had their potential fully 
evaluated.
TIMP-1 regulates the endogenous proteolytic MMP 
system involving discordant inhibition and in chronic 
inflammatory states stimulating collagen synthesis and 
myocardial fibrosis.5 24 Tolosana et al24 observed a signif-
icant baseline difference in RvsNR expression with 
lower TIMP-1 in responders. Tolosana et al24 demon-
strated that baseline TIMP-1 (≥248 ug/L) predicted CRT 
non-response. Trucco et al29 in long-term follow-up of 
the same cohort demonstrated that the same threshold 
independently predicted mortality at 60±34 months 
(sensitivity 80% and specificity 71%). Tolosana et al24 also 
demonstrated that statistically significant lower TIMP-1 is 
found in participants that do LV reverse remodel (LVESV 
reduction ≥10%). Umar et al10 and Garcia-Bolao et al9 
observed no difference statistically at baseline. Variation 
between the reported literature in the magnitude of asso-
ciation of TIMP-1 exists; however, Tolosana et al24 offers 
a well-designed prospective observational study which is 
powered giving strength to the conclusions drawn.
Gal-3 stimulates fibroblasts to release TIMPs and MMPs 
that regulate collagen turnover, resulting in myocardial 
fibrosis.14 Elevated levels are independent predictors 
of adverse outcomes in HF.14 Evaluation of Gal-3 as a 
predictor of response was limited, as RvsNR was not 
reported in either of the two studies.8 25 Truong et al25 
demonstrated peripheral baseline Gal-3 ≥25.9 ug/L had 
specificity for predicting CRT response. Lopez-Andres 
et al8 observed Gal-3 baseline expression ≥30 ng/L had 
nearly threefold increased risk of death or hospitalisation 
for worsening HF following CRT. Though not demon-
strated to be a strong predictor, the evidence suggests 
that Gal-3 is a good biomarker for predicting poor 
outcomes in HF and needs further evaluation.
The greatest challenge for research into CRT 
response and one this review demonstrated is lack of 
an accepted response definition. Differing definitions 
rarely correlate,18 which our review clearly demonstrates. 
Echocardiographic and clinical/functional definitions 
correlate very poorly and should never be compared or 
applied in a composite definition18; LV reverse remodel-
ling should be considered separately.18 30
study limitations
Heterogeneity among included studies was widespread 
despite a rigorous eligibility and screening criteria. The 
variations in study design, cohort characteristics and 
response definitions made pooling data in a meta-analysis 
impractical. CRT implantation techniques and indica-
tions have evolved over the last 15 years and offer another 
source of heterogeneity. Furthermore differences in 
laboratory techniques account for some variation among 
biomarker results. These limitations are particularly 
important to consider in future research studies.
COnClusIOns
Collagen synthesis biomarkers have shown the most 
potential, particularly PINP and PIIINP, but will require 
further study. MMP-2 and MMP-9 have no conclusive 
predictive value and need further investigation. Hetero-
geneity is the greatest challenge for research in this field 
and needs to be minimised in future studies. The most 
important initial step is for a universal response defini-
tion to be adopted and applied.
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